{"a8b5c23ea9e05aca02dc71156e030efcbe9cd0c6": [["IntroductionThe airborne transmission of respiratory pathogens such as measles, tuberculosis, severe acute respiratory syndrome (SARS), influenza, rhinovirus, and others in indoor environments and the associated risk of infection presented to uninfected occupants are governed by several complex physical and biological processes.", [["respiratory pathogens", "DISEASE", 41, 62], ["measles", "DISEASE", 71, 78], ["tuberculosis", "DISEASE", 80, 92], ["acute respiratory syndrome", "DISEASE", 101, 127], ["SARS", "DISEASE", 129, 133], ["influenza", "DISEASE", 136, 145], ["rhinovirus", "DISEASE", 147, 157], ["infection", "DISEASE", 220, 229], ["rhinovirus", "ORGANISM", 147, 157], ["respiratory pathogens", "PROBLEM", 41, 62], ["measles", "PROBLEM", 71, 78], ["tuberculosis", "PROBLEM", 80, 92], ["severe acute respiratory syndrome", "PROBLEM", 94, 127], ["SARS", "PROBLEM", 129, 133], ["influenza", "PROBLEM", 136, 145], ["rhinovirus", "PROBLEM", 147, 157], ["infection", "PROBLEM", 220, 229], ["respiratory pathogens", "OBSERVATION", 41, 62], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["respiratory syndrome", "OBSERVATION", 107, 127], ["infection", "OBSERVATION", 220, 229]]], ["Communicable respiratory illnesses lead to large excesses in expenses associated with healthcare, absence from work, and lost worker productivity [1] , but the control of airborne infectious disease transmission in indoor environments is not yet entirely understood [2] .", [["respiratory", "ANATOMY", 13, 24], ["respiratory illnesses", "DISEASE", 13, 34], ["infectious disease", "DISEASE", 180, 198], ["Communicable respiratory illnesses", "PROBLEM", 0, 34], ["large excesses in expenses", "PROBLEM", 43, 69], ["large", "OBSERVATION_MODIFIER", 43, 48], ["excesses", "OBSERVATION", 49, 57]]], ["Several studies have shown that building design and operational characteristics such as increased outdoor air ventilation rates, lower occupant density, and use of UV germicidal irradiation can reduce the risk of infectious disease transmission inside buildings [3e7] .", [["UV germicidal", "CHEMICAL", 164, 177], ["Several studies", "TEST", 0, 15], ["increased outdoor air ventilation rates", "PROBLEM", 88, 127], ["lower occupant density", "PROBLEM", 129, 151], ["UV germicidal irradiation", "TREATMENT", 164, 189], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["air ventilation", "OBSERVATION", 106, 121], ["lower", "OBSERVATION_MODIFIER", 129, 134], ["occupant density", "OBSERVATION", 135, 151], ["infectious", "OBSERVATION", 213, 223]]], ["Similarly, commonly available particle filters in recirculating heating, ventilating, and air-conditioning (HVAC) systems may also be used to reduce the risk of airborne infectious disease transmission, depending on the nature of infectious aerosols and some important building characteristics [2,4,8e12] .IntroductionHowever, key questions remain about (i) the effectiveness of particle filtration for controlling airborne infectious aerosols, (ii) the associated risk reductions achievable with HVAC filtration, and (iii) the relative costs of risk reduction by HVAC filtration versus other control mechanisms such as increased outdoor air ventilation rates.", [["infectious disease transmission", "DISEASE", 170, 201], ["particle filters", "TREATMENT", 30, 46], ["recirculating heating", "TREATMENT", 50, 71], ["ventilating", "TREATMENT", 73, 84], ["air-conditioning (HVAC) systems", "TREATMENT", 90, 121], ["airborne infectious disease transmission", "PROBLEM", 161, 201], ["infectious aerosols", "PROBLEM", 230, 249], ["particle filtration", "TREATMENT", 379, 398], ["HVAC filtration", "TREATMENT", 497, 512], ["risk reduction", "TREATMENT", 546, 560], ["HVAC filtration", "TREATMENT", 564, 579], ["other control mechanisms", "TREATMENT", 587, 611], ["increased outdoor air ventilation rates", "PROBLEM", 620, 659], ["particle filters", "OBSERVATION", 30, 46], ["infectious", "OBSERVATION", 230, 240], ["air ventilation", "OBSERVATION", 638, 653]]], ["To address these questions, this article describes and applies a methodology for estimating the impact of recirculating HVAC filters on the control of size-resolved infectious aerosols in indoor environments using a modified version of the Wells-Riley model for predicting risks of airborne infectious disease transmission.", [["infectious disease transmission", "DISEASE", 291, 322], ["recirculating HVAC filters", "TREATMENT", 106, 132], ["a modified version of the Wells-Riley model", "TREATMENT", 214, 257], ["airborne infectious disease transmission", "PROBLEM", 282, 322], ["size", "OBSERVATION_MODIFIER", 151, 155], ["infectious", "OBSERVATION_MODIFIER", 165, 175], ["airborne infectious", "OBSERVATION", 282, 301]]], ["Estimates of likely risk reductions and associated operational costs of both HVAC filtration and equivalent outdoor air ventilation are modeled and compared using a case study of airborne transmission of influenza in a hypothetical office space in multiple climates.Estimating risks of airborne disease transmissionAerosol transmission has been shown to be a predominant route of transmission for a number of communicable diseases, including rhinovirus [7, 13] , influenza [14e16], tuberculosis [17] , and SARS [18] .", [["influenza", "DISEASE", 204, 213], ["airborne disease transmission", "DISEASE", 286, 315], ["communicable diseases", "DISEASE", 409, 430], ["rhinovirus", "DISEASE", 442, 452], ["influenza", "DISEASE", 463, 472], ["tuberculosis", "DISEASE", 482, 494], ["SARS", "DISEASE", 506, 510], ["rhinovirus", "ORGANISM", 442, 452], ["risk reductions", "PROBLEM", 20, 35], ["both HVAC filtration", "TREATMENT", 72, 92], ["outdoor air ventilation", "TREATMENT", 108, 131], ["a case study", "TEST", 163, 175], ["influenza", "PROBLEM", 204, 213], ["airborne disease transmission", "PROBLEM", 286, 315], ["Aerosol transmission", "TREATMENT", 315, 335], ["communicable diseases", "PROBLEM", 409, 430], ["rhinovirus", "PROBLEM", 442, 452], ["influenza", "PROBLEM", 463, 472], ["tuberculosis", "PROBLEM", 482, 494], ["likely", "UNCERTAINTY", 13, 19], ["risk", "OBSERVATION_MODIFIER", 20, 24], ["reductions", "OBSERVATION_MODIFIER", 25, 35], ["both", "ANATOMY_MODIFIER", 72, 76], ["HVAC", "ANATOMY", 77, 81], ["equivalent", "OBSERVATION_MODIFIER", 97, 107], ["outdoor", "OBSERVATION_MODIFIER", 108, 115], ["air ventilation", "OBSERVATION", 116, 131], ["influenza", "OBSERVATION", 204, 213], ["airborne disease", "OBSERVATION", 286, 302]]], ["There is also growing empirical evidence that increased outdoor air ventilation rates in buildings can reduce the transmission of some of these same diseases [19] , which further confirms the likely importance of airborne transmission via infectious aerosols in indoor environments.", [["increased outdoor air ventilation rates", "PROBLEM", 46, 85], ["these same diseases", "PROBLEM", 138, 157], ["growing", "OBSERVATION_MODIFIER", 14, 21], ["increased", "OBSERVATION_MODIFIER", 46, 55], ["outdoor", "OBSERVATION_MODIFIER", 56, 63], ["air ventilation", "OBSERVATION", 64, 79]]], ["One often-used approach to estimating the risks associated with airborne transmission of respiratory diseases is the Wells-Riley model, as shown in Equation (1) [20] .Estimating risks of airborne disease transmissionwhere P infection \u00bc the probability of infection; cases \u00bc the number of infection cases; susceptibles \u00bc number of susceptible individuals; I \u00bc number of infector individuals; p \u00bc pulmonary ventilation rate of a person (m 3 /hour); q \u00bc quanta generation rate (1/hr); t \u00bc exposure time (hr); and Q oa \u00bc room ventilation rate with pathogen-free air (m 3 /hour).Estimating risks of airborne disease transmissionThe Wells-Riley model is based on a concept of \"quantum of infection,\" whereby the rate of generation of infectious airborne particles (or quanta) can be used to model the likelihood of an individual in a steady-state well-mixed indoor environment being exposed to the infectious particles and subsequently succumbing to infection.", [["pulmonary", "ANATOMY", 395, 404], ["respiratory diseases", "DISEASE", 89, 109], ["infection", "DISEASE", 224, 233], ["infection", "DISEASE", 255, 264], ["infection", "DISEASE", 288, 297], ["infection", "DISEASE", 682, 691], ["infection", "DISEASE", 944, 953], ["pulmonary", "ORGAN", 395, 404], ["person", "SPECIES", 427, 433], ["respiratory diseases", "PROBLEM", 89, 109], ["airborne disease transmissionwhere", "PROBLEM", 187, 221], ["infection", "PROBLEM", 224, 233], ["infection", "PROBLEM", 255, 264], ["infection cases", "PROBLEM", 288, 303], ["pulmonary ventilation rate", "TREATMENT", 395, 421], ["airborne disease transmission", "PROBLEM", 594, 623], ["\"quantum of infection", "PROBLEM", 670, 691], ["infectious airborne particles", "TREATMENT", 728, 757], ["the infectious particles", "PROBLEM", 888, 912], ["infection", "PROBLEM", 944, 953], ["respiratory diseases", "OBSERVATION", 89, 109], ["airborne disease", "OBSERVATION", 187, 203], ["infection", "OBSERVATION", 255, 264], ["pulmonary", "ANATOMY", 395, 404], ["airborne disease", "OBSERVATION", 594, 610], ["infection", "OBSERVATION", 682, 691], ["infectious", "OBSERVATION", 892, 902], ["infection", "OBSERVATION", 944, 953]]], ["Note that some researchers have also expanded this model to include time-varying exposures [21] and others have developed zonal versions that account for incomplete mixing in an indoor environment [22] .Estimating risks of airborne disease transmissionThe quantum of infection term (q) in this risk model is not an actual physical unit; it is a hypothetical infectious dose unit that is typically back calculated from observational epidemiological studies.", [["airborne disease transmission", "DISEASE", 223, 252], ["infection", "DISEASE", 267, 276], ["zonal versions", "TREATMENT", 122, 136], ["airborne disease transmission", "PROBLEM", 223, 252], ["infection term", "PROBLEM", 267, 281], ["observational epidemiological studies", "TEST", 418, 455], ["airborne disease", "OBSERVATION", 223, 239], ["infection", "OBSERVATION", 267, 276], ["infectious", "OBSERVATION", 358, 368]]], ["Conceptually, it describes the number of infectious particles in a way that implicitly accounts for both the amount of particles generated over time and the infectivity of particles, which also inherently captures susceptibility of individuals and particle size effects such as the probability of deposition in relevant regions of the respiratory system.", [["respiratory system", "ANATOMY", 335, 353], ["infectious particles", "PROBLEM", 41, 61], ["the infectivity of particles", "PROBLEM", 153, 181], ["particle size effects", "PROBLEM", 248, 269], ["infectious", "OBSERVATION", 41, 51], ["amount", "OBSERVATION_MODIFIER", 109, 115], ["particles", "OBSERVATION", 119, 128], ["infectivity", "OBSERVATION_MODIFIER", 157, 168], ["particles", "OBSERVATION_MODIFIER", 172, 181], ["particle", "OBSERVATION_MODIFIER", 248, 256], ["size", "OBSERVATION_MODIFIER", 257, 261], ["deposition", "OBSERVATION", 297, 307], ["respiratory system", "ANATOMY", 335, 353]]], ["Because of the empirical nature of the model in Equation (1), existing literature on quanta generation rates (q) is relatively limited.", [["quanta generation rates", "TEST", 85, 108]]], ["Published ranges of q for several infectious airborne diseases are shown in Table 1 .Estimating risks of airborne disease transmissionIt is also important to note the assumption of well-mixed indoor environments in this model and in previous derivations of quanta generation rates.", [["airborne diseases", "DISEASE", 45, 62], ["airborne disease transmission", "DISEASE", 105, 134], ["several infectious airborne diseases", "PROBLEM", 26, 62], ["airborne disease transmission", "PROBLEM", 105, 134], ["quanta generation rates", "TREATMENT", 257, 280], ["airborne disease", "OBSERVATION", 105, 121]]], ["Because of this assumption, the model cannot distinguish between long-range transport of smaller infectious aerosols (i.e., droplet nuclei) and close-contact airborne spread of infectious diseases that occurs when expelled infectious aerosols deposit directly on susceptible parts of the human body (i.e., large droplets).", [["droplet nuclei", "ANATOMY", 124, 138], ["body", "ANATOMY", 294, 298], ["infectious diseases", "DISEASE", 177, 196], ["human", "ORGANISM", 288, 293], ["body", "ORGANISM_SUBDIVISION", 294, 298], ["human", "SPECIES", 288, 293], ["human", "SPECIES", 288, 293], ["smaller infectious aerosols", "PROBLEM", 89, 116], ["infectious diseases", "PROBLEM", 177, 196], ["expelled infectious aerosols deposit", "PROBLEM", 214, 250], ["smaller", "OBSERVATION_MODIFIER", 89, 96], ["infectious aerosols", "OBSERVATION", 97, 116], ["infectious", "OBSERVATION", 177, 187], ["infectious", "OBSERVATION_MODIFIER", 223, 233], ["aerosols deposit", "OBSERVATION", 234, 250], ["human body", "ANATOMY_MODIFIER", 288, 298], ["large", "OBSERVATION_MODIFIER", 306, 311], ["droplets", "OBSERVATION", 312, 320]]], ["However, quanta generation rates are usually back calculated from scenarios where long-range transport was very likely a major factor.", [["quanta generation rates", "TEST", 9, 32]]], ["For example, Rudnick and Milton (2003) estimated quanta generation rates of 15e128 per hour for influenza (depending on steady-state or dynamic assumptions) using data from a grounded passenger airplane where the majority of passengers throughout the airplane acquired the influenza virus from one infected individual [23] .", [["influenza", "DISEASE", 96, 105], ["influenza virus from one infected", "DISEASE", 273, 306], ["influenza virus", "ORGANISM", 273, 288], ["quanta generation rates", "TEST", 49, 72], ["influenza", "PROBLEM", 96, 105], ["the influenza virus", "PROBLEM", 269, 288]]], ["While the quanta generation rates in this case may have accounted for some close-range transport, it is reasonable to assume that many passengers would also have been infected by longer-range aerosol transport.Estimating risks of airborne disease transmissionDespite some of these limitations, the Wells-Riley model has been used previously to show that some building factors, particularly outdoor air ventilation rates, can be an important removal mechanism for airborne infectious agents [17, 30, 31] .", [["airborne disease", "DISEASE", 230, 246], ["airborne disease transmission", "PROBLEM", 230, 259], ["an important removal mechanism", "TREATMENT", 428, 458], ["airborne disease", "OBSERVATION", 230, 246]]], ["Because the removal mechanisms of any aerosol (including HVAC filtration) are primarily functions of particle size [32, 33] , it is important to consider the actual particle size distributions of infectious aerosols in indoor environments for use with this model.", [["the removal", "TREATMENT", 8, 19], ["any aerosol (including HVAC filtration", "TREATMENT", 34, 72], ["this model", "TREATMENT", 252, 262], ["particle", "OBSERVATION_MODIFIER", 101, 109], ["size", "OBSERVATION_MODIFIER", 110, 114], ["size", "OBSERVATION_MODIFIER", 174, 178], ["infectious aerosols", "OBSERVATION", 196, 215]]], ["Although the original Wells-Riley model does not explicitly account for the sizeresolved nature of infectious aerosols, modifications have been made by others to do so [4, 34, 35] .", [["infectious aerosols", "TREATMENT", 99, 118], ["infectious", "OBSERVATION", 99, 109]]], ["Therefore, the next sections describe previous efforts to integrate other size-dependent loss terms into the Wells-Riley equation and then review existing knowledge of particle size distributions of infectious aerosols to inform the modeling effort herein.", [["dependent loss terms", "PROBLEM", 79, 99], ["infectious aerosols", "TREATMENT", 199, 218], ["dependent", "OBSERVATION_MODIFIER", 79, 88], ["loss", "OBSERVATION", 89, 93], ["particle", "OBSERVATION_MODIFIER", 168, 176], ["size", "OBSERVATION_MODIFIER", 177, 181], ["infectious aerosols", "OBSERVATION", 199, 218]]], ["Infectious particle size distributions are explored with the specific intent of generalizing for use with the particle size range relevant to a common HVAC filtration standard: ASHRAE Standard 52.2 [36] .Incorporating size-dependent loss terms into the Wells-Riley equationFrom a mass balance perspective, HVAC filtration and other removal mechanisms are treated similarly to outdoor air ventilation because they both can be used to reduce indoor concentrations of airborne infectious particles.", [["Infectious particle size distributions", "PROBLEM", 0, 38], ["dependent loss terms", "PROBLEM", 223, 243], ["a mass balance perspective", "TREATMENT", 278, 304], ["HVAC filtration", "TREATMENT", 306, 321], ["other removal mechanisms", "TREATMENT", 326, 350], ["outdoor air ventilation", "TREATMENT", 376, 399], ["airborne infectious particles", "PROBLEM", 465, 494], ["size", "OBSERVATION_MODIFIER", 20, 24], ["size", "OBSERVATION_MODIFIER", 218, 222], ["dependent", "OBSERVATION_MODIFIER", 223, 232], ["loss", "OBSERVATION", 233, 237], ["mass", "OBSERVATION", 280, 284]]], ["In fact, the steady-state Wells-Riley equation has previously been modified in other investigations to include additional removal terms other than outdoor air ventilation, including filtration by personal respirators, UV degradation, particle deposition, and HVAC particle filtration [3, 4, 10, 31] .", [["additional removal terms", "TREATMENT", 111, 135], ["outdoor air ventilation", "TREATMENT", 147, 170], ["filtration", "TREATMENT", 182, 192], ["personal respirators", "TREATMENT", 196, 216], ["UV degradation", "TREATMENT", 218, 232], ["particle deposition", "TREATMENT", 234, 253], ["HVAC particle filtration", "TREATMENT", 259, 283]]], ["Equation (2) follows the same procedures by including both HVAC filtration and deposition loss terms.Incorporating size-dependent loss terms into the Wells-Riley equationwhere V \u00bc indoor air volume (m 3 ); l ventilation \u00bc outdoor air ventilation rate (Q oa /V, 1/hr); k filtration \u00bc infectious particle removal rate due to filtration (1/hr); and k deposition \u00bc infectious particle deposition rate (1/hr).", [["both HVAC filtration", "TREATMENT", 54, 74], ["deposition loss terms", "PROBLEM", 79, 100], ["dependent loss terms", "PROBLEM", 120, 140], ["the Wells", "TEST", 146, 155], ["indoor air volume", "TEST", 180, 197], ["l ventilation", "TREATMENT", 206, 219], ["k filtration", "TREATMENT", 268, 280], ["infectious particle removal rate", "TREATMENT", 283, 315], ["filtration", "TREATMENT", 323, 333], ["k deposition", "TREATMENT", 346, 358], ["infectious particle deposition rate", "TREATMENT", 361, 396], ["deposition loss", "OBSERVATION", 79, 94], ["size", "OBSERVATION_MODIFIER", 115, 119], ["dependent", "OBSERVATION_MODIFIER", 120, 129], ["loss", "OBSERVATION", 130, 134], ["infectious", "OBSERVATION", 361, 371]]], ["Deposition removal rates (k deposition ) depend primarily on particle size, density, and room characteristics such as airspeeds and surface areas [35, 37] .", [["surface", "ANATOMY", 132, 139], ["Deposition removal rates (k deposition )", "TREATMENT", 0, 40], ["particle size", "OBSERVATION_MODIFIER", 61, 74], ["density", "OBSERVATION", 76, 83], ["surface", "OBSERVATION_MODIFIER", 132, 139]]], ["Filtration removal rates (k filtration ) depend on the rate of airflow through the HVAC filter (Q filter ), the fractional operation time of the HVAC system (f HVAC ), and the size-resolved infectious particle removal efficiency of the filter or air-cleaning device installed (h filter ) as shown in Equation (3).", [["Filtration removal rates (k filtration", "TREATMENT", 0, 38], ["the HVAC filter (Q filter", "TREATMENT", 79, 104], ["the fractional operation", "TREATMENT", 108, 132], ["the HVAC system", "TREATMENT", 141, 156], ["infectious particle removal", "TREATMENT", 190, 217], ["the filter", "TREATMENT", 232, 242], ["air-cleaning device", "TREATMENT", 246, 265], ["size", "OBSERVATION_MODIFIER", 176, 180], ["resolved", "OBSERVATION_MODIFIER", 181, 189], ["infectious", "OBSERVATION_MODIFIER", 190, 200], ["particle removal", "OBSERVATION", 201, 217], ["filter", "OBSERVATION", 236, 242]]], ["The airflow rate through the filter divided by the volume of the indoor air space served and multiplied by fractional operation time is also called the recirculation rate (l recirculated ).Incorporating size-dependent loss terms into the Wells-Riley equationwhere f HVAC \u00bc fractional HVAC operation time (\u00c0); Q filter \u00bc airflow rate through filter (m 3 /hr); h filter \u00bc particle removal efficiency of the filter (\u00c0); and l recirculated \u00bc recirculation rate through the HVAC filter (1/hr).", [["The airflow rate", "TREATMENT", 0, 16], ["the filter", "TREATMENT", 25, 35], ["the recirculation rate", "TEST", 148, 170], ["dependent loss terms", "PROBLEM", 208, 228], ["HVAC", "TREATMENT", 266, 270], ["fractional HVAC operation", "TREATMENT", 273, 298], ["Q filter \u00bc airflow rate through filter", "TREATMENT", 309, 347], ["h filter \u00bc particle removal", "TREATMENT", 359, 386], ["the filter", "TREATMENT", 401, 411], ["l recirculated \u00bc recirculation rate", "TREATMENT", 421, 456], ["the HVAC filter", "TREATMENT", 465, 480], ["airflow", "OBSERVATION", 4, 11], ["filter", "OBSERVATION", 29, 35], ["volume", "OBSERVATION_MODIFIER", 51, 57], ["indoor", "OBSERVATION", 65, 71], ["air space", "OBSERVATION", 72, 81], ["size", "OBSERVATION_MODIFIER", 203, 207], ["dependent", "OBSERVATION_MODIFIER", 208, 217], ["loss", "OBSERVATION", 218, 222], ["filter", "OBSERVATION", 405, 411]]], ["Depending on the nature of the virus or bacteria of concern inside of expelled droplets or droplet nuclei, some rate of inactivation may also occur as aerosols are exposed to indoor air [34] .", [["droplet nuclei", "ANATOMY", 91, 105], ["droplet nuclei", "CELLULAR_COMPONENT", 91, 105], ["the virus", "PROBLEM", 27, 36], ["bacteria", "PROBLEM", 40, 48], ["expelled droplets", "PROBLEM", 70, 87], ["droplet nuclei", "PROBLEM", 91, 105], ["droplet nuclei", "OBSERVATION", 91, 105]]], ["This rate has been explored for some viruses [38, 39] and is dependent in part on environmental conditions such as relative humidity.", [["This rate", "TEST", 0, 9], ["some viruses", "PROBLEM", 32, 44]]], ["However, we have excluded this loss rate in this work in [20] part because of a lack of existing data on size-resolved inactivation rates for multiple infectious aerosols of concern and in part because quanta generation rates, when back calculated using Equation (1), should inherently account for any inactivation that occurred during the case study period.", [["this loss rate", "PROBLEM", 26, 40], ["inactivation rates", "PROBLEM", 119, 137], ["multiple infectious aerosols", "PROBLEM", 142, 170], ["quanta generation rates", "TEST", 202, 225], ["any inactivation", "PROBLEM", 298, 314], ["infectious", "OBSERVATION_MODIFIER", 151, 161]]], ["Additionally, although Equations 2 and 3 are shown without explicitly considering particle size effects, both the filtration and deposition loss parameters (k deposition and k filtration ) are size-dependent.", [["Equations", "TEST", 23, 32], ["particle size effects", "PROBLEM", 82, 103], ["the filtration", "TREATMENT", 110, 124], ["deposition loss parameters", "PROBLEM", 129, 155], ["k deposition and k filtration", "TREATMENT", 157, 186], ["size", "OBSERVATION_MODIFIER", 91, 95], ["deposition loss", "OBSERVATION", 129, 144], ["size", "OBSERVATION_MODIFIER", 193, 197], ["dependent", "OBSERVATION_MODIFIER", 198, 207]]], ["Therefore, the following sections describe existing knowledge of the particle size distributions of infectious aerosols.Particle size distributions of infectious aerosolsWhen an individual coughs, sneezes, speaks, or breathes, droplets consisting of liquid water, proteins, salts, and various other organic and inorganic matter are expelled into the air.", [["salts", "CHEMICAL", 274, 279], ["salts", "SIMPLE_CHEMICAL", 274, 279], ["infectious aerosols", "PROBLEM", 100, 119], ["infectious aerosols", "PROBLEM", 151, 170], ["an individual coughs", "PROBLEM", 175, 195], ["salts", "TREATMENT", 274, 279], ["various other organic and inorganic matter", "TREATMENT", 285, 327], ["particle", "OBSERVATION_MODIFIER", 69, 77], ["size", "OBSERVATION_MODIFIER", 78, 82], ["infectious aerosols", "OBSERVATION", 100, 119], ["size", "OBSERVATION_MODIFIER", 129, 133], ["distributions", "OBSERVATION_MODIFIER", 134, 147], ["infectious aerosols", "OBSERVATION", 151, 170], ["inorganic matter", "OBSERVATION", 311, 327], ["air", "ANATOMY", 350, 353]]], ["If the emitter is infected with a particular respiratory infection, those droplets may also contain smaller infectious particles themselves, which may be viruses or bacteria depending on the type of infection.", [["respiratory infection", "DISEASE", 45, 66], ["infection", "DISEASE", 199, 208], ["a particular respiratory infection", "PROBLEM", 32, 66], ["those droplets", "PROBLEM", 68, 82], ["smaller infectious particles themselves", "PROBLEM", 100, 139], ["viruses", "PROBLEM", 154, 161], ["bacteria", "PROBLEM", 165, 173], ["infection", "PROBLEM", 199, 208], ["infected", "OBSERVATION_MODIFIER", 18, 26], ["infection", "OBSERVATION", 57, 66], ["smaller", "OBSERVATION_MODIFIER", 100, 107], ["infectious", "OBSERVATION", 108, 118], ["may be", "UNCERTAINTY", 147, 153], ["viruses", "OBSERVATION", 154, 161], ["bacteria", "OBSERVATION", 165, 173], ["infection", "OBSERVATION", 199, 208]]], ["Viruses are typically an order of magnitude or more smaller in size than bacteria: w20e200 nm for viruses vs. w0.2e5 mm for most bacteria [40] .", [["Viruses", "PROBLEM", 0, 7], ["viruses", "PROBLEM", 98, 105], ["most bacteria", "PROBLEM", 124, 137], ["smaller", "OBSERVATION_MODIFIER", 52, 59], ["size", "OBSERVATION_MODIFIER", 63, 67]]], ["In other explorations of the impacts of particle filtration and other size-dependent processes on virus and bacteria disease transmission, some researchers have assumed that the individual virus or bacteria particles are aerosolized and exist suspended as individual organisms [11, 41] ; however, it is likely more appropriate to consider the particles as larger expelled droplets that contain aggregates of the smaller infectious particles within Refs.", [["particle filtration", "TREATMENT", 40, 59], ["other size-dependent processes", "PROBLEM", 64, 94], ["virus", "PROBLEM", 98, 103], ["bacteria disease transmission", "PROBLEM", 108, 137], ["the individual virus", "PROBLEM", 174, 194], ["bacteria particles", "PROBLEM", 198, 216], ["larger expelled droplets", "PROBLEM", 356, 380], ["the smaller infectious particles", "PROBLEM", 408, 440], ["particle filtration", "OBSERVATION", 40, 59], ["size", "OBSERVATION_MODIFIER", 70, 74], ["dependent", "OBSERVATION_MODIFIER", 75, 84], ["processes", "OBSERVATION", 85, 94], ["bacteria disease", "OBSERVATION", 108, 124], ["aggregates", "OBSERVATION_MODIFIER", 394, 404], ["smaller", "OBSERVATION_MODIFIER", 412, 419], ["infectious particles", "OBSERVATION", 420, 440]]], ["[8, 35, 42, 43] .Particle size distributions of infectious aerosolsOnce expelled from a high relative humidity environment (the human body) to a relatively less humid environment (most indoor environments), droplets rapidly decrease in size as the surrounding liquid evaporates.", [["body", "ANATOMY", 134, 138], ["human", "ORGANISM", 128, 133], ["body", "ORGANISM_SUBDIVISION", 134, 138], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["infectious aerosols", "PROBLEM", 48, 67], ["a high relative humidity environment", "TREATMENT", 86, 122], ["size", "OBSERVATION_MODIFIER", 26, 30], ["distributions", "OBSERVATION_MODIFIER", 31, 44], ["infectious aerosols", "OBSERVATION", 48, 67], ["decrease", "OBSERVATION_MODIFIER", 224, 232], ["size", "OBSERVATION_MODIFIER", 236, 240]]], ["Several studies have shown that this liquid evaporation typically occurs within less than 1 s of emission for particles smaller than w50 mm in diameter [44] .", [["Several studies", "TEST", 0, 15], ["this liquid evaporation", "TREATMENT", 32, 55], ["smaller", "OBSERVATION_MODIFIER", 120, 127]]], ["After rapid evaporation, droplet nuclei containing the mix of solid particles (including any infectious particles) remain.", [["droplet nuclei", "ANATOMY", 25, 39], ["rapid evaporation", "TREATMENT", 6, 23], ["solid particles", "PROBLEM", 62, 77], ["any infectious particles", "PROBLEM", 89, 113], ["droplet nuclei", "OBSERVATION", 25, 39], ["solid particles", "OBSERVATION", 62, 77], ["infectious", "OBSERVATION_MODIFIER", 93, 103]]], ["Droplet nuclei typically have particle diameters that are 40e50% of the original droplet size [35, 39] .Particle size distributions of infectious aerosolsIt is commonly believed that droplet nuclei particles average 1e 3 mm in diameter [42] , although several recent studies have shown considerable variation in the size distribution of expelled droplets and droplet nuclei.", [["nuclei", "ANATOMY", 8, 14], ["droplet nuclei", "ANATOMY", 359, 373], ["droplet nuclei", "CELLULAR_COMPONENT", 359, 373], ["Droplet nuclei", "TEST", 0, 14], ["particle diameters", "TEST", 30, 48], ["the original droplet size", "TEST", 68, 93], ["infectious aerosols", "PROBLEM", 135, 154], ["droplet nuclei particles", "PROBLEM", 183, 207], ["several recent studies", "TEST", 252, 274], ["particle", "OBSERVATION_MODIFIER", 30, 38], ["diameters", "OBSERVATION_MODIFIER", 39, 48], ["droplet", "OBSERVATION_MODIFIER", 81, 88], ["size", "OBSERVATION_MODIFIER", 89, 93], ["size", "OBSERVATION_MODIFIER", 113, 117], ["distributions", "OBSERVATION_MODIFIER", 118, 131], ["infectious aerosols", "OBSERVATION", 135, 154], ["droplet nuclei", "OBSERVATION", 183, 197], ["considerable", "OBSERVATION_MODIFIER", 286, 298], ["variation", "OBSERVATION_MODIFIER", 299, 308], ["size", "OBSERVATION_MODIFIER", 316, 320], ["expelled droplets", "OBSERVATION", 337, 354], ["droplet nuclei", "OBSERVATION", 359, 373]]], ["Nicas et al. [35] summarized nearly 50 years of measurements of particle size distributions of droplets emitted by humans during coughing and sneezing and reported that coughgenerated aerosols could be divided into two lognormally distributed modes: (i) a small particle size distribution with a geometric mean diameter of w10 mm (ii) a large particle size distribution with a geometric mean diameter of w160 mm.", [["coughing", "DISEASE", 129, 137], ["humans", "ORGANISM", 115, 121], ["humans", "SPECIES", 115, 121], ["humans", "SPECIES", 115, 121], ["coughing", "PROBLEM", 129, 137], ["sneezing", "PROBLEM", 142, 150], ["coughgenerated aerosols", "PROBLEM", 169, 192], ["a small particle size distribution", "PROBLEM", 254, 288], ["a large particle size distribution", "PROBLEM", 335, 369], ["particle size", "OBSERVATION_MODIFIER", 64, 77], ["droplets emitted", "OBSERVATION", 95, 111], ["small", "OBSERVATION_MODIFIER", 256, 261], ["particle", "OBSERVATION_MODIFIER", 262, 270], ["size", "OBSERVATION_MODIFIER", 271, 275], ["geometric", "OBSERVATION_MODIFIER", 296, 305], ["mean diameter", "OBSERVATION_MODIFIER", 306, 319], ["10 mm", "OBSERVATION_MODIFIER", 324, 329], ["large", "OBSERVATION_MODIFIER", 337, 342], ["particle", "OBSERVATION_MODIFIER", 343, 351], ["size", "OBSERVATION_MODIFIER", 352, 356], ["distribution", "OBSERVATION_MODIFIER", 357, 369], ["geometric", "OBSERVATION_MODIFIER", 377, 386], ["mean", "OBSERVATION_MODIFIER", 387, 391], ["diameter", "OBSERVATION_MODIFIER", 392, 400], ["160 mm", "OBSERVATION_MODIFIER", 405, 411]]], ["However, the smaller particle size distribution was found to contain the majority of cough particles (w70%).", [["cough", "DISEASE", 85, 90], ["the smaller particle size distribution", "PROBLEM", 9, 47], ["cough particles", "PROBLEM", 85, 100], ["smaller", "OBSERVATION_MODIFIER", 13, 20], ["particle", "OBSERVATION_MODIFIER", 21, 29], ["size", "OBSERVATION_MODIFIER", 30, 34], ["distribution", "OBSERVATION_MODIFIER", 35, 47], ["majority", "OBSERVATION_MODIFIER", 73, 81], ["cough", "OBSERVATION", 85, 90]]], ["Given that the same authors described some evidence of smaller particles being more infectious than largerParticle size distributions of infectious aerosolsparticles, it appears that smaller (i.e., <10 mm) particles are likely of greatest concern for droplet nuclei transmission of infectious diseases.", [["droplet nuclei", "ANATOMY", 251, 265], ["infectious diseases", "DISEASE", 282, 301], ["smaller particles", "PROBLEM", 55, 72], ["infectious aerosolsparticles", "PROBLEM", 137, 165], ["smaller (i.e., <10 mm) particles", "PROBLEM", 183, 215], ["infectious diseases", "PROBLEM", 282, 301], ["some evidence of", "UNCERTAINTY", 38, 54], ["smaller", "OBSERVATION_MODIFIER", 55, 62], ["particles", "OBSERVATION", 63, 72], ["more", "OBSERVATION_MODIFIER", 79, 83], ["infectious", "OBSERVATION", 84, 94], ["size", "OBSERVATION_MODIFIER", 115, 119], ["distributions", "OBSERVATION_MODIFIER", 120, 133], ["infectious aerosolsparticles", "OBSERVATION", 137, 165], ["smaller", "OBSERVATION_MODIFIER", 183, 190], ["likely of", "UNCERTAINTY", 220, 229], ["greatest", "OBSERVATION_MODIFIER", 230, 238], ["droplet nuclei", "OBSERVATION", 251, 265], ["infectious", "OBSERVATION", 282, 292]]], ["Several more recent studies utilizing more advanced measurement techniques have revealed a general consensus that the majority (often 80e90%) of particles expelled during various human activities are actually smaller than 1e2 mm in diameter [45e 50], although it is not clear whether actual virus content scales more with particle number, surface area, or volume distributions.Infectious particles within droplet nucleiWhile previous studies have been helpful for identifying the size of particles expelled during human activities, several more recent studies have utilized more sophisticated techniques (e.g., quantitative polymerase chain reaction, or q-PCR) to identify the presence of viruses or bacteria in expelled droplets and droplet nuclei collected on multi-stage bioaerosol samplers [46,51e55] .", [["surface area", "ANATOMY", 339, 351], ["droplets", "ANATOMY", 721, 729], ["droplet nuclei", "ANATOMY", 734, 748], ["human", "ORGANISM", 179, 184], ["human", "ORGANISM", 514, 519], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 514, 519], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 514, 519], ["advanced measurement techniques", "TEST", 43, 74], ["actual virus content scales", "PROBLEM", 284, 311], ["Infectious particles", "PROBLEM", 377, 397], ["previous studies", "TEST", 425, 441], ["quantitative polymerase chain reaction", "PROBLEM", 611, 649], ["q-PCR", "TEST", 654, 659], ["viruses", "PROBLEM", 689, 696], ["bacteria in expelled droplets", "PROBLEM", 700, 729], ["droplet nuclei", "PROBLEM", 734, 748], ["multi-stage bioaerosol samplers", "TREATMENT", 762, 793], ["smaller", "OBSERVATION_MODIFIER", 209, 216], ["virus", "OBSERVATION", 291, 296], ["surface", "OBSERVATION_MODIFIER", 339, 346], ["area", "OBSERVATION_MODIFIER", 347, 351], ["volume distributions", "OBSERVATION", 356, 376], ["size", "OBSERVATION_MODIFIER", 480, 484], ["particles", "OBSERVATION", 488, 497], ["viruses", "OBSERVATION", 689, 696], ["bacteria", "OBSERVATION", 700, 708], ["expelled droplets", "OBSERVATION", 712, 729], ["droplet nuclei", "OBSERVATION", 734, 748]]], ["These studies offer insight not only into what size aerosols exist after expulsion from the human body, but in what size-fractions are viruses or bacteria actually present and are thus of most concern for infectious disease transmission.", [["body", "ANATOMY", 98, 102], ["infectious disease transmission", "DISEASE", 205, 236], ["human", "ORGANISM", 92, 97], ["body", "ORGANISM_SUBDIVISION", 98, 102], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["These studies", "TEST", 0, 13], ["expulsion from the human body", "PROBLEM", 73, 102], ["viruses", "PROBLEM", 135, 142], ["bacteria", "PROBLEM", 146, 154], ["infectious disease transmission", "PROBLEM", 205, 236], ["human body", "ANATOMY", 92, 102], ["viruses", "OBSERVATION", 135, 142], ["most concern for", "UNCERTAINTY", 188, 204], ["infectious", "OBSERVATION", 205, 215]]], ["Several of these recent studies have focused on the particle size distributions of influenza in indoor and personal airborne particulate matter in indoor environments, as summarized in Table 2 .Infectious particles within droplet nucleiIn these recent investigations, the amount of influenza virus content in a range of particle sizes was quantified using a variety of bioaerosol samplers installed in a variety of locations and indoor environments.", [["influenza", "DISEASE", 83, 92], ["influenza virus", "ORGANISM", 282, 297], ["these recent studies", "TEST", 11, 31], ["influenza", "PROBLEM", 83, 92], ["Infectious particles", "PROBLEM", 194, 214], ["influenza virus content", "PROBLEM", 282, 305], ["bioaerosol samplers", "TREATMENT", 369, 388], ["particle size", "OBSERVATION_MODIFIER", 52, 65], ["influenza", "OBSERVATION", 83, 92], ["amount", "OBSERVATION_MODIFIER", 272, 278], ["influenza virus content", "OBSERVATION", 282, 305]]], ["Sampling environments included healthcare centers, daycare centers, hospital emergency rooms, simulated patient rooms, and in the coughing/breathing zone of both people and manikins.", [["patient", "ORGANISM", 104, 111], ["people", "ORGANISM", 162, 168], ["patient", "SPECIES", 104, 111], ["people", "SPECIES", 162, 168]]], ["Sampling locations within each environment included both stationary indoor measurements and personal measurements.", [["personal measurements", "TEST", 92, 113]]], ["Importantly, the variety of aerosol samplers used also varied in their particle size cut-off points.", [["aerosol samplers", "TREATMENT", 28, 44], ["variety", "OBSERVATION_MODIFIER", 17, 24], ["particle", "OBSERVATION_MODIFIER", 71, 79], ["size", "OBSERVATION_MODIFIER", 80, 84]]], ["However, each study characterized Fortunately for this work, the size bins from the selected studies aligned relatively closely to the three size bins outlined in the most commonly used HVAC filtration standard in the U.S., ASHRAE Standard 52.2, which classifies filtration efficiency in bins of 0.3e 1 mm, 1e3 mm, and 3e10 mm [36] .", [["each study", "TEST", 9, 19], ["the selected studies", "TEST", 80, 100], ["size", "OBSERVATION_MODIFIER", 141, 145], ["filtration", "OBSERVATION_MODIFIER", 263, 273], ["efficiency", "OBSERVATION_MODIFIER", 274, 284]]], ["Therefore, we adjusted each of the reported size distributions in Table 2 to fit within those three particle size ranges by assuming that the virus content has a uniform distribution in each particle size bin.", [["the virus content", "PROBLEM", 138, 155], ["size", "OBSERVATION_MODIFIER", 44, 48], ["distributions", "OBSERVATION_MODIFIER", 49, 62], ["particle", "OBSERVATION_MODIFIER", 100, 108], ["size", "OBSERVATION_MODIFIER", 109, 113], ["virus content", "OBSERVATION", 142, 155], ["uniform", "OBSERVATION_MODIFIER", 162, 169], ["distribution", "OBSERVATION_MODIFIER", 170, 182], ["particle", "OBSERVATION_MODIFIER", 191, 199], ["size", "OBSERVATION_MODIFIER", 200, 204]]], ["These assumed distributions are shown in the rightmost columns in Table 2 .", [["distributions", "OBSERVATION_MODIFIER", 14, 27]]], ["We do however explore uncertainty in a later section using both the mean and relative standard deviations of the assumed viral size distributions, as summarized in the bottom of Table 2 , which can place likely bounds on risk estimates made using Equation (2).Infectious particles within droplet nucleiOn average across all of these studies, we estimate that approximately 20% of influenza virus content is associated with particles in the 0.3e1 mm size range in these recent studies; 29% is associated with the 1e3 mm size range, and 51% is associated with the 3e10 mm size range.", [["influenza", "DISEASE", 380, 389], ["influenza virus", "ORGANISM", 380, 395], ["a later section", "TREATMENT", 37, 52], ["Infectious particles", "PROBLEM", 260, 280], ["these studies", "TEST", 327, 340], ["influenza virus content", "PROBLEM", 380, 403], ["these recent studies", "TEST", 463, 483], ["standard deviations", "OBSERVATION", 86, 105], ["viral", "OBSERVATION_MODIFIER", 121, 126], ["size", "OBSERVATION_MODIFIER", 127, 131], ["distributions", "OBSERVATION_MODIFIER", 132, 145], ["droplet nucleiOn", "OBSERVATION", 288, 304], ["influenza virus", "OBSERVATION", 380, 395], ["e1 mm", "OBSERVATION_MODIFIER", 443, 448], ["size", "OBSERVATION_MODIFIER", 449, 453], ["1e3 mm", "OBSERVATION_MODIFIER", 512, 518], ["size", "OBSERVATION_MODIFIER", 519, 523], ["3e10 mm", "OBSERVATION_MODIFIER", 562, 569], ["size", "OBSERVATION_MODIFIER", 570, 574]]], ["The smallest size range has the highest relative standard deviation from that mean (70%), followed by the middle size range (44%) and the largest size range (36%).", [["smallest", "OBSERVATION_MODIFIER", 4, 12], ["size", "OBSERVATION_MODIFIER", 13, 17], ["range", "OBSERVATION_MODIFIER", 18, 23], ["highest", "OBSERVATION_MODIFIER", 32, 39], ["relative", "OBSERVATION_MODIFIER", 40, 48], ["standard deviation", "OBSERVATION", 49, 67], ["mean", "OBSERVATION_MODIFIER", 78, 82], ["middle", "OBSERVATION_MODIFIER", 106, 112], ["size", "OBSERVATION_MODIFIER", 113, 117], ["largest", "OBSERVATION_MODIFIER", 138, 145], ["size", "OBSERVATION_MODIFIER", 146, 150], ["range", "OBSERVATION_MODIFIER", 151, 156]]], ["At this point, we have reviewed enough background knowledge of the nature of infectious particles emitted during various human activities and the likelihood of those aerosols containing virus content to inform a mechanistic study of droplet nuclei transport and control based on these infectious aerosol characteristics.MethodsThis work uses the modified particle-size-resolved version of the Wells-Riley model in Equation (2) to estimate the risk reductions likely achievable by common HVAC filters for a case study of influenza transmission in a hypothetical office building.", [["nuclei", "ANATOMY", 241, 247], ["influenza", "DISEASE", 520, 529], ["human", "ORGANISM", 121, 126], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["infectious particles", "PROBLEM", 77, 97], ["those aerosols containing virus content", "PROBLEM", 160, 199], ["a mechanistic study", "TEST", 210, 229], ["droplet nuclei transport", "TREATMENT", 233, 257], ["the risk reductions", "PROBLEM", 439, 458], ["a case study", "TEST", 504, 516], ["influenza", "PROBLEM", 520, 529], ["infectious", "OBSERVATION", 77, 87], ["size", "OBSERVATION_MODIFIER", 364, 368]]], ["Estimates of operational costs are also made for both HVAC filtration and an equivalent amount of outdoor air ventilation in a range of climate zones across the U.S. in order to compare the likely costs of both control methods.", [["both HVAC filtration", "TREATMENT", 49, 69], ["outdoor air ventilation", "TREATMENT", 98, 121], ["equivalent", "OBSERVATION_MODIFIER", 77, 87], ["amount", "OBSERVATION_MODIFIER", 88, 94], ["air ventilation", "OBSERVATION", 106, 121]]], ["The next sections describe our methodology for connecting the modified Wells-Riley model to HVAC filtration (i.e., MERV) and estimating operational costs.HVAC filtration and the modified Wells-Riley equationTo connect the modified Wells-Riley equation to HVAC filtration, we first linked likely infectious particle removal efficiency with the Minimum Efficiency Reporting Value (MERV) classification from ASHRAE Standard 52.2.", [["the modified Wells", "TREATMENT", 58, 76], ["HVAC filtration", "TREATMENT", 92, 107], ["HVAC filtration", "TREATMENT", 154, 169], ["the modified Wells", "TREATMENT", 174, 192], ["the modified Wells-Riley equation to HVAC filtration", "TREATMENT", 218, 270], ["infectious particle removal efficiency", "TREATMENT", 295, 333], ["likely", "UNCERTAINTY", 288, 294], ["infectious", "OBSERVATION_MODIFIER", 295, 305]]], ["A summary of the MERV table from Standard 52.2 is shown in Table 3 along with best estimates of particle filtration efficiency for lower-MERV filters that have no MERV requirement for certain particle size bins (i.e., MERV 4e11).", [["particle filtration efficiency", "TREATMENT", 96, 126], ["lower-MERV filters", "TREATMENT", 131, 149], ["MERV requirement", "PROBLEM", 163, 179], ["MERV filters", "OBSERVATION", 137, 149], ["no", "UNCERTAINTY", 160, 162]]], ["Average values across each of the 0.3e1 mm and 1e3 mm size bins were taken from a previous study that measured the in-situ removal efficiency of lower efficiency filters [56] ; these values also align similarly to other previous studies [57, 58] .HVAC filtration and the modified Wells-Riley equationSubsequently, the range of infectious particle size distributions for influenza virus from Table 2 were linked to the filter removal efficiencies in Table 3 by an infectious particle size-weighting procedure, as shown in Equation (4).HVAC filtration and the modified Wells-Riley equationwhere h filter \u00bc infectious particle size weighted filtration efficiency (\u00c0); h i \u00bc size-resolved particle filtration efficiency for the geometric mean diameter of particle size bin i (from Table 3 ); and F i \u00bc the fraction of virus content associated with particle size bin i (from Table 2 ).", [["influenza", "DISEASE", 370, 379], ["influenza virus", "SPECIES", 370, 385], ["Average values", "TEST", 0, 14], ["a previous study", "TEST", 80, 96], ["lower efficiency filters", "PROBLEM", 145, 169], ["these values", "TEST", 177, 189], ["other previous studies", "TEST", 214, 236], ["HVAC filtration", "TREATMENT", 247, 262], ["the modified Wells", "TREATMENT", 267, 285], ["infectious particle size distributions", "TREATMENT", 327, 365], ["influenza virus", "PROBLEM", 370, 385], ["the filter removal efficiencies", "TREATMENT", 414, 445], ["an infectious particle size", "TREATMENT", 460, 487], ["weighting procedure", "TREATMENT", 488, 507], ["HVAC filtration", "TREATMENT", 534, 549], ["the modified Wells", "TREATMENT", 554, 572], ["Riley equationwhere h filter", "TREATMENT", 573, 601], ["infectious particle size weighted filtration efficiency", "PROBLEM", 604, 659], ["h i \u00bc size", "PROBLEM", 665, 675], ["particle filtration efficiency", "PROBLEM", 685, 715], ["virus content", "PROBLEM", 814, 827], ["lower efficiency", "OBSERVATION_MODIFIER", 145, 161], ["filtration", "OBSERVATION", 252, 262], ["infectious", "OBSERVATION_MODIFIER", 327, 337], ["particle", "OBSERVATION_MODIFIER", 338, 346], ["size", "OBSERVATION_MODIFIER", 347, 351], ["influenza virus", "OBSERVATION", 370, 385], ["filter", "OBSERVATION", 418, 424], ["removal efficiencies", "OBSERVATION", 425, 445], ["infectious", "OBSERVATION_MODIFIER", 463, 473], ["particle", "OBSERVATION_MODIFIER", 474, 482], ["size", "OBSERVATION_MODIFIER", 483, 487], ["infectious", "OBSERVATION_MODIFIER", 604, 614], ["size", "OBSERVATION_MODIFIER", 671, 675], ["particle filtration efficiency", "OBSERVATION", 685, 715], ["virus content", "OBSERVATION", 814, 827]]], ["Because there are multiple references for the distribution of influenza virus content in size-fractioned aerosols, we introduced an estimate of uncertainty by assuming the infectious particle size distributions from each environment in each referenced study were equally likely to be present in the modeled indoor environment.", [["influenza virus", "ORGANISM", 62, 77], ["influenza virus content", "PROBLEM", 62, 85], ["the infectious particle size distributions", "PROBLEM", 168, 210], ["multiple", "OBSERVATION_MODIFIER", 18, 26], ["influenza virus", "OBSERVATION", 62, 77], ["size", "OBSERVATION_MODIFIER", 89, 93], ["infectious", "OBSERVATION_MODIFIER", 172, 182], ["particle", "OBSERVATION_MODIFIER", 183, 191], ["size", "OBSERVATION_MODIFIER", 192, 196]]], ["These distributions for each filter are shown in Table 4 , along with the mean infectious particle removal efficiency for each filter averaged across each study in Table 2 Mean filtration efficiency values for infectious droplet nuclei are estimated to range from 10.5% for MERV 4 filters to 99.9% for HEPA filters.", [["droplet nuclei", "ANATOMY", 221, 235], ["each filter", "TREATMENT", 24, 35], ["the mean infectious particle removal efficiency", "TREATMENT", 70, 117], ["each filter", "TREATMENT", 122, 133], ["each study", "TEST", 150, 160], ["Mean filtration efficiency values", "TEST", 172, 205], ["infectious droplet nuclei", "PROBLEM", 210, 235], ["MERV 4 filters", "TREATMENT", 274, 288], ["HEPA filters", "TREATMENT", 302, 314], ["filter", "OBSERVATION", 29, 35], ["infectious", "OBSERVATION_MODIFIER", 79, 89], ["particle removal", "OBSERVATION", 90, 106], ["filter", "OBSERVATION", 127, 133], ["infectious", "OBSERVATION_MODIFIER", 210, 220], ["droplet nuclei", "OBSERVATION", 221, 235]]], ["Assumptions across the wide range of infectious particle size distributions summarized in Table 2 lead to infectious droplet nuclei removal efficiencies that vary by as much as 19% absolutely (although the range narrows for higher MERV filters because of high removal efficiencies for all particle size ranges).HVAC filtration and the modified Wells-Riley equationWhile Table 4 provides estimates for assumed removal efficiencies for various MERV filters across the size ranges of concern for infectious droplet nuclei transmission, other important parameters for determining the impact of filtration on infectious disease risk in indoor environments include the infectious particle deposition rate and the recirculation rate through the HVAC system (which is a function of specific building characteristics).Infectious particle deposition and the modified Wells-Riley equationParticle deposition rates (k deposition ) are important for removal of indoor aerosols but are highly variable depending on the nature of the indoor environment [59, 60] .", [["nuclei", "ANATOMY", 125, 131], ["nuclei", "ANATOMY", 512, 518], ["infectious disease", "DISEASE", 604, 622], ["infectious droplet nuclei removal efficiencies", "TREATMENT", 106, 152], ["higher MERV filters", "TREATMENT", 224, 243], ["high removal efficiencies", "TREATMENT", 255, 280], ["HVAC filtration", "TREATMENT", 311, 326], ["the modified Wells-Riley equationWhile Table", "TREATMENT", 331, 375], ["assumed removal efficiencies", "TREATMENT", 401, 429], ["various MERV filters", "TREATMENT", 434, 454], ["infectious droplet nuclei transmission", "PROBLEM", 493, 531], ["filtration", "TREATMENT", 590, 600], ["the infectious particle deposition rate", "TREATMENT", 659, 698], ["Infectious particle deposition", "PROBLEM", 809, 839], ["the modified Wells-Riley equationParticle deposition rates (k deposition", "TREATMENT", 844, 916], ["removal of indoor aerosols", "TREATMENT", 937, 963], ["wide", "OBSERVATION_MODIFIER", 23, 27], ["infectious", "OBSERVATION_MODIFIER", 37, 47], ["particle", "OBSERVATION_MODIFIER", 48, 56], ["size", "OBSERVATION_MODIFIER", 57, 61], ["infectious", "OBSERVATION_MODIFIER", 106, 116], ["droplet nuclei", "OBSERVATION", 117, 131], ["removal efficiencies", "OBSERVATION", 132, 152], ["size", "OBSERVATION_MODIFIER", 298, 302], ["size", "OBSERVATION_MODIFIER", 466, 470], ["infectious", "OBSERVATION_MODIFIER", 663, 673], ["deposition", "OBSERVATION_MODIFIER", 829, 839]]], ["The original Wells-Riley model neglected particle deposition; however, for the particle sizes considered, it is more appropriate to account for deposition [4, 34, 35] .", [["Wells", "OBSERVATION_MODIFIER", 13, 18], ["Riley model", "OBSERVATION_MODIFIER", 19, 30], ["neglected", "OBSERVATION_MODIFIER", 31, 40], ["particle deposition", "OBSERVATION", 41, 60]]], ["For simplicity, we assume constant values of k deposition based on size-resolved values used in Riley et al. (2002) [33, 61] .Infectious particle deposition and the modified Wells-Riley equationUsing a geometric mean diameter between 0.3 and 1 mm (0.55 mm), between 1 and 3 mm (1.7 mm), and between 3 and 10 mm (5.5 mm), deposition rates were estimated as w0.10 per hour, w0.45 per hour, and w3.0 per hour, respectively (taken directly from their Fig. 3 ).", [["k deposition", "PROBLEM", 45, 57], ["size", "TEST", 67, 71], ["Infectious particle deposition", "PROBLEM", 126, 156], ["a geometric mean diameter", "TEST", 200, 225], ["deposition rates", "TEST", 321, 337], ["size", "OBSERVATION_MODIFIER", 67, 71], ["geometric", "OBSERVATION_MODIFIER", 202, 211], ["mean", "OBSERVATION_MODIFIER", 212, 216], ["diameter", "OBSERVATION_MODIFIER", 217, 225], ["3 mm", "OBSERVATION_MODIFIER", 272, 276], ["1.7 mm", "OBSERVATION_MODIFIER", 278, 284], ["10 mm", "OBSERVATION_MODIFIER", 305, 310]]], ["When combined with the mean infectious particle size distributions from Table 2 , these lead to a mean size-weighted estimate of w1.7 per hour for k deposition for particles containing the influenza virus.", [["influenza virus", "ORGANISM", 189, 204], ["influenza virus", "SPECIES", 189, 204], ["the mean infectious particle size distributions", "PROBLEM", 19, 66], ["a mean size", "TEST", 96, 107], ["k deposition", "TREATMENT", 147, 159], ["particles", "PROBLEM", 164, 173], ["the influenza virus", "PROBLEM", 185, 204], ["infectious", "OBSERVATION_MODIFIER", 28, 38], ["particle", "OBSERVATION_MODIFIER", 39, 47], ["size", "OBSERVATION_MODIFIER", 48, 52], ["size", "OBSERVATION_MODIFIER", 103, 107], ["influenza virus", "OBSERVATION", 189, 204]]], ["Values for k deposition ranged from w1.0 to w2.3 per hour depending on the range of infectious particle size distributions assumed from Table 2 .", [["Values", "TEST", 0, 6], ["k deposition", "TEST", 11, 23], ["infectious", "OBSERVATION", 84, 94], ["size", "OBSERVATION_MODIFIER", 104, 108]]], ["These values for k deposition for influenza were kept constant in each model scenario.Application to a case study office environmentThis section relies on a case study of a particular indoor environment (an office) to demonstrate the likely impacts that HVAC filtration can have on the risk of spreading a particular airborne infectious disease (influenza).", [["influenza", "DISEASE", 34, 43], ["airborne infectious disease", "DISEASE", 317, 344], ["influenza", "DISEASE", 346, 355], ["These values", "TEST", 0, 12], ["k deposition", "TEST", 17, 29], ["influenza", "PROBLEM", 34, 43], ["a case study", "TEST", 155, 167], ["HVAC filtration", "TREATMENT", 254, 269], ["a particular airborne infectious disease (influenza)", "PROBLEM", 304, 356]]], ["We assume the office space has 25 occupants, one of which is infected with the influenza virus (I \u00bc 1; susceptibles \u00bc 24).", [["influenza", "DISEASE", 79, 88], ["influenza virus", "ORGANISM", 79, 94], ["the influenza virus", "PROBLEM", 75, 94], ["infected", "OBSERVATION", 61, 69], ["influenza virus", "OBSERVATION", 79, 94]]], ["Per ASHRAE Standard 62.1 [62] , the minimum outdoor air ventilation rate should be 8.5 m 3 /hr per person \u00fe 1.1 m 3 /hr per m 2 of floor area, which is equivalent to w760 m 3 /hr in the assumed space (yielding an air exchange rate (AER) \u00bc 0.51/hr).", [["floor area", "ANATOMY", 131, 141], ["person", "SPECIES", 99, 105], ["the minimum outdoor air ventilation rate", "TREATMENT", 32, 72], ["an air exchange rate", "TREATMENT", 210, 230]]], ["Assuming the outdoor air supply fraction of total airflow is 25% [63] , the total supply airflow rate is w3000 m 3 /hr, with w2300 m 3 /hr provided as recirculated air.", [["the outdoor air supply fraction", "TEST", 9, 40], ["total airflow", "TEST", 44, 57], ["the total supply airflow rate", "TREATMENT", 72, 101], ["total", "OBSERVATION_MODIFIER", 44, 49], ["airflow", "OBSERVATION_MODIFIER", 50, 57], ["air", "OBSERVATION", 164, 167]]], ["The removal rate due to recirculated air filtration is thus w1.52 \u00c2 h filter per hour (where 2300 m 3 /hr divided by 1500 m 3 \u00bc 1.52/hour; multiply by particle removal efficiency to get k filtration , assuming that f HVAC \u00bc 1).", [["The removal rate", "TREATMENT", 0, 16], ["recirculated air filtration", "PROBLEM", 24, 51], ["k filtration", "TREATMENT", 186, 198], ["air filtration", "OBSERVATION", 37, 51]]], ["We relied on a central estimate of previously published values of quanta generation rate (q) for influenza: q \u00bc 100 per hour.", [["influenza", "DISEASE", 97, 106], ["quanta generation rate", "TREATMENT", 66, 88], ["influenza", "PROBLEM", 97, 106]]], ["However we also explore the sensitivity to our modeling results using both upper bounds (q \u00bc 500 per hour) and lower bounds (q \u00bc 15 per hour) in the uncertainty analysis.Estimating costs of controlling infectious disease with ventilation and filtrationAlthough outdoor air ventilation rates have been shown to decrease the risk of spreading some infectious airborne diseases, introducing more ventilation air also comes with an energy penalty.", [["infectious disease", "DISEASE", 202, 220], ["airborne diseases", "DISEASE", 357, 374], ["the uncertainty analysis", "TEST", 145, 169], ["controlling infectious disease", "PROBLEM", 190, 220], ["ventilation", "TREATMENT", 226, 237], ["filtration", "TREATMENT", 242, 252], ["outdoor air ventilation", "TREATMENT", 261, 284], ["some infectious airborne diseases", "PROBLEM", 341, 374], ["infectious", "OBSERVATION_MODIFIER", 202, 212], ["spreading", "OBSERVATION_MODIFIER", 331, 340], ["some", "OBSERVATION_MODIFIER", 341, 345], ["infectious", "OBSERVATION_MODIFIER", 346, 356], ["airborne diseases", "OBSERVATION", 357, 374], ["ventilation air", "OBSERVATION", 393, 408]]], ["Conversely, the introduction of higher efficiency filtration typically increases the pressure drop across the filter, which, in commercial systems with variable air volume fans and airflow controls, will generally increase the amount of energy required to move the same amount of airflow.", [["higher efficiency filtration", "PROBLEM", 32, 60], ["the pressure drop", "PROBLEM", 81, 98], ["the filter", "TREATMENT", 106, 116], ["variable air volume fans", "TREATMENT", 152, 176], ["airflow controls", "TREATMENT", 181, 197], ["pressure", "OBSERVATION_MODIFIER", 85, 93], ["drop", "OBSERVATION_MODIFIER", 94, 98], ["filter", "OBSERVATION", 110, 116], ["air volume", "OBSERVATION", 161, 171]]], ["The next sections describe methods to estimate the annual costs of both outdoor air ventilation and various levels of filtration.Cost of outdoor air deliveryThe amount of energy required to condition excess ventilation air varies according to the magnitude of outdoor airflow rates, climate conditions, and system and equipment efficiency.", [["sections", "ANATOMY", 9, 17], ["outdoor air ventilation", "TREATMENT", 72, 95], ["filtration", "TREATMENT", 118, 128], ["outdoor air delivery", "TREATMENT", 137, 157], ["condition excess ventilation air varies", "PROBLEM", 190, 229], ["outdoor airflow rates", "TEST", 260, 281], ["air ventilation", "OBSERVATION", 80, 95], ["amount", "OBSERVATION_MODIFIER", 161, 167], ["ventilation air", "OBSERVATION", 207, 222]]], ["However, approximate estimates of the amount of energy required to condition the sensible load from outdoor air ventilation can be made using metrics of heating-degree-days (HDD) and cooling-degreedays (CDD) and by making assumptions about equipment efficiency and system operational times [65, 66] .", [["outdoor air ventilation", "TREATMENT", 100, 123]]], ["An approximation of the amount of energy required for heating on an annual basis was made using Equation (5) .", [["amount", "OBSERVATION_MODIFIER", 24, 30]]], ["This equation assumes that outdoor air ventilation rates do not vary during operational times.Cost of outdoor air deliverywhere E heating \u00bc energy required for heating (MJ); r air \u00bc density of air (1.2 kg/m 3 ); C p,air \u00bc specific heat capacity of air (1000 J/(kg-K)); HDD \u00bc heating degree days during times of building operation (Kdays); h heating \u00bc conversion efficiency of heating equipment (\u00c0); and a \u00bc units conversion factor (24 h/day \u00c2 10 \u00c06 MJ/J).", [["This equation", "TEST", 0, 13], ["outdoor air ventilation rates", "TEST", 27, 56], ["heating (MJ)", "TREATMENT", 160, 172], ["r air \u00bc density of air", "PROBLEM", 174, 196], ["building operation", "TREATMENT", 311, 329], ["heating equipment", "TREATMENT", 376, 393], ["a \u00bc units conversion factor", "TREATMENT", 403, 430], ["air", "ANATOMY", 193, 196], ["air", "ANATOMY", 216, 219]]], ["Similarly, the amount of energy required for cooling on an annual basis was approximated using Equation (6) (and utilizing the same assumptions as Equation (5)):Cost of outdoor air deliverywhere E cooling \u00bc electricity required for cooling (kWh); h cooling \u00bc electric efficiency of cooling equipment (\u00c0);Cost of outdoor air deliveryCDD \u00bc cooling degree days during times of building operation (Kdays); and b \u00bc units conversion factor (24 h/day \u00c2 0.277 kWh/ MJ \u00c2 10 \u00c06 MJ/J).", [["cooling", "TREATMENT", 45, 52], ["cooling equipment", "TREATMENT", 282, 299], ["building operation", "TREATMENT", 374, 392], ["factor", "TEST", 427, 433], ["amount", "OBSERVATION_MODIFIER", 15, 21], ["energy", "OBSERVATION", 25, 31]]], ["We assumed that electricity was used for cooling and natural gas was used for heating.", [["cooling", "TREATMENT", 41, 48], ["natural gas", "TREATMENT", 53, 64]]], ["We estimated the cost of outdoor air delivery in the case study office environment for four different locations across the United States: Chicago, IL, Charlotte, NC, Houston, TX, and Phoenix, AZ.", [["outdoor air delivery", "TREATMENT", 25, 45], ["TX", "TREATMENT", 175, 177]]], ["We assumed that a 90% efficient natural gas boiler or furnace was used for heating and the air-conditioning equipment had a constant electric coefficient of performance (COP) of 3.0 (or approximately SEER 12, which is in line with many relatively new existing commercial buildings [67] ).", [["natural gas boiler", "TREATMENT", 32, 50], ["furnace", "TREATMENT", 54, 61], ["heating", "TREATMENT", 75, 82], ["the air-conditioning equipment", "TREATMENT", 87, 117], ["gas boiler", "OBSERVATION", 40, 50], ["relatively", "OBSERVATION_MODIFIER", 236, 246], ["new", "OBSERVATION_MODIFIER", 247, 250]]], ["We used the defined operational schedule and hourly TMY3 (typical meteorological year) weather data to calculate HDDs and CDDs for each hour of assumed operation [68] .", [["HDDs", "TEST", 113, 117], ["CDDs", "TREATMENT", 122, 126]]], ["HDDs and CDDs were calculated using a base temperature of 18.3 C. Estimates of HDDs and CDDs utilized in the model are shown in Table 5 , along with estimated annual costs of supplying one unit of outdoor ventilation air in each climate.", [["HDDs", "SIMPLE_CHEMICAL", 0, 4], ["CDDs", "SIMPLE_CHEMICAL", 9, 13], ["CDDs", "TEST", 9, 13], ["a base temperature", "TEST", 36, 54], ["HDDs", "TEST", 79, 83], ["CDDs", "TEST", 88, 92], ["outdoor ventilation air", "TREATMENT", 197, 220], ["ventilation air", "OBSERVATION", 205, 220]]], ["We assumed electricity rates were constant at $0.12/kWh and that natural gas rates were ); t operating \u00bc amount of time that the building is occupied (hours); and P electricity \u00bc electric price ($/Wh).", [["natural gas rates", "TEST", 65, 82]]], ["The fan was assumed to operate 100% of the time that the building was occupied.Cost of HVAC filtrationTo estimate the total cost of filtration, one must also consider the initial cost of the filtration product itself, the number of filters required for each installation, the typical lifespan of filtration products, and the labor for filter installation and subsequent disposal at the end of its useful life [70] .", [["HVAC filtration", "TREATMENT", 87, 102], ["filtration", "TREATMENT", 132, 142], ["the filtration product", "TREATMENT", 187, 209], ["filters", "TREATMENT", 232, 239], ["each installation", "TREATMENT", 253, 270], ["the typical lifespan of filtration products", "TREATMENT", 272, 315], ["the labor", "PROBLEM", 321, 330], ["filter installation", "TREATMENT", 335, 354], ["HVAC filtration", "OBSERVATION", 87, 102]]], ["Labor costs were estimated directly from Bek\u00f6 et al. (2008) as $12 per filter installation and $5 per filter disposal.", [["Labor costs", "PROBLEM", 0, 11]]], ["Assuming each filter is 24 00 \u00c2 24 00 (0.6 \u00c2 0.6 m), the number of filters required for the office environment was estimated by (i) dividing the airflow rate through the HVAC filter by an assumed constant 2 m/s face velocity, which yields the approximate area of filtration required, and (ii) determining the number of 24 00 \u00c2 24 00 (61 \u00c2 61 cm) filters to achieve that approximate area, rounding to the nearest whole number.", [["each filter", "TEST", 9, 20], ["the airflow rate", "TEST", 141, 157], ["the HVAC filter", "TREATMENT", 166, 181], ["filters", "TREATMENT", 346, 353], ["filter", "OBSERVATION", 14, 20], ["area", "OBSERVATION_MODIFIER", 255, 259], ["filtration", "OBSERVATION", 263, 273]]], ["This yielded one filter required in the hypothetical office environment.", [["one filter", "TREATMENT", 13, 23], ["one", "OBSERVATION_MODIFIER", 13, 16], ["filter", "OBSERVATION", 17, 23]]], ["Annual labor costs were estimated by multiplying the labor cost of changing one filter ($12 \u00fe $5 \u00bc $17 per filter) by the estimated number of filter replacements during one year of operation.", [["Annual labor costs", "PROBLEM", 0, 18], ["filter", "TREATMENT", 107, 113], ["filter replacements", "TREATMENT", 142, 161], ["operation", "TREATMENT", 181, 190], ["filter replacements", "OBSERVATION", 142, 161], ["operation", "OBSERVATION", 181, 190]]], ["The initial costs of filtration products and the typical expected filter life spans were taken from an anonymous contact in the commercial filtration industry, as shown in Table 6 .", [["filtration products", "TREATMENT", 21, 40], ["the typical expected filter life spans", "TREATMENT", 45, 83], ["filter", "OBSERVATION", 66, 72]]], ["The AHU fan in the office environment was assumed to operate 2717 h per year (or 31%) as described in Section 3.4.1.ResultsThis section first describes results from the infection risk modeling effort, followed by results from cost estimates and cost comparisons between filtration and outdoor air ventilation.", [["infection", "DISEASE", 169, 178], ["the infection risk modeling effort", "PROBLEM", 165, 199], ["filtration", "TREATMENT", 270, 280], ["outdoor air ventilation", "TREATMENT", 285, 308], ["infection", "OBSERVATION", 169, 178], ["air ventilation", "OBSERVATION", 293, 308]]], ["Fig. 1 shows the predicted risk of infection by the influenza virus during an 8-h workday in the hypothetical office building with 25 occupants using a range of HVAC filters installed in the constant operation HVAC system.", [["infection", "DISEASE", 35, 44], ["influenza", "DISEASE", 52, 61], ["influenza virus", "ORGANISM", 52, 67], ["influenza virus", "SPECIES", 52, 67], ["influenza virus", "SPECIES", 52, 67], ["infection", "PROBLEM", 35, 44], ["the influenza virus", "PROBLEM", 48, 67], ["a range of HVAC filters", "TREATMENT", 150, 173], ["the constant operation HVAC system", "TREATMENT", 187, 221], ["infection", "OBSERVATION", 35, 44]]], ["The central estimates represent risks predicted using Equation (2) with a quanta generation rate of 100 per hour and the mean assumption of viral particle size distributions from Table 2 .", [["a quanta generation rate", "TREATMENT", 72, 96], ["central", "ANATOMY_MODIFIER", 4, 11], ["viral particle", "OBSERVATION", 140, 154], ["size", "OBSERVATION_MODIFIER", 155, 159]]], ["The error bars represent minimum and maximum risks predicted according to the range of assumptions for viral particle size distributions in Table 2 and infectious aerosol removal efficiencies in Table 4 (assuming the same quanta generation rate).Estimates of absolute risk in the case study office environmentUsing the central estimate for infectious particle size distributions (i.e., the mean from Table 2 ) and q \u00bc 100 per hour, 15% of the susceptible occupants (4 out of 24) are estimated to acquire the flu virus from the sole infectious individual if the building is operated without a filter installed.", [["flu virus", "SPECIES", 508, 517], ["viral particle size distributions", "PROBLEM", 103, 136], ["infectious aerosol removal efficiencies", "TREATMENT", 152, 191], ["the flu virus", "PROBLEM", 504, 517], ["a filter", "TREATMENT", 590, 598], ["minimum", "OBSERVATION_MODIFIER", 25, 32], ["viral particle", "OBSERVATION", 103, 117], ["size", "OBSERVATION_MODIFIER", 118, 122], ["infectious", "OBSERVATION_MODIFIER", 152, 162], ["aerosol removal", "OBSERVATION", 163, 178], ["absolute risk", "OBSERVATION", 259, 272], ["infectious", "OBSERVATION", 340, 350], ["size", "OBSERVATION_MODIFIER", 360, 364], ["infectious", "OBSERVATION", 532, 542], ["filter", "OBSERVATION", 592, 598]]], ["The various assumptions for infectious aerosol size distributions from Table 2 impact estimates of absolute risk in each scenario, although trends across filter scenarios are unaffected.", [["infectious aerosol size distributions", "PROBLEM", 28, 65], ["absolute risk in each scenario", "PROBLEM", 99, 129], ["infectious", "OBSERVATION_MODIFIER", 28, 38], ["size", "OBSERVATION_MODIFIER", 47, 51], ["absolute risk", "OBSERVATION", 99, 112], ["filter scenarios", "OBSERVATION", 154, 170]]], ["For example, the range of assumptions for size-resolved distributions of virus content in indoor aerosols results in an estimate of the absolute risk of acquiring influenza of between 12% and 21% without a filter installed.Estimates of absolute risk in the case study office environmentContinuing with the central estimate of infectious particle size distributions, even a relatively low efficiency filter (MERV 7) is predicted to reduce the number of infected individuals by 1 (to 12% risk).", [["influenza", "DISEASE", 163, 172], ["virus content", "PROBLEM", 73, 86], ["influenza", "PROBLEM", 163, 172], ["a filter", "TREATMENT", 204, 212], ["infectious particle size distributions", "PROBLEM", 326, 364], ["a relatively low efficiency filter", "PROBLEM", 371, 405], ["infected individuals", "PROBLEM", 452, 472], ["size", "OBSERVATION_MODIFIER", 42, 46], ["resolved", "OBSERVATION_MODIFIER", 47, 55], ["distributions", "OBSERVATION_MODIFIER", 56, 69], ["virus content", "OBSERVATION", 73, 86], ["filter", "OBSERVATION", 206, 212], ["absolute risk", "OBSERVATION", 236, 249], ["infectious", "OBSERVATION", 326, 336], ["particle", "OBSERVATION_MODIFIER", 337, 345], ["size", "OBSERVATION_MODIFIER", 346, 350], ["relatively", "OBSERVATION_MODIFIER", 373, 383], ["low efficiency", "OBSERVATION_MODIFIER", 384, 398], ["filter", "OBSERVATION", 399, 405], ["number", "OBSERVATION_MODIFIER", 442, 448], ["infected", "OBSERVATION", 452, 460]]], ["Increasing to MERV 13 or higher likely prevents another individual from airborne influenza infection (to 10% or lower risk).", [["influenza infection", "DISEASE", 81, 100], ["MERV 13", "DNA", 14, 21], ["MERV", "TEST", 14, 18], ["airborne influenza infection", "PROBLEM", 72, 100], ["airborne influenza", "OBSERVATION", 72, 90]]], ["Finally, increasing to MERV 16 or HEPA filtration has the same effect of lowering the likely number of infected individuals to 2 (with a w35e40% reduction relative to no or low filtration efficiency).", [["MERV", "TEST", 23, 27], ["HEPA filtration", "TREATMENT", 34, 49], ["infected individuals", "PROBLEM", 103, 123], ["a w35e40% reduction", "TREATMENT", 135, 154], ["low filtration efficiency", "PROBLEM", 173, 198], ["likely", "UNCERTAINTY", 86, 92], ["number", "OBSERVATION_MODIFIER", 93, 99], ["infected", "OBSERVATION", 103, 111]]], ["For MERV 13 and greater, risk reductions are limited not by filtration efficiency but by the amount of airflow recirculating through the HVAC system and filter.", [["MERV", "TEST", 4, 8], ["filtration efficiency", "PROBLEM", 60, 81], ["the HVAC system", "TREATMENT", 133, 148], ["filter", "TREATMENT", 153, 159], ["amount", "OBSERVATION_MODIFIER", 93, 99], ["airflow", "OBSERVATION", 103, 110], ["HVAC", "ANATOMY", 137, 141], ["filter", "OBSERVATION", 153, 159]]], ["Increasing recirculation rates may show stronger impacts of higher efficiency filters; however, these results Table 5 Climate conditions (HDD and CDD) and annual cost of outdoor air delivery used for the office environment under the assumed operational schedule in each location. suggest that MERV 13 can reduce the risk of influenza infection by as many as two individuals in this environment.", [["MERV 13", "CHEMICAL", 293, 300], ["influenza infection", "DISEASE", 324, 343], ["MERV 13", "ORGANISM", 293, 300], ["Increasing recirculation rates", "PROBLEM", 0, 30], ["higher efficiency filters", "PROBLEM", 60, 85], ["outdoor air delivery", "TREATMENT", 170, 190], ["influenza infection", "PROBLEM", 324, 343], ["stronger", "OBSERVATION_MODIFIER", 40, 48], ["higher efficiency filters", "OBSERVATION", 60, 85], ["influenza", "OBSERVATION", 324, 333]]], ["For reference, one avoided influenza case has been estimated to provide approximately $375 in economic benefits in the United States [1] .Estimates of relative risks in the case study office environmentWhile the infection risk reductions shown in the previous section are absolute, we can also explore trends in risk reductions for each filtration case using a measure of relative risk (RR), as shown in Fig. 2 .", [["influenza", "DISEASE", 27, 36], ["infection", "DISEASE", 212, 221], ["influenza", "PROBLEM", 27, 36], ["the infection risk reductions", "PROBLEM", 208, 237], ["each filtration case", "TREATMENT", 332, 352], ["RR", "TEST", 387, 389], ["infection", "OBSERVATION", 212, 221]]], ["RR values use the \"no filter\" condition as a baseline; thus, each RR is calculated as the probability of infection with a particular filter installed divided by the probability of infection without a filter installed.", [["infection", "DISEASE", 105, 114], ["infection", "DISEASE", 180, 189], ["RR values", "TEST", 0, 9], ["filter\" condition", "PROBLEM", 22, 39], ["each RR", "TEST", 61, 68], ["infection", "PROBLEM", 105, 114], ["a particular filter", "TREATMENT", 120, 139], ["infection", "PROBLEM", 180, 189], ["a filter", "TREATMENT", 198, 206], ["infection", "OBSERVATION", 105, 114], ["infection", "OBSERVATION", 180, 189], ["filter", "OBSERVATION", 200, 206]]], ["The black line shows the RR in the office assuming the mean assumption for infectious aerosol size distributions and a quanta generation rate of 100 per hour.", [["infectious aerosol size distributions", "TREATMENT", 75, 112], ["a quanta generation rate", "TEST", 117, 141], ["black line", "OBSERVATION", 4, 14], ["infectious", "OBSERVATION_MODIFIER", 75, 85], ["aerosol size", "OBSERVATION", 86, 98]]], ["The gray area shows how RR responds to the different assumptions for viral particle size distributions in Table 2 .Estimates of relative risks in the case study office environmentIn Fig. 2 , MERV 4 filters are shown to provide only a 6e7% reduction in risk relative to no filtration.", [["viral particle size distributions", "PROBLEM", 69, 102], ["MERV 4 filters", "TREATMENT", 191, 205], ["a 6e7% reduction", "TREATMENT", 232, 248], ["filtration", "PROBLEM", 272, 282], ["viral particle", "OBSERVATION", 69, 83], ["size", "OBSERVATION_MODIFIER", 84, 88]]], ["MERV 7 filters are likely to provide a 19e25% reduction in risk (RR \u00bc 0.75e0.81) and MERV 11 filters are expected to provide 28e35% risk reductions (RR \u00bc 0.65e 0.72).", [["MERV 7 filters", "TREATMENT", 0, 14], ["a 19e25% reduction", "TREATMENT", 37, 55], ["RR", "TEST", 65, 67], ["MERV 11 filters", "TREATMENT", 85, 100], ["RR", "TEST", 149, 151]]], ["MERV 13 and greater levels of filtration are expected to provide between 31% and 47% risk reductions compared to an environment without filtration installed (RR \u00bc 0.53e0.69).Estimates of relative risks in the case study office environmentAlthough not shown here, we also explored the effects of assuming different values of quanta generation rates for the influenza virus (ranging from 15 to 500 per hour).", [["influenza", "DISEASE", 356, 365], ["influenza virus", "ORGANISM", 356, 371], ["influenza virus", "SPECIES", 356, 371], ["MERV", "TEST", 0, 4], ["filtration", "TEST", 136, 146], ["RR", "TEST", 158, 160], ["quanta generation rates", "TREATMENT", 324, 347], ["the influenza virus", "PROBLEM", 352, 371]]], ["Ranges in assumptions for q greatly impact absolute risks as Equation (2) demonstrates (and more so than assumptions for particle size distributions of viral content), but relative risks remain largely unchanged (although the bounds on uncertainty are higher).Cost comparisonThe following sections summarize results from the operational cost analysis for both HVAC filtration and outdoor air ventilation.Costs of filtrationUsing the costs and physical properties for filters described in Table 5 in conjunction with the procedure outlined in Section 3.4.2, estimates of the annual costs of filtration were made for each filtration scenario.", [["sections", "ANATOMY", 289, 297], ["viral content", "PROBLEM", 152, 165], ["the operational cost analysis", "TEST", 321, 350], ["both HVAC filtration", "TREATMENT", 355, 375], ["outdoor air ventilation", "TREATMENT", 380, 403], ["filters", "TREATMENT", 467, 474], ["the procedure", "TREATMENT", 516, 529], ["filtration", "TREATMENT", 590, 600], ["each filtration scenario", "TREATMENT", 615, 639], ["viral content", "OBSERVATION", 152, 165], ["largely", "OBSERVATION_MODIFIER", 194, 201], ["unchanged", "OBSERVATION_MODIFIER", 202, 211], ["air ventilation", "OBSERVATION", 388, 403]]], ["Results are shown graphically in Fig. 3 and in tabular form in Table 7 .", [["graphically", "OBSERVATION_MODIFIER", 18, 29]]], ["Total annual costs of filtration are divided into annual fan energy costs, filter purchase costs, and labor costs (which includes the cost of disposal).Costs of filtrationAnnual HVAC filtration costs are predicted to range from $112 for the MERVCosts of filtration versus outdoor air ventilationIn order to compare estimates of annual HVAC filtration costs to the annual costs for delivering outdoor air ventilation, Fig. 4 shows annual costs of both filtration and outdoor air (OA) ventilation normalized by unit removal rate of each scenario.", [["Total annual costs of filtration", "TREATMENT", 0, 32], ["annual fan energy costs", "TREATMENT", 50, 73], ["filter purchase costs", "TREATMENT", 75, 96], ["labor costs", "PROBLEM", 102, 113], ["filtration", "TREATMENT", 161, 171], ["Annual HVAC filtration costs", "TREATMENT", 171, 199], ["the MERVCosts of filtration", "TREATMENT", 237, 264], ["outdoor air ventilationIn", "TREATMENT", 272, 297], ["annual HVAC filtration", "TREATMENT", 328, 350], ["outdoor air ventilation", "TREATMENT", 392, 415], ["both filtration", "TREATMENT", 446, 461], ["ventilation", "TREATMENT", 483, 494], ["unit removal rate", "TREATMENT", 509, 526], ["filtration", "OBSERVATION", 161, 171], ["both", "OBSERVATION_MODIFIER", 446, 450], ["filtration", "OBSERVATION", 451, 461]]], ["This normalized filtration cost is the total cost of filtration (i.e., the sum of annual labor, filter, and fan energy costs) divided by the average estimate of the infectious aerosol removal rate (i.e., the mean infectious removal efficiency from Table 4 multiplied by the HVAC recirculation rate in the space).", [["filtration", "TREATMENT", 53, 63], ["annual labor", "PROBLEM", 82, 94], ["filter", "TREATMENT", 96, 102], ["fan energy costs", "TREATMENT", 108, 124], ["the infectious aerosol removal rate", "TREATMENT", 161, 196], ["the mean infectious removal efficiency", "TREATMENT", 204, 242], ["the HVAC recirculation rate", "TREATMENT", 270, 297], ["filtration", "OBSERVATION", 16, 26], ["infectious", "OBSERVATION_MODIFIER", 165, 175], ["aerosol removal", "OBSERVATION", 176, 191]]], ["This provides a measure of the cost of each control mechanism relative to its ability to remove infectious droplet nuclei from indoor air in units of $ per 1/hr.", [["nuclei", "ANATOMY", 115, 121], ["infectious droplet nuclei", "PROBLEM", 96, 121]]], ["Fig. 4 contains data for both outdoor air ventilation in each of the four U.S. cities described previously and each level of HVAC filtration operating in the hypothetical office environment (assuming the central estimate of viral content distributions in indoor aerosols).Costs of filtration versus outdoor air ventilationAccording to Fig. 4 , MERV 13 and 14 filtration products are estimated to provide the least expensive removal mechanism in this office environment (in terms of per 1/hr) ventilation energy costs from Table 5 was used to estimate the cost of providing this equivalent reduction.Costs of filtration and outdoor air ventilation versus risk reductionsAs Fig. 5 shows, for each level of risk reduction achievable by the use of every level of HVAC filtration except MERV 4, filtration is estimated to be less expensive on an annual basis than equivalent outdoor air ventilation in each of the four climate zones.", [["both outdoor air ventilation", "TREATMENT", 25, 53], ["HVAC filtration", "TREATMENT", 125, 140], ["filtration", "TREATMENT", 281, 291], ["outdoor air ventilationAccording", "TREATMENT", 299, 331], ["MERV 13 and 14 filtration products", "TREATMENT", 344, 378], ["the least expensive removal mechanism", "TREATMENT", 404, 441], ["ventilation energy costs", "TREATMENT", 492, 516], ["this equivalent reduction", "TREATMENT", 573, 598], ["filtration", "TREATMENT", 608, 618], ["outdoor air ventilation", "TREATMENT", 623, 646], ["risk reductions", "PROBLEM", 654, 669], ["risk reduction", "TREATMENT", 704, 718], ["HVAC filtration", "TREATMENT", 759, 774], ["filtration", "TREATMENT", 790, 800], ["outdoor air ventilation", "TREATMENT", 870, 893], ["air ventilation", "OBSERVATION", 38, 53], ["viral content", "OBSERVATION", 224, 237], ["filtration", "OBSERVATION", 281, 291], ["filtration", "OBSERVATION", 608, 618], ["air ventilation", "OBSERVATION", 631, 646], ["air ventilation", "OBSERVATION", 878, 893]]], ["MERV 13 and MERV 14 filters appear to achieve an optimal combination of lowest risk reductions at least costs.", [["MERV", "TEST", 0, 4], ["MERV 14 filters", "TREATMENT", 12, 27]]], ["MERV 4 is actually more expensive to operate than providing equivalent outdoor air ventilation in each climate, primarily because of the very low effectiveness in controlling infectious aerosols.", [["outdoor air ventilation", "TREATMENT", 71, 94], ["the very low effectiveness", "PROBLEM", 133, 159], ["air ventilation", "OBSERVATION", 79, 94], ["infectious aerosols", "OBSERVATION", 175, 194]]], ["HEPA filtration appears to offer only a small incremental advantage over MERV 13e16 filters (i.e., 1e4% lower RR) for as much as 1.6e2.3 times the cost of operation, which suggests that MERV 13e16 filters may be most appropriate for cost-effectively reducing risks of influenza transmission in this particular indoor environment.", [["influenza", "DISEASE", 268, 277], ["MERV", "SPECIES", 73, 77], ["MERV", "SPECIES", 186, 190], ["HEPA filtration", "TREATMENT", 0, 15], ["a small incremental advantage over MERV 13e16 filters", "TREATMENT", 38, 91], ["operation", "TREATMENT", 155, 164], ["MERV 13e16 filters", "TREATMENT", 186, 204], ["influenza transmission", "PROBLEM", 268, 290], ["filtration", "OBSERVATION", 5, 15], ["small", "OBSERVATION_MODIFIER", 40, 45]]], ["In fact, switching from MERV 7 to MERV 13 could likely reduce the number of infected individuals in this office environment by one person at an additional annual cost of only $17.", [["person", "SPECIES", 131, 137], ["infected", "OBSERVATION", 76, 84]]], ["Compared to the estimated economic losses of a single influenza case of $375, MERV 13 Table 7 Estimated annual cost of filtration in the office environment.FilterAnnual filter product costs filtration could provide a benefit-to-cost ratio of 20 or more.", [["influenza", "DISEASE", 54, 63], ["FilterAnnual filter product costs filtration", "TREATMENT", 156, 200], ["cost ratio", "TEST", 228, 238], ["filter", "OBSERVATION", 169, 175], ["costs filtration", "OBSERVATION", 184, 200]]], ["These basic relationships were not sensitive to the various assumptions for infectious particle size distributions.DiscussionAccording to the results herein, filtration of recirculated air may be able to reduce the transmission of airborne infectious diseases in this particular indoor environment.", [["infectious diseases", "DISEASE", 240, 259], ["infectious particle size distributions", "PROBLEM", 76, 114], ["airborne infectious diseases", "PROBLEM", 231, 259], ["infectious", "OBSERVATION", 76, 86], ["size", "OBSERVATION_MODIFIER", 96, 100], ["airborne", "OBSERVATION_MODIFIER", 231, 239], ["infectious", "OBSERVATION", 240, 250]]], ["Although there is a tremendous amount of uncertainty involved in each step of this modeling effort, the sensitivity of the model to input parameters for both infectious aerosol size distributions and for quanta generation rates was shown to be relatively small for relative risks.", [["input parameters", "TEST", 132, 148], ["both infectious aerosol size distributions", "TREATMENT", 153, 195], ["quanta generation rates", "TEST", 204, 227], ["tremendous", "OBSERVATION_MODIFIER", 20, 30], ["amount", "OBSERVATION_MODIFIER", 31, 37], ["infectious", "OBSERVATION_MODIFIER", 158, 168], ["size", "OBSERVATION_MODIFIER", 177, 181]]], ["The sensitivity to each parameter was larger for absolute risks, with much greater uncertainty associated with assumptions for quanta generation rates.DiscussionWhile this case study on a single office environment has been presented for demonstration, more robust statistical techniques could also be used to simulate a wide range of buildings, occupants, and infectious aerosol properties to provide a more generalizable estimate of the likely impacts of filtration across the building stock.", [["absolute risks", "PROBLEM", 49, 63], ["quanta generation rates", "TEST", 127, 150], ["infectious aerosol properties", "TREATMENT", 360, 389]]], ["Additionally, risk models should be used in conjunction with more detailed hourly building energy balances to more accurately explore the energy impacts of infectious disease filtration relative to control by outdoor air ventilation, which will necessarily vary by climate, human occupancy and activity, and building operational characteristics.", [["human", "ORGANISM", 274, 279], ["human", "SPECIES", 274, 279], ["human", "SPECIES", 274, 279], ["infectious disease filtration", "TREATMENT", 156, 185], ["outdoor air ventilation", "TREATMENT", 209, 232], ["infectious", "OBSERVATION", 156, 166]]], ["Additionally, it is clear that particle size distributions of expelled droplet nuclei should be measured in more standardized ways with much greater numbers of individuals than only those studies identified in the literature review and summarized in Table 2 .", [["droplet nuclei", "ANATOMY", 71, 85], ["expelled droplet nuclei", "PROBLEM", 62, 85], ["those studies", "TEST", 182, 195], ["clear", "OBSERVATION_MODIFIER", 20, 25], ["particle", "OBSERVATION_MODIFIER", 31, 39], ["size", "OBSERVATION_MODIFIER", 40, 44], ["expelled", "OBSERVATION_MODIFIER", 62, 70], ["droplet nuclei", "OBSERVATION", 71, 85]]], ["Last, future epidemiological work should also validate the predictions herein.DiscussionIt should be noted that there are also more physically and biologically grounded models for assessing risks of infectious respiratory diseases, such as doseeresponse (DeR) models that incorporate mass balances and/or Markov chains that predict infectious particle concentrations, exposures, and doses, the \"infectivity\" of the particles, and the organism's susceptibility to disease [29, 71, 72] .", [["respiratory", "ANATOMY", 210, 221], ["respiratory diseases", "DISEASE", 210, 230], ["infectious respiratory diseases", "PROBLEM", 199, 230], ["mass balances", "PROBLEM", 284, 297], ["Markov chains", "PROBLEM", 305, 318], ["infectious particle concentrations", "PROBLEM", 332, 366], ["the \"infectivity\" of the particles", "PROBLEM", 390, 424], ["the organism's susceptibility to disease", "PROBLEM", 430, 470], ["infectious", "OBSERVATION_MODIFIER", 199, 209], ["mass", "OBSERVATION", 284, 288]]], ["DeR models have been used in recent studies to model infectious disease transmission using more mechanistic properties of both tuberculosis [73] and influenza [39, 71] ; however, DeR models also have their own inherent limitations, including often requiring interspecies extrapolation to estimate susceptibility of a human subject.", [["infectious disease transmission", "DISEASE", 53, 84], ["tuberculosis", "DISEASE", 127, 139], ["influenza", "DISEASE", 149, 158], ["human", "ORGANISM", 317, 322], ["human", "SPECIES", 317, 322], ["human", "SPECIES", 317, 322], ["model infectious disease transmission", "PROBLEM", 47, 84], ["both tuberculosis", "PROBLEM", 122, 139], ["influenza", "PROBLEM", 149, 158], ["tuberculosis", "OBSERVATION", 127, 139]]], ["Regardless, results from the modeling effort herein demonstrate that HVAC filtration can very likely play a role in preventing the transmission of airborne infectious diseases at lower costs than providing an equivalent amount of outdoor air ventilation, as previous studies have typically explored [3, 4, 6, 7] .ConclusionIn this work, an existing airborne infectious disease risk model (the Wells-Riley equation) was modified to include removal by recirculating HVAC filters and linked directly to the primary rating metric of ASHRAE Standard 52.2 for filtration products: MERV.", [["infectious diseases", "DISEASE", 156, 175], ["infectious disease", "DISEASE", 358, 376], ["MERV", "PROTEIN", 575, 579], ["HVAC filtration", "PROBLEM", 69, 84], ["airborne infectious diseases", "PROBLEM", 147, 175], ["outdoor air ventilation", "TREATMENT", 230, 253], ["previous studies", "TEST", 258, 274], ["an existing airborne infectious disease risk model", "PROBLEM", 337, 387], ["the Wells-Riley equation", "TREATMENT", 389, 413], ["removal", "TREATMENT", 439, 446], ["recirculating HVAC filters", "TREATMENT", 450, 476], ["filtration products", "TREATMENT", 554, 573], ["MERV", "TREATMENT", 575, 579], ["air ventilation", "OBSERVATION", 238, 253]]], ["Based on a series of assumptions about infectious particle size distributions resulting from human activities in indoor environments, the risk of acquiring the influenza virus from a single infector was modeled in a hypothetical office environment with a particular focus on what levels of risk reductions could be achieved by different levels of HVAC filtration and equivalent outdoor air ventilation, and at what costs of operation.", [["influenza", "DISEASE", 160, 169], ["human", "ORGANISM", 93, 98], ["influenza virus", "ORGANISM", 160, 175], ["human", "SPECIES", 93, 98], ["human", "SPECIES", 93, 98], ["infectious particle size distributions", "PROBLEM", 39, 77], ["the influenza virus", "PROBLEM", 156, 175], ["a single infector", "PROBLEM", 181, 198], ["risk reductions", "TREATMENT", 290, 305], ["HVAC filtration", "TREATMENT", 347, 362], ["outdoor air ventilation", "TREATMENT", 378, 401], ["operation", "TREATMENT", 424, 433], ["size", "OBSERVATION_MODIFIER", 59, 63], ["human activities", "OBSERVATION_MODIFIER", 93, 109], ["influenza virus", "OBSERVATION", 160, 175], ["air ventilation", "OBSERVATION", 386, 401]]], ["Overall, recirculating HVAC filtration was predicted to achieve the greatest risk reductions at lower costs of operation than equivalent outdoor air ventilation, particularly for MERV 13e16 filters.", [["MERV", "SPECIES", 179, 183], ["recirculating HVAC filtration", "TREATMENT", 9, 38], ["operation", "TREATMENT", 111, 120], ["outdoor air ventilation", "TREATMENT", 137, 160], ["MERV 13e16 filters", "TREATMENT", 179, 197], ["HVAC filtration", "OBSERVATION", 23, 38], ["reductions", "OBSERVATION_MODIFIER", 82, 92], ["air ventilation", "OBSERVATION", 145, 160]]], ["Medium efficiency filtration products (MERV 7e11) are also inexpensive to operate but appear less effective in reducing infectious disease risks.", [["MERV 7e11", "CHEMICAL", 39, 48], ["Medium efficiency filtration products", "TREATMENT", 0, 37], ["reducing infectious disease risks", "PROBLEM", 111, 144], ["efficiency filtration", "OBSERVATION", 7, 28], ["less effective", "OBSERVATION_MODIFIER", 93, 107], ["infectious", "OBSERVATION_MODIFIER", 120, 130]]]], "PMC7122776": [["Introduction to Community-Acquired PneumoniaCommunity-acquired pneumonia (CAP) is a leading cause of morbidity and mortality in the world, with an annual incidence ranking from 1.6 to 10.6 per 1.000 people in Europe.", [["Acquired PneumoniaCommunity-acquired pneumonia", "DISEASE", 26, 72], ["CAP", "DISEASE", 74, 77], ["people", "SPECIES", 199, 205], ["acquired pneumonia (CAP", "PROBLEM", 54, 77], ["morbidity", "PROBLEM", 101, 110], ["pneumonia", "OBSERVATION", 63, 72], ["morbidity", "OBSERVATION", 101, 110]]], ["Up to 75 % of CAP patients with pulmonary diseases need hospitalization, and up to a 10 % of these are admitted to an intensive care unit (ICU) due to complications like sepsis, septic shock, and acute respiratory distress syndrome (ARDS) [1\u20133].", [["pulmonary", "ANATOMY", 32, 41], ["respiratory", "ANATOMY", 202, 213], ["CAP", "DISEASE", 14, 17], ["pulmonary diseases", "DISEASE", 32, 50], ["sepsis", "DISEASE", 170, 176], ["septic shock", "DISEASE", 178, 190], ["acute respiratory distress syndrome", "DISEASE", 196, 231], ["ARDS", "DISEASE", 233, 237], ["patients", "ORGANISM", 18, 26], ["pulmonary", "ORGAN", 32, 41], ["patients", "SPECIES", 18, 26], ["pulmonary diseases", "PROBLEM", 32, 50], ["complications", "PROBLEM", 151, 164], ["sepsis", "PROBLEM", 170, 176], ["septic shock", "PROBLEM", 178, 190], ["acute respiratory distress syndrome", "PROBLEM", 196, 231], ["ARDS", "PROBLEM", 233, 237], ["pulmonary", "ANATOMY", 32, 41], ["diseases", "OBSERVATION", 42, 50], ["sepsis", "OBSERVATION", 170, 176], ["septic shock", "OBSERVATION", 178, 190], ["acute", "OBSERVATION_MODIFIER", 196, 201], ["respiratory distress", "OBSERVATION", 202, 222]]], ["Up to 8 % of CAP patients die within 90 days of disease onset; 21 % die within a year [4] making CAP the most frequent cause of death from infection in Europe and the third most common cause of death in general [5].", [["CAP", "DISEASE", 13, 16], ["CAP", "DISEASE", 97, 100], ["death", "DISEASE", 128, 133], ["infection", "DISEASE", 139, 148], ["death", "DISEASE", 194, 199], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["disease onset", "PROBLEM", 48, 61], ["death", "PROBLEM", 128, 133], ["infection", "PROBLEM", 139, 148], ["death", "PROBLEM", 194, 199], ["infection", "OBSERVATION", 139, 148]]], ["Mortality is highest in ICU patients.Introduction to Community-Acquired PneumoniaCAP is usually associated with fever, productive cough, hemoptysis (couch containing blood), dyspnea (shortness of breath), and pleuritic and chest pain with a consolidation on the chest X-ray.", [["blood", "ANATOMY", 166, 171], ["chest", "ANATOMY", 223, 228], ["chest", "ANATOMY", 262, 267], ["PneumoniaCAP", "DISEASE", 72, 84], ["fever", "DISEASE", 112, 117], ["cough", "DISEASE", 130, 135], ["hemoptysis", "DISEASE", 137, 147], ["dyspnea", "DISEASE", 174, 181], ["shortness of breath", "DISEASE", 183, 202], ["chest pain", "DISEASE", 223, 233], ["patients", "ORGANISM", 28, 36], ["blood", "ORGANISM_SUBSTANCE", 166, 171], ["chest", "ORGANISM_SUBDIVISION", 223, 228], ["patients", "SPECIES", 28, 36], ["fever", "PROBLEM", 112, 117], ["productive cough", "PROBLEM", 119, 135], ["hemoptysis (couch containing blood)", "PROBLEM", 137, 172], ["dyspnea", "PROBLEM", 174, 181], ["shortness of breath", "PROBLEM", 183, 202], ["pleuritic and chest pain", "PROBLEM", 209, 233], ["a consolidation", "PROBLEM", 239, 254], ["the chest X-ray", "TEST", 258, 273], ["highest", "OBSERVATION_MODIFIER", 13, 20], ["productive", "OBSERVATION_MODIFIER", 119, 129], ["cough", "OBSERVATION", 130, 135], ["hemoptysis", "OBSERVATION", 137, 147], ["pleuritic", "ANATOMY", 209, 218], ["chest", "ANATOMY", 223, 228], ["consolidation", "OBSERVATION", 241, 254], ["chest", "ANATOMY", 262, 267]]], ["Many factors influence the clinical presentation of pneumonia including pathogen virulence and age as well as some risk factors like chronic obstructive pulmonary disease (COPD; see chapter \u201c10.1007/978-3-7091-0715-7_33\u201d), diabetes (see chapter \u201c10.1007/978-3-7091-0715-7_26\u201d), alcoholism, smoking, malnutrition, immunodeficiency, and cardiovascular and renal comorbidities [6, 7].Introduction to Community-Acquired PneumoniaCAP can be caused by (i) typical pathogens (such as Streptococcus pneumoniae, Haemophilus influenzae), (ii) atypical pathogens (such as Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydia pneumoniae), and (iii) viruses (such as adenovirus, respiratory syncytial virus, and human parainfluenza virus).", [["pulmonary", "ANATOMY", 153, 162], ["cardiovascular", "ANATOMY", 335, 349], ["renal", "ANATOMY", 354, 359], ["pneumonia", "DISEASE", 52, 61], ["chronic obstructive pulmonary disease", "DISEASE", 133, 170], ["COPD", "DISEASE", 172, 176], ["diabetes", "DISEASE", 223, 231], ["10.1007/978-3-7091-0715-7_26\u201d", "CHEMICAL", 246, 275], ["alcoholism", "DISEASE", 278, 288], ["smoking", "CHEMICAL", 290, 297], ["malnutrition", "DISEASE", 299, 311], ["immunodeficiency", "DISEASE", 313, 329], ["cardiovascular and renal comorbidities", "DISEASE", 335, 373], ["PneumoniaCAP", "DISEASE", 416, 428], ["Streptococcus pneumoniae", "DISEASE", 477, 501], ["Haemophilus influenzae", "DISEASE", 503, 525], ["Legionella pneumophila", "DISEASE", 561, 583], ["Mycoplasma pneumoniae", "DISEASE", 585, 606], ["Chlamydia pneumoniae", "DISEASE", 612, 632], ["respiratory syncytial virus", "DISEASE", 674, 701], ["human parainfluenza virus", "DISEASE", 707, 732], ["pulmonary", "ORGAN", 153, 162], ["renal", "ORGAN", 354, 359], ["Streptococcus pneumoniae", "ORGANISM", 477, 501], ["Haemophilus influenzae", "ORGANISM", 503, 525], ["Legionella pneumophila", "ORGANISM", 561, 583], ["Mycoplasma pneumoniae", "ORGANISM", 585, 606], ["Chlamydia pneumoniae", "ORGANISM", 612, 632], ["adenovirus", "ORGANISM", 662, 672], ["respiratory syncytial virus", "ORGANISM", 674, 701], ["human", "ORGANISM", 707, 712], ["parainfluenza virus", "ORGANISM", 713, 732], ["Streptococcus pneumoniae", "SPECIES", 477, 501], ["Haemophilus influenzae", "SPECIES", 503, 525], ["Legionella pneumophila", "SPECIES", 561, 583], ["Mycoplasma pneumoniae", "SPECIES", 585, 606], ["Chlamydia pneumoniae", "SPECIES", 612, 632], ["respiratory syncytial virus", "SPECIES", 674, 701], ["human", "SPECIES", 707, 712], ["parainfluenza virus", "SPECIES", 713, 732], ["Streptococcus pneumoniae", "SPECIES", 477, 501], ["Haemophilus influenzae", "SPECIES", 503, 525], ["Legionella pneumophila", "SPECIES", 561, 583], ["Mycoplasma pneumoniae", "SPECIES", 585, 606], ["Chlamydia pneumoniae", "SPECIES", 612, 632], ["respiratory syncytial virus", "SPECIES", 674, 701], ["human parainfluenza virus", "SPECIES", 707, 732], ["pneumonia", "PROBLEM", 52, 61], ["pathogen virulence", "PROBLEM", 72, 90], ["chronic obstructive pulmonary disease", "PROBLEM", 133, 170], ["COPD", "PROBLEM", 172, 176], ["diabetes", "PROBLEM", 223, 231], ["alcoholism", "PROBLEM", 278, 288], ["malnutrition", "PROBLEM", 299, 311], ["immunodeficiency", "PROBLEM", 313, 329], ["cardiovascular and renal comorbidities", "PROBLEM", 335, 373], ["typical pathogens", "PROBLEM", 450, 467], ["Streptococcus pneumoniae", "PROBLEM", 477, 501], ["Haemophilus influenzae", "PROBLEM", 503, 525], ["atypical pathogens", "PROBLEM", 533, 551], ["Legionella pneumophila", "PROBLEM", 561, 583], ["Mycoplasma pneumoniae", "PROBLEM", 585, 606], ["Chlamydia pneumoniae)", "PROBLEM", 612, 633], ["(iii) viruses", "PROBLEM", 639, 652], ["adenovirus", "PROBLEM", 662, 672], ["respiratory syncytial virus", "PROBLEM", 674, 701], ["human parainfluenza virus", "PROBLEM", 707, 732], ["pneumonia", "OBSERVATION", 52, 61], ["chronic", "OBSERVATION_MODIFIER", 133, 140], ["obstructive", "OBSERVATION_MODIFIER", 141, 152], ["pulmonary", "ANATOMY", 153, 162], ["disease", "OBSERVATION", 163, 170], ["COPD", "OBSERVATION", 172, 176], ["alcoholism", "OBSERVATION", 278, 288], ["immunodeficiency", "OBSERVATION", 313, 329], ["renal", "ANATOMY", 354, 359], ["comorbidities", "OBSERVATION", 360, 373], ["Mycoplasma pneumoniae", "OBSERVATION", 585, 606], ["respiratory syncytial", "ANATOMY", 674, 695]]], ["A mixed etiology accounts for 10\u201320 % of causes (typical plus atypical) [8, 9].Introduction to Community-Acquired PneumoniaValid sputum can be collected from about 40 % of patients and the Gram stain allows diagnosis in 80 % of patients [10].", [["sputum", "ANATOMY", 129, 135], ["patients", "ORGANISM", 172, 180], ["patients", "ORGANISM", 228, 236], ["patients", "SPECIES", 172, 180], ["patients", "SPECIES", 228, 236], ["Acquired PneumoniaValid sputum", "PROBLEM", 105, 135], ["the Gram stain", "TEST", 185, 199], ["mixed", "OBSERVATION_MODIFIER", 2, 7]]], ["The Infectious Diseases Society of America guidelines recommend that the sputum specimen must be obtained before the initiation of antibiotic therapy in inpatients.", [["sputum specimen", "ANATOMY", 73, 88], ["sputum specimen", "MULTI-TISSUE_STRUCTURE", 73, 88], ["the sputum specimen", "TEST", 69, 88], ["antibiotic therapy", "TREATMENT", 131, 149], ["Infectious", "OBSERVATION_MODIFIER", 4, 14]]], ["Additionally, blood culture testing is recommended in all patients with severe CAP, showing cavitary infiltrates, leukopenia (decreased numbers of leukocytes), alcohol abuse, chronic severe liver disease, or asplenia (disturbed spleen function).", [["blood", "ANATOMY", 14, 19], ["cavitary infiltrates", "ANATOMY", 92, 112], ["leukocytes", "ANATOMY", 147, 157], ["liver", "ANATOMY", 190, 195], ["spleen", "ANATOMY", 228, 234], ["CAP", "DISEASE", 79, 82], ["leukopenia", "DISEASE", 114, 124], ["alcohol abuse", "DISEASE", 160, 173], ["liver disease", "DISEASE", 190, 203], ["asplenia", "DISEASE", 208, 216], ["alcohol", "CHEMICAL", 160, 167], ["blood", "ORGANISM_SUBSTANCE", 14, 19], ["patients", "ORGANISM", 58, 66], ["cavitary infiltrates", "PATHOLOGICAL_FORMATION", 92, 112], ["leukocytes", "CELL", 147, 157], ["alcohol", "SIMPLE_CHEMICAL", 160, 167], ["liver", "ORGAN", 190, 195], ["spleen", "ORGAN", 228, 234], ["leukocytes", "CELL_TYPE", 147, 157], ["patients", "SPECIES", 58, 66], ["blood culture testing", "TEST", 14, 35], ["severe CAP", "PROBLEM", 72, 82], ["cavitary infiltrates", "PROBLEM", 92, 112], ["leukopenia", "PROBLEM", 114, 124], ["decreased numbers of leukocytes", "PROBLEM", 126, 157], ["chronic severe liver disease", "PROBLEM", 175, 203], ["asplenia (disturbed spleen function", "PROBLEM", 208, 243], ["cavitary", "OBSERVATION_MODIFIER", 92, 100], ["infiltrates", "OBSERVATION", 101, 112], ["leukopenia", "OBSERVATION", 114, 124], ["decreased", "OBSERVATION_MODIFIER", 126, 135], ["numbers", "OBSERVATION_MODIFIER", 136, 143], ["leukocytes", "OBSERVATION", 147, 157], ["chronic", "OBSERVATION_MODIFIER", 175, 182], ["severe", "OBSERVATION_MODIFIER", 183, 189], ["liver", "ANATOMY", 190, 195], ["disease", "OBSERVATION", 196, 203], ["asplenia", "OBSERVATION", 208, 216], ["spleen", "ANATOMY", 228, 234]]], ["Bronchoalveolar lavage to obtain fluid from a small part of the lung via bronchoscopy is suitable for patients with life-threatening CAP or worsening pneumonia despite antimicrobial therapy.", [["Bronchoalveolar lavage", "ANATOMY", 0, 22], ["fluid", "ANATOMY", 33, 38], ["lung", "ANATOMY", 64, 68], ["CAP", "DISEASE", 133, 136], ["pneumonia", "DISEASE", 150, 159], ["Bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 0, 22], ["lung", "ORGAN", 64, 68], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["Bronchoalveolar lavage", "TEST", 0, 22], ["fluid", "PROBLEM", 33, 38], ["bronchoscopy", "TEST", 73, 85], ["life-threatening CAP", "PROBLEM", 116, 136], ["worsening pneumonia", "PROBLEM", 140, 159], ["antimicrobial therapy", "TREATMENT", 168, 189], ["lavage", "OBSERVATION", 16, 22], ["fluid", "OBSERVATION", 33, 38], ["small", "OBSERVATION_MODIFIER", 46, 51], ["lung", "ANATOMY", 64, 68], ["bronchoscopy", "OBSERVATION", 73, 85], ["worsening", "OBSERVATION_MODIFIER", 140, 149], ["pneumonia", "OBSERVATION", 150, 159], ["antimicrobial therapy", "OBSERVATION", 168, 189]]], ["Urinary antigen determination may detect Legionella pneumophila and S. pneumoniae.", [["Urinary", "ANATOMY", 0, 7], ["Legionella pneumophila", "DISEASE", 41, 63], ["Urinary", "ORGANISM_SUBSTANCE", 0, 7], ["Legionella pneumophila", "ORGANISM", 41, 63], ["S. pneumoniae", "ORGANISM", 68, 81], ["Legionella pneumophila", "SPECIES", 41, 63], ["S. pneumoniae", "SPECIES", 68, 81], ["Legionella pneumophila", "SPECIES", 41, 63], ["S. pneumoniae", "SPECIES", 68, 81], ["Urinary antigen determination", "TEST", 0, 29], ["Legionella pneumophila", "PROBLEM", 41, 63], ["S. pneumoniae", "PROBLEM", 68, 81], ["Legionella pneumophila", "OBSERVATION", 41, 63], ["pneumoniae", "OBSERVATION", 71, 81]]], ["Serum biomarkers like C-reactive protein (CRP) and procalcitonin (PCT) may be used as indicators of bacterial infection [11\u201313].Pathophysiology of Community-Acquired PneumoniaThe pathophysiology of CAP involves both host defense and microbial virulence factors.", [["Serum", "ANATOMY", 0, 5], ["bacterial infection", "DISEASE", 100, 119], ["Pneumonia", "DISEASE", 166, 175], ["CAP", "DISEASE", 198, 201], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 22, 40], ["CRP", "GENE_OR_GENE_PRODUCT", 42, 45], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 51, 64], ["C-reactive protein", "PROTEIN", 22, 40], ["CRP", "PROTEIN", 42, 45], ["procalcitonin", "PROTEIN", 51, 64], ["PCT", "PROTEIN", 66, 69], ["microbial virulence factors", "PROTEIN", 233, 260], ["Serum biomarkers", "TEST", 0, 16], ["C", "TEST", 22, 23], ["reactive protein", "TEST", 24, 40], ["CRP", "TEST", 42, 45], ["procalcitonin", "TEST", 51, 64], ["PCT", "TEST", 66, 69], ["bacterial infection", "PROBLEM", 100, 119], ["Community-Acquired Pneumonia", "PROBLEM", 147, 175], ["CAP", "PROBLEM", 198, 201], ["microbial virulence factors", "PROBLEM", 233, 260], ["reactive protein", "OBSERVATION", 24, 40], ["bacterial", "OBSERVATION_MODIFIER", 100, 109], ["infection", "OBSERVATION", 110, 119], ["Pneumonia", "OBSERVATION", 166, 175], ["CAP", "OBSERVATION_MODIFIER", 198, 201], ["host defense", "OBSERVATION", 216, 228], ["microbial virulence", "OBSERVATION", 233, 252]]], ["Constant exposure to contaminated air and frequent aspiration of nasopharyngeal flora make lung parenchyma susceptible to virulent microorganisms, commonly reaching the lower respiratory tract as inhaled and contaminated microdroplets.", [["nasopharyngeal flora", "ANATOMY", 65, 85], ["lung parenchyma", "ANATOMY", 91, 106], ["lower respiratory tract", "ANATOMY", 169, 192], ["nasopharyngeal flora", "PATHOLOGICAL_FORMATION", 65, 85], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 91, 106], ["lower", "ORGANISM_SUBDIVISION", 169, 174], ["respiratory tract", "ORGANISM_SUBDIVISION", 175, 192], ["contaminated air", "PROBLEM", 21, 37], ["frequent aspiration", "TREATMENT", 42, 61], ["nasopharyngeal flora", "PROBLEM", 65, 85], ["lung parenchyma", "PROBLEM", 91, 106], ["virulent microorganisms", "PROBLEM", 122, 145], ["contaminated air", "OBSERVATION", 21, 37], ["frequent", "OBSERVATION_MODIFIER", 42, 50], ["aspiration", "OBSERVATION", 51, 61], ["nasopharyngeal", "ANATOMY", 65, 79], ["flora", "OBSERVATION", 80, 85], ["lung", "ANATOMY", 91, 95], ["parenchyma", "ANATOMY_MODIFIER", 96, 106], ["virulent", "OBSERVATION_MODIFIER", 122, 130], ["microorganisms", "OBSERVATION", 131, 145], ["lower", "ANATOMY_MODIFIER", 169, 174], ["respiratory tract", "ANATOMY", 175, 192]]], ["Mucociliary clearance and cough reflex are important initial defenses against infection and can be inhibited by neurologic diseases and conditions that impair the mucociliary mechanism [6, 8].Pathophysiology of Community-Acquired PneumoniaMost CAPs are bacterial in origin and often follow brief viral upper respiratory tract infection.", [["Mucociliary", "ANATOMY", 0, 11], ["neurologic", "ANATOMY", 112, 122], ["mucociliary", "ANATOMY", 163, 174], ["upper respiratory tract", "ANATOMY", 302, 325], ["cough", "DISEASE", 26, 31], ["infection", "DISEASE", 78, 87], ["neurologic diseases", "DISEASE", 112, 131], ["viral upper respiratory tract infection", "DISEASE", 296, 335], ["mucociliary", "ORGAN", 163, 174], ["upper", "ORGANISM_SUBDIVISION", 302, 307], ["respiratory tract", "ORGANISM_SUBDIVISION", 308, 325], ["Mucociliary clearance", "TEST", 0, 21], ["cough reflex", "PROBLEM", 26, 38], ["infection", "PROBLEM", 78, 87], ["neurologic diseases and conditions", "PROBLEM", 112, 146], ["Acquired PneumoniaMost CAPs", "PROBLEM", 221, 248], ["bacterial in origin", "PROBLEM", 253, 272], ["brief viral upper respiratory tract infection", "PROBLEM", 290, 335], ["Community", "OBSERVATION_MODIFIER", 211, 220], ["PneumoniaMost CAPs", "OBSERVATION", 230, 248], ["bacterial", "OBSERVATION_MODIFIER", 253, 262], ["upper", "ANATOMY_MODIFIER", 302, 307], ["respiratory tract", "ANATOMY", 308, 325], ["infection", "OBSERVATION", 326, 335]]], ["There are two main mechanisms to acquire pneumonia.", [["pneumonia", "DISEASE", 41, 50], ["pneumonia", "PROBLEM", 41, 50], ["main", "OBSERVATION_MODIFIER", 14, 18], ["pneumonia", "OBSERVATION", 41, 50]]], ["Firstly, inhalation causes pneumonia due to microorganisms that can remain suspended in air and evade local host defenses.", [["pneumonia", "DISEASE", 27, 36], ["pneumonia", "PROBLEM", 27, 36], ["microorganisms", "PROBLEM", 44, 58], ["pneumonia", "OBSERVATION", 27, 36], ["host defenses", "OBSERVATION", 108, 121]]], ["In addition, aerosolization is the route of infection by intracellular bacteria such as Mycoplasma pneumoniae, Chlamydophila spp., Coxiella burnetii, and Legionella pneumophila [6, 8, 9].", [["intracellular", "ANATOMY", 57, 70], ["infection", "DISEASE", 44, 53], ["Mycoplasma pneumoniae", "DISEASE", 88, 109], ["Coxiella burnetii", "DISEASE", 131, 148], ["Legionella pneumophila", "DISEASE", 154, 176], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 57, 70], ["Mycoplasma pneumoniae", "ORGANISM", 88, 109], ["Chlamydophila spp.", "ORGANISM", 111, 129], ["Coxiella burnetii", "ORGANISM", 131, 148], ["Legionella pneumophila", "ORGANISM", 154, 176], ["Mycoplasma pneumoniae", "SPECIES", 88, 109], ["Chlamydophila spp.", "SPECIES", 111, 129], ["Coxiella burnetii", "SPECIES", 131, 148], ["Legionella pneumophila", "SPECIES", 154, 176], ["Mycoplasma pneumoniae", "SPECIES", 88, 109], ["Chlamydophila spp.", "SPECIES", 111, 129], ["Coxiella burnetii", "SPECIES", 131, 148], ["Legionella pneumophila", "SPECIES", 154, 176], ["aerosolization", "TREATMENT", 13, 27], ["infection", "PROBLEM", 44, 53], ["intracellular bacteria", "PROBLEM", 57, 79], ["Mycoplasma pneumoniae", "PROBLEM", 88, 109], ["Chlamydophila spp.", "PROBLEM", 111, 129], ["Coxiella burnetii", "PROBLEM", 131, 148], ["Legionella pneumophila", "PROBLEM", 154, 176], ["aerosolization", "OBSERVATION", 13, 27], ["infection", "OBSERVATION", 44, 53], ["Mycoplasma pneumoniae", "OBSERVATION", 88, 109]]], ["Secondly, aspiration of oropharyngeal flora can cause CAP.", [["oropharyngeal flora", "ANATOMY", 24, 43], ["CAP", "DISEASE", 54, 57], ["oropharyngeal flora", "PATHOLOGICAL_FORMATION", 24, 43], ["aspiration of oropharyngeal flora", "PROBLEM", 10, 43], ["CAP", "PROBLEM", 54, 57], ["oropharyngeal", "ANATOMY", 24, 37], ["flora", "OBSERVATION", 38, 43], ["CAP", "OBSERVATION_MODIFIER", 54, 57]]], ["The ability of virulent bacteria such as Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Klebsiella pneumoniae to colonize the oropharynx is determined by the interaction of specific microbial adhesins with cellular receptors.", [["oropharynx", "ANATOMY", 156, 166], ["cellular", "ANATOMY", 236, 244], ["Streptococcus pneumoniae", "DISEASE", 41, 65], ["Streptococcus pneumoniae", "ORGANISM", 41, 65], ["Staphylococcus aureus", "ORGANISM", 67, 88], ["Pseudomonas aeruginosa", "ORGANISM", 90, 112], ["Klebsiella pneumoniae", "ORGANISM", 118, 139], ["oropharynx", "ORGAN", 156, 166], ["cellular", "CELL", 236, 244], ["microbial adhesins", "PROTEIN", 212, 230], ["cellular receptors", "PROTEIN", 236, 254], ["Streptococcus pneumoniae", "SPECIES", 41, 65], ["Staphylococcus aureus", "SPECIES", 67, 88], ["Pseudomonas aeruginosa", "SPECIES", 90, 112], ["Klebsiella pneumoniae", "SPECIES", 118, 139], ["Streptococcus pneumoniae", "SPECIES", 41, 65], ["Staphylococcus aureus", "SPECIES", 67, 88], ["Pseudomonas aeruginosa", "SPECIES", 90, 112], ["Klebsiella pneumoniae", "SPECIES", 118, 139], ["virulent bacteria", "PROBLEM", 15, 32], ["Streptococcus pneumoniae", "PROBLEM", 41, 65], ["Staphylococcus aureus", "PROBLEM", 67, 88], ["Pseudomonas aeruginosa", "PROBLEM", 90, 112], ["Klebsiella pneumoniae", "PROBLEM", 118, 139], ["colonize the oropharynx", "PROBLEM", 143, 166], ["cellular receptors", "TREATMENT", 236, 254], ["Streptococcus pneumoniae", "OBSERVATION", 41, 65], ["Staphylococcus aureus", "OBSERVATION", 67, 88], ["Klebsiella pneumoniae", "OBSERVATION", 118, 139], ["oropharynx", "ANATOMY", 156, 166]]], ["For example, components of the extracellular matrix (ECM) such as fibronectin in oral mucus promote the adherence of viridans streptococci.", [["extracellular matrix", "ANATOMY", 31, 51], ["ECM", "ANATOMY", 53, 56], ["oral mucus", "ANATOMY", 81, 91], ["extracellular matrix", "CELLULAR_COMPONENT", 31, 51], ["ECM", "CELLULAR_COMPONENT", 53, 56], ["fibronectin", "GENE_OR_GENE_PRODUCT", 66, 77], ["oral mucus", "MULTI-TISSUE_STRUCTURE", 81, 91], ["viridans streptococci", "CELL", 117, 138], ["fibronectin", "PROTEIN", 66, 77], ["the extracellular matrix (ECM)", "PROBLEM", 27, 57], ["fibronectin in oral mucus", "PROBLEM", 66, 91], ["viridans streptococci", "PROBLEM", 117, 138], ["extracellular", "ANATOMY_MODIFIER", 31, 44], ["matrix", "OBSERVATION_MODIFIER", 45, 51], ["viridans streptococci", "OBSERVATION", 117, 138]]], ["In contrast, salivary fibronectin prevents colonization by Gram-negative bacilli, and decreased levels of fibronectin due to alcoholism, diabetes, malnutrition, and other severe comorbidities might contribute to an increased CAP risk.", [["salivary", "ANATOMY", 13, 21], ["alcoholism", "DISEASE", 125, 135], ["diabetes", "DISEASE", 137, 145], ["malnutrition", "DISEASE", 147, 159], ["CAP", "DISEASE", 225, 228], ["salivary fibronectin", "GENE_OR_GENE_PRODUCT", 13, 33], ["Gram", "GENE_OR_GENE_PRODUCT", 59, 63], ["fibronectin", "GENE_OR_GENE_PRODUCT", 106, 117], ["salivary fibronectin", "PROTEIN", 13, 33], ["fibronectin", "PROTEIN", 106, 117], ["salivary fibronectin prevents colonization", "PROBLEM", 13, 55], ["Gram", "TEST", 59, 63], ["decreased levels of fibronectin", "PROBLEM", 86, 117], ["alcoholism", "PROBLEM", 125, 135], ["diabetes", "PROBLEM", 137, 145], ["malnutrition", "PROBLEM", 147, 159], ["other severe comorbidities", "PROBLEM", 165, 191], ["an increased CAP risk", "PROBLEM", 212, 233], ["negative bacilli", "OBSERVATION", 64, 80], ["alcoholism", "OBSERVATION", 125, 135], ["malnutrition", "OBSERVATION", 147, 159], ["severe", "OBSERVATION_MODIFIER", 171, 177], ["comorbidities", "OBSERVATION", 178, 191], ["increased", "OBSERVATION_MODIFIER", 215, 224], ["CAP risk", "OBSERVATION", 225, 233]]], ["The presence of local immunoglobulins, particularly immunoglobulin A (IgA), complement, and normal flora also prevents colonization of the oropharynx by virulent organisms [6, 8, 9].Pathophysiology of Community-Acquired PneumoniaPatients with pneumonia frequently show moderate to severe arterial hypoxemia (an abnormally low O2 level in arterial blood), probably due to pulmonary shunts (i.e., when ventilation fails to supply O2 to alveoli that receive normal blood perfusion, which happens, e.g., when alveoli are filled with fluid), increased whole-body O2 uptake, ventilation-perfusion (VA/Q) mismatching, and/or limited alveolar O2 diffusion into the blood [14].Pathophysiology of Community-Acquired PneumoniaPrevious studies in animal models of pneumonia [15] and in humans [16] have demonstrated that the most common pattern of VA/Q mismatching is a combination of both intrapulmonary shunt and mild to moderate areas of low ventilation-perfusion (VA/Q) ratios.", [["oropharynx", "ANATOMY", 139, 149], ["arterial", "ANATOMY", 288, 296], ["arterial blood", "ANATOMY", 338, 352], ["pulmonary", "ANATOMY", 371, 380], ["alveoli", "ANATOMY", 434, 441], ["blood", "ANATOMY", 462, 467], ["alveoli", "ANATOMY", 505, 512], ["fluid", "ANATOMY", 529, 534], ["body", "ANATOMY", 553, 557], ["alveolar", "ANATOMY", 626, 634], ["blood", "ANATOMY", 657, 662], ["intrapulmonary", "ANATOMY", 878, 892], ["colonization of the oropharynx", "DISEASE", 119, 149], ["pneumonia", "DISEASE", 243, 252], ["hypoxemia", "DISEASE", 297, 306], ["O2", "CHEMICAL", 558, 560], ["pneumonia", "DISEASE", 752, 761], ["O2", "CHEMICAL", 326, 328], ["O2", "CHEMICAL", 428, 430], ["O2", "CHEMICAL", 558, 560], ["O2", "CHEMICAL", 635, 637], ["immunoglobulins", "GENE_OR_GENE_PRODUCT", 22, 37], ["immunoglobulin A", "GENE_OR_GENE_PRODUCT", 52, 68], ["IgA", "GENE_OR_GENE_PRODUCT", 70, 73], ["oropharynx", "ORGAN", 139, 149], ["arterial", "MULTI-TISSUE_STRUCTURE", 288, 296], ["O2", "SIMPLE_CHEMICAL", 326, 328], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 338, 352], ["pulmonary", "ORGAN", 371, 380], ["O2", "SIMPLE_CHEMICAL", 428, 430], ["alveoli", "MULTI-TISSUE_STRUCTURE", 434, 441], ["blood", "ORGANISM_SUBSTANCE", 462, 467], ["alveoli", "MULTI-TISSUE_STRUCTURE", 505, 512], ["O2", "SIMPLE_CHEMICAL", 558, 560], ["alveolar", "MULTI-TISSUE_STRUCTURE", 626, 634], ["O2", "SIMPLE_CHEMICAL", 635, 637], ["blood", "ORGANISM_SUBSTANCE", 657, 662], ["humans", "ORGANISM", 774, 780], ["intrapulmonary", "MULTI-TISSUE_STRUCTURE", 878, 892], ["local immunoglobulins", "PROTEIN", 16, 37], ["immunoglobulin A", "PROTEIN", 52, 68], ["IgA", "PROTEIN", 70, 73], ["humans", "SPECIES", 774, 780], ["humans", "SPECIES", 774, 780], ["local immunoglobulins", "TEST", 16, 37], ["colonization of the oropharynx", "PROBLEM", 119, 149], ["virulent organisms", "PROBLEM", 153, 171], ["Community-Acquired PneumoniaPatients", "PROBLEM", 201, 237], ["pneumonia", "PROBLEM", 243, 252], ["moderate to severe arterial hypoxemia", "PROBLEM", 269, 306], ["an abnormally low O2 level in arterial blood", "PROBLEM", 308, 352], ["pulmonary shunts", "PROBLEM", 371, 387], ["ventilation", "TREATMENT", 400, 411], ["O2", "TREATMENT", 428, 430], ["fluid", "PROBLEM", 529, 534], ["increased whole-body O2 uptake", "PROBLEM", 537, 567], ["ventilation", "TEST", 569, 580], ["VA/Q) mismatching", "TEST", 592, 609], ["limited alveolar O2 diffusion", "PROBLEM", 618, 647], ["pneumonia", "PROBLEM", 752, 761], ["VA/Q mismatching", "PROBLEM", 836, 852], ["both intrapulmonary shunt", "TREATMENT", 873, 898], ["mild to moderate areas of low ventilation-perfusion (VA/Q) ratios", "PROBLEM", 903, 968], ["local immunoglobulins", "OBSERVATION", 16, 37], ["normal flora", "OBSERVATION", 92, 104], ["oropharynx", "ANATOMY", 139, 149], ["pneumonia", "OBSERVATION", 243, 252], ["moderate", "OBSERVATION_MODIFIER", 269, 277], ["severe", "OBSERVATION_MODIFIER", 281, 287], ["arterial", "ANATOMY_MODIFIER", 288, 296], ["hypoxemia", "OBSERVATION", 297, 306], ["abnormally", "OBSERVATION_MODIFIER", 311, 321], ["low O2", "OBSERVATION_MODIFIER", 322, 328], ["arterial", "ANATOMY", 338, 346], ["probably due to", "UNCERTAINTY", 355, 370], ["pulmonary", "ANATOMY", 371, 380], ["shunts", "OBSERVATION", 381, 387], ["alveolar", "ANATOMY_MODIFIER", 626, 634], ["pneumonia", "OBSERVATION", 752, 761], ["VA", "OBSERVATION", 836, 838], ["Q mismatching", "OBSERVATION", 839, 852], ["both", "OBSERVATION_MODIFIER", 873, 877], ["intrapulmonary shunt", "OBSERVATION", 878, 898], ["mild", "OBSERVATION_MODIFIER", 903, 907], ["moderate", "OBSERVATION_MODIFIER", 911, 919], ["areas", "OBSERVATION_MODIFIER", 920, 925], ["low ventilation", "OBSERVATION", 929, 944]]], ["Pulmonary hypoxia (i.e., low O2 levels in the lung) causes vasoconstriction to avoid perfusion of non-ventilated alveoli and redistribution of the blood flow to better-ventilated lung areas.", [["Pulmonary", "ANATOMY", 0, 9], ["lung", "ANATOMY", 46, 50], ["alveoli", "ANATOMY", 113, 120], ["blood", "ANATOMY", 147, 152], ["lung", "ANATOMY", 179, 183], ["hypoxia", "DISEASE", 10, 17], ["O2", "CHEMICAL", 29, 31], ["O2", "CHEMICAL", 29, 31], ["Pulmonary", "ORGAN", 0, 9], ["O2", "SIMPLE_CHEMICAL", 29, 31], ["lung", "ORGAN", 46, 50], ["alveoli", "MULTI-TISSUE_STRUCTURE", 113, 120], ["blood", "ORGANISM_SUBSTANCE", 147, 152], ["lung", "ORGAN", 179, 183], ["Pulmonary hypoxia", "PROBLEM", 0, 17], ["low O2 levels in the lung", "PROBLEM", 25, 50], ["vasoconstriction", "PROBLEM", 59, 75], ["perfusion of non-ventilated alveoli", "PROBLEM", 85, 120], ["the blood flow", "TEST", 143, 157], ["hypoxia", "OBSERVATION", 10, 17], ["low", "OBSERVATION_MODIFIER", 25, 28], ["lung", "ANATOMY", 46, 50], ["vasoconstriction", "OBSERVATION", 59, 75], ["non-ventilated alveoli", "OBSERVATION", 98, 120], ["redistribution", "OBSERVATION_MODIFIER", 125, 139], ["blood flow", "OBSERVATION", 147, 157], ["better", "OBSERVATION_MODIFIER", 161, 167], ["ventilated", "ANATOMY_MODIFIER", 168, 178], ["lung", "ANATOMY", 179, 183], ["areas", "ANATOMY_MODIFIER", 184, 189]]], ["This response is often blunted in CAP patients (causing intrapulmonary increased shunts and decreased VA/Q ratios) due to local release of vasodilatory prostacyclins.Pathophysiology of Community-Acquired PneumoniaProlonged systemic inflammation and bacterial translocation to the blood cause sepsis (see chapter \u201c10.1007/978-3-7091-0715-7_46\u201d), a common consequence of CAP.", [["intrapulmonary", "ANATOMY", 56, 70], ["blood", "ANATOMY", 280, 285], ["CAP", "DISEASE", 34, 37], ["inflammation", "DISEASE", 232, 244], ["sepsis", "DISEASE", 292, 298], ["CAP", "DISEASE", 369, 372], ["patients", "ORGANISM", 38, 46], ["prostacyclins", "GENE_OR_GENE_PRODUCT", 152, 165], ["blood", "ORGANISM_SUBSTANCE", 280, 285], ["patients", "SPECIES", 38, 46], ["intrapulmonary increased shunts", "PROBLEM", 56, 87], ["decreased VA/Q ratios", "PROBLEM", 92, 113], ["vasodilatory prostacyclins", "TREATMENT", 139, 165], ["Acquired PneumoniaProlonged systemic inflammation", "PROBLEM", 195, 244], ["bacterial translocation", "PROBLEM", 249, 272], ["sepsis", "PROBLEM", 292, 298], ["CAP", "PROBLEM", 369, 372], ["often", "OBSERVATION_MODIFIER", 17, 22], ["blunted", "OBSERVATION", 23, 30], ["CAP", "OBSERVATION_MODIFIER", 34, 37], ["intrapulmonary", "ANATOMY", 56, 70], ["increased shunts", "OBSERVATION", 71, 87], ["vasodilatory prostacyclins", "OBSERVATION", 139, 165], ["systemic", "OBSERVATION_MODIFIER", 223, 231], ["inflammation", "OBSERVATION", 232, 244], ["bacterial translocation", "OBSERVATION", 249, 272], ["sepsis", "OBSERVATION", 292, 298], ["CAP", "OBSERVATION", 369, 372]]], ["Impaired tissue oxygenation, as commonly occurs in CAP, is a major mechanism of organ failure in sepsis [17, 18].Pathophysiology of Community-Acquired PneumoniaThe host response to sepsis is characterized by both pro- and anti-inflammatory responses (see also chapter \u201c10.1007/978-3-7091-0715-7_44\u201d under the part \u201cImmune system\u201d).", [["tissue", "ANATOMY", 9, 15], ["organ", "ANATOMY", 80, 85], ["CAP", "DISEASE", 51, 54], ["organ failure", "DISEASE", 80, 93], ["sepsis", "DISEASE", 97, 103], ["Pneumonia", "DISEASE", 151, 160], ["sepsis", "DISEASE", 181, 187], ["tissue", "TISSUE", 9, 15], ["organ", "ORGAN", 80, 85], ["Impaired tissue oxygenation", "PROBLEM", 0, 27], ["organ failure", "PROBLEM", 80, 93], ["sepsis", "PROBLEM", 97, 103], ["Community-Acquired Pneumonia", "PROBLEM", 132, 160], ["sepsis", "PROBLEM", 181, 187], ["tissue oxygenation", "OBSERVATION", 9, 27], ["organ", "ANATOMY", 80, 85], ["failure", "OBSERVATION", 86, 93], ["sepsis", "OBSERVATION", 97, 103], ["Pneumonia", "OBSERVATION", 151, 160], ["sepsis", "OBSERVATION", 181, 187]]], ["The extent and duration of these reactions are determined by host factors (age, comorbidities, medications, and genetic characteristics) and pathogen factors (microbial load and virulence) [17, 19].", [["pathogen factors", "PROTEIN", 141, 157], ["these reactions", "PROBLEM", 27, 42], ["medications", "TREATMENT", 95, 106], ["pathogen factors", "PROBLEM", 141, 157], ["extent", "OBSERVATION_MODIFIER", 4, 10]]], ["Proinflammatory reactions directed at eliminating invading pathogens are thought to be responsible for collateral tissue damage.", [["collateral tissue", "ANATOMY", 103, 120], ["collateral tissue", "TISSUE", 103, 120], ["Proinflammatory reactions", "PROBLEM", 0, 25], ["invading pathogens", "PROBLEM", 50, 68], ["collateral tissue damage", "PROBLEM", 103, 127], ["thought to be responsible for", "UNCERTAINTY", 73, 102], ["collateral tissue", "OBSERVATION", 103, 120]]], ["In contrast, anti-inflammatory responses are important to limit tissue injury, yet enhance susceptibility to secondary infections.Treatment of Community-Acquired PneumoniaCAP treatment is still largely empirical because of the difficulties to detect the infective pathogen(s) from lung samples and should follow an approach according to the individual risk of mortality [6, 9].", [["tissue", "ANATOMY", 64, 70], ["lung samples", "ANATOMY", 281, 293], ["infections", "DISEASE", 119, 129], ["PneumoniaCAP", "DISEASE", 162, 174], ["tissue", "TISSUE", 64, 70], ["lung samples", "CANCER", 281, 293], ["tissue injury", "PROBLEM", 64, 77], ["secondary infections", "PROBLEM", 109, 129], ["Community-Acquired PneumoniaCAP treatment", "TREATMENT", 143, 184], ["the infective pathogen", "PROBLEM", 250, 272], ["lung samples", "TEST", 281, 293], ["limit tissue", "OBSERVATION_MODIFIER", 58, 70], ["injury", "OBSERVATION", 71, 77], ["secondary", "OBSERVATION_MODIFIER", 109, 118], ["infections", "OBSERVATION", 119, 129], ["infective", "OBSERVATION_MODIFIER", 254, 263], ["pathogen", "OBSERVATION", 264, 272], ["lung", "ANATOMY", 281, 285]]], ["Although the most common bacterium identified in CAP patients is S. pneumoniae, other microorganisms (see above) are frequently involved, dependent on the place of care (see Table 1).", [["CAP", "DISEASE", 49, 52], ["CAP", "ORGANISM", 49, 52], ["patients", "ORGANISM", 53, 61], ["S. pneumoniae", "ORGANISM", 65, 78], ["patients", "SPECIES", 53, 61], ["S. pneumoniae", "SPECIES", 65, 78], ["S. pneumoniae", "SPECIES", 65, 78], ["the most common bacterium", "PROBLEM", 9, 34], ["S. pneumoniae", "PROBLEM", 65, 78], ["other microorganisms", "PROBLEM", 80, 100], ["most common", "OBSERVATION_MODIFIER", 13, 24], ["CAP", "OBSERVATION_MODIFIER", 49, 52], ["pneumoniae", "OBSERVATION", 68, 78]]]], "f8939358300d875903d87204759d41f8c3f1f197": [["COVID-19 Associated Pulmonary and Cerebral Thromboembolic DiseaseIleana Gill, MD MPH, Shirley Chan, MD, Darren Fitzpatrick, MD.COVID-19 Associated Pulmonary and Cerebral Thromboembolic DiseaseFrom the Department of Radiology, Mount Sinai Queens, Astoria, NY.", [["Pulmonary", "ANATOMY", 20, 29], ["Cerebral", "ANATOMY", 34, 42], ["Pulmonary", "ANATOMY", 147, 156], ["Cerebral", "ANATOMY", 161, 169], ["MPH", "CHEMICAL", 81, 84], ["Cerebral Thromboembolic DiseaseFrom", "DISEASE", 161, 196], ["Pulmonary", "ORGAN", 20, 29], ["COVID", "TEST", 0, 5], ["Pulmonary", "ANATOMY", 20, 29], ["Cerebral", "ANATOMY", 34, 42], ["Thromboembolic", "OBSERVATION", 43, 57], ["Pulmonary", "ANATOMY", 147, 156], ["Cerebral", "ANATOMY", 161, 169], ["Thromboembolic", "OBSERVATION", 170, 184]]], ["Address correspondence to IG (email: ileana.gill@mountsinai.org ) Abstract:COVID-19 Associated Pulmonary and Cerebral Thromboembolic DiseasePatients infected with the new SARS-CoV-2 appear to be associated with higher risk of thromboembolic disease, especially stroke and pulmonary embolism.", [["Pulmonary", "ANATOMY", 95, 104], ["Cerebral", "ANATOMY", 109, 117], ["pulmonary", "ANATOMY", 272, 281], ["Cerebral Thromboembolic DiseasePatients infected", "DISEASE", 109, 157], ["thromboembolic disease", "DISEASE", 226, 248], ["stroke", "DISEASE", 261, 267], ["pulmonary embolism", "DISEASE", 272, 290], ["Pulmonary", "ORGAN", 95, 104], ["pulmonary", "ORGAN", 272, 281], ["SARS-CoV", "SPECIES", 171, 179], ["COVID", "TEST", 75, 80], ["Pulmonary and Cerebral Thromboembolic DiseasePatients", "PROBLEM", 95, 148], ["the new SARS", "PROBLEM", 163, 175], ["thromboembolic disease", "PROBLEM", 226, 248], ["stroke", "PROBLEM", 261, 267], ["pulmonary embolism", "PROBLEM", 272, 290], ["Pulmonary", "ANATOMY", 95, 104], ["Cerebral", "ANATOMY", 109, 117], ["Thromboembolic", "OBSERVATION", 118, 132], ["thromboembolic disease", "OBSERVATION", 226, 248], ["pulmonary", "ANATOMY", 272, 281], ["embolism", "OBSERVATION", 282, 290]]], ["We report a case of a 79-year-old woman that presented with stroke and was found to have COVID-19 pneumonia and concomitant large burden pulmonary arterial clot.", [["pulmonary arterial clot", "ANATOMY", 137, 160], ["stroke", "DISEASE", 60, 66], ["pneumonia", "DISEASE", 98, 107], ["pulmonary arterial clot", "DISEASE", 137, 160], ["woman", "ORGANISM", 34, 39], ["pulmonary arterial", "MULTI-TISSUE_STRUCTURE", 137, 155], ["clot", "ORGANISM_SUBSTANCE", 156, 160], ["woman", "SPECIES", 34, 39], ["stroke", "PROBLEM", 60, 66], ["COVID", "TEST", 89, 94], ["pneumonia", "PROBLEM", 98, 107], ["concomitant large burden pulmonary arterial clot", "PROBLEM", 112, 160], ["stroke", "OBSERVATION", 60, 66], ["pneumonia", "OBSERVATION", 98, 107], ["concomitant", "OBSERVATION_MODIFIER", 112, 123], ["large", "OBSERVATION_MODIFIER", 124, 129], ["burden", "OBSERVATION_MODIFIER", 130, 136], ["pulmonary arterial", "ANATOMY", 137, 155], ["clot", "OBSERVATION", 156, 160]]], ["Early imaging of suspected thromboembolic disease may lead to improved patient morbidity and mortality.COVID-19 Associated Pulmonary and Cerebral Thromboembolic DiseaseIntroduction:COVID-19 Associated Pulmonary and Cerebral Thromboembolic DiseaseThe outbreak of Coronavirus disease (COVID-19) was first reported in Wuhan, China, in December 2019, and has quickly reached pandemic levels in the United States.", [["Pulmonary", "ANATOMY", 123, 132], ["Cerebral", "ANATOMY", 137, 145], ["Pulmonary", "ANATOMY", 201, 210], ["Cerebral", "ANATOMY", 215, 223], ["thromboembolic disease", "DISEASE", 27, 49], ["Cerebral Thromboembolic DiseaseIntroduction", "DISEASE", 137, 180], ["Cerebral Thromboembolic Disease", "DISEASE", 215, 246], ["Coronavirus disease", "DISEASE", 262, 281], ["COVID-19", "CHEMICAL", 283, 291], ["patient", "ORGANISM", 71, 78], ["Pulmonary", "ORGAN", 123, 132], ["patient", "SPECIES", 71, 78], ["Early imaging", "TEST", 0, 13], ["suspected thromboembolic disease", "PROBLEM", 17, 49], ["improved patient morbidity", "PROBLEM", 62, 88], ["COVID", "TEST", 103, 108], ["Pulmonary and Cerebral Thromboembolic DiseaseIntroduction", "PROBLEM", 123, 180], ["COVID", "TEST", 181, 186], ["Pulmonary and Cerebral Thromboembolic Disease", "PROBLEM", 201, 246], ["Coronavirus disease", "PROBLEM", 262, 281], ["COVID", "TEST", 283, 288], ["suspected", "UNCERTAINTY", 17, 26], ["thromboembolic disease", "OBSERVATION", 27, 49], ["improved", "OBSERVATION_MODIFIER", 62, 70], ["Pulmonary", "ANATOMY", 123, 132], ["Cerebral", "ANATOMY", 137, 145], ["Thromboembolic", "OBSERVATION", 146, 160], ["Pulmonary", "ANATOMY", 201, 210], ["Cerebral", "ANATOMY", 215, 223], ["Thromboembolic", "OBSERVATION", 224, 238], ["outbreak", "OBSERVATION_MODIFIER", 250, 258], ["Coronavirus disease", "OBSERVATION", 262, 281]]], ["Coronavirus disease is a highly contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and appears to be associated with increased thrombotic disease (1-3) The novel coronavirus is theorized to cause both venous and arterial thromboembolic disease due to a cytokine cascade causing excessive inflammation, hypoxia, immobilization and diffuse intravascular coagulation (2) (3) (4) .", [["venous", "ANATOMY", 240, 246], ["arterial", "ANATOMY", 251, 259], ["intravascular", "ANATOMY", 377, 390], ["Coronavirus disease", "DISEASE", 0, 19], ["acute respiratory syndrome coronavirus", "DISEASE", 68, 106], ["thrombotic disease", "DISEASE", 166, 184], ["coronavirus", "DISEASE", 201, 212], ["venous and arterial thromboembolic disease", "DISEASE", 240, 282], ["inflammation", "DISEASE", 327, 339], ["hypoxia", "DISEASE", 341, 348], ["intravascular coagulation", "DISEASE", 377, 402], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 61, 108], ["SARS-CoV-2", "ORGANISM", 110, 120], ["coronavirus", "ORGANISM", 201, 212], ["venous", "MULTI-TISSUE_STRUCTURE", 240, 246], ["arterial", "MULTI-TISSUE_STRUCTURE", 251, 259], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 377, 390], ["cytokine", "PROTEIN", 292, 300], ["severe acute respiratory syndrome coronavirus", "SPECIES", 61, 106], ["SARS-CoV-2", "SPECIES", 110, 120], ["Coronavirus disease", "PROBLEM", 0, 19], ["a highly contagious disease", "PROBLEM", 23, 50], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 61, 106], ["SARS-CoV", "TEST", 110, 118], ["increased thrombotic disease", "PROBLEM", 156, 184], ["The novel coronavirus", "PROBLEM", 191, 212], ["both venous and arterial thromboembolic disease", "PROBLEM", 235, 282], ["a cytokine cascade", "PROBLEM", 290, 308], ["excessive inflammation", "PROBLEM", 317, 339], ["hypoxia", "PROBLEM", 341, 348], ["immobilization", "TREATMENT", 350, 364], ["diffuse intravascular coagulation", "PROBLEM", 369, 402], ["highly", "OBSERVATION_MODIFIER", 25, 31], ["contagious", "OBSERVATION_MODIFIER", 32, 42], ["severe", "OBSERVATION_MODIFIER", 61, 67], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["respiratory syndrome", "OBSERVATION", 74, 94], ["appears to be associated with", "UNCERTAINTY", 126, 155], ["increased", "OBSERVATION_MODIFIER", 156, 165], ["thrombotic", "OBSERVATION", 166, 176], ["coronavirus", "OBSERVATION", 201, 212], ["venous", "ANATOMY", 240, 246], ["arterial", "ANATOMY", 251, 259], ["thromboembolic", "OBSERVATION", 260, 274], ["cytokine cascade", "OBSERVATION", 292, 308], ["excessive", "OBSERVATION_MODIFIER", 317, 326], ["inflammation", "OBSERVATION", 327, 339], ["hypoxia", "OBSERVATION", 341, 348], ["immobilization", "OBSERVATION_MODIFIER", 350, 364], ["diffuse", "OBSERVATION_MODIFIER", 369, 376], ["intravascular coagulation", "OBSERVATION", 377, 402]]], ["We present a unique case of a 79-year-old COVID positive female with imaging features of simultaneous acute pulmonary embolism and stroke secondary to large intracranial vessel occlusion.Case Presentation:A 79-year-old, previously functionally independent female with a past medical history of hypertension, hyperlipidemia and diabetes was brought to the emergency department with slurred speech and left sided weakness upon awakening.", [["pulmonary", "ANATOMY", 108, 117], ["intracranial vessel", "ANATOMY", 157, 176], ["acute pulmonary embolism", "DISEASE", 102, 126], ["stroke", "DISEASE", 131, 137], ["intracranial vessel occlusion", "DISEASE", 157, 186], ["hypertension", "DISEASE", 294, 306], ["hyperlipidemia", "DISEASE", 308, 322], ["diabetes", "DISEASE", 327, 335], ["COVID", "ORGANISM", 42, 47], ["female", "ORGANISM", 57, 63], ["pulmonary", "ORGAN", 108, 117], ["intracranial vessel", "MULTI-TISSUE_STRUCTURE", 157, 176], ["female", "ORGANISM", 256, 262], ["imaging features", "TEST", 69, 85], ["simultaneous acute pulmonary embolism", "PROBLEM", 89, 126], ["stroke", "PROBLEM", 131, 137], ["large intracranial vessel occlusion", "PROBLEM", 151, 186], ["hypertension", "PROBLEM", 294, 306], ["hyperlipidemia", "PROBLEM", 308, 322], ["diabetes", "PROBLEM", 327, 335], ["slurred speech", "PROBLEM", 381, 395], ["left sided weakness", "PROBLEM", 400, 419], ["simultaneous", "OBSERVATION_MODIFIER", 89, 101], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["pulmonary", "ANATOMY", 108, 117], ["embolism", "OBSERVATION", 118, 126], ["stroke", "OBSERVATION", 131, 137], ["large", "OBSERVATION_MODIFIER", 151, 156], ["intracranial", "ANATOMY_MODIFIER", 157, 169], ["vessel", "ANATOMY", 170, 176], ["occlusion", "OBSERVATION", 177, 186], ["hypertension", "OBSERVATION", 294, 306], ["hyperlipidemia", "OBSERVATION", 308, 322], ["diabetes", "OBSERVATION", 327, 335], ["left", "ANATOMY_MODIFIER", 400, 404], ["sided", "ANATOMY_MODIFIER", 405, 410], ["weakness", "OBSERVATION", 411, 419]]], ["On examination, she was found to have aphasia and left hemiparesis with a National Institutes of Health Stroke Scale (NIHSS) of 21.", [["aphasia", "DISEASE", 38, 45], ["left hemiparesis", "DISEASE", 50, 66], ["Stroke", "DISEASE", 104, 110], ["examination", "TEST", 3, 14], ["aphasia", "PROBLEM", 38, 45], ["left hemiparesis", "PROBLEM", 50, 66], ["NIHSS", "TEST", 118, 123], ["aphasia", "OBSERVATION", 38, 45], ["left", "ANATOMY_MODIFIER", 50, 54], ["hemiparesis", "OBSERVATION", 55, 66]]], ["She was afebrile, had a normal sinus rate and rhythm, but tachypneic with an oxygen saturation of 88%.Case Presentation:Code stroke work-up was initiated.", [["sinus", "ANATOMY", 31, 36], ["tachypneic", "DISEASE", 58, 68], ["oxygen", "CHEMICAL", 77, 83], ["stroke", "DISEASE", 125, 131], ["oxygen", "CHEMICAL", 77, 83], ["sinus", "ORGAN", 31, 36], ["oxygen", "SIMPLE_CHEMICAL", 77, 83], ["afebrile", "PROBLEM", 8, 16], ["tachypneic", "PROBLEM", 58, 68], ["an oxygen saturation", "TEST", 74, 94], ["sinus", "ANATOMY", 31, 36]]], ["Non contrast head CT did not demonstrate hemorrhage.", [["head", "ANATOMY", 13, 17], ["hemorrhage", "DISEASE", 41, 51], ["head", "ORGAN", 13, 17], ["Non contrast head CT", "TEST", 0, 20], ["hemorrhage", "PROBLEM", 41, 51], ["hemorrhage", "OBSERVATION", 41, 51]]], ["CT angiogram (CTA) of the head and neck demonstrated a partial right Sylvian segment (M2), superior division occlusion and right opercular (M3), parietal segment occlusions, respectively (Fig 1) .", [["head", "ANATOMY", 26, 30], ["neck", "ANATOMY", 35, 39], ["right Sylvian segment", "ANATOMY", 63, 84], ["right opercular", "ANATOMY", 123, 138], ["M3", "ANATOMY", 140, 142], ["parietal segment", "ANATOMY", 145, 161], ["parietal segment occlusions", "DISEASE", 145, 172], ["head", "ORGANISM_SUBDIVISION", 26, 30], ["neck", "ORGAN", 35, 39], ["parietal segment", "MULTI-TISSUE_STRUCTURE", 145, 161], ["CT angiogram", "TEST", 0, 12], ["CTA) of the head and neck", "TEST", 14, 39], ["a partial right Sylvian segment (M2)", "PROBLEM", 53, 89], ["superior division occlusion and right opercular (M3), parietal segment occlusions", "PROBLEM", 91, 172], ["head", "ANATOMY", 26, 30], ["neck", "ANATOMY", 35, 39], ["partial", "ANATOMY_MODIFIER", 55, 62], ["right", "ANATOMY_MODIFIER", 63, 68], ["Sylvian", "ANATOMY_MODIFIER", 69, 76], ["segment", "ANATOMY_MODIFIER", 77, 84], ["M2", "ANATOMY_MODIFIER", 86, 88], ["superior", "OBSERVATION_MODIFIER", 91, 99], ["division", "OBSERVATION_MODIFIER", 100, 108], ["occlusion", "OBSERVATION", 109, 118], ["right", "ANATOMY_MODIFIER", 123, 128], ["opercular", "ANATOMY_MODIFIER", 129, 138], ["M3", "ANATOMY_MODIFIER", 140, 142], ["parietal", "ANATOMY_MODIFIER", 145, 153], ["segment", "ANATOMY_MODIFIER", 154, 161], ["occlusions", "OBSERVATION", 162, 172]]], ["Bilateral, peripheral, upper lobe ground glass opacities were also found in the lung apices in the CTA of the neck suggesting a severe viral pneumonia (Fig 2A) .", [["lung apices", "ANATOMY", 80, 91], ["neck", "ANATOMY", 110, 114], ["viral pneumonia", "DISEASE", 135, 150], ["lung apices", "MULTI-TISSUE_STRUCTURE", 80, 91], ["neck", "ORGAN", 110, 114], ["Bilateral, peripheral, upper lobe ground glass opacities", "PROBLEM", 0, 56], ["the CTA", "TEST", 95, 102], ["a severe viral pneumonia", "PROBLEM", 126, 150], ["peripheral", "ANATOMY_MODIFIER", 11, 21], ["upper lobe", "ANATOMY", 23, 33], ["glass opacities", "OBSERVATION", 41, 56], ["lung", "ANATOMY", 80, 84], ["apices", "ANATOMY_MODIFIER", 85, 91], ["CTA", "ANATOMY", 99, 102], ["neck", "ANATOMY", 110, 114], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["viral", "OBSERVATION_MODIFIER", 135, 140], ["pneumonia", "OBSERVATION", 141, 150]]], ["CT perfusion revealed a large area of penumbra involving the right MCA territory with a comparatively tiny infarction (Fig. 3 ).Case Presentation:Intravenous tissue plasminogen activator (tPA) was withheld, as the patient was outside of the tPA window.", [["area", "ANATOMY", 30, 34], ["penumbra", "ANATOMY", 38, 46], ["right MCA territory", "ANATOMY", 61, 80], ["infarction", "DISEASE", 107, 117], ["tissue plasminogen activator", "GENE_OR_GENE_PRODUCT", 158, 186], ["patient", "ORGANISM", 214, 221], ["tPA", "GENE_OR_GENE_PRODUCT", 241, 244], ["tPA", "PROTEIN", 241, 244], ["patient", "SPECIES", 214, 221], ["CT perfusion", "TEST", 0, 12], ["a large area of penumbra", "PROBLEM", 22, 46], ["a comparatively tiny infarction", "PROBLEM", 86, 117], ["Intravenous tissue plasminogen activator (tPA)", "TREATMENT", 146, 192], ["the tPA window", "TREATMENT", 237, 251], ["large", "OBSERVATION_MODIFIER", 24, 29], ["area", "OBSERVATION_MODIFIER", 30, 34], ["penumbra", "OBSERVATION", 38, 46], ["right", "ANATOMY_MODIFIER", 61, 66], ["MCA", "ANATOMY", 67, 70], ["territory", "ANATOMY_MODIFIER", 71, 80], ["comparatively", "OBSERVATION_MODIFIER", 88, 101], ["tiny", "OBSERVATION_MODIFIER", 102, 106], ["infarction", "OBSERVATION", 107, 117]]], ["She was sent to the interventional radiology (IR) suite for thrombectomy.", [["thrombectomy", "TREATMENT", 60, 72], ["thrombectomy", "OBSERVATION", 60, 72]]], ["After four passes, partial recanalization of an occluded superior M2 branch was obtained, with no significant change in patients NIHSS score of 20-21 (Fig 4) .Case Presentation:A follow up brain magnetic resonance imaging (MRI) and Head CT showed multiple, discrete, peripheral acute infarctions of the right MCA territory with some hemorrhagic conversion (Fig 6) .Case Presentation:The patient continued to require high flow oxygen with D-dimer of 8.24 units and C reactive protein of 50 mg/L. Given the patient's declining oxygen saturation, a chest radiograph was obtained and demonstrated bilateral peripheral opacities (Fig 5) .", [["brain", "ANATOMY", 189, 194], ["right MCA territory", "ANATOMY", 303, 322], ["chest", "ANATOMY", 546, 551], ["infarctions of the right MCA", "DISEASE", 284, 312], ["hemorrhagic", "DISEASE", 333, 344], ["oxygen", "CHEMICAL", 426, 432], ["oxygen", "CHEMICAL", 525, 531], ["peripheral opacities", "DISEASE", 603, 623], ["oxygen", "CHEMICAL", 426, 432], ["D-dimer", "CHEMICAL", 438, 445], ["oxygen", "CHEMICAL", 525, 531], ["patients", "ORGANISM", 120, 128], ["brain", "ORGAN", 189, 194], ["patient", "ORGANISM", 387, 394], ["oxygen", "SIMPLE_CHEMICAL", 426, 432], ["D-dimer", "SIMPLE_CHEMICAL", 438, 445], ["C reactive", "SIMPLE_CHEMICAL", 464, 474], ["patient", "ORGANISM", 505, 512], ["oxygen", "SIMPLE_CHEMICAL", 525, 531], ["patients", "SPECIES", 120, 128], ["patient", "SPECIES", 387, 394], ["patient", "SPECIES", 505, 512], ["partial recanalization", "TREATMENT", 19, 41], ["an occluded superior M2 branch", "PROBLEM", 45, 75], ["significant change", "PROBLEM", 98, 116], ["patients NIHSS score", "TEST", 120, 140], ["brain magnetic resonance imaging", "TEST", 189, 221], ["MRI", "TEST", 223, 226], ["Head CT", "TEST", 232, 239], ["multiple, discrete, peripheral acute infarctions of the right MCA territory", "PROBLEM", 247, 322], ["some hemorrhagic conversion", "PROBLEM", 328, 355], ["high flow oxygen", "TREATMENT", 416, 432], ["D-dimer", "TREATMENT", 438, 445], ["C reactive protein", "TREATMENT", 464, 482], ["the patient's declining oxygen saturation", "PROBLEM", 501, 542], ["a chest radiograph", "TEST", 544, 562], ["bilateral peripheral opacities", "PROBLEM", 593, 623], ["partial", "OBSERVATION_MODIFIER", 19, 26], ["recanalization", "OBSERVATION", 27, 41], ["occluded", "OBSERVATION", 48, 56], ["superior", "ANATOMY_MODIFIER", 57, 65], ["M2", "ANATOMY_MODIFIER", 66, 68], ["branch", "ANATOMY_MODIFIER", 69, 75], ["no", "UNCERTAINTY", 95, 97], ["significant", "OBSERVATION_MODIFIER", 98, 109], ["change", "OBSERVATION_MODIFIER", 110, 116], ["Head", "ANATOMY", 232, 236], ["multiple", "OBSERVATION_MODIFIER", 247, 255], ["discrete", "OBSERVATION_MODIFIER", 257, 265], ["peripheral", "ANATOMY_MODIFIER", 267, 277], ["acute", "OBSERVATION_MODIFIER", 278, 283], ["infarctions", "OBSERVATION", 284, 295], ["right", "ANATOMY_MODIFIER", 303, 308], ["MCA", "ANATOMY", 309, 312], ["territory", "ANATOMY_MODIFIER", 313, 322], ["some", "OBSERVATION_MODIFIER", 328, 332], ["hemorrhagic", "OBSERVATION_MODIFIER", 333, 344], ["chest", "ANATOMY", 546, 551], ["bilateral", "ANATOMY_MODIFIER", 593, 602], ["peripheral", "ANATOMY_MODIFIER", 603, 613], ["opacities", "OBSERVATION", 614, 623]]], ["A positive nasopharyngeal swab Polymerase chain reaction (PCR) test confirmed suspicion for COVID -19.Case Presentation:At this time, the upper chest on the initial CTA of the neck was re-reviewed with the added finding of a single segmental thrombus within a left upper lobe pulmonary artery (Fig 2B) .", [["upper chest", "ANATOMY", 138, 149], ["neck", "ANATOMY", 176, 180], ["thrombus", "ANATOMY", 242, 250], ["left upper lobe pulmonary artery", "ANATOMY", 260, 292], ["thrombus", "DISEASE", 242, 250], ["upper chest", "ORGANISM_SUBDIVISION", 138, 149], ["neck", "ORGAN", 176, 180], ["thrombus", "PATHOLOGICAL_FORMATION", 242, 250], ["upper lobe pulmonary artery", "MULTI-TISSUE_STRUCTURE", 265, 292], ["A positive nasopharyngeal swab Polymerase chain reaction", "PROBLEM", 0, 56], ["PCR) test", "TEST", 58, 67], ["COVID", "TEST", 92, 97], ["the initial CTA of the neck", "TEST", 153, 180], ["a single segmental thrombus", "PROBLEM", 223, 250], ["positive", "OBSERVATION_MODIFIER", 2, 10], ["nasopharyngeal", "ANATOMY", 11, 25], ["upper", "ANATOMY_MODIFIER", 138, 143], ["chest", "ANATOMY", 144, 149], ["neck", "ANATOMY", 176, 180], ["segmental", "OBSERVATION_MODIFIER", 232, 241], ["thrombus", "OBSERVATION", 242, 250], ["left upper lobe", "ANATOMY", 260, 275], ["pulmonary artery", "ANATOMY", 276, 292], ["Fig 2B", "OBSERVATION", 294, 300]]], ["A lower extremity venous ultrasound was performed with no deep vein thrombosis identified.Case Presentation:A subsequent CTA of the pulmonary arteries revealed diffuse ground-glass opacities and bibasilar consolidations compatible with severe COVID-19 pneumonia with high burden bilateral acute pulmonary emboli (Fig 7) .", [["lower extremity venous", "ANATOMY", 2, 24], ["deep vein", "ANATOMY", 58, 67], ["pulmonary arteries", "ANATOMY", 132, 150], ["pulmonary", "ANATOMY", 295, 304], ["thrombosis", "DISEASE", 68, 78], ["consolidations", "DISEASE", 205, 219], ["pneumonia", "DISEASE", 252, 261], ["acute pulmonary emboli", "DISEASE", 289, 311], ["lower extremity venous", "MULTI-TISSUE_STRUCTURE", 2, 24], ["deep vein", "MULTI-TISSUE_STRUCTURE", 58, 67], ["pulmonary arteries", "MULTI-TISSUE_STRUCTURE", 132, 150], ["pulmonary emboli", "PATHOLOGICAL_FORMATION", 295, 311], ["A lower extremity venous ultrasound", "TEST", 0, 35], ["deep vein thrombosis", "PROBLEM", 58, 78], ["A subsequent CTA of the pulmonary arteries", "TEST", 108, 150], ["diffuse ground-glass opacities", "PROBLEM", 160, 190], ["bibasilar consolidations", "PROBLEM", 195, 219], ["severe COVID", "PROBLEM", 236, 248], ["pneumonia", "PROBLEM", 252, 261], ["high burden bilateral acute pulmonary emboli", "PROBLEM", 267, 311], ["lower", "ANATOMY_MODIFIER", 2, 7], ["extremity venous", "ANATOMY", 8, 24], ["deep", "ANATOMY_MODIFIER", 58, 62], ["vein", "ANATOMY", 63, 67], ["thrombosis", "OBSERVATION", 68, 78], ["pulmonary arteries", "ANATOMY", 132, 150], ["diffuse", "OBSERVATION_MODIFIER", 160, 167], ["glass opacities", "OBSERVATION", 175, 190], ["bibasilar", "ANATOMY_MODIFIER", 195, 204], ["consolidations", "OBSERVATION", 205, 219], ["compatible with", "UNCERTAINTY", 220, 235], ["severe", "OBSERVATION_MODIFIER", 236, 242], ["pneumonia", "OBSERVATION", 252, 261], ["high", "OBSERVATION_MODIFIER", 267, 271], ["burden", "OBSERVATION_MODIFIER", 272, 278], ["bilateral", "OBSERVATION_MODIFIER", 279, 288], ["acute", "OBSERVATION_MODIFIER", 289, 294], ["pulmonary", "ANATOMY", 295, 304], ["emboli", "OBSERVATION", 305, 311]]], ["Pulmonary emboli involved the right main pulmonary artery, right lung lobar arteries and bilateral segmental arteries.", [["Pulmonary emboli", "ANATOMY", 0, 16], ["right main pulmonary artery", "ANATOMY", 30, 57], ["right lung lobar arteries", "ANATOMY", 59, 84], ["segmental arteries", "ANATOMY", 99, 117], ["Pulmonary emboli", "DISEASE", 0, 16], ["Pulmonary emboli", "MULTI-TISSUE_STRUCTURE", 0, 16], ["pulmonary artery", "MULTI-TISSUE_STRUCTURE", 41, 57], ["lung lobar arteries", "MULTI-TISSUE_STRUCTURE", 65, 84], ["segmental arteries", "MULTI-TISSUE_STRUCTURE", 99, 117], ["Pulmonary emboli", "PROBLEM", 0, 16], ["emboli", "OBSERVATION", 10, 16], ["right main pulmonary artery", "ANATOMY", 30, 57], ["right lung", "ANATOMY", 59, 69], ["lobar arteries", "ANATOMY", 70, 84], ["bilateral", "ANATOMY_MODIFIER", 89, 98], ["segmental arteries", "ANATOMY", 99, 117]]], ["No radiological signs for right heart strain were identified.Case Presentation:During the admission, the patient continued to require oxygen supplementation and was treated with nonbolus intravenous Heparin drip and hydroxychloroquine.", [["right heart", "ANATOMY", 26, 37], ["intravenous", "ANATOMY", 187, 198], ["oxygen", "CHEMICAL", 134, 140], ["Heparin", "CHEMICAL", 199, 206], ["hydroxychloroquine", "CHEMICAL", 216, 234], ["oxygen", "CHEMICAL", 134, 140], ["hydroxychloroquine", "CHEMICAL", 216, 234], ["heart", "ORGAN", 32, 37], ["patient", "ORGANISM", 105, 112], ["oxygen", "SIMPLE_CHEMICAL", 134, 140], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 187, 198], ["Heparin", "SIMPLE_CHEMICAL", 199, 206], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 216, 234], ["patient", "SPECIES", 105, 112], ["radiological signs", "TEST", 3, 21], ["right heart strain", "PROBLEM", 26, 44], ["oxygen supplementation", "TREATMENT", 134, 156], ["nonbolus intravenous Heparin drip", "TREATMENT", 178, 211], ["hydroxychloroquine", "TREATMENT", 216, 234], ["right", "ANATOMY_MODIFIER", 26, 31], ["heart", "ANATOMY", 32, 37], ["strain", "OBSERVATION", 38, 44]]], ["At the time of submission, the patient was hospitalized with stable respiratory symptoms and progressive neurological improvement.Discussion:This case illustrates why the COVID-19 pandemic leads to poor outcomes and thrombotic complications in some patients.", [["respiratory", "ANATOMY", 68, 79], ["neurological", "ANATOMY", 105, 117], ["respiratory symptoms", "DISEASE", 68, 88], ["thrombotic complications", "DISEASE", 216, 240], ["patient", "ORGANISM", 31, 38], ["patients", "ORGANISM", 249, 257], ["patient", "SPECIES", 31, 38], ["patients", "SPECIES", 249, 257], ["stable respiratory symptoms", "PROBLEM", 61, 88], ["progressive neurological improvement", "PROBLEM", 93, 129], ["the COVID", "TEST", 167, 176], ["thrombotic complications", "PROBLEM", 216, 240], ["progressive", "OBSERVATION_MODIFIER", 93, 104], ["neurological improvement", "OBSERVATION", 105, 129], ["thrombotic", "OBSERVATION_MODIFIER", 216, 226], ["complications", "OBSERVATION", 227, 240]]], ["This case demonstrates the presence of concomitant thromboembolic events in the cerebral arterial system and pulmonary vasculature, in the absence of additional risk factors including atrial fibrillation, family history of hypercoagulability, and lower extremity deep vein thrombosis.", [["cerebral arterial system", "ANATOMY", 80, 104], ["pulmonary vasculature", "ANATOMY", 109, 130], ["atrial", "ANATOMY", 184, 190], ["lower extremity deep vein", "ANATOMY", 247, 272], ["thromboembolic", "DISEASE", 51, 65], ["atrial fibrillation", "DISEASE", 184, 203], ["hypercoagulability", "DISEASE", 223, 241], ["deep vein thrombosis", "DISEASE", 263, 283], ["cerebral arterial system", "MULTI-TISSUE_STRUCTURE", 80, 104], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 109, 130], ["atrial", "MULTI-TISSUE_STRUCTURE", 184, 190], ["deep vein", "MULTI-TISSUE_STRUCTURE", 263, 272], ["concomitant thromboembolic events in the cerebral arterial system and pulmonary vasculature", "PROBLEM", 39, 130], ["atrial fibrillation", "PROBLEM", 184, 203], ["hypercoagulability", "PROBLEM", 223, 241], ["lower extremity deep vein thrombosis", "PROBLEM", 247, 283], ["concomitant", "OBSERVATION_MODIFIER", 39, 50], ["thromboembolic", "OBSERVATION", 51, 65], ["cerebral", "ANATOMY_MODIFIER", 80, 88], ["arterial system", "ANATOMY_MODIFIER", 89, 104], ["pulmonary vasculature", "ANATOMY", 109, 130], ["atrial", "ANATOMY", 184, 190], ["fibrillation", "OBSERVATION", 191, 203], ["hypercoagulability", "OBSERVATION", 223, 241], ["lower extremity", "ANATOMY", 247, 262], ["deep vein", "ANATOMY", 263, 272], ["thrombosis", "OBSERVATION", 273, 283]]], ["These findings are supported by the current evidence that COVID-19 may predispose patients to increased thromboembolic disease (1) (2) (3) (4) (5) .", [["COVID-19", "CHEMICAL", 58, 66], ["thromboembolic disease", "DISEASE", 104, 126], ["COVID-19", "CHEMICAL", 58, 66], ["COVID-19", "GENE_OR_GENE_PRODUCT", 58, 66], ["patients", "ORGANISM", 82, 90], ["patients", "SPECIES", 82, 90], ["COVID", "TEST", 58, 63], ["increased thromboembolic disease", "PROBLEM", 94, 126], ["increased", "OBSERVATION_MODIFIER", 94, 103], ["thromboembolic", "OBSERVATION", 104, 118]]], ["Furthermore, patients may present with thromboembolic complications, such as stroke prior to respiratory symptoms.Discussion:COVID-19 has presented a number of diagnostic challenges, in particular those with neurological and respiratory findings.", [["respiratory", "ANATOMY", 93, 104], ["neurological", "ANATOMY", 208, 220], ["respiratory", "ANATOMY", 225, 236], ["thromboembolic complications", "DISEASE", 39, 67], ["stroke", "DISEASE", 77, 83], ["respiratory symptoms", "DISEASE", 93, 113], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["thromboembolic complications", "PROBLEM", 39, 67], ["stroke", "PROBLEM", 77, 83], ["respiratory symptoms", "PROBLEM", 93, 113], ["neurological and respiratory findings", "PROBLEM", 208, 245], ["thromboembolic", "OBSERVATION_MODIFIER", 39, 53], ["complications", "OBSERVATION", 54, 67], ["respiratory", "ANATOMY", 225, 236]]], ["Our patient was admitted with the diagnosis of stroke and the concomitant decreased oxygen saturation that was initially attributed to COVID -19 pneumonia.", [["stroke", "DISEASE", 47, 53], ["oxygen", "CHEMICAL", 84, 90], ["pneumonia", "DISEASE", 145, 154], ["oxygen", "CHEMICAL", 84, 90], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 84, 90], ["patient", "SPECIES", 4, 11], ["stroke", "PROBLEM", 47, 53], ["the concomitant decreased oxygen saturation", "PROBLEM", 58, 101], ["COVID", "TEST", 135, 140], ["pneumonia", "PROBLEM", 145, 154], ["stroke", "OBSERVATION", 47, 53], ["concomitant", "OBSERVATION_MODIFIER", 62, 73], ["decreased", "OBSERVATION_MODIFIER", 74, 83], ["oxygen saturation", "OBSERVATION", 84, 101], ["pneumonia", "OBSERVATION", 145, 154]]], ["The suspicion for pulmonary embolism occurred later in the inpatient hospital course, resulting in re-reviewing the initial neck CTA to diagnose the initial pulmonary embolism and triggered a subsequent CT pulmonary angiogram that showed high burden pulmonary emboli.Discussion:This case also highlights that treating physicians should have a low threshold for diagnostic head and neck CTA and CT pulmonary angiogram in COVID-19 patients with respiratory deterioration and neurologic findings.", [["pulmonary", "ANATOMY", 18, 27], ["neck", "ANATOMY", 124, 128], ["pulmonary", "ANATOMY", 157, 166], ["pulmonary", "ANATOMY", 206, 215], ["pulmonary emboli", "ANATOMY", 250, 266], ["head", "ANATOMY", 372, 376], ["neck", "ANATOMY", 381, 385], ["pulmonary", "ANATOMY", 397, 406], ["respiratory", "ANATOMY", 443, 454], ["neurologic", "ANATOMY", 473, 483], ["pulmonary embolism", "DISEASE", 18, 36], ["pulmonary embolism", "DISEASE", 157, 175], ["pulmonary emboli", "DISEASE", 250, 266], ["respiratory deterioration", "DISEASE", 443, 468], ["pulmonary", "ORGAN", 18, 27], ["neck", "ORGAN", 124, 128], ["pulmonary", "ORGAN", 157, 166], ["pulmonary", "ORGAN", 206, 215], ["pulmonary emboli", "PATHOLOGICAL_FORMATION", 250, 266], ["head", "ORGANISM_SUBDIVISION", 372, 376], ["neck", "ORGAN", 381, 385], ["pulmonary", "ORGAN", 397, 406], ["patients", "ORGANISM", 429, 437], ["patients", "SPECIES", 429, 437], ["pulmonary embolism", "PROBLEM", 18, 36], ["the initial neck CTA", "TEST", 112, 132], ["the initial pulmonary embolism", "PROBLEM", 145, 175], ["a subsequent CT pulmonary angiogram", "TEST", 190, 225], ["high burden pulmonary emboli", "PROBLEM", 238, 266], ["diagnostic head and neck CTA", "TEST", 361, 389], ["CT pulmonary angiogram", "TEST", 394, 416], ["respiratory deterioration and neurologic findings", "PROBLEM", 443, 492], ["suspicion for", "UNCERTAINTY", 4, 17], ["pulmonary", "ANATOMY", 18, 27], ["embolism", "OBSERVATION", 28, 36], ["neck", "ANATOMY", 124, 128], ["pulmonary", "ANATOMY", 157, 166], ["embolism", "OBSERVATION", 167, 175], ["pulmonary", "ANATOMY", 206, 215], ["high", "OBSERVATION_MODIFIER", 238, 242], ["burden", "OBSERVATION_MODIFIER", 243, 249], ["pulmonary", "ANATOMY", 250, 259], ["emboli", "OBSERVATION", 260, 266], ["neck", "ANATOMY", 381, 385], ["pulmonary", "ANATOMY", 397, 406], ["respiratory", "ANATOMY", 443, 454], ["deterioration", "OBSERVATION", 455, 468]]], ["Early recognition and treatment of thromboembolic disease may lead to improved patient morbidity and mortality.", [["thromboembolic disease", "DISEASE", 35, 57], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["Early recognition", "PROBLEM", 0, 17], ["thromboembolic disease", "PROBLEM", 35, 57], ["improved patient morbidity", "PROBLEM", 70, 96], ["thromboembolic", "OBSERVATION", 35, 49]]], ["This case supports the growing body of data that hypercoagulability is a major contributor to COVID-19 related complications and may serve to alert the medical community to heightened vigilance for thromboembolic complications in COVID-19 positive patients.", [["hypercoagulability", "DISEASE", 49, 67], ["thromboembolic", "DISEASE", 198, 212], ["patients", "ORGANISM", 248, 256], ["patients", "SPECIES", 248, 256], ["hypercoagulability", "PROBLEM", 49, 67], ["COVID-19 related complications", "PROBLEM", 94, 124], ["thromboembolic complications", "PROBLEM", 198, 226], ["COVID", "TEST", 230, 235], ["hypercoagulability", "OBSERVATION", 49, 67]]], ["Thromboembolic disease may even be the initial presentation of the disease.", [["Thromboembolic disease", "DISEASE", 0, 22], ["Thromboembolic disease", "PROBLEM", 0, 22], ["the disease", "PROBLEM", 63, 74], ["disease", "OBSERVATION", 67, 74]]], ["COVID-19 has been shown in preliminary analysis to be an independent risk factor for stroke and possibly large vessel occlusion (6) .", [["vessel", "ANATOMY", 111, 117], ["stroke", "DISEASE", 85, 91], ["vessel occlusion", "DISEASE", 111, 127], ["vessel", "MULTI-TISSUE_STRUCTURE", 111, 117], ["COVID-19", "DNA", 0, 8], ["COVID", "TEST", 0, 5], ["stroke", "PROBLEM", 85, 91], ["large vessel occlusion", "PROBLEM", 105, 127], ["possibly", "UNCERTAINTY", 96, 104], ["large", "OBSERVATION_MODIFIER", 105, 110], ["vessel", "ANATOMY", 111, 117], ["occlusion", "OBSERVATION", 118, 127]]], ["Larger cohorts of patients of COVID-19 need to be studied to assess the risk of acute thromboembolic disease, of all types, as an independent risk factor.", [["acute thromboembolic disease", "DISEASE", 80, 108], ["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["COVID", "TEST", 30, 35], ["acute thromboembolic disease", "PROBLEM", 80, 108], ["an independent risk factor", "PROBLEM", 127, 153], ["acute", "OBSERVATION_MODIFIER", 80, 85], ["thromboembolic", "OBSERVATION", 86, 100]]]], "PMC7104618": [["IntroductionGlobal environmental change can unfold rapidly and sometimes irreversibly if anthropogenic pressures exceed critical thresholds.", [["Global environmental change", "PROBLEM", 12, 39], ["anthropogenic pressures", "TEST", 89, 112]]], ["Such nonlinear change dynamics have been referred to as \u201ctipping points\u201d.1 Evidence indicates that many global environmental challenges such as coral reef degradation, ocean acidification, the productivity of agro-ecosystems, and critical Earth system functions such as global climate regulation display nonlinear properties that could imply rapid and practically irreversible shifts in bio-geophysical and social\u2013ecological systems critical for human well-being (Steffen et al. 2011; Rockstr\u00f6m et al. 2009; Lenton et al. 2008).IntroductionThe potential existence of \u201ctipping points\u201d represents a substantial multilevel governance challenge for several reasons.", [["human", "ORGANISM", 446, 451], ["human", "SPECIES", 446, 451], ["human", "SPECIES", 446, 451], ["Such nonlinear change dynamics", "PROBLEM", 0, 30], ["many global environmental challenges", "PROBLEM", 99, 135], ["coral reef degradation", "PROBLEM", 144, 166], ["ocean acidification", "PROBLEM", 168, 187], ["the productivity of agro-ecosystems", "PROBLEM", 189, 224], ["global climate regulation", "PROBLEM", 270, 295], ["rapid and practically irreversible shifts", "PROBLEM", 342, 383], ["\u201ctipping points", "TREATMENT", 567, 582], ["a substantial multilevel governance challenge", "TREATMENT", 595, 640], ["many", "OBSERVATION_MODIFIER", 99, 103], ["global", "OBSERVATION_MODIFIER", 104, 110], ["environmental", "OBSERVATION", 111, 124], ["substantial", "OBSERVATION_MODIFIER", 597, 608], ["multilevel", "OBSERVATION_MODIFIER", 609, 619], ["governance", "OBSERVATION", 620, 630]]], ["First, it is difficult to a priori predict how much disturbances and change a system can absorb before reaching such a perceived \u201ctipping points\u201d (Scheffer et al. 2009; Scheffer and Carpenter 2003), a fact that seriously hampers, and even undermines preventive decision making (Galaz et al. 2010a; Barrett and Dannenberg 2012).", [["much disturbances", "PROBLEM", 47, 64]]], ["It has also been argued that even with certainty about the location of a catastrophic \u201ctipping point,\u201d present generations still have an incentive to avoid costly preventive measures, and instead are likely to pass on the costs to future generations (Gardiner 2009, see also Brook et al. 2013; Schlesinger 2009).", [["catastrophic", "OBSERVATION_MODIFIER", 73, 85]]], ["Second, the transgression of \u201ctipping points\u201d\u2014such as those proposed for coral reef ecosystems due to ocean acidification\u2014can have social\u2013ecological effects that occur over large geographical scales, creating difficult \u201cinstitutional mismatches\u201d as policy makers respond too late or at the wrong organizational level (Walker et al. 2009).", [["coral reef ecosystems", "TREATMENT", 73, 94], ["social\u2013ecological effects", "PROBLEM", 131, 156]]], ["Third, institutional fragmentation has been argued to seriously limit the ability of actors to effectively address perceived \u201ctipping point\u201d characteristics due to inherent system uncertainties, information integration difficulties, and poor incentives for collective action across different sectors and segments of society (Biermann 2012; Galaz et al. 2012).IntroductionResearch initiatives such as the Earth System Governance Project have made important analytical advances the last few years (Biermann et al. 2012).", [["Third, institutional fragmentation", "PROBLEM", 0, 34], ["inherent system uncertainties", "PROBLEM", 164, 193], ["IntroductionResearch initiatives", "TREATMENT", 359, 391], ["fragmentation", "OBSERVATION", 21, 34]]], ["This progress is particularly clear in research areas such as institutional fragmentation, segmentation, and interactions; the changing influence of non-state actors in international environmental governance; novel institutional mechanisms such as norm-setting and implementation; and changing power dynamics in complex actor settings (Young 2008; Biermann and Pattberg 2012; Oberth\u00fcr and Stokke 2011).", [["institutional fragmentation", "PROBLEM", 62, 89]]], ["The mechanisms which allow institutions and state and non-state actors to adapt to changing circumstances (by some denoted adaptiveness) are also gaining increased interest by scholars (Biermann 2007:333; Young 2010).IntroductionAnother stream of literature elaborates a suite of multilevel mechanisms that seem to be able to \u201cmatch\u201d institutions with the dynamic behavior of social\u2013ecological systems (Dietz et al. 2003; Folke et al. 2005; Cash et al. 2006; Galaz et al. 2008; Pahl-Wostl 2009).IntroductionDespite an increased interest, however, few empirical studies exist that explicitly explores the capacity of international actors, institutions, and global networks to deal with perceived \u201ctipping point\u201d dynamics in human\u2013environmental systems.", [["multilevel mechanisms", "PROBLEM", 280, 301], ["few empirical studies", "TEST", 547, 568], ["increased", "OBSERVATION_MODIFIER", 518, 527], ["interest", "OBSERVATION", 528, 536]]], ["This is troublesome considering that the human enterprise now affects systems with proposed nonlinear properties at the global scale (Steffen et al. 2011; Rockstr\u00f6m et al. 2009) and that the features of global environmental governance\u2014i.e., institutions and patterns of collaboration\u2014required to address \u201ctipping point\u201d changes are likely to be very different from those needed to harness incremental (linear) environmental stresses (Folke et al. 2005; Duit and Galaz 2008).", [["human", "ORGANISM", 41, 46], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46]]], ["While some of the challenges explored here have parallels to attempts to understand the features of international responses to international social nonlinear \u201csurprise\u201d phenomena such as financial shocks and other global risks (e.g., Claessens et al. 2010; OECD 2011), we are particularly interested in the \u201ctipping point\u201d dynamics created by coupled human\u2013environmental change.A contributionThere is an increasing need to empirically explore and theorize the way state and non-state actors perceive, respond to and try to prevent large-scale abrupt environmental changes.", [["large-scale abrupt environmental changes", "PROBLEM", 531, 571], ["increasing", "OBSERVATION_MODIFIER", 404, 414]]], ["First, because the definitions of \u201cthresholds,\u201d their reversibility, and their scale remain contested issues.", [["\u201cthresholds", "PROBLEM", 34, 45], ["reversibility", "OBSERVATION_MODIFIER", 54, 67]]], ["There is currently an intense scientific debate on the most appropriate way to define and delineate the correct spatial (local\u2013regional\u2013global) and temporal (slow\u2013fast) progression of thresholds (for example, see Brook et al. 2013, as well as debates about the \u201c2-degree\u201d climate target, Hulme 2012 in Knopf et al. 2012).", [["the correct spatial (local\u2013regional\u2013global) and temporal (slow\u2013fast) progression of thresholds", "PROBLEM", 100, 194], ["intense", "OBSERVATION_MODIFIER", 22, 29], ["temporal", "ANATOMY_MODIFIER", 148, 156]]], ["Second, because the number and types of potential \u201ctipping points\u201d relevant for the study of biophysical systems at global scales are too large to be quantifiable, this makes it difficult to draw general conclusions from a limited set of cases studies.", [["the study", "TEST", 80, 89], ["cases studies", "TEST", 238, 251]]], ["Third, while the governance challenges associated with \u201ctipping points\u201d have been studied extensively for local- and regional-scale human\u2013environmental systems such as forest ecosystems, freshwater lakes, wetlands, and marine systems (see Plummer et al. 2012 for a synthesis), governance challenges associated with global scale or global change-induced tipping point dynamics are seldom explored despite their identified urgency (Young 2011: 6).A contributionIn this study, we analyze current attempts by three global networks to address perceived \u201ctipping points\u201d induced by global change, here exemplified by the combined impacts of loss of marine biodiversity and ocean acidification, pending fisheries collapse, and infectious disease outbreaks, respectively.", [["infectious disease outbreaks", "DISEASE", 720, 748], ["forest ecosystems", "TREATMENT", 168, 185], ["a synthesis)", "TREATMENT", 263, 275], ["governance challenges", "TREATMENT", 277, 298], ["global scale", "PROBLEM", 315, 327], ["global change", "PROBLEM", 331, 344], ["induced tipping point dynamics", "PROBLEM", 345, 375], ["this study", "TEST", 462, 472], ["loss of marine biodiversity", "PROBLEM", 635, 662], ["ocean acidification", "PROBLEM", 667, 686], ["fisheries collapse", "PROBLEM", 696, 714], ["infectious disease outbreaks", "PROBLEM", 720, 748], ["global", "OBSERVATION_MODIFIER", 576, 582], ["change", "OBSERVATION", 583, 589], ["marine biodiversity", "OBSERVATION", 643, 662], ["infectious", "OBSERVATION_MODIFIER", 720, 730]]], ["While these \u201ctipping points\u201d are in many ways different, they have one important thing in common: they are all globally occurring phenomena where the interplay between technological change, increased human and infrastructural interconnectedness, and continuous biophysical resource overexploitation creates possible \u201ctipping point\u201d dynamics (see definition below).", [["human", "ORGANISM", 200, 205], ["human", "SPECIES", 200, 205], ["human", "SPECIES", 200, 205], ["increased human and infrastructural interconnectedness", "PROBLEM", 190, 244]]], ["Despite this diversity, the phenomena studied here all pose similar detection, prevention, and coordination challenges for social actors at multiple scales of social organization (as elaborated by, e.g., Adger et al. 2009; Pahl-Wostl 2009; Galaz et al. 2010a; Young 2011).", [["the phenomena", "PROBLEM", 24, 37]]], ["Hence, they provide interesting and preliminary insights into the sort of multilevel governance challenges associated with nonlinear global change-induced change.", [["multilevel governance challenges", "TREATMENT", 74, 106], ["nonlinear global change", "PROBLEM", 123, 146]]]], "38784f85fdbe7ab7800e39e473bd7d9907ba5e2e": [["antibodies, particularly following mild infection, there is likely a limited window of opportunity to realise the benefit of serology testing for individuals infected during the \"first-wave\" before they potentially fall below a measurable threshold.", [["infection", "DISEASE", 40, 49], ["antibodies", "TEST", 0, 10], ["mild infection", "PROBLEM", 35, 49], ["serology testing", "TEST", 125, 141], ["individuals infected", "PROBLEM", 146, 166], ["mild", "OBSERVATION_MODIFIER", 35, 39], ["infection", "OBSERVATION", 40, 49]]], ["Rapidly expanding availability of serology services for NHS patients will also help understand the long-term implications of serostatus and prior infection in different patient groups, particularly before emergence of any \"second-wave\" outbreak or introduction of a vaccination programme.INTRODUCTIONInfection with SARS-CoV-2 leads to production of a detectable antibody response in most people, however, the clinical utility of routine serological testing has been questioned.", [["infection", "DISEASE", 146, 155], ["SARS", "DISEASE", 315, 319], ["patients", "ORGANISM", 60, 68], ["patient", "ORGANISM", 169, 176], ["SARS-CoV-2", "ORGANISM", 315, 325], ["people", "ORGANISM", 388, 394], ["patients", "SPECIES", 60, 68], ["patient", "SPECIES", 169, 176], ["people", "SPECIES", 388, 394], ["SARS-CoV", "SPECIES", 315, 323], ["serostatus", "PROBLEM", 125, 135], ["prior infection", "PROBLEM", 140, 155], ["a vaccination programme", "TREATMENT", 264, 287], ["SARS", "PROBLEM", 315, 319], ["a detectable antibody response", "PROBLEM", 349, 379], ["routine serological testing", "TEST", 429, 456], ["infection", "OBSERVATION", 146, 155], ["antibody response", "OBSERVATION", 362, 379]]], ["(1, 2) There is uncertainty about what proportion of infected individuals produce serum antibodies, how long they persist for, and whether their detection provides protection against reinfection or disease manifestations upon re-exposure to the virus.", [["serum", "ANATOMY", 82, 87], ["reinfection", "DISEASE", 183, 194], ["individuals", "ORGANISM", 62, 73], ["serum", "ORGANISM_SUBSTANCE", 82, 87], ["serum antibodies", "PROTEIN", 82, 98], ["infected individuals", "PROBLEM", 53, 73], ["serum antibodies", "TEST", 82, 98], ["reinfection", "PROBLEM", 183, 194], ["disease manifestations", "PROBLEM", 198, 220], ["the virus", "PROBLEM", 241, 250], ["infected", "OBSERVATION", 53, 61]]], ["These uncertainties, coupled with the fact that antibody testing for other respiratory viral infection is not standard practice and concerns regarding production and validation of rapidly developed new tests, (1, 3) have led to hesitancy introducing them into widespread clinical practice.INTRODUCTIONFrom late May 2020 the UK government prioritised serological testing in NHS staff, reserving patient testing for those interested and undergoing other blood tests with a requirement for written consent.", [["blood", "ANATOMY", 452, 457], ["respiratory viral infection", "DISEASE", 75, 102], ["patient", "ORGANISM", 394, 401], ["blood", "ORGANISM_SUBSTANCE", 452, 457], ["patient", "SPECIES", 394, 401], ["antibody testing", "TEST", 48, 64], ["other respiratory viral infection", "PROBLEM", 69, 102], ["new tests", "TEST", 198, 207], ["serological testing", "TEST", 350, 369], ["reserving patient testing", "TEST", 384, 409], ["other blood tests", "TEST", 446, 463], ["infection", "OBSERVATION", 93, 102]]], ["By that time our virology department had received many enquiries from different specialties asking whether SARS-CoV 2 infection might be contributing to patient presentation despite negative conventional RT-PCR testing.INTRODUCTIONWe recently completed parallel validation of eight lateral flow immunoassay (LFIA) devices and two commercial ELISA platforms against an ELISA assay developed at King's College London (KCL) that measures IgG, IgA and IgM against the main SARS-CoV-2 antigens (nucleocapsid (N) and spike (S) proteins and the S receptor binding domain (RBD).", [["SARS", "DISEASE", 107, 111], ["infection", "DISEASE", 118, 127], ["SARS-CoV 2", "ORGANISM", 107, 117], ["patient", "ORGANISM", 153, 160], ["IgG", "GENE_OR_GENE_PRODUCT", 435, 438], ["IgA", "GENE_OR_GENE_PRODUCT", 440, 443], ["IgM", "GENE_OR_GENE_PRODUCT", 448, 451], ["SARS-CoV-2", "ORGANISM", 469, 479], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 490, 506], ["spike (S) proteins", "GENE_OR_GENE_PRODUCT", 511, 529], ["IgG", "PROTEIN", 435, 438], ["IgA", "PROTEIN", 440, 443], ["IgM", "PROTEIN", 448, 451], ["SARS-CoV-2 antigens", "PROTEIN", 469, 488], ["nucleocapsid (N) and spike (S) proteins", "PROTEIN", 490, 529], ["S receptor binding domain", "PROTEIN", 538, 563], ["RBD", "PROTEIN", 565, 568], ["patient", "SPECIES", 153, 160], ["SARS-CoV", "SPECIES", 107, 115], ["SARS-CoV", "SPECIES", 469, 477], ["SARS", "PROBLEM", 107, 111], ["CoV 2 infection", "PROBLEM", 112, 127], ["conventional RT-PCR testing", "TEST", 191, 218], ["eight lateral flow immunoassay", "TEST", 276, 306], ["LFIA) devices", "TREATMENT", 308, 321], ["an ELISA assay", "TEST", 365, 379], ["KCL)", "TREATMENT", 416, 420], ["IgG", "TEST", 435, 438], ["IgA", "TEST", 440, 443], ["IgM", "TEST", 448, 451], ["the main SARS", "TEST", 460, 473], ["CoV", "TEST", 474, 477], ["nucleocapsid", "TEST", 490, 502], ["spike (S) proteins", "PROBLEM", 511, 529], ["the S receptor binding domain (RBD)", "PROBLEM", 534, 569]]], ["Viral neutralisation assays were also established alongside the in-house ELISA to correlate antibody titres with functional activity.", [["Viral neutralisation assays", "TEST", 0, 27], ["antibody titres", "TEST", 92, 107], ["neutralisation", "OBSERVATION", 6, 20]]], ["Validation was initially performed on a cohort of patients presenting to Guy's and St Thomas' NHS Foundation Trust and showed that the accuracy of some of the lateral flow devices was comparable to our ELISA (paper submitted for publication).INTRODUCTIONWe therefore submitted a formal request to the hospital Risk & Assurance Board subcommittee to provide a pilot clinical SARS-CoV-2 serology service for children and adults.", [["patients", "ORGANISM", 50, 58], ["children", "ORGANISM", 406, 414], ["patients", "SPECIES", 50, 58], ["children", "SPECIES", 406, 414], ["the lateral flow devices", "TREATMENT", 155, 179], ["our ELISA", "TEST", 198, 207]]], ["The SureScreen LFIA was selected based on a range of factors including gaining confidence on performance and procurement during validation.", [["SureScreen LFIA", "DNA", 4, 19], ["The SureScreen LFIA", "TEST", 0, 19]]], ["Pilot approval was obtained on May 29 th 2020 following review of protocols and laboratory data including a further validation set reported here.", [["laboratory data", "TEST", 80, 95], ["a further validation set", "TEST", 106, 130]]], ["No reuse allowed without permission.INTRODUCTION(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.INTRODUCTIONThe copyright holder for this preprint this version posted July 11, 2020. . https://doi.org/10.1101/2020.07.10.20150540 doi: medRxiv preprintSureScreen Diagnostics LFIA validationCommercial LFIAs were selected for further validation based on results from previous head-to-head analyses.(4) Sensitivity and specificity experiments were designed with reference to MHRA and other validation guidance published at various times during the first wave, using serum samples from SARS-CoV-2 RNA positive (AusDiagnostics)(5) patients taken 14 or more (n=301) and 20 or more (n=204) days post onset of symptoms (POS) and 300 pre-pandemic samples.", [["head", "ANATOMY", 459, 463], ["serum samples", "ANATOMY", 648, 661], ["samples", "ANATOMY", 823, 830], ["head", "ORGANISM_SUBDIVISION", 459, 463], ["serum samples", "ORGANISM_SUBSTANCE", 648, 661], ["SARS-CoV-2", "ORGANISM", 667, 677], ["patients", "ORGANISM", 711, 719], ["patients", "SPECIES", 711, 719], ["SARS-CoV", "SPECIES", 667, 675], ["further validation", "TEST", 409, 427], ["previous head-to-head analyses", "TEST", 450, 480], ["Sensitivity", "TEST", 485, 496], ["specificity experiments", "TEST", 501, 524], ["serum samples", "TEST", 648, 661], ["SARS", "TEST", 667, 671], ["CoV", "TEST", 672, 675], ["symptoms", "PROBLEM", 787, 795], ["pre-pandemic samples", "TEST", 810, 830], ["med", "ANATOMY", 127, 130], ["head", "ANATOMY", 467, 471]]], ["This included 200 stored serum samples and a panel of 100 stored acute and convalescent confounder samples taken from individuals with EBV, CMV, HIV and a range of other viral, bacterial and fungal pathogens.", [["serum samples", "ANATOMY", 25, 38], ["samples", "ANATOMY", 99, 106], ["EBV, CMV, HIV", "DISEASE", 135, 148], ["serum samples", "ORGANISM_SUBSTANCE", 25, 38], ["EBV", "ORGANISM", 135, 138], ["CMV", "ORGANISM", 140, 143], ["HIV", "SPECIES", 145, 148], ["EBV", "SPECIES", 135, 138], ["CMV", "SPECIES", 140, 143], ["HIV", "SPECIES", 145, 148], ["serum samples", "TEST", 25, 38], ["a panel", "TEST", 43, 50], ["convalescent confounder samples", "TEST", 75, 106], ["EBV", "PROBLEM", 135, 138], ["CMV", "PROBLEM", 140, 143], ["HIV", "PROBLEM", 145, 148], ["other viral, bacterial and fungal pathogens", "PROBLEM", 164, 207], ["fungal pathogens", "OBSERVATION", 191, 207]]], ["95% confidence intervals were determined using the Wilson/Brown Binomial test.", [["the Wilson/Brown Binomial test", "TEST", 47, 77]]], ["Sera from individuals diagnosed with seasonal coronaviruses were not available for testing.", [["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["coronaviruses", "ORGANISM", 46, 59], ["seasonal coronaviruses", "PROBLEM", 37, 59], ["testing", "TEST", 83, 90]]], ["The research reagent for anti-SARS-CoV-2 Ab (NIBSC 20/130) obtained from the National Institute for Biological Standards and Control (NIBSC), UK, was used as a positive control for reproducibility and limit of detection experiments.Service deliveryInternal governance approval for service delivery was based on the laboratory validation data, clinical oversight, confirmation of an ability to request and report tests on electronic systems, a review of risks and their mitigation and agreement to report back on completion of the pilot.", [["anti-SARS-CoV-2", "ORGANISM", 25, 40], ["anti-SARS", "TEST", 25, 34], ["CoV", "TEST", 35, 38], ["NIBSC", "TEST", 45, 50], ["Biological Standards", "TREATMENT", 100, 120], ["service delivery", "TREATMENT", 281, 297], ["the laboratory validation data", "TEST", 311, 341], ["electronic systems", "TEST", 421, 439]]], ["Service commenced on June 3rd and was delivered by scientists from the KCL Department of Infectious Diseases who had conducted all the LFIA validations.", [["Infectious Diseases", "DISEASE", 89, 108], ["Infectious", "OBSERVATION", 89, 99]]], ["Tests were performed in and provided by the Guy's and St Thomas' Hospital Centre for Clinical Infection and Diagnostics Research (CIDR), located adjacent to hospital routine diagnostic virology and blood sciences laboratories on the St Thomas' Hospital site.Service deliveryAvailability of SARS-CoV-2 serology service was communicated through clinical networks with requests vetted by the clinical virology team.", [["blood", "ANATOMY", 198, 203], ["blood", "ORGANISM_SUBSTANCE", 198, 203], ["Tests", "TEST", 0, 5], ["Clinical Infection", "PROBLEM", 85, 103], ["blood sciences", "TEST", 198, 212]]], ["Samples were requested as part of routine laboratory testing route and serology was performed once daily, Monday to Friday, using the SureScreen Diagnostics LFIA as per manufacturer's instructions with two independent operators evaluating the result.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["routine laboratory testing route", "TEST", 34, 66], ["serology", "TEST", 71, 79]]], ["A detectable band of either IgM or IgG (or both) was reported to the clinician as \"antibodies detected\".", [["IgM", "GENE_OR_GENE_PRODUCT", 28, 31], ["IgG", "GENE_OR_GENE_PRODUCT", 35, 38], ["IgM", "PROTEIN", 28, 31], ["IgG", "PROTEIN", 35, 38], ["antibodies", "PROTEIN", 83, 93], ["A detectable band of either IgM", "PROBLEM", 0, 31], ["IgG", "PROBLEM", 35, 38], ["detectable", "OBSERVATION_MODIFIER", 2, 12], ["band", "OBSERVATION_MODIFIER", 13, 17], ["IgM", "OBSERVATION", 28, 31]]], ["Results were uploaded onto hospital electronic patient records as a scanned image of the lateral flow cassette with a written comment alongside telephoning where appropriate.", [["patient", "ORGANISM", 47, 54], ["lateral flow cassette", "DNA", 89, 110], ["patient", "SPECIES", 47, 54], ["a scanned image", "TEST", 66, 81]]], ["Differential detection of IgM and IgG was not taken into account as part of verbal or written advice.", [["IgM", "GENE_OR_GENE_PRODUCT", 26, 29], ["IgG", "GENE_OR_GENE_PRODUCT", 34, 37], ["IgM", "PROTEIN", 26, 29], ["IgG", "PROTEIN", 34, 37], ["Differential detection", "TEST", 0, 22], ["IgM", "TEST", 26, 29], ["IgG", "TEST", 34, 37]]], ["Repeat testing was recommended when there was a high index of clinical suspicion and no antibodies were detected, or a weak positive IgM or IgG was the only observed band.", [["IgM", "GENE_OR_GENE_PRODUCT", 133, 136], ["IgG", "GENE_OR_GENE_PRODUCT", 140, 143], ["antibodies", "PROTEIN", 88, 98], ["IgM", "PROTEIN", 133, 136], ["IgG", "PROTEIN", 140, 143], ["Repeat testing", "TEST", 0, 14], ["antibodies", "PROBLEM", 88, 98], ["a weak positive IgM or IgG", "PROBLEM", 117, 143]]], ["A standard set of demographics, clinical information, request details and SARS-CoV-2 PCR results were recorded for each participant and stored in a clinical database.", [["participant", "SPECIES", 120, 131], ["CoV-2 PCR", "TEST", 79, 88]]], ["Sera were batched for testing on the KCL ELISA platform with additional assessment for neutralizing antibodies where appropriate.", [["Sera", "ANATOMY", 0, 4], ["Sera", "ORGANISM_SUBSTANCE", 0, 4], ["neutralizing antibodies", "PROTEIN", 87, 110], ["testing", "TEST", 22, 29], ["the KCL ELISA platform", "TEST", 33, 55], ["additional assessment", "TEST", 61, 82], ["neutralizing antibodies", "PROBLEM", 87, 110]]], ["This was undertaken as a further level of validation, but at a time remote from clinical decision making.ELISAHigh-binding ELISA plates (Corning, 3690) were coated with antigen (N, S) at 3 \u00b5g/mL (25 \u00b5L per well) in PBS.", [["ELISAHigh", "SIMPLE_CHEMICAL", 105, 114], ["antigen (N, S)", "TREATMENT", 169, 183]]], ["Wells were washed with PBS-T (PBS with 0.05% Tween-20) and then blocked with 100 \u00b5L 5% milk in PBS-T for 1 hr at room temperature.", [["milk", "ANATOMY", 87, 91], ["PBS-T", "CHEMICAL", 23, 28], ["Tween-20", "CHEMICAL", 45, 53], ["Tween-20", "CHEMICAL", 45, 53], ["PBS-T", "SIMPLE_CHEMICAL", 23, 28], ["Tween-20", "SIMPLE_CHEMICAL", 45, 53], ["milk", "ORGANISM_SUBSTANCE", 87, 91], ["PBS-T (PBS", "TREATMENT", 23, 33], ["0.05% Tween", "TREATMENT", 39, 50]]], ["Wells were emptied and sera diluted at 1:50 in milk was added and incubated for 2 hr at room temperature.", [["sera", "ANATOMY", 23, 27], ["milk", "ANATOMY", 47, 51], ["sera", "ORGANISM_SUBSTANCE", 23, 27], ["milk", "ORGANISM_SUBSTANCE", 47, 51], ["sera", "TREATMENT", 23, 27]]], ["Control reagents included CR3009 (2 \u00b5g/mL), CR3022 (0.2 \u00b5g/mL), negative control plasma (1:25 dilution), positive control plasma (1:50) and blank wells.", [["plasma", "ANATOMY", 81, 87], ["plasma", "ANATOMY", 122, 128], ["CR3009", "CHEMICAL", 26, 32], ["CR3022", "CHEMICAL", 44, 50], ["CR3009", "CHEMICAL", 26, 32], ["CR3022", "CHEMICAL", 44, 50], ["CR3009", "SIMPLE_CHEMICAL", 26, 32], ["CR3022", "SIMPLE_CHEMICAL", 44, 50], ["plasma", "ORGANISM_SUBSTANCE", 81, 87], ["plasma", "ORGANISM_SUBSTANCE", 122, 128], ["CR3009", "TEST", 26, 32], ["CR3022", "TEST", 44, 50]]], ["Wells were washed with PBS-T.", [["PBS", "TREATMENT", 23, 26]]], ["Secondary antibody was added and incubated for 1 hr at room temperature.", [["Secondary antibody", "PROBLEM", 0, 18]]], ["IgM was detected using goat-anti-human-IgM-HRP (1:1,000) (Sigma: A6907), IgG was detected using goat-anti-human-Fc-AP (1:1,000) (Jackson: 109-055-043-JIR).", [["IgM", "GENE_OR_GENE_PRODUCT", 0, 3], ["HRP", "GENE_OR_GENE_PRODUCT", 43, 46], ["IgG", "ORGANISM", 73, 76], ["IgM", "PROTEIN", 0, 3], ["IgM", "PROTEIN", 39, 42], ["HRP", "PROTEIN", 43, 46], ["1:1,000", "PROTEIN", 48, 55], ["A6907", "PROTEIN", 65, 70], ["IgG", "PROTEIN", 73, 76], ["Fc", "PROTEIN", 112, 114], ["AP", "PROTEIN", 115, 117], ["JIR", "PROTEIN", 150, 153], ["goat", "SPECIES", 23, 27], ["goat", "SPECIES", 96, 100], ["goat", "SPECIES", 23, 27], ["IgM", "TEST", 0, 3], ["goat", "TEST", 23, 27], ["anti-human", "TEST", 28, 38], ["IgG", "TEST", 73, 76], ["goat", "TEST", 96, 100], ["anti-human", "TEST", 101, 111]]], ["Wells were washed with PBS-T and either Alkaline Phosphatase (AP) substrate (Sigma) was added and read at 405 nm (AP) or 1-step TMB substrate (Thermo Scientific) was added and quenched with 0.5 M H 2 SO 4 before reading at 450 nm (HRP).", [["TMB", "CHEMICAL", 128, 131], ["H 2 SO 4", "CHEMICAL", 196, 204], ["Alkaline Phosphatase", "SIMPLE_CHEMICAL", 40, 60], ["AP", "SIMPLE_CHEMICAL", 62, 64], ["Alkaline Phosphatase (AP) substrate", "PROTEIN", 40, 75], ["PBS", "TEST", 23, 26], ["Alkaline Phosphatase", "TEST", 40, 60], ["AP", "TEST", 114, 116]]], ["Antibodies were considered detected if OD values were 4-fold or greater above background.Neutralising antibody assaySerial dilutions of serum samples were prepared with DMEM media and incubated with pseudotyped HIV virus incorporating the SARS-Cov2 spike protein(6) for 1-hour at 37\u00b0C in 96-well plates.", [["serum samples", "ANATOMY", 136, 149], ["serum samples", "ORGANISM_SUBSTANCE", 136, 149], ["pseudotyped HIV virus", "ORGANISM", 199, 220], ["SARS-Cov2 spike protein", "PROTEIN", 239, 262], ["HIV", "SPECIES", 211, 214], ["HIV virus", "SPECIES", 211, 220], ["Antibodies", "TEST", 0, 10], ["OD values", "TEST", 39, 48], ["Neutralising antibody", "TEST", 89, 110], ["serum samples", "TEST", 136, 149], ["DMEM media", "TREATMENT", 169, 179], ["pseudotyped HIV virus", "PROBLEM", 199, 220], ["the SARS", "TEST", 235, 243], ["Cov2 spike protein", "TEST", 244, 262]]], ["Next, HeLa cells stably expressing the ACE2 receptor (provided by Dr James Voss, The Scripps Research Institute) were added and the plates were left for 72 hours.", [["HeLa cells", "ANATOMY", 6, 16], ["HeLa cells", "CELL", 6, 16], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 39, 52], ["HeLa cells", "CELL_LINE", 6, 16], ["ACE2 receptor", "PROTEIN", 39, 52], ["HeLa cells", "TREATMENT", 6, 16], ["the ACE2 receptor", "TREATMENT", 35, 52], ["the plates", "TREATMENT", 128, 138], ["HeLa cells", "OBSERVATION", 6, 16]]], ["Infection level was assessed in lysed cells with the Bright-Glo luciferase kit (Promega), using a Victor\u2122 X3 multilabel reader (Perkin Elmer).", [["cells", "ANATOMY", 38, 43], ["cells", "CELL", 38, 43], ["luciferase", "GENE_OR_GENE_PRODUCT", 64, 74], ["lysed cells", "CELL_TYPE", 32, 43], ["Infection level", "PROBLEM", 0, 15], ["a Victor\u2122", "TREATMENT", 96, 105]]], ["The ID50 for each sera was calculated using GraphPad Prism.The ID 50 for each sera was calculated using GraphPad Prism.", [["sera", "ANATOMY", 18, 22], ["sera", "ANATOMY", 78, 82], ["sera", "ORGANISM_SUBSTANCE", 18, 22], ["sera", "ORGANISM_SUBSTANCE", 78, 82], ["The ID50", "TREATMENT", 0, 8], ["each sera", "TEST", 13, 22], ["GraphPad Prism", "TREATMENT", 44, 58], ["each sera", "TEST", 73, 82], ["GraphPad Prism", "TREATMENT", 104, 118]]], ["Neutralisation titres were classified as low (50-200), moderate (201-500), high (501-2000), or potent (2001+).Patient and public involvementPatients were not involved in the development of the study or its outcome measures, conduct of the research, or preparation of the manuscript.RESULTSComprehensive LFIA validation was performed using serum samples from 301 PCRconfirmed SARS-CoV-2 positive individuals collected 14 or more days POS and 300 pre-pandemic serum samples including 100 (acute and convalescent) from patients with a range of other infections that could give a false positive result (table 1a) .", [["serum samples", "ANATOMY", 339, 352], ["serum samples", "ANATOMY", 458, 471], ["infections", "DISEASE", 547, 557], ["Patients", "ORGANISM", 140, 148], ["serum samples", "ORGANISM_SUBSTANCE", 339, 352], ["SARS-CoV-2", "ORGANISM", 375, 385], ["individuals", "ORGANISM", 395, 406], ["serum samples", "ORGANISM_SUBSTANCE", 458, 471], ["patients", "ORGANISM", 516, 524], ["Patient", "SPECIES", 110, 117], ["Patients", "SPECIES", 140, 148], ["patients", "SPECIES", 516, 524], ["SARS-CoV", "SPECIES", 375, 383], ["Neutralisation titres", "TEST", 0, 21], ["the study", "TEST", 189, 198], ["RESULTSComprehensive LFIA validation", "TEST", 282, 318], ["serum samples", "TEST", 339, 352], ["PCRconfirmed SARS", "TEST", 362, 379], ["CoV", "TEST", 380, 383], ["pre-pandemic serum samples", "TEST", 445, 471], ["other infections", "PROBLEM", 541, 557], ["moderate", "OBSERVATION_MODIFIER", 55, 63], ["infections", "OBSERVATION", 547, 557]]], ["168 (of the 301) samples were specifically evaluated head-to-head with an in-house ELISA for IgM and IgG to N, S and RBD (supplementary figure 1) .", [["samples", "ANATOMY", 17, 24], ["head", "ANATOMY", 53, 57], ["head", "ANATOMY", 61, 65], ["samples", "CANCER", 17, 24], ["head", "ORGANISM_SUBDIVISION", 53, 57], ["head", "ORGAN", 61, 65], ["IgM", "GENE_OR_GENE_PRODUCT", 93, 96], ["IgG", "GENE_OR_GENE_PRODUCT", 101, 104], ["IgM", "PROTEIN", 93, 96], ["IgG", "PROTEIN", 101, 104], ["RBD", "PROTEIN", 117, 120], ["IgM", "TEST", 93, 96], ["IgG", "TEST", 101, 104], ["RBD", "PROBLEM", 117, 120], ["head", "ANATOMY", 61, 65]]], ["Sensitivity at 14 and 20 days or more POS was 94.4% and 96.1% respectively and specificity was 99.3% (table 1b) .", [["Sensitivity", "TEST", 0, 11], ["specificity", "TEST", 79, 90]]], ["Limit of detection based on visual inspection of LFIA bands by two operators was determined using the NIBSC reference standard to a dilution of 1 in 500, consistent with the expected limit of detection of the NIBSC in-house assay(7).RESULTSOverall 49/108 (45%) participants had detectable IgG and/or IgM SARS-CoV-2 antibodies on their first serum sample that was communicated to clinicians as \"antibodies detected\" (table 2) .", [["serum sample", "ANATOMY", 341, 353], ["participants", "ORGANISM", 261, 273], ["IgG", "GENE_OR_GENE_PRODUCT", 289, 292], ["CoV-2", "GENE_OR_GENE_PRODUCT", 309, 314], ["serum", "ORGANISM_SUBSTANCE", 341, 346], ["IgG", "PROTEIN", 289, 292], ["IgM SARS-CoV-2 antibodies", "PROTEIN", 300, 325], ["antibodies", "PROTEIN", 394, 404], ["participants", "SPECIES", 261, 273], ["visual inspection", "TEST", 28, 45], ["RESULTSOverall", "TEST", 233, 247], ["IgG", "TEST", 289, 292], ["IgM SARS", "TEST", 300, 308], ["CoV", "TEST", 309, 312], ["serum sample", "TEST", 341, 353]]], ["38/49 (78%) had IgM and 48/49 (98%) had IgG bands.", [["IgM", "GENE_OR_GENE_PRODUCT", 16, 19], ["IgM", "PROTEIN", 16, 19], ["IgG bands", "PROTEIN", 40, 49], ["IgM", "TEST", 16, 19], ["IgG bands", "TEST", 40, 49]]], ["Five participants with a high index of suspicion but no detectable antibodies had a further serum sample tested at least one week after initial testing.", [["serum sample", "ANATOMY", 92, 104], ["serum", "ORGANISM_SUBSTANCE", 92, 97], ["antibodies", "PROTEIN", 67, 77], ["participants", "SPECIES", 5, 17], ["detectable antibodies", "PROBLEM", 56, 77], ["a further serum sample", "TEST", 82, 104], ["initial testing", "TEST", 136, 151]]], ["All repeat samples had no detectable antibodies.", [["samples", "ANATOMY", 11, 18], ["antibodies", "PROTEIN", 37, 47], ["All repeat samples", "TEST", 0, 18], ["detectable antibodies", "PROBLEM", 26, 47]]], ["Rationale for testing broadly fell into three referral categories.", [["testing", "TEST", 14, 21]]], ["First, acute presentations with new symptoms potentially triggered by SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 70, 90], ["SARS-CoV-2", "ORGANISM", 70, 80], ["SARS-CoV", "SPECIES", 70, 78], ["new symptoms", "PROBLEM", 32, 44], ["SARS", "PROBLEM", 70, 74], ["CoV-2 infection", "PROBLEM", 75, 90], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["infection", "OBSERVATION", 81, 90]]], ["This included suspected cases of Paediatric Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2 (PIMS-TS) (n=29), plus adults (n=27) and children (n=6) presenting with other clinical syndromes including thrombotic events such as strokes and pulmonary emboli (collectively called COVID-19 syndromes).", [["pulmonary emboli", "ANATOMY", 261, 277], ["Inflammatory Multisystem Syndrome", "DISEASE", 44, 77], ["thrombotic events", "DISEASE", 223, 240], ["strokes", "DISEASE", 249, 256], ["pulmonary emboli", "DISEASE", 261, 277], ["children", "ORGANISM", 157, 165], ["pulmonary", "ORGAN", 261, 270], ["children", "SPECIES", 157, 165], ["Paediatric Inflammatory Multisystem Syndrome", "PROBLEM", 33, 77], ["SARS", "PROBLEM", 105, 109], ["CoV", "TEST", 110, 113], ["other clinical syndromes", "PROBLEM", 188, 212], ["thrombotic events", "PROBLEM", 223, 240], ["strokes", "PROBLEM", 249, 256], ["pulmonary emboli", "PROBLEM", 261, 277], ["COVID", "TEST", 299, 304], ["syndromes", "PROBLEM", 308, 317], ["Inflammatory Multisystem Syndrome", "OBSERVATION", 44, 77], ["thrombotic", "OBSERVATION", 223, 233], ["strokes", "OBSERVATION", 249, 256], ["pulmonary", "ANATOMY", 261, 270], ["emboli", "OBSERVATION", 271, 277]]], ["Second, suspected \"missed\" diagnoses in individuals with a (recent) COVID-19 compatible illness who either never had an RNA test performed (n=18) or viral RNA was not detected in respiratory specimens (n=22).", [["respiratory specimens", "ANATOMY", 179, 200], ["viral RNA", "RNA", 149, 158], ["an RNA test", "TEST", 117, 128], ["viral RNA", "PROBLEM", 149, 158], ["respiratory specimens", "TEST", 179, 200]]], ["Third, those for whom antibody detection made a significant contribution to decisions on infection control management or immunosuppressive treatment (n=6).RESULTSOf 29 children with suspected PIMS-TS, 12 had detectable antibodies (41%).", [["infection", "DISEASE", 89, 98], ["PIMS-TS", "DISEASE", 192, 199], ["children", "ORGANISM", 168, 176], ["antibodies", "PROTEIN", 219, 229], ["children", "SPECIES", 168, 176], ["whom antibody detection", "TEST", 17, 40], ["infection control management", "TREATMENT", 89, 117], ["immunosuppressive treatment", "TREATMENT", 121, 148], ["suspected PIMS", "TEST", 182, 196], ["detectable antibodies", "PROBLEM", 208, 229]]], ["Reviewing the clinical history of the 17 with no detectable antibodies, seven (41%) had an alternate plausible diagnosis, or did not fulfill PIMS-TS diagnostic criteria at the time of discharge and 10 (59%) had ongoing high clinical suspicion of PIMS-TS.", [["PIMS", "DISEASE", 246, 250], ["antibodies", "PROTEIN", 60, 70], ["detectable antibodies", "PROBLEM", 49, 70], ["PIMS", "PROBLEM", 246, 250]]], ["Two children had repeat testing, neither had detectable antibodies at this stage.", [["children", "ORGANISM", 4, 12], ["antibodies", "PROTEIN", 56, 66], ["children", "SPECIES", 4, 12], ["repeat testing", "TEST", 17, 31], ["detectable antibodies", "PROBLEM", 45, 66]]], ["For the remaining 33 RNA PCR negative individuals presenting with a potential post-COVID syndrome, seven (21.2%) had antibodies detected.", [["COVID syndrome", "DISEASE", 83, 97], ["antibodies", "PROTEIN", 117, 127], ["the remaining 33 RNA PCR", "TEST", 4, 28], ["a potential post-COVID syndrome", "PROBLEM", 66, 97], ["antibodies", "PROBLEM", 117, 127]]], ["This included two with the diagnosis of pulmonary embolism (PE), one with a new diagnosis of interstitial lung disease (ILD), two with a hyperinflammatory syndrome (akin to PIMS-TS), and one patient with paracentral acute middle maculopathy.", [["pulmonary", "ANATOMY", 40, 49], ["interstitial lung", "ANATOMY", 93, 110], ["pulmonary embolism", "DISEASE", 40, 58], ["PE", "DISEASE", 60, 62], ["interstitial lung disease", "DISEASE", 93, 118], ["ILD", "DISEASE", 120, 123], ["hyperinflammatory syndrome", "DISEASE", 137, 163], ["acute middle maculopathy", "DISEASE", 216, 240], ["pulmonary", "ORGAN", 40, 49], ["lung", "ORGAN", 106, 110], ["patient", "ORGANISM", 191, 198], ["patient", "SPECIES", 191, 198], ["pulmonary embolism", "PROBLEM", 40, 58], ["PE", "PROBLEM", 60, 62], ["interstitial lung disease", "PROBLEM", 93, 118], ["ILD)", "PROBLEM", 120, 124], ["a hyperinflammatory syndrome", "PROBLEM", 135, 163], ["paracentral acute middle maculopathy", "PROBLEM", 204, 240], ["pulmonary", "ANATOMY", 40, 49], ["embolism", "OBSERVATION", 50, 58], ["PE", "OBSERVATION", 60, 62], ["new", "OBSERVATION_MODIFIER", 76, 79], ["interstitial", "ANATOMY_MODIFIER", 93, 105], ["lung", "ANATOMY", 106, 110], ["disease", "OBSERVATION", 111, 118], ["hyperinflammatory syndrome", "OBSERVATION", 137, 163], ["paracentral", "OBSERVATION_MODIFIER", 204, 215], ["acute", "OBSERVATION_MODIFIER", 216, 221], ["middle", "ANATOMY_MODIFIER", 222, 228], ["maculopathy", "OBSERVATION", 229, 240]]], ["No reuse allowed without permission.RESULTS(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.RESULTSThe copyright holder for this preprint this version posted July 11, 2020. .", [["med", "ANATOMY", 122, 125]]], ["40 individuals were tested to identify potential missed COVID-19 diagnoses comprising nine presenting to hospital with ongoing compatible symptoms but negative SARS-CoV-2 RNA tests, and 31 who had recovered from a recent compatible illness in the community, including 15 individuals with end-stage renal failure, who had been advised to shield, and 12 patients attending the respiratory led post-COVID clinic due to failure to return to their baseline level of function.", [["renal", "ANATOMY", 298, 303], ["end-stage renal failure", "DISEASE", 288, 311], ["individuals", "ORGANISM", 3, 14], ["renal", "ORGAN", 298, 303], ["patients", "ORGANISM", 352, 360], ["patients", "SPECIES", 352, 360], ["ongoing compatible symptoms", "PROBLEM", 119, 146], ["CoV", "TEST", 165, 168], ["RNA tests", "TEST", 171, 180], ["end-stage renal failure", "PROBLEM", 288, 311], ["failure", "PROBLEM", 416, 423], ["renal", "ANATOMY", 298, 303], ["failure", "OBSERVATION", 304, 311]]], ["Serological testing was performed no earlier than 21 days post onset of symptoms (POS), up to approximately 90 days POS.", [["Serological testing", "TEST", 0, 19], ["symptoms", "PROBLEM", 72, 80]]], ["Overall, 22/40 (55.0%) had detectable antibodies, including two patients admitted to ITU but with repeatedly negative RNA results on upper and lower respiratory sampling.RESULTSOf the 6 individuals with persistent SARS-CoV-2 RNA on nose and throat swabs tested to guide infection control or immunosuppression decisions, all had detectable antibodies on SureScreen LFIA, and when tested, moderate (n=1), high (n=1), or potent (n=4) neutralising antibodies titres.", [["nose", "ANATOMY", 232, 236], ["throat swabs", "ANATOMY", 241, 253], ["SARS", "DISEASE", 214, 218], ["infection", "DISEASE", 270, 279], ["patients", "ORGANISM", 64, 72], ["upper", "ORGANISM_SUBDIVISION", 133, 138], ["nose", "ORGANISM_SUBDIVISION", 232, 236], ["antibodies", "PROTEIN", 38, 48], ["antibodies", "PROTEIN", 339, 349], ["neutralising antibodies", "PROTEIN", 431, 454], ["patients", "SPECIES", 64, 72], ["detectable antibodies", "PROBLEM", 27, 48], ["upper and lower respiratory sampling", "PROBLEM", 133, 169], ["persistent SARS", "PROBLEM", 203, 218], ["CoV", "TEST", 219, 222], ["nose", "TREATMENT", 232, 236], ["throat swabs", "TEST", 241, 253], ["infection control", "TREATMENT", 270, 287], ["immunosuppression", "TREATMENT", 291, 308], ["SureScreen LFIA", "TEST", 353, 368], ["moderate (n=1), high (n=1)", "PROBLEM", 387, 413], ["potent (n=4) neutralising antibodies titres", "PROBLEM", 418, 461], ["upper", "ANATOMY_MODIFIER", 133, 138], ["lower", "ANATOMY_MODIFIER", 143, 148], ["respiratory", "ANATOMY", 149, 160], ["persistent", "OBSERVATION_MODIFIER", 203, 213], ["SARS", "OBSERVATION", 214, 218], ["nose", "ANATOMY", 232, 236], ["throat", "ANATOMY", 241, 247], ["moderate", "OBSERVATION_MODIFIER", 387, 395]]], ["This implied, when considered with other factors such as time from first positive RNA test, and threshold cycle for RNA detection, that they were no longer infectious, and had a degree of protection from reinfection.RESULTSELISA testing confirmed the LFIA result in all but three samples -in two cases the ELISA did not detect antibodies (whereas the SureScreen LFIA did), and in one case antibodies were detected (whereas the SureScreen LFIA detected none) (see table 2 ).DISCUSSIONThis pilot SARS-CoV-2 serology service was introduced two months after the peak of acute UK COVID-19 admissions and provided results on 108 patients over a three-week period.", [["samples", "ANATOMY", 280, 287], ["LFIA", "CANCER", 251, 255], ["patients", "ORGANISM", 623, 631], ["LFIA", "DNA", 251, 255], ["antibodies", "PROTEIN", 327, 337], ["SureScreen LFIA", "PROTEIN", 351, 366], ["antibodies", "PROTEIN", 389, 399], ["SureScreen LFIA", "PROTEIN", 427, 442], ["patients", "SPECIES", 623, 631], ["first positive RNA test", "PROBLEM", 67, 90], ["RNA detection", "TEST", 116, 129], ["reinfection", "PROBLEM", 204, 215], ["RESULTSELISA testing", "TEST", 216, 236], ["the LFIA", "TEST", 247, 255], ["three samples", "TEST", 274, 287], ["the ELISA", "TEST", 302, 311], ["antibodies", "PROBLEM", 327, 337], ["the SureScreen LFIA", "TEST", 347, 366], ["the SureScreen LFIA", "TEST", 423, 442], ["no longer", "UNCERTAINTY", 146, 155], ["reinfection", "OBSERVATION", 204, 215]]], ["It included a large number of children presenting with a new hyperinflammatory, Kawasaki-like syndrome, termed PIMS-TS (8) , to the on-site Evelina London Children's Hospital that provides tertiary referral and regional specialist services.", [["Kawasaki-like syndrome", "DISEASE", 80, 102], ["PIMS-TS", "DISEASE", 111, 118], ["children", "ORGANISM", 30, 38], ["children", "SPECIES", 30, 38], ["Children", "SPECIES", 155, 163], ["a new hyperinflammatory, Kawasaki-like syndrome", "PROBLEM", 55, 102], ["large", "OBSERVATION_MODIFIER", 14, 19]]], ["41% had antibodies detected, lower than previously reported (8, 9) , potentially due to increased awareness and broadening of clinical evaluation criteria, supported by a number of children having this diagnosis removed from discharge coding.DISCUSSIONSerology was particularly helpful aiding diagnosis and management of what is an increasing range of assumed COVID-19 triggered conditions.(10-15) For example, antibodies were detected in two patients presenting with a PE that was therefore considered a provoked event, limiting the need for additional investigations and reducing the period of anticoagulation.", [["PE", "DISEASE", 470, 472], ["children", "ORGANISM", 181, 189], ["patients", "ORGANISM", 443, 451], ["antibodies", "PROTEIN", 8, 18], ["antibodies", "PROTEIN", 411, 421], ["children", "SPECIES", 181, 189], ["patients", "SPECIES", 443, 451], ["antibodies", "TEST", 8, 18], ["increased awareness", "PROBLEM", 88, 107], ["clinical evaluation criteria", "TEST", 126, 154], ["management", "TREATMENT", 307, 317], ["antibodies", "TEST", 411, 421], ["a PE", "PROBLEM", 468, 472], ["additional investigations", "TEST", 543, 568], ["anticoagulation", "TREATMENT", 596, 611], ["lower", "OBSERVATION_MODIFIER", 29, 34], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["PE", "OBSERVATION", 470, 472]]], ["Negative serology also helped discount COVID-19 as a potential trigger for newly presenting conditions, which included acquired haemophilia A and a range of unusual dermatological presentations e.g.", [["haemophilia", "DISEASE", 128, 139], ["serology", "TEST", 9, 17], ["newly presenting conditions", "PROBLEM", 75, 102], ["acquired haemophilia A", "PROBLEM", 119, 141], ["haemophilia", "OBSERVATION", 128, 139]]], ["'Covid toes'.DISCUSSIONDetecting antibodies in patients with persistently positive SARS-CoV-2 PCR tests despite symptom resolution, a phenomenon reported elsewhere (16) , enabled important decisions for infection control and immunosuppression.", [["infection", "DISEASE", 203, 212], ["patients", "ORGANISM", 47, 55], ["DISCUSSIONDetecting antibodies", "PROTEIN", 13, 43], ["patients", "SPECIES", 47, 55], ["persistently positive SARS", "PROBLEM", 61, 87], ["CoV", "TEST", 88, 91], ["PCR tests", "TEST", 94, 103], ["symptom resolution", "PROBLEM", 112, 130], ["a phenomenon", "PROBLEM", 132, 144], ["infection control", "TREATMENT", 203, 220], ["immunosuppression", "TREATMENT", 225, 242], ["toes", "ANATOMY", 7, 11]]], ["These decisions were supported by data that antibodies against spike protein (personal communication with SureScreen Diagnostics Ltd) correlate with neutralization (17) and there is published guidance that neutralisation can be used as a proxy for reduced risk of transmission (18, 19) .", [["antibodies against spike protein", "GENE_OR_GENE_PRODUCT", 44, 76], ["antibodies", "PROTEIN", 44, 54], ["spike protein", "PROTEIN", 63, 76], ["spike protein", "PROBLEM", 63, 76]]], ["Since neutralising experiments are time-consuming and complex, rapid tests that detect antibodies against spike, such as the SureScreen LFIA and some, but not other technologies (20, 21) are a practical alternative (22) when considered alongside other factors including timing from symptom onset, ongoing symptoms, and cycle threshold or take-off values of PCR results.DISCUSSIONThe strength of this study includes the extensive prior comparison of multiple technologies using a large panel of serum samples to inform choice and validation of the selected LFIA for clinical service.", [["serum samples", "ANATOMY", 494, 507], ["serum", "ORGANISM_SUBSTANCE", 494, 499], ["antibodies", "PROTEIN", 87, 97], ["rapid tests", "TEST", 63, 74], ["antibodies", "PROBLEM", 87, 97], ["spike", "PROBLEM", 106, 111], ["the SureScreen LFIA", "TEST", 121, 140], ["symptom onset", "PROBLEM", 282, 295], ["ongoing symptoms", "PROBLEM", 297, 313], ["cycle threshold", "PROBLEM", 319, 334], ["PCR", "TEST", 357, 360], ["this study", "TEST", 395, 405], ["serum samples", "TEST", 494, 507]]], ["Results were also consistent with recommendations from a Cochrane review published after completion of our pilot, which suggested a benefit for serology to confirm a COVID-19 diagnosis in patients who did not have SARS-CoV-2 RNA testing performed, or who had a negative result despite an ongoing high index of clinical suspicion.(3) All rights reserved.", [["patients", "ORGANISM", 188, 196], ["patients", "SPECIES", 188, 196], ["serology", "TEST", 144, 152], ["a COVID", "TEST", 164, 171], ["SARS", "PROBLEM", 214, 218], ["CoV", "TEST", 219, 222], ["RNA testing", "TEST", 225, 236]]], ["No reuse allowed without permission.DISCUSSION(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DISCUSSIONThe copyright holder for this preprint this version posted July 11, 2020. .", [["med", "ANATOMY", 125, 128]]], ["There were also only 3 cases where concordance was not seen between the LFIA and ELISA, consistent with the sensitivity estimates from our validation.", [["ELISA", "TEST", 81, 86], ["consistent with", "UNCERTAINTY", 88, 103]]], ["With high pre-test probability (e.g. 45%), the positive predictive value (PPV) is 99.2%, with an acceptable negative predictive value (NPV) of 96.9%.", [["high pre-test probability", "PROBLEM", 5, 30], ["PPV", "TEST", 74, 77], ["NPV", "TEST", 135, 138], ["high", "OBSERVATION_MODIFIER", 5, 9]]], ["However, it is of note that if testing were to be extended to a population where prevalence is low (e.g. 5%) the PPV falls to <90%.", [["testing", "TEST", 31, 38], ["the PPV", "TEST", 109, 116], ["low", "OBSERVATION_MODIFIER", 95, 98]]], ["This re-enforces the importance of providing serology for defined patient cohorts where the pre-test probability is high and the potential clinical utility is understood.DISCUSSIONThe main limitation of this study is in being performed at a single-centre at a discrete time-point in the COVID-19 pandemic.", [["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73], ["serology", "TEST", 45, 53], ["the pre-test probability", "TEST", 88, 112], ["this study", "TEST", 203, 213], ["the COVID", "TEST", 283, 292], ["main", "OBSERVATION_MODIFIER", 184, 188], ["limitation", "OBSERVATION_MODIFIER", 189, 199]]], ["It is impossible to predict precise future serology service needs, whether that be aiding acute diagnosis alongside PCR testing, (23) informing patients that they have or have not had COVID-19, helping guide infection control decisions in hospitals or helping diagnose emerging post-inflammatory syndromes.", [["infection", "DISEASE", 208, 217], ["patients", "ORGANISM", 144, 152], ["patients", "SPECIES", 144, 152], ["PCR testing", "TEST", 116, 127], ["inflammatory syndromes", "PROBLEM", 283, 305], ["inflammatory syndromes", "OBSERVATION", 283, 305]]], ["Faster, more accurate even point of care SARS-CoV-2 virus detection assays may become widely available in hospitals and the community during a second wave, reducing the number of missed or delayed diagnoses and thus reduce demand for serological testing.", [["CoV-2 virus", "ORGANISM", 46, 57], ["CoV-2 virus", "SPECIES", 46, 57], ["SARS-CoV-2 virus", "SPECIES", 41, 57], ["care SARS", "TEST", 36, 45], ["CoV-2 virus detection assays", "TEST", 46, 74], ["serological testing", "TEST", 234, 253]]], ["The second limitation, although not technology specific, is that using serology as the marker of previous SARS-CoV-2 infection will likely only identify a proportion of infected patients given emerging evidence that seronegative individuals can show T-cell specific responses.", [["T-cell", "ANATOMY", 250, 256], ["SARS", "DISEASE", 106, 110], ["infection", "DISEASE", 117, 126], ["SARS-CoV-2", "ORGANISM", 106, 116], ["patients", "ORGANISM", 178, 186], ["individuals", "ORGANISM", 229, 240], ["T-cell", "CELL", 250, 256], ["patients", "SPECIES", 178, 186], ["SARS-CoV-2", "SPECIES", 106, 116], ["serology", "TEST", 71, 79], ["previous SARS", "PROBLEM", 97, 110], ["CoV-2 infection", "PROBLEM", 111, 126], ["seronegative individuals", "PROBLEM", 216, 240], ["infected", "OBSERVATION", 169, 177]]], ["(24) Nevertheless, LFIAs are quick (10 minute test), straightforward to perform by trained operators, inexpensive and are already used in many diagnostic laboratories for example for detecting pneumococcal and legionella urinary antigens.", [["urinary", "ANATOMY", 221, 228], ["pneumococcal", "ORGANISM", 193, 205], ["legionella urinary antigens", "GENE_OR_GENE_PRODUCT", 210, 237], ["pneumococcal and legionella urinary antigens", "PROTEIN", 193, 237], ["pneumococcal", "SPECIES", 193, 205], ["legionella", "SPECIES", 210, 220], ["LFIAs", "TEST", 19, 24], ["pneumococcal and legionella urinary antigens", "PROBLEM", 193, 237], ["legionella", "OBSERVATION", 210, 220]]], ["This could include community healthcare facilities after appropriate training and mechanisms to record and disseminate the results.", [["appropriate training", "TREATMENT", 57, 77]]], ["It should be noted however that as only serum was tested in our study, validation of LFIAs on capillary blood requires further work.DISCUSSIONIn summary, we conclude there is clinical utility in providing a SARS-CoV-2 patient serology service detecting spike proteins that can be feasibly delivered using LFIA devices.", [["serum", "ANATOMY", 40, 45], ["capillary blood", "ANATOMY", 94, 109], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["LFIAs", "SIMPLE_CHEMICAL", 85, 90], ["capillary blood", "ORGANISM_SUBSTANCE", 94, 109], ["patient", "ORGANISM", 218, 225], ["spike proteins", "PROTEIN", 253, 267], ["patient", "SPECIES", 218, 225], ["our study", "TEST", 60, 69], ["capillary blood", "TEST", 94, 109], ["spike proteins", "PROBLEM", 253, 267], ["LFIA devices", "TREATMENT", 305, 317]]], ["Further service evaluation at other centres will help track the emerging utility of serology testing and inform guidance on the indications and interpretation.", [["Further service evaluation", "TEST", 0, 26], ["serology testing", "TEST", 84, 100]]], ["There is a compelling case to provide such testing as soon as possible given emerging evidence(25) of a rapid decline in antibody levels, particularly in pauci-symptomatic patients.DISCUSSIONAll rights reserved.", [["patients", "ORGANISM", 172, 180], ["patients", "SPECIES", 172, 180], ["such testing", "TEST", 38, 50], ["a rapid decline in antibody levels", "PROBLEM", 102, 136], ["rapid", "OBSERVATION_MODIFIER", 104, 109], ["decline", "OBSERVATION", 110, 117]]], ["No reuse allowed without permission.DISCUSSION(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DISCUSSIONThe copyright holder for this preprint this version posted July 11, 2020. . https://doi.org/10.1101/2020.07.10.20150540 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DISCUSSIONThe copyright holder for this preprint this version posted July 11, 2020. . https://doi.org/10.1101/2020.07.10.20150540 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DISCUSSIONThe copyright holder for this preprint this version posted July 11, 2020. . https://doi.org/10.1101/2020.07.10.20150540 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DISCUSSIONThe copyright holder for this preprint this version posted July 11, 2020. . https://doi.org/10.1101/2020.07.10.20150540 doi: medRxiv preprint \u271d E L I S A d e t e c t e d / S u r e S c r e e n n o t d e t e c t e d ( 1 p a r t i c i p a n t ) ELISA not detected/ SureScreen detected (1 participant in each group, 2 in to All rights reserved.", [["medRxiv", "TEST", 1177, 1184], ["a n t", "TEST", 1286, 1291], ["ELISA", "TEST", 1294, 1299], ["SureScreen", "TEST", 1314, 1324], ["med", "ANATOMY", 125, 128], ["med", "ANATOMY", 412, 415], ["med", "ANATOMY", 699, 702], ["med", "ANATOMY", 986, 989]]], ["No reuse allowed without permission.DISCUSSION(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DISCUSSIONThe copyright holder for this preprint this version posted July 11, 2020. . https://doi.org/10.1101/2020.07.10.20150540 doi: medRxiv preprint", [["medRxiv", "TREATMENT", 316, 323], ["med", "ANATOMY", 125, 128]]]], "PMC7487339": [["IntroductionThe recent outbreak of SARS-CoV-2 has caused a serious global threat.", [["SARS", "DISEASE", 35, 39], ["SARS-CoV-2", "ORGANISM", 35, 45], ["CoV-", "SPECIES", 40, 44], ["SARS-CoV", "SPECIES", 35, 43], ["SARS", "PROBLEM", 35, 39], ["a serious global threat", "PROBLEM", 57, 80]]], ["The speed with which this virus is spreading all over the world has crossed the rate at which the understanding of the disease and its effects is evolving amongst scientists, public health officials, and other members of the global health community.", [["this virus", "PROBLEM", 21, 31], ["the disease", "PROBLEM", 115, 126], ["disease", "OBSERVATION", 119, 126]]], ["While the pandemic continues, scientists are looking at tracing the species from which the infection may have originated (Guo et al. 2020).", [["infection", "DISEASE", 91, 100], ["the infection", "PROBLEM", 87, 100], ["infection", "OBSERVATION", 91, 100]]], ["In the light of the evidence depicting its first circulation in bats before transmitting via intermediate host to humans, a new question on whether this virus has the capability of transfer from human to animal is trending.", [["humans", "ORGANISM", 114, 120], ["human", "ORGANISM", 195, 200], ["humans", "SPECIES", 114, 120], ["human", "SPECIES", 195, 200], ["humans", "SPECIES", 114, 120], ["human", "SPECIES", 195, 200], ["this virus", "PROBLEM", 148, 158]]], ["Various new cases have come forward in revealing the transmission of this novel virus from infected humans to animals (Ng and Hiscox 2020).", [["humans", "ORGANISM", 100, 106], ["humans", "SPECIES", 100, 106], ["humans", "SPECIES", 100, 106], ["this novel virus", "PROBLEM", 69, 85]]], ["Moreover, the risk of reverse transmission from companion animals to humans can also increase the risk of COVID-19 infection.", [["infection", "DISEASE", 115, 124], ["humans", "ORGANISM", 69, 75], ["COVID-19", "GENE_OR_GENE_PRODUCT", 106, 114], ["humans", "SPECIES", 69, 75], ["humans", "SPECIES", 69, 75], ["COVID-19", "SPECIES", 106, 114], ["COVID-19 infection", "PROBLEM", 106, 124], ["infection", "OBSERVATION", 115, 124]]], ["Although there is limited evidence of transmission of the virus among pets, yet the likelihood of its transmission to companion humans has also been discussed by various scientists and public health officials.", [["humans", "ORGANISM", 128, 134], ["humans", "SPECIES", 128, 134], ["humans", "SPECIES", 128, 134], ["the virus among pets", "PROBLEM", 54, 74], ["limited evidence of", "UNCERTAINTY", 18, 37], ["virus", "OBSERVATION", 58, 63]]], ["The goal of this article is to review the possible transmission of COVID-19 in animal species in the context of positive animal corona cases worldwide and reach a possible conclusion.", [["COVID-19", "CHEMICAL", 67, 75], ["COVID-19", "CHEMICAL", 67, 75], ["COVID-19", "CELL", 67, 75], ["COVID", "TEST", 67, 72], ["animal species", "PROBLEM", 79, 93], ["corona", "OBSERVATION_MODIFIER", 128, 134]]], ["Moreover, precautionary measures to protect pets and other animals from the virus have also been discussed.", [["precautionary measures", "TREATMENT", 10, 32], ["the virus", "PROBLEM", 72, 81]]], ["This review is built on a narrow range of data available till date and general instructions for preventing and monitoring the consequences of the human animal interface.", [["human", "ORGANISM", 146, 151], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 146, 151]]], ["There is an urgent need to promote awareness and corroborate practices for helping people as well as animals to stay secure and healthy.", [["people", "ORGANISM", 83, 89], ["people", "SPECIES", 83, 89]]], ["Furthermore, it provides a quick insight into the suspected SARS-CoV-2 reservoirs and introduces some safety measures for humans as well as companion animals to control the spread of COVID-19.Corona viruses and history of their originCoronaviruses (CoV) are a group of viruses belonging to the family of Coronaviridae.", [["SARS", "DISEASE", 60, 64], ["humans", "ORGANISM", 122, 128], ["Corona viruses", "ORGANISM", 192, 206], ["originCoronaviruses", "GENE_OR_GENE_PRODUCT", 228, 247], ["CoV", "ORGANISM", 249, 252], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 304, 317], ["humans", "SPECIES", 122, 128], ["humans", "SPECIES", 122, 128], ["CoV", "SPECIES", 249, 252], ["CoV-2 reservoirs", "TREATMENT", 65, 81], ["some safety measures", "TREATMENT", 97, 117], ["humans", "TREATMENT", 122, 128], ["companion animals", "TREATMENT", 140, 157], ["COVID", "TEST", 183, 188], ["Corona viruses", "PROBLEM", 192, 206], ["Coronaviridae", "TREATMENT", 304, 317], ["viruses", "OBSERVATION", 199, 206]]], ["These families of viruses infect both humans and vertebrate animals (Ng and Hiscox 2020).", [["humans", "ORGANISM", 38, 44], ["humans", "SPECIES", 38, 44], ["humans", "SPECIES", 38, 44], ["viruses infect", "PROBLEM", 18, 32], ["viruses", "OBSERVATION", 18, 25]]], ["Four types of corona viruses, namely, HKUI, NL63, OC43, and 229E, also known to cause respiratory diseases (Saif et al. 2019), while SARS-CoV, MERS-CoV, and SARS-CoV-2 can be responsible for causing severe pulmonary injury and respiratory distress which may cause fatality in humans.Corona viruses and history of their originThe two major events in the past resulted in severe diseases due to the transmission of viruses of beta (\u03b2) genera from animals to humans (Guarner 2020).", [["respiratory", "ANATOMY", 86, 97], ["pulmonary", "ANATOMY", 206, 215], ["respiratory", "ANATOMY", 227, 238], ["respiratory diseases", "DISEASE", 86, 106], ["pulmonary injury", "DISEASE", 206, 222], ["respiratory distress", "DISEASE", 227, 247], ["HKUI", "GENE_OR_GENE_PRODUCT", 38, 42], ["NL63", "GENE_OR_GENE_PRODUCT", 44, 48], ["OC43", "GENE_OR_GENE_PRODUCT", 50, 54], ["229E", "GENE_OR_GENE_PRODUCT", 60, 64], ["SARS-CoV", "ORGANISM", 133, 141], ["MERS-CoV", "ORGANISM", 143, 151], ["SARS-CoV-2", "ORGANISM", 157, 167], ["pulmonary", "ORGAN", 206, 215], ["humans", "ORGANISM", 276, 282], ["Corona viruses", "ORGANISM", 283, 297], ["beta (\u03b2)", "GENE_OR_GENE_PRODUCT", 424, 432], ["humans", "ORGANISM", 456, 462], ["humans", "SPECIES", 276, 282], ["humans", "SPECIES", 456, 462], ["SARS-CoV", "SPECIES", 133, 141], ["MERS-CoV", "SPECIES", 143, 151], ["SARS-CoV", "SPECIES", 157, 165], ["humans", "SPECIES", 276, 282], ["humans", "SPECIES", 456, 462], ["corona viruses", "PROBLEM", 14, 28], ["HKUI", "TEST", 38, 42], ["respiratory diseases", "PROBLEM", 86, 106], ["SARS", "PROBLEM", 133, 137], ["MERS", "PROBLEM", 143, 147], ["CoV", "PROBLEM", 148, 151], ["SARS", "PROBLEM", 157, 161], ["CoV", "PROBLEM", 162, 165], ["severe pulmonary injury", "PROBLEM", 199, 222], ["respiratory distress", "PROBLEM", 227, 247], ["fatality in humans", "PROBLEM", 264, 282], ["Corona viruses", "PROBLEM", 283, 297], ["severe diseases", "PROBLEM", 370, 385], ["corona viruses", "OBSERVATION", 14, 28], ["severe", "OBSERVATION_MODIFIER", 199, 205], ["pulmonary", "ANATOMY", 206, 215], ["injury", "OBSERVATION", 216, 222], ["respiratory distress", "OBSERVATION", 227, 247], ["viruses", "OBSERVATION", 290, 297], ["origin", "ANATOMY_MODIFIER", 319, 325], ["two", "OBSERVATION_MODIFIER", 329, 332], ["major", "OBSERVATION_MODIFIER", 333, 338], ["severe", "OBSERVATION_MODIFIER", 370, 376], ["diseases", "OBSERVATION", 377, 385]]], ["In 2002\u20132003, the first event occurred in China into Guangdong province when a beta coronavirus which originated in bats moved to human via palm civet cats which acted as their intermediate host (Martina et al. 2003).", [["beta coronavirus", "ORGANISM", 79, 95], ["bats", "ORGANISM", 116, 120], ["human", "ORGANISM", 130, 135], ["palm civet cats", "ORGANISM", 140, 155], ["human", "SPECIES", 130, 135], ["cats", "SPECIES", 151, 155], ["beta coronavirus", "SPECIES", 79, 95], ["human", "SPECIES", 130, 135], ["a beta coronavirus", "PROBLEM", 77, 95]]], ["A decade later, in 2012, another coronavirus named as the Middle East Respiratory Syndrome coronavirus, designated as MERS-CoV was originated in Saudi Arabia and its transmission took place from bats with dromedary camels being the intermediate host (Qian et al. 2013).", [["coronavirus", "DISEASE", 33, 44], ["Middle East Respiratory Syndrome coronavirus", "DISEASE", 58, 102], ["coronavirus", "ORGANISM", 33, 44], ["Middle East Respiratory Syndrome coronavirus", "ORGANISM", 58, 102], ["MERS-CoV", "ORGANISM", 118, 126], ["Middle East Respiratory Syndrome coronavirus", "SPECIES", 58, 102], ["MERS-CoV", "SPECIES", 118, 126], ["another coronavirus", "PROBLEM", 25, 44], ["the Middle East Respiratory Syndrome coronavirus", "PROBLEM", 54, 102], ["Middle", "ANATOMY_MODIFIER", 58, 64], ["Respiratory Syndrome coronavirus", "OBSERVATION", 70, 102]]], ["It was reported to infect about 2494 people with 858 fatalities.", [["fatalities", "DISEASE", 53, 63], ["people", "ORGANISM", 37, 43], ["people", "SPECIES", 37, 43]]], ["Recently, at the end of the year 2019, Wuhan, a major business centre in China, experienced an emergence of a new corona virus, i.e., SARS-CoV-2 (COVID-19) which is also described to be a subtype of the \u03b2 subgroup of coronaviruses (Xu et al. 2020a).", [["SARS", "DISEASE", 134, 138], ["SARS-CoV-2", "ORGANISM", 134, 144], ["COVID-19", "ORGANISM", 146, 154], ["coronaviruses", "ORGANISM", 217, 230], ["SARS-CoV-2 (COVID-19", "SPECIES", 134, 154], ["a new corona virus", "PROBLEM", 108, 126], ["SARS-CoV", "TEST", 134, 142], ["COVID", "TEST", 146, 151]]], ["SARS-CoV-2 has drastically spread over more than 200 countries and territories around the world, infecting around 2 million people across the world.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["people", "ORGANISM", 124, 130], ["people", "SPECIES", 124, 130], ["SARS-CoV", "SPECIES", 0, 8], ["drastically", "OBSERVATION_MODIFIER", 15, 26], ["spread", "OBSERVATION_MODIFIER", 27, 33]]], ["Not only does this virus attack on various organs of the body including the respiratory system, gastrointestinal system, liver, but as well as invades the central nervous system, and causes illness to both humans and various animals such as bats, cattle, birds, mice etc. (Salata et al. 2019).The host and primary reservoirs of SARS-CoV-2The findings of the genetic sequence testing reveal that the new SARS-CoV-2 has about 80% similarity with SARS-CoV.", [["organs", "ANATOMY", 43, 49], ["body", "ANATOMY", 57, 61], ["respiratory system", "ANATOMY", 76, 94], ["gastrointestinal system", "ANATOMY", 96, 119], ["liver", "ANATOMY", 121, 126], ["central nervous system", "ANATOMY", 155, 177], ["SARS", "DISEASE", 403, 407], ["SARS", "DISEASE", 444, 448], ["organs", "ORGAN", 43, 49], ["body", "ORGANISM_SUBDIVISION", 57, 61], ["respiratory system", "ANATOMICAL_SYSTEM", 76, 94], ["gastrointestinal system", "ANATOMICAL_SYSTEM", 96, 119], ["liver", "ORGAN", 121, 126], ["central nervous system", "ANATOMICAL_SYSTEM", 155, 177], ["humans", "ORGANISM", 206, 212], ["cattle", "ORGANISM", 247, 253], ["birds", "ORGANISM", 255, 260], ["mice", "ORGANISM", 262, 266], ["SARS-CoV-2", "ORGANISM", 403, 413], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 444, 452], ["SARS-CoV-2", "DNA", 403, 413], ["humans", "SPECIES", 206, 212], ["cattle", "SPECIES", 247, 253], ["mice", "SPECIES", 262, 266], ["humans", "SPECIES", 206, 212], ["cattle", "SPECIES", 247, 253], ["mice", "SPECIES", 262, 266], ["SARS-CoV", "SPECIES", 403, 411], ["SARS-CoV", "SPECIES", 444, 452], ["this virus attack", "PROBLEM", 14, 31], ["illness", "PROBLEM", 190, 197], ["SARS-CoV", "TEST", 328, 336], ["the genetic sequence testing", "TEST", 354, 382], ["the new SARS", "TEST", 395, 407], ["CoV", "TEST", 408, 411], ["SARS", "PROBLEM", 444, 448], ["virus", "OBSERVATION", 19, 24], ["body", "ANATOMY_MODIFIER", 57, 61], ["respiratory system", "ANATOMY", 76, 94], ["gastrointestinal system", "ANATOMY", 96, 119], ["liver", "ANATOMY", 121, 126], ["central", "ANATOMY_MODIFIER", 155, 162], ["nervous system", "ANATOMY", 163, 177], ["SARS-CoV", "OBSERVATION", 328, 336], ["new", "OBSERVATION_MODIFIER", 399, 402], ["SARS", "OBSERVATION", 403, 407]]], ["Another report by Shi et al. described the SARS-CoV-2 to share 96.2% similarity with the SARS-CoV coronavirus that originated from Rhinolophus affini (bats) (Xu et al. 2020b).", [["SARS-CoV coronavirus", "DISEASE", 89, 109], ["SARS-CoV coronavirus", "ORGANISM", 89, 109], ["Rhinolophus affini", "ORGANISM", 131, 149], ["CoV coronavirus", "SPECIES", 94, 109], ["Rhinolophus affini", "SPECIES", 131, 149], ["SARS-CoV", "SPECIES", 43, 51], ["SARS-CoV coronavirus", "SPECIES", 89, 109], ["Rhinolophus affini", "SPECIES", 131, 149], ["the SARS", "PROBLEM", 39, 47], ["CoV", "TEST", 48, 51], ["the SARS-CoV coronavirus", "PROBLEM", 85, 109]]], ["This clearly illustrates that the new emerging virus may have also originated from bats.", [["the new emerging virus", "PROBLEM", 30, 52]]], ["However, the intermediate host for this virus is elusive, some reports have stated snakes or minks to be the intermediate hosts.", [["this virus", "PROBLEM", 35, 45], ["intermediate host", "OBSERVATION_MODIFIER", 13, 30]]], ["Recently, a group of researchers from the Agricultural university of South China analyzed over one thousand metagenomic samples and observed that about 70% pangolins out of more than 1000 metagenomic samples were found to be positive for the coronavirus (Lu et al. 2020).", [["samples", "ANATOMY", 120, 127], ["samples", "ANATOMY", 200, 207], ["pangolins", "GENE_OR_GENE_PRODUCT", 156, 165], ["samples", "CANCER", 200, 207], ["coronavirus", "ORGANISM", 242, 253], ["metagenomic samples", "TEST", 188, 207], ["the coronavirus", "PROBLEM", 238, 253]]], ["Also, there was 99% similarity of the genetic sequence between the pangolins and the present infectious human strain (Zhang and Holmes 2020).", [["pangolins", "GENE_OR_GENE_PRODUCT", 67, 76], ["human", "ORGANISM", 104, 109], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 104, 109], ["infectious", "OBSERVATION_MODIFIER", 93, 103]]], ["Based on these evidence, there is a high probability of the pangolins to be one of the intermediate host of COVID-19 (Zhang et al. 2020a; Lam et al. 2020).Zoonotic origins of SARS-CoV-2Bats have been identified to be an important reservoir host for an array of coronaviruses.", [["SARS", "DISEASE", 175, 179], ["pangolins", "GENE_OR_GENE_PRODUCT", 60, 69], ["COVID-19", "CELL", 108, 116], ["SARS-CoV-2Bats", "ORGANISM", 175, 189], ["coronaviruses", "ORGANISM", 261, 274], ["SARS-CoV-2Bats", "DNA", 175, 189], ["CoV-2Bats", "SPECIES", 180, 189], ["SARS-CoV-2Bats", "SPECIES", 175, 189], ["the pangolins", "PROBLEM", 56, 69], ["COVID", "TEST", 108, 113], ["CoV-2Bats", "TREATMENT", 180, 189], ["coronaviruses", "PROBLEM", 261, 274], ["high", "OBSERVATION_MODIFIER", 36, 40], ["intermediate host", "OBSERVATION_MODIFIER", 87, 104], ["coronaviruses", "OBSERVATION", 261, 274]]], ["In the past several years, frequent sampling has recognized various bat corona viruses.", [["bat corona viruses", "ORGANISM", 68, 86], ["frequent sampling", "PROBLEM", 27, 44], ["various bat corona viruses", "PROBLEM", 60, 86], ["corona viruses", "OBSERVATION", 72, 86]]], ["The data from the genomic comparisons exhibited viruses from bat to have a major correlation with SARS-CoV-2 (Zhang and Holmes 2020).", [["bat", "ORGANISM", 61, 64], ["SARS-CoV", "SPECIES", 98, 106], ["The data", "TEST", 0, 8], ["viruses", "PROBLEM", 48, 55], ["viruses", "OBSERVATION", 48, 55]]], ["Another study by Yadav et al. tested bat samples from seven different states of India and found the rectal swab test of eight samples of Rousettus spp. and Pteropus spp. to be positive for RdRp gene.", [["samples", "ANATOMY", 41, 48], ["rectal swab", "ANATOMY", 100, 111], ["samples", "ANATOMY", 126, 133], ["rectal swab", "MULTI-TISSUE_STRUCTURE", 100, 111], ["Rousettus spp", "ORGANISM", 137, 150], ["Pteropus spp", "ORGANISM", 156, 168], ["RdRp", "GENE_OR_GENE_PRODUCT", 189, 193], ["RdRp gene", "DNA", 189, 198], ["Rousettus spp", "SPECIES", 137, 150], ["Another study", "TEST", 0, 13], ["the rectal swab test", "TEST", 96, 116], ["Rousettus spp", "PROBLEM", 137, 150], ["Pteropus spp", "PROBLEM", 156, 168], ["RdRp gene", "PROBLEM", 189, 198], ["rectal", "ANATOMY", 100, 106], ["Pteropus spp", "OBSERVATION", 156, 168], ["positive for", "UNCERTAINTY", 176, 188], ["RdRp gene", "OBSERVATION", 189, 198]]], ["Additionally, in the same study, the results of the next generation sequencing revealed that the four sequence regions of Rousettus spp. had about approximately 94.3% similarity to the previously found coronaviruses in bat (Yadav et al. 2020).", [["Rousettus spp", "ORGANISM", 122, 135], ["coronaviruses", "ORGANISM", 202, 215], ["the same study", "TEST", 17, 31], ["the next generation sequencing", "TEST", 48, 78], ["Rousettus spp", "PROBLEM", 122, 135], ["coronaviruses", "PROBLEM", 202, 215], ["coronaviruses", "OBSERVATION", 202, 215]]], ["Since there is a general ecological separation between bats and humans, it is possible that some mammalian species act as an \u2018intermediate\u2019 or \u2018amplifying\u2019 host.", [["humans", "ORGANISM", 64, 70], ["humans", "SPECIES", 64, 70], ["humans", "SPECIES", 64, 70], ["separation", "OBSERVATION", 36, 46]]], ["It is likely that the recently emerged coronavirus acquired the much) needed mutations within these hosts for human transmission (Ahmad et al. 2020).", [["coronavirus", "ORGANISM", 39, 50], ["human", "ORGANISM", 110, 115], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115], ["coronavirus", "PROBLEM", 39, 50], ["mutations", "PROBLEM", 77, 86]]], ["Civets and camels acted as the intermediate host for SARS and MERS, respectively, white camels are thought to be the true reservoir hosts from MERS (de Wit et al. 2016).", [["SARS", "DISEASE", 53, 57], ["camels", "ORGANISM", 11, 17], ["Civets", "TREATMENT", 0, 6], ["SARS", "PROBLEM", 53, 57]]], ["The recently discovered SARS-CoV-2 virus is found to be closely related to the Malayan pangolins (Manis javanica).", [["SARS-CoV-2 virus", "ORGANISM", 24, 40], ["Malayan pangolins", "ORGANISM", 79, 96], ["Manis javanica", "ORGANISM", 98, 112], ["CoV-2 virus", "SPECIES", 29, 40], ["Manis javanica", "SPECIES", 98, 112], ["SARS-CoV-2 virus", "SPECIES", 24, 40], ["Malayan pangolins", "SPECIES", 79, 96], ["Manis javanica", "SPECIES", 98, 112], ["SARS", "PROBLEM", 24, 28], ["CoV-2 virus", "PROBLEM", 29, 40], ["SARS", "OBSERVATION", 24, 28]]], ["These pangolins were imported illegally from the Guangdong and Guangxi provinces of Southern China (Lake 2020).", [["pangolins", "CHEMICAL", 6, 15], ["pangolins", "GENE_OR_GENE_PRODUCT", 6, 15]]], ["The Guangdong pangolin viruses are explicitly related to the SARS-CoV-2 in the receptor binding domain and containing all six key mutations that are believed to shape the virus for binding to the Angiotensin Converting Enzyme (ACE) 2 receptor and manifesting about 97% similarity of the amino acid sequence (Hasan et al. 2020).", [["Angiotensin", "CHEMICAL", 196, 207], ["amino acid", "CHEMICAL", 287, 297], ["amino acid", "CHEMICAL", 287, 297], ["Guangdong pangolin viruses", "ORGANISM", 4, 30], ["SARS-CoV-2", "ORGANISM", 61, 71], ["Angiotensin Converting Enzyme (ACE) 2 receptor", "GENE_OR_GENE_PRODUCT", 196, 242], ["amino acid", "AMINO_ACID", 287, 297], ["SARS-CoV-2", "DNA", 61, 71], ["receptor binding domain", "PROTEIN", 79, 102], ["Angiotensin Converting Enzyme (ACE) 2 receptor", "PROTEIN", 196, 242], ["amino acid sequence", "PROTEIN", 287, 306], ["Guangdong pangolin viruses", "SPECIES", 4, 30], ["SARS-CoV", "SPECIES", 61, 69], ["The Guangdong pangolin viruses", "PROBLEM", 0, 30], ["the SARS-CoV", "PROBLEM", 57, 69], ["all six key mutations", "PROBLEM", 118, 139], ["the virus", "PROBLEM", 167, 176], ["the Angiotensin Converting Enzyme (ACE)", "TREATMENT", 192, 231], ["the amino acid sequence", "TEST", 283, 306], ["Guangdong", "OBSERVATION_MODIFIER", 4, 13], ["pangolin viruses", "OBSERVATION", 14, 30], ["key mutations", "OBSERVATION", 126, 139], ["virus", "OBSERVATION", 171, 176]]], ["However, the Guangdong pangolin viruses showed high divergence in the remaining genome.", [["Guangdong pangolin viruses", "ORGANISM", 13, 39], ["Guangdong pangolin viruses", "SPECIES", 13, 39], ["the Guangdong pangolin viruses", "PROBLEM", 9, 39], ["high divergence", "PROBLEM", 47, 62], ["high divergence", "OBSERVATION", 47, 62], ["remaining genome", "OBSERVATION", 70, 86]]], ["The various evidence from the past clearly suggest that the evolution of the virus in both reservoir and intermediate animal hosts needs to be explored to better evaluate the emergence of SARS-CoV-2 in humans.", [["SARS", "DISEASE", 188, 192], ["SARS-CoV-2", "ORGANISM", 188, 198], ["humans", "ORGANISM", 202, 208], ["humans", "SPECIES", 202, 208], ["SARS-CoV", "SPECIES", 188, 196], ["humans", "SPECIES", 202, 208], ["the virus", "PROBLEM", 73, 82], ["SARS", "TEST", 188, 192], ["CoV", "TEST", 193, 196], ["virus", "OBSERVATION", 77, 82]]], ["However, studies revealing the acquirement of key mutations by the virus during abstruse transmission in humans prior to its detection should not be ignored.Mechanism of entry and transmission of SARS-CoV-2A group of researchers suggested that pangolins and bats act as a carrier for SARS-CoV-2 due to similarity in their genetic makeup.", [["SARS", "DISEASE", 196, 200], ["pangolins", "CHEMICAL", 244, 253], ["SARS", "DISEASE", 284, 288], ["humans", "ORGANISM", 105, 111], ["SARS-CoV-2A", "ORGANISM", 196, 207], ["pangolins", "GENE_OR_GENE_PRODUCT", 244, 253], ["bats", "ORGANISM", 258, 262], ["SARS-CoV-2", "ORGANISM", 284, 294], ["humans", "SPECIES", 105, 111], ["humans", "SPECIES", 105, 111], ["SARS-CoV", "SPECIES", 284, 292], ["studies", "TEST", 9, 16], ["key mutations", "PROBLEM", 46, 59], ["the virus", "PROBLEM", 63, 72], ["SARS", "PROBLEM", 196, 200], ["SARS", "PROBLEM", 284, 288], ["CoV", "TEST", 289, 292]]], ["Inspite of there being a reasonable correlation of SARS-CoV-2 with MERS-CoV and SARS-CoV, there are some remarkable differences between these viruses.", [["SARS", "DISEASE", 51, 55], ["SARS", "DISEASE", 80, 84], ["SARS-CoV-2", "ORGANISM", 51, 61], ["MERS-CoV", "ORGANISM", 67, 75], ["SARS-CoV", "ORGANISM", 80, 88], ["SARS-CoV", "SPECIES", 51, 59], ["MERS-CoV", "SPECIES", 67, 75], ["SARS-CoV", "SPECIES", 80, 88], ["SARS", "PROBLEM", 51, 55], ["CoV", "TEST", 56, 59], ["remarkable", "OBSERVATION_MODIFIER", 105, 115], ["viruses", "OBSERVATION", 142, 149]]], ["SARS-CoV-2 gains entry into human cells using spike proteins followed by a series of complex processes (Shereen et al. 2020) (Fig. 1).", [["cells", "ANATOMY", 34, 39], ["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["human", "ORGANISM", 28, 33], ["cells", "CELL", 34, 39], ["human cells", "CELL_TYPE", 28, 39], ["spike proteins", "PROTEIN", 46, 60], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["SARS", "TEST", 0, 4], ["spike proteins", "PROBLEM", 46, 60], ["complex processes", "PROBLEM", 85, 102]]], ["Once SARS-CoV enters inside the host body, it targets cells through an endosomal pathway.", [["body", "ANATOMY", 37, 41], ["cells", "ANATOMY", 54, 59], ["endosomal", "ANATOMY", 71, 80], ["SARS", "DISEASE", 5, 9], ["SARS-CoV", "ORGANISM", 5, 13], ["body", "ORGANISM_SUBDIVISION", 37, 41], ["cells", "CELL", 54, 59], ["endosomal", "CELLULAR_COMPONENT", 71, 80], ["SARS-CoV", "SPECIES", 5, 13], ["SARS", "PROBLEM", 5, 9], ["an endosomal pathway", "TEST", 68, 88], ["host body", "ANATOMY", 32, 41]]], ["The initial attachment of the virion to cells occurs via S protein binding to the ACE-2 receptors (Ji et al. 2020).", [["virion", "ANATOMY", 30, 36], ["cells", "ANATOMY", 40, 45], ["virion", "CELLULAR_COMPONENT", 30, 36], ["cells", "CELL", 40, 45], ["ACE-2", "GENE_OR_GENE_PRODUCT", 82, 87], ["S protein", "PROTEIN", 57, 66], ["ACE-2 receptors", "PROTEIN", 82, 97], ["the virion to cells", "TREATMENT", 26, 45]]], ["The conformational change in S protein assists the fusion of the viral envelope with the cell membrane, thereby liberating the infectious RNA in the host cell.", [["cell membrane", "ANATOMY", 89, 102], ["cell", "ANATOMY", 154, 158], ["S protein", "GENE_OR_GENE_PRODUCT", 29, 38], ["cell membrane", "CELLULAR_COMPONENT", 89, 102], ["host cell", "CELL", 149, 158], ["S protein", "PROTEIN", 29, 38], ["infectious RNA", "RNA", 127, 141], ["host cell", "CELL_TYPE", 149, 158], ["The conformational change in S protein", "PROBLEM", 0, 38], ["the fusion", "TREATMENT", 47, 57], ["the cell membrane", "TREATMENT", 85, 102], ["the infectious RNA in the host cell", "PROBLEM", 123, 158], ["change", "OBSERVATION_MODIFIER", 19, 25], ["viral envelope", "OBSERVATION", 65, 79], ["cell membrane", "OBSERVATION", 89, 102], ["infectious RNA", "OBSERVATION", 127, 141], ["host cell", "OBSERVATION", 149, 158]]], ["This RNA is then translated by viral replicase polyproteins PP1a and PP1ab, followed by its cleavage by the viral proteinases into smaller products forming a full length negative-strand template for the genomic RNA (Song et al. 2019).", [["PP1a", "GENE_OR_GENE_PRODUCT", 60, 64], ["PP1", "GENE_OR_GENE_PRODUCT", 69, 72], ["viral replicase polyproteins", "PROTEIN", 31, 59], ["PP1a", "PROTEIN", 60, 64], ["PP1", "PROTEIN", 69, 72], ["viral proteinases", "PROTEIN", 108, 125], ["full length negative-strand template", "DNA", 158, 194], ["viral replicase polyproteins PP1a", "TREATMENT", 31, 64], ["PP1ab", "TEST", 69, 74], ["the viral proteinases", "PROBLEM", 104, 125], ["strand template", "TREATMENT", 179, 194], ["the genomic RNA", "PROBLEM", 199, 214]]], ["During translation, viral protein particles are formed.", [["viral protein particles", "TEST", 20, 43], ["viral protein particles", "OBSERVATION", 20, 43]]], ["Viral protein and genome RNA are assembled in a step-wise manner by virion in the endoplasmic reticulum and golgi.", [["endoplasmic reticulum", "ANATOMY", 82, 103], ["golgi", "ANATOMY", 108, 113], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 82, 103], ["golgi", "CELLULAR_COMPONENT", 108, 113], ["Viral protein", "PROTEIN", 0, 13], ["genome RNA", "RNA", 18, 28], ["Viral protein and genome RNA", "PROBLEM", 0, 28], ["genome RNA", "OBSERVATION", 18, 28], ["endoplasmic reticulum", "ANATOMY", 82, 103]]], ["The new virion is then released from the cell through exocytosis (Zhang et al. 2020b).", [["cell", "ANATOMY", 41, 45], ["cell", "CELL", 41, 45], ["The new virion", "TREATMENT", 0, 14], ["new", "OBSERVATION_MODIFIER", 4, 7], ["virion", "OBSERVATION", 8, 14]]], ["Now, the new virions have the ability to infect other body organs.", [["virions", "ANATOMY", 13, 20], ["body organs", "ANATOMY", 54, 65], ["body organs", "MULTI-TISSUE_STRUCTURE", 54, 65], ["the new virions", "PROBLEM", 5, 20]]], ["These virions can contaminate other humans via close contact in communities.", [["virions", "ANATOMY", 6, 13], ["humans", "ORGANISM", 36, 42], ["humans", "SPECIES", 36, 42], ["humans", "SPECIES", 36, 42]]], ["Some evidence also suggested that it can also affect pets like cats and dogs.Do coronaviruses infect animals?Coronaviruses are generally found in various domestic and wild animal species including cattles, horses, ferrets, bats, dogs, and others (Ng and Hiscox 2020).", [["cattles", "ANATOMY", 197, 204], ["cats", "ORGANISM", 63, 67], ["dogs", "ORGANISM", 72, 76], ["coronaviruses", "ORGANISM", 80, 93], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 109, 122], ["horses", "ORGANISM_SUBDIVISION", 206, 212], ["ferrets", "ORGANISM", 214, 221], ["dogs", "ORGANISM", 229, 233], ["cats", "SPECIES", 63, 67], ["dogs", "SPECIES", 72, 76], ["cattles", "SPECIES", 197, 204], ["horses", "SPECIES", 206, 212], ["ferrets", "SPECIES", 214, 221], ["dogs", "SPECIES", 229, 233], ["coronaviruses infect animals", "PROBLEM", 80, 108], ["Coronaviruses", "PROBLEM", 109, 122]]], ["Current evidence suggest that the major transmission route is from human to human.", [["human", "ORGANISM", 67, 72], ["human", "ORGANISM", 76, 81], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 67, 72], ["human", "SPECIES", 76, 81]]], ["Although not common, coronaviruses can also be transmitted from animals to humans.", [["coronaviruses", "ORGANISM", 21, 34], ["humans", "ORGANISM", 75, 81], ["humans", "SPECIES", 75, 81], ["humans", "SPECIES", 75, 81], ["coronaviruses", "PROBLEM", 21, 34], ["coronaviruses", "OBSERVATION", 21, 34]]], ["The outbreak of the major coronaviruses in the past in humans suggested that bats act as reservoirs for these viruses that crossed the species barrier and infected humans as well as other domestic and wild mammals (Malik et al. 2020).", [["coronaviruses", "ORGANISM", 26, 39], ["humans", "ORGANISM", 55, 61], ["bats", "ORGANISM", 77, 81], ["humans", "ORGANISM", 164, 170], ["humans", "SPECIES", 55, 61], ["humans", "SPECIES", 164, 170], ["humans", "SPECIES", 55, 61], ["humans", "SPECIES", 164, 170], ["these viruses", "PROBLEM", 104, 117], ["major", "OBSERVATION_MODIFIER", 20, 25], ["coronaviruses", "OBSERVATION", 26, 39], ["infected", "OBSERVATION", 155, 163]]], ["There were also studies which reported the fact that palm civet cats (SARS) and dromedary camels (MERS) acted as the intermediate host (Abdullahi et al. 2020).", [["SARS", "DISEASE", 70, 74], ["palm", "ORGANISM_SUBDIVISION", 53, 57], ["civet cats", "ORGANISM", 58, 68], ["camels", "ORGANISM_SUBDIVISION", 90, 96], ["cats", "SPECIES", 64, 68], ["palm civet cats", "SPECIES", 53, 68], ["studies", "TEST", 16, 23]]], ["The origins of COVID-19 virus are also believed to be from animal source.", [["COVID-19 virus", "ORGANISM", 15, 29], ["COVID-19 virus", "SPECIES", 15, 29], ["COVID", "TEST", 15, 20], ["virus", "PROBLEM", 24, 29], ["19 virus", "OBSERVATION", 21, 29], ["believed to be", "UNCERTAINTY", 39, 53]]], ["At present, there are numerous research programs dedicated to finding the potential source as well as species involved in the emergence of this pandemic.", [["this pandemic", "PROBLEM", 139, 152]]], ["The genomic sequence data reveals 80% similarity between the SARS-CoV-2 and the previous human coronavirus (SARS-CoV), establishing its close relation to the Rhinolophus bat (Horseshoe bat) population (Fig. 2).", [["SARS", "DISEASE", 108, 112], ["SARS-CoV-2", "ORGANISM", 61, 71], ["human coronavirus", "ORGANISM", 89, 106], ["SARS-CoV", "ORGANISM", 108, 116], ["Rhinolophus bat", "ORGANISM", 158, 173], ["Horseshoe bat", "ORGANISM", 175, 188], ["human", "SPECIES", 89, 94], ["coronavirus", "SPECIES", 95, 106], ["SARS-CoV-2", "SPECIES", 61, 71], ["human coronavirus", "SPECIES", 89, 106], ["SARS-CoV", "SPECIES", 108, 116], ["Rhinolophus bat (Horseshoe bat", "SPECIES", 158, 188], ["The genomic sequence data", "TEST", 0, 25], ["the SARS", "TEST", 57, 65], ["CoV", "TEST", 66, 69], ["the previous human coronavirus", "PROBLEM", 76, 106], ["SARS", "OBSERVATION", 61, 65], ["human coronavirus", "ANATOMY", 89, 106]]], ["There is also a possibility of the involvement of an intermediate host for transmission to humans.", [["humans", "ORGANISM", 91, 97], ["humans", "SPECIES", 91, 97], ["humans", "SPECIES", 91, 97], ["intermediate host", "OBSERVATION", 53, 70]]], ["Health officials have found the first SARS-CoV-2 infections to be linked to the live animal market in China (Liu and Saif 2020).", [["infections", "DISEASE", 49, 59], ["CoV-2", "ORGANISM", 43, 48], ["the first SARS", "PROBLEM", 28, 42], ["2 infections", "PROBLEM", 47, 59]]], ["However, till date, there are not enough scientific documental evidence to explain the original route of transmission from animal to human sources.Are other species such as mosquitoes, houseflies responsible for the transmission of virus to humans?Till date, there is no evidence that COVID-19 or any other similar corona viruses such as SARS or MERS are spread through mosquitoes or ticks because the virus needs to replicate inside the mosquito if it has to pass to a person through the mosquito (Eslami and Jalili 2020).Study on ferrets (China) ::: In-vivo experimental studies of SARS-CoV-2 transmission between animalsTo check the susceptibility of SARS-CoV-2 in ferret a two virus samples, F13-E and CTan-H that were previously isolated from environmental samples in the Huanan Seafood market in Wuhan and human patients respectively, were inoculated intranasal in a pair of ferrets (105 pfu).", [["samples", "ANATOMY", 687, 694], ["samples", "ANATOMY", 762, 769], ["SARS", "DISEASE", 338, 342], ["SARS", "DISEASE", 584, 588], ["human", "ORGANISM", 133, 138], ["humans", "ORGANISM", 241, 247], ["COVID-19", "GENE_OR_GENE_PRODUCT", 285, 293], ["corona viruses", "ORGANISM", 315, 329], ["MERS", "GENE_OR_GENE_PRODUCT", 346, 350], ["mosquito", "ORGANISM", 438, 446], ["ferrets", "ORGANISM", 532, 539], ["SARS-CoV-2", "ORGANISM", 584, 594], ["animals", "ORGANISM", 616, 623], ["SARS-CoV-2", "ORGANISM", 654, 664], ["ferret", "ORGANISM", 668, 674], ["F13-E", "CELL", 696, 701], ["CTan-H", "CELL", 706, 712], ["human", "ORGANISM", 812, 817], ["patients", "ORGANISM", 818, 826], ["ferrets", "ORGANISM", 881, 888], ["human", "SPECIES", 133, 138], ["humans", "SPECIES", 241, 247], ["person", "SPECIES", 470, 476], ["ferrets", "SPECIES", 532, 539], ["ferret", "SPECIES", 668, 674], ["human", "SPECIES", 812, 817], ["patients", "SPECIES", 818, 826], ["ferrets", "SPECIES", 881, 888], ["human", "SPECIES", 133, 138], ["humans", "SPECIES", 241, 247], ["SARS-CoV", "SPECIES", 584, 592], ["SARS-CoV", "SPECIES", 654, 662], ["human", "SPECIES", 812, 817], ["other species", "PROBLEM", 151, 164], ["COVID", "TEST", 285, 290], ["any other similar corona viruses", "PROBLEM", 297, 329], ["SARS", "PROBLEM", 338, 342], ["MERS", "PROBLEM", 346, 350], ["the virus", "PROBLEM", 398, 407], ["SARS", "PROBLEM", 584, 588], ["CoV", "TEST", 589, 592], ["SARS", "TEST", 654, 658], ["CoV", "TEST", 659, 662], ["no evidence", "UNCERTAINTY", 268, 279], ["corona", "OBSERVATION_MODIFIER", 315, 321], ["viruses", "OBSERVATION", 322, 329]]], ["The qPCR and virus titration test conducted on the various isolated organs of the ferrets on day 4 post inoculation detected infectious virus in the nasal turbinate, soft palate and tonsils of ferrets indicating the possible replication of the virus in the upper respiratory tract of the ferrets while no infection was found in other organs such as trachea, lung, heart, spleen, kidneys, pancreas, small intestine, brain and liver of the ferrets (Kim et al. 2020).", [["organs", "ANATOMY", 68, 74], ["nasal turbinate", "ANATOMY", 149, 164], ["soft palate", "ANATOMY", 166, 177], ["tonsils", "ANATOMY", 182, 189], ["upper respiratory tract", "ANATOMY", 257, 280], ["organs", "ANATOMY", 334, 340], ["trachea", "ANATOMY", 349, 356], ["lung", "ANATOMY", 358, 362], ["heart", "ANATOMY", 364, 369], ["spleen", "ANATOMY", 371, 377], ["kidneys", "ANATOMY", 379, 386], ["pancreas", "ANATOMY", 388, 396], ["small intestine", "ANATOMY", 398, 413], ["brain", "ANATOMY", 415, 420], ["liver", "ANATOMY", 425, 430], ["infection", "DISEASE", 305, 314], ["organs", "ORGAN", 68, 74], ["ferrets", "ORGANISM", 82, 89], ["nasal turbinate", "MULTI-TISSUE_STRUCTURE", 149, 164], ["soft palate", "ORGAN", 166, 177], ["tonsils", "ORGAN", 182, 189], ["ferrets", "ORGANISM", 193, 200], ["upper respiratory", "ORGANISM_SUBDIVISION", 257, 274], ["tract", "ORGANISM_SUBDIVISION", 275, 280], ["ferrets", "ORGANISM", 288, 295], ["organs", "ORGAN", 334, 340], ["trachea", "MULTI-TISSUE_STRUCTURE", 349, 356], ["lung", "ORGAN", 358, 362], ["heart", "ORGAN", 364, 369], ["spleen", "ORGAN", 371, 377], ["kidneys", "ORGAN", 379, 386], ["pancreas", "ORGAN", 388, 396], ["small intestine", "ORGAN", 398, 413], ["brain", "ORGAN", 415, 420], ["liver", "ORGAN", 425, 430], ["ferrets", "ORGANISM", 438, 445], ["ferrets", "SPECIES", 82, 89], ["ferrets", "SPECIES", 193, 200], ["ferrets", "SPECIES", 288, 295], ["ferrets", "SPECIES", 438, 445], ["ferrets", "SPECIES", 288, 295], ["The qPCR", "TEST", 0, 8], ["virus titration test", "TEST", 13, 33], ["inoculation", "PROBLEM", 104, 115], ["infectious virus in the nasal turbinate", "PROBLEM", 125, 164], ["soft palate and tonsils of ferrets", "PROBLEM", 166, 200], ["the virus", "PROBLEM", 240, 249], ["infection", "PROBLEM", 305, 314], ["trachea, lung, heart, spleen, kidneys, pancreas, small intestine, brain and liver of the ferrets", "PROBLEM", 349, 445], ["infectious virus", "OBSERVATION", 125, 141], ["nasal turbinate", "ANATOMY", 149, 164], ["soft palate", "ANATOMY", 166, 177], ["tonsils", "ANATOMY", 182, 189], ["virus", "OBSERVATION", 244, 249], ["upper", "ANATOMY_MODIFIER", 257, 262], ["respiratory tract", "ANATOMY", 263, 280], ["infection", "OBSERVATION", 305, 314], ["trachea", "ANATOMY", 349, 356], ["lung", "ANATOMY", 358, 362], ["heart", "ANATOMY", 364, 369], ["spleen", "ANATOMY", 371, 377], ["kidneys", "ANATOMY", 379, 386], ["pancreas", "ANATOMY", 388, 396], ["small intestine", "ANATOMY", 398, 413], ["brain", "ANATOMY", 415, 420], ["liver", "ANATOMY", 425, 430]]], ["Further, when a group of three animals intranasal inoculated with 105pfu of F13-E and CTan-H placed in three separate cages with uninfected ferrets, the nasal washes of six ferrets were detected with viral RNA after day 2, 4, 6 and 8 of inoculation.", [["nasal", "ANATOMY", 153, 158], ["F13-E", "CHEMICAL", 76, 81], ["CTan-H", "CHEMICAL", 86, 92], ["F13-E", "CELL", 76, 81], ["CTan-H", "CELL", 86, 92], ["ferrets", "ORGANISM", 140, 147], ["nasal", "ORGANISM_SUBDIVISION", 153, 158], ["ferrets", "ORGANISM", 173, 180], ["viral RNA", "RNA", 200, 209], ["ferrets", "SPECIES", 140, 147], ["ferrets", "SPECIES", 173, 180], ["ferrets", "SPECIES", 140, 147], ["ferrets", "SPECIES", 173, 180], ["F13", "TEST", 76, 79], ["CTan-H", "TREATMENT", 86, 92], ["uninfected ferrets", "TREATMENT", 129, 147], ["the nasal washes", "TREATMENT", 149, 165], ["inoculation", "PROBLEM", 237, 248], ["uninfected ferrets", "OBSERVATION", 129, 147], ["nasal", "ANATOMY", 153, 158]]], ["However, the rectal swabs of the ferrets were noted to have lower copy numbers of the infectious virus RNA.", [["rectal swabs", "ANATOMY", 13, 25], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 13, 25], ["ferrets", "ORGANISM", 33, 40], ["infectious virus RNA", "RNA", 86, 106], ["ferrets", "SPECIES", 33, 40], ["ferrets", "SPECIES", 33, 40], ["infectious virus", "SPECIES", 86, 102], ["the rectal swabs", "TEST", 9, 25], ["the infectious virus RNA", "PROBLEM", 82, 106], ["rectal", "ANATOMY", 13, 19], ["infectious virus RNA", "OBSERVATION", 86, 106]]], ["Three ferrets also had a loss of appetite and developed fever on days 10 and 12 (Stittelaar et al. 2016).", [["loss of appetite", "DISEASE", 25, 41], ["fever", "DISEASE", 56, 61], ["ferrets", "ORGANISM", 6, 13], ["ferrets", "SPECIES", 6, 13], ["a loss of appetite", "PROBLEM", 23, 41], ["fever", "PROBLEM", 56, 61], ["fever", "OBSERVATION", 56, 61]]], ["To check whether the symptoms were caused due to the virus, the tissues and organs of the two ferrets were euthanized at p.i 13.", [["tissues", "ANATOMY", 64, 71], ["organs", "ANATOMY", 76, 82], ["tissues", "TISSUE", 64, 71], ["organs", "ORGAN", 76, 82], ["ferrets", "ORGANISM", 94, 101], ["ferrets", "SPECIES", 94, 101], ["the symptoms", "PROBLEM", 17, 29], ["the virus", "PROBLEM", 49, 58], ["virus", "OBSERVATION", 53, 58]]], ["Low copy number of the virus RNA was detected in the turbinate of the CTan-H inoculated ferret.", [["turbinate", "ANATOMY", 53, 62], ["turbinate", "ORGAN", 53, 62], ["ferret", "ORGANISM", 88, 94], ["virus RNA", "RNA", 23, 32], ["ferret", "SPECIES", 88, 94], ["the virus RNA", "PROBLEM", 19, 32], ["virus RNA", "OBSERVATION", 23, 32], ["turbinate", "ANATOMY", 53, 62]]], ["Furthermore, the ELISA results revealed the presence of antibodies against SARS-CoV-2 in all the ferrets (El-Duah et al. 2019).", [["SARS-CoV-2", "ORGANISM", 75, 85], ["ferrets", "ORGANISM", 97, 104], ["antibodies", "PROTEIN", 56, 66], ["ferrets", "SPECIES", 97, 104], ["SARS-CoV", "SPECIES", 75, 83], ["the ELISA", "TEST", 13, 22], ["antibodies", "TEST", 56, 66], ["SARS", "PROBLEM", 75, 79], ["CoV", "TEST", 80, 83]]], ["The investigation on the lungs of the ferrets to check the viral replication in these organs was done by intratracheal inoculation of eight ferrets with 105pfu of CTan-H.", [["lungs", "ANATOMY", 25, 30], ["organs", "ANATOMY", 86, 92], ["lungs", "ORGAN", 25, 30], ["ferrets", "ORGANISM", 38, 45], ["organs", "ORGAN", 86, 92], ["ferrets", "ORGANISM", 140, 147], ["ferrets", "SPECIES", 38, 45], ["ferrets", "SPECIES", 140, 147], ["the viral replication in these organs", "PROBLEM", 55, 92], ["CTan", "TEST", 163, 167], ["lungs", "ANATOMY", 25, 30], ["organs", "ANATOMY", 86, 92]]], ["The animals were euthanized on p.i days 2, 4, 8, and 14 to check the viral RNA in various tissues and organs.", [["tissues", "ANATOMY", 90, 97], ["organs", "ANATOMY", 102, 108], ["animals", "ORGANISM", 4, 11], ["tissues", "TISSUE", 90, 97], ["organs", "ORGAN", 102, 108], ["viral RNA", "RNA", 69, 78], ["the viral RNA in various tissues and organs", "PROBLEM", 65, 108], ["viral RNA", "OBSERVATION", 69, 78], ["various tissues", "ANATOMY", 82, 97], ["organs", "ANATOMY", 102, 108]]], ["The results indicated that the SARS-CoV-2 replicates upto 8 days in the upper respiratory tract of the ferrets without causing any severe disease.Experiment on ferrets (South Korea) ::: In-vivo experimental studies of SARS-CoV-2 transmission between animalsYoung-ll Kim et al. checked the transmission of SARS-CoV-2 in ferrets in an experimental setting (van den Brand et al. 2008).", [["upper respiratory tract", "ANATOMY", 72, 95], ["SARS", "DISEASE", 31, 35], ["SARS", "DISEASE", 218, 222], ["SARS", "DISEASE", 305, 309], ["upper respiratory", "ORGANISM_SUBDIVISION", 72, 89], ["tract", "ORGANISM_SUBDIVISION", 90, 95], ["ferrets", "ORGANISM", 103, 110], ["ferrets", "ORGANISM", 160, 167], ["SARS-CoV-2", "ORGANISM", 218, 228], ["animals", "ORGANISM", 250, 257], ["SARS-CoV-2", "ORGANISM", 305, 315], ["ferrets", "ORGANISM", 319, 326], ["ferrets", "SPECIES", 103, 110], ["ferrets", "SPECIES", 160, 167], ["ferrets", "SPECIES", 319, 326], ["SARS-CoV", "SPECIES", 31, 39], ["ferrets", "SPECIES", 103, 110], ["SARS-CoV", "SPECIES", 218, 226], ["SARS-CoV", "SPECIES", 305, 313], ["the SARS", "TEST", 27, 35], ["CoV", "TEST", 36, 39], ["any severe disease", "PROBLEM", 127, 145], ["SARS", "PROBLEM", 218, 222], ["CoV", "TEST", 223, 226], ["SARS", "TEST", 305, 309], ["CoV", "TEST", 310, 313], ["upper", "ANATOMY_MODIFIER", 72, 77], ["respiratory tract", "ANATOMY", 78, 95], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["disease", "OBSERVATION", 138, 145]]], ["The study was conducted for a period of 12 days.", [["The study", "TEST", 0, 9]]], ["Two ferrets were intranasally inoculated with an isolated strain (105.5 TCID50 of NMC-nCoV02) of a COVID-19 positive South Korea patient.", [["ferrets", "ORGANISM", 4, 11], ["patient", "ORGANISM", 129, 136], ["ferrets", "SPECIES", 4, 11], ["patient", "SPECIES", 129, 136], ["an isolated strain", "PROBLEM", 46, 64], ["NMC", "TEST", 82, 85], ["a COVID", "TEST", 97, 104]]], ["After 2 days post inoculation, two naive ferrets per group were either housed together with infected ferrets (direct contact) or were kept in cages having a permeable partition to separate them from the inoculated ferrets (indirect contact).", [["ferrets", "ORGANISM", 41, 48], ["ferrets", "ORGANISM", 101, 108], ["ferrets", "ORGANISM", 214, 221], ["ferrets", "SPECIES", 41, 48], ["ferrets", "SPECIES", 101, 108], ["ferrets", "SPECIES", 214, 221], ["ferrets", "SPECIES", 101, 108], ["inoculation", "TREATMENT", 18, 29]]], ["The results of this experiment revealed a rise in the body temperature of all the direct contact ferrets to about 39 \u00b0C on average, accompanied by reduced activity.", [["body", "ANATOMY", 54, 58], ["body", "ORGANISM_SUBDIVISION", 54, 58], ["ferrets", "ORGANISM", 97, 104], ["this experiment", "TEST", 15, 30], ["the body temperature", "TEST", 50, 70], ["reduced activity", "PROBLEM", 147, 163], ["rise", "OBSERVATION_MODIFIER", 42, 46], ["reduced activity", "OBSERVATION", 147, 163]]], ["On the contrary, none of the indirect contact ferrets acquired elevated body temperatures.", [["body", "ANATOMY", 72, 76], ["ferrets", "ORGANISM", 46, 53], ["body", "ORGANISM_SUBDIVISION", 72, 76], ["elevated body temperatures", "PROBLEM", 63, 89]]], ["Thus, we can infer that the efficient transmission of SARS-CoV-2 clinical symptoms requires direct contact with the infected animals (Shi et al. 2020).", [["SARS", "DISEASE", 54, 58], ["SARS-CoV-2", "ORGANISM", 54, 64], ["SARS-CoV", "SPECIES", 54, 62], ["SARS", "PROBLEM", 54, 58], ["CoV", "PROBLEM", 59, 62], ["2 clinical symptoms", "PROBLEM", 63, 82]]], ["Further, the replication of the virus amongst all groups of ferrets was investigated by collecting saliva, nasal washes, blood, urine and fecal samples consecutively for 12 days.", [["saliva", "ANATOMY", 99, 105], ["nasal", "ANATOMY", 107, 112], ["blood", "ANATOMY", 121, 126], ["urine", "ANATOMY", 128, 133], ["fecal samples", "ANATOMY", 138, 151], ["ferrets", "ORGANISM", 60, 67], ["saliva", "ORGANISM_SUBSTANCE", 99, 105], ["nasal", "ORGANISM_SUBDIVISION", 107, 112], ["blood", "ORGANISM_SUBSTANCE", 121, 126], ["urine", "ORGANISM_SUBSTANCE", 128, 133], ["fecal samples", "ORGANISM_SUBSTANCE", 138, 151], ["ferrets", "SPECIES", 60, 67], ["ferrets", "SPECIES", 60, 67], ["the virus", "PROBLEM", 28, 37], ["collecting saliva, nasal washes, blood, urine and fecal samples", "TEST", 88, 151], ["nasal", "ANATOMY", 107, 112], ["fecal", "ANATOMY", 138, 143]]], ["The viral RNA copies were calculated using quantitative RT-PCR.", [["viral RNA copies", "RNA", 4, 20], ["The viral RNA copies", "TEST", 0, 20], ["quantitative RT-PCR", "TEST", 43, 62], ["viral RNA", "OBSERVATION", 4, 13]]], ["These viral RNA copies were then compared with the number of standard control copies.", [["These viral RNA copies", "TEST", 0, 22]]], ["The results of the viral RNA showed the maximum viral RNA in the nasal washes at pi days 4 and 8.", [["nasal", "ANATOMY", 65, 70], ["nasal", "ORGAN", 65, 70], ["viral RNA", "RNA", 19, 28], ["viral RNA", "RNA", 48, 57], ["the viral RNA", "TEST", 15, 28], ["the maximum viral RNA", "PROBLEM", 36, 57], ["the nasal washes", "TREATMENT", 61, 77], ["maximum", "OBSERVATION_MODIFIER", 40, 47], ["viral RNA", "OBSERVATION", 48, 57], ["nasal washes", "ANATOMY", 65, 77]]], ["The saliva as well as the fecal matter of the direct contact ferrets was detected with viral RNA on p.i day 8.", [["saliva", "ANATOMY", 4, 10], ["fecal matter", "ANATOMY", 26, 38], ["saliva", "ORGANISM_SUBSTANCE", 4, 10], ["fecal", "ORGANISM_SUBDIVISION", 26, 31], ["ferrets", "ORGANISM", 61, 68], ["viral RNA", "RNA", 87, 96], ["fecal", "ANATOMY", 26, 31]]], ["For the indirect contact group, only two out of six ferrets had viral RNA in nasal washes as well as fecal specimens from pi day 4.", [["nasal", "ANATOMY", 77, 82], ["fecal specimens", "ANATOMY", 101, 116], ["ferrets", "ORGANISM", 52, 59], ["nasal", "ORGANISM_SUBDIVISION", 77, 82], ["fecal specimens", "ORGANISM_SUBSTANCE", 101, 116], ["viral RNA", "RNA", 64, 73], ["ferrets", "SPECIES", 52, 59], ["ferrets", "SPECIES", 52, 59], ["viral RNA", "PROBLEM", 64, 73], ["nasal washes", "TREATMENT", 77, 89], ["fecal specimens", "TEST", 101, 116], ["viral RNA", "OBSERVATION", 64, 73], ["nasal", "ANATOMY", 77, 82], ["washes", "OBSERVATION", 83, 89]]], ["In addition, the copy number of the viral RNA in the indirect contact ferrets was lower than in the direct contact ferrets.", [["ferrets", "ORGANISM", 70, 77], ["ferrets", "ORGANISM", 115, 122], ["viral RNA", "RNA", 36, 45], ["ferrets", "SPECIES", 70, 77], ["ferrets", "SPECIES", 115, 122], ["the viral RNA", "PROBLEM", 32, 45], ["viral RNA", "OBSERVATION", 36, 45]]], ["The nasal turbinate and lung tissues had the highest number of viral RNA copies, 4 dpi.", [["nasal turbinate", "ANATOMY", 4, 19], ["lung tissues", "ANATOMY", 24, 36], ["nasal turbinate", "MULTI-TISSUE_STRUCTURE", 4, 19], ["lung tissues", "TISSUE", 24, 36], ["viral RNA copies", "RNA", 63, 79], ["The nasal turbinate and lung tissues", "PROBLEM", 0, 36], ["nasal turbinate", "ANATOMY", 4, 19], ["lung tissues", "ANATOMY", 24, 36], ["highest", "OBSERVATION_MODIFIER", 45, 52]]], ["Moreover, there was the presence of a small amount of viral RNA in the kidney and intestine of ferrets after day 4 of inoculation.", [["kidney", "ANATOMY", 71, 77], ["intestine", "ANATOMY", 82, 91], ["kidney", "ORGAN", 71, 77], ["intestine", "ORGAN", 82, 91], ["ferrets", "ORGANISM", 95, 102], ["viral RNA", "RNA", 54, 63], ["ferrets", "SPECIES", 95, 102], ["ferrets", "SPECIES", 95, 102], ["viral RNA in the kidney", "PROBLEM", 54, 77], ["inoculation", "PROBLEM", 118, 129], ["small", "OBSERVATION_MODIFIER", 38, 43], ["amount", "OBSERVATION_MODIFIER", 44, 50], ["viral RNA", "OBSERVATION", 54, 63], ["kidney", "ANATOMY", 71, 77], ["intestine", "ANATOMY", 82, 91], ["ferrets", "OBSERVATION_MODIFIER", 95, 102]]], ["The virus was also tracked down in the lungs, kidney, trachea, nasal turbinate, and intestine at 8 dpi.", [["lungs", "ANATOMY", 39, 44], ["kidney", "ANATOMY", 46, 52], ["trachea", "ANATOMY", 54, 61], ["nasal turbinate", "ANATOMY", 63, 78], ["intestine", "ANATOMY", 84, 93], ["lungs", "ORGAN", 39, 44], ["kidney", "ORGAN", 46, 52], ["trachea", "MULTI-TISSUE_STRUCTURE", 54, 61], ["nasal turbinate", "MULTI-TISSUE_STRUCTURE", 63, 78], ["intestine", "ORGAN", 84, 93], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["lungs", "ANATOMY", 39, 44], ["kidney", "ANATOMY", 46, 52], ["trachea", "ANATOMY", 54, 61], ["nasal turbinate", "ANATOMY", 63, 78], ["intestine", "ANATOMY", 84, 93]]], ["Additionally, the immunohistochemistry and histopathological examination of the various tissues of ferrets revealed that cells in the nasal turbinate, lung, and trachea of the infected ferrets were positive for SARS-CoV-and acute bronchiolitis by NMC-nCoV02 infection (van den Brand et al. 2008).", [["tissues", "ANATOMY", 88, 95], ["cells", "ANATOMY", 121, 126], ["nasal turbinate", "ANATOMY", 134, 149], ["lung", "ANATOMY", 151, 155], ["trachea", "ANATOMY", 161, 168], ["SARS", "DISEASE", 211, 215], ["bronchiolitis", "DISEASE", 230, 243], ["infection", "DISEASE", 258, 267], ["tissues", "TISSUE", 88, 95], ["ferrets", "ORGANISM", 99, 106], ["cells", "CELL", 121, 126], ["nasal turbinate", "MULTI-TISSUE_STRUCTURE", 134, 149], ["lung", "ORGAN", 151, 155], ["trachea", "ORGAN", 161, 168], ["ferrets", "ORGANISM", 185, 192], ["SARS-CoV", "ORGANISM", 211, 219], ["ferrets", "SPECIES", 99, 106], ["ferrets", "SPECIES", 185, 192], ["ferrets", "SPECIES", 185, 192], ["SARS-CoV", "SPECIES", 211, 219], ["the immunohistochemistry", "TEST", 14, 38], ["histopathological examination", "TEST", 43, 72], ["cells in the nasal turbinate, lung, and trachea of the infected ferrets", "PROBLEM", 121, 192], ["SARS", "PROBLEM", 211, 215], ["CoV", "PROBLEM", 216, 219], ["acute bronchiolitis", "PROBLEM", 224, 243], ["NMC", "PROBLEM", 247, 250], ["nCoV02 infection", "PROBLEM", 251, 267], ["nasal turbinate", "ANATOMY", 134, 149], ["lung", "ANATOMY", 151, 155], ["trachea", "ANATOMY", 161, 168], ["infected", "OBSERVATION", 176, 184], ["acute", "OBSERVATION_MODIFIER", 224, 229], ["bronchiolitis", "OBSERVATION", 230, 243]]], ["This study results stipulate ferret to have high susceptibility for the SARS-CoV-2 and this infectious virus sheds by multiple routes of body discharge specimens such as urine and faeces of the infected ferrets which serve as a potential source of viral transmission to close contact.Study on cats ::: In-vivo experimental studies of SARS-CoV-2 transmission between animalsTo investigate the replication of the SARS-CoV-2 virus in cats, an in- vivo study was performed in which five cats were inoculated with 105pfu (intranasal) of CTan-H.", [["body", "ANATOMY", 137, 141], ["specimens", "ANATOMY", 152, 161], ["urine", "ANATOMY", 170, 175], ["faeces", "ANATOMY", 180, 186], ["SARS", "DISEASE", 72, 76], ["SARS", "DISEASE", 334, 338], ["ferret", "ORGANISM", 29, 35], ["SARS-CoV-2", "ORGANISM", 72, 82], ["body", "ORGANISM_SUBDIVISION", 137, 141], ["urine", "ORGANISM_SUBSTANCE", 170, 175], ["faeces", "ORGANISM_SUBSTANCE", 180, 186], ["ferrets", "ORGANISM", 203, 210], ["cats", "ORGANISM", 293, 297], ["SARS-CoV-2", "ORGANISM", 334, 344], ["animals", "ORGANISM", 366, 373], ["SARS-CoV-2 virus", "ORGANISM", 411, 427], ["cats", "ORGANISM", 431, 435], ["cats", "ORGANISM", 483, 487], ["ferrets", "SPECIES", 203, 210], ["cats", "SPECIES", 293, 297], ["CoV-2 virus", "SPECIES", 416, 427], ["cats", "SPECIES", 431, 435], ["cats", "SPECIES", 483, 487], ["SARS-CoV-2", "SPECIES", 72, 82], ["ferrets", "SPECIES", 203, 210], ["SARS-CoV", "SPECIES", 334, 342], ["SARS-CoV-2 virus", "SPECIES", 411, 427], ["This study", "TEST", 0, 10], ["high susceptibility", "PROBLEM", 44, 63], ["the SARS", "PROBLEM", 68, 76], ["CoV", "TEST", 77, 80], ["this infectious virus sheds", "PROBLEM", 87, 114], ["body discharge specimens", "TEST", 137, 161], ["urine", "TEST", 170, 175], ["the infected ferrets", "PROBLEM", 190, 210], ["SARS", "PROBLEM", 334, 338], ["CoV", "TEST", 339, 342], ["the SARS", "PROBLEM", 407, 415], ["CoV", "TEST", 416, 419], ["an in- vivo study", "TEST", 437, 454]]], ["Amongst them, two of the infected cats were sacrificed on pi 6 and viral RNA was found in the various isolated organs of the cat after euthanizing them on p.i day 6 (Mallapaty 2020).", [["organs", "ANATOMY", 111, 117], ["cats", "ORGANISM", 34, 38], ["organs", "ORGAN", 111, 117], ["cat", "ORGANISM", 125, 128], ["viral RNA", "RNA", 67, 76], ["cats", "SPECIES", 34, 38], ["cat", "SPECIES", 125, 128], ["the infected cats", "PROBLEM", 21, 38], ["viral RNA", "PROBLEM", 67, 76], ["infected", "OBSERVATION", 25, 33]]], ["The virus was detected in the nasal turbinates, tonsils, soft palates and trachea.", [["nasal turbinates", "ANATOMY", 30, 46], ["tonsils", "ANATOMY", 48, 55], ["soft palates", "ANATOMY", 57, 69], ["trachea", "ANATOMY", 74, 81], ["nasal turbinates", "MULTI-TISSUE_STRUCTURE", 30, 46], ["tonsils", "ORGAN", 48, 55], ["soft palates", "TISSUE", 57, 69], ["trachea", "ORGAN", 74, 81], ["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9], ["nasal turbinates", "ANATOMY", 30, 46], ["tonsils", "ANATOMY", 48, 55], ["soft palates", "ANATOMY", 57, 69], ["trachea", "ANATOMY", 74, 81]]], ["However, no infection was found in the lung samples of the animal.", [["lung samples", "ANATOMY", 39, 51], ["infection", "DISEASE", 12, 21], ["lung samples", "MULTI-TISSUE_STRUCTURE", 39, 51], ["infection", "PROBLEM", 12, 21], ["no", "UNCERTAINTY", 9, 11], ["infection", "OBSERVATION", 12, 21], ["lung", "ANATOMY", 39, 43]]], ["The other three sub adult cats were placed separately with three uninfected cats in different cages (Kim et al. 2020).", [["cats", "ORGANISM", 26, 30], ["cats", "ORGANISM", 76, 80], ["cats", "SPECIES", 26, 30], ["cats", "SPECIES", 76, 80]]], ["The fecal samples of all virus inoculated sub adult cats were detected with viral RNA on p.i day 5 while only one exposed cat showed viral RNA in the feces.", [["fecal samples", "ANATOMY", 4, 17], ["feces", "ANATOMY", 150, 155], ["fecal samples", "ORGANISM_SUBSTANCE", 4, 17], ["cats", "ORGANISM", 52, 56], ["cat", "ORGANISM", 122, 125], ["feces", "ORGANISM_SUBDIVISION", 150, 155], ["viral RNA", "RNA", 76, 85], ["viral RNA", "RNA", 133, 142], ["cats", "SPECIES", 52, 56], ["cat", "SPECIES", 122, 125], ["The fecal samples", "TEST", 0, 17], ["all virus", "PROBLEM", 21, 30], ["viral RNA", "PROBLEM", 76, 85], ["viral RNA in the feces", "PROBLEM", 133, 155], ["fecal", "ANATOMY", 4, 9], ["viral RNA", "OBSERVATION", 133, 142], ["feces", "ANATOMY", 150, 155]]], ["After the cats were euthanized on p.i day 11, viral RNA was also found in the tonsils and soft palate of the infected cat, while in the nasal turbinate, soft palate, tonsils and trachea of the exposed cat.", [["tonsils", "ANATOMY", 78, 85], ["soft palate", "ANATOMY", 90, 101], ["cat", "ANATOMY", 118, 121], ["nasal turbinate", "ANATOMY", 136, 151], ["soft palate", "ANATOMY", 153, 164], ["tonsils", "ANATOMY", 166, 173], ["trachea", "ANATOMY", 178, 185], ["cats", "ORGANISM", 10, 14], ["tonsils", "ORGAN", 78, 85], ["palate", "ORGAN", 95, 101], ["cat", "ORGANISM", 118, 121], ["nasal turbinate", "MULTI-TISSUE_STRUCTURE", 136, 151], ["palate", "ORGAN", 158, 164], ["tonsils", "ORGAN", 166, 173], ["trachea", "ORGAN", 178, 185], ["cat", "ORGANISM", 201, 204], ["viral RNA", "RNA", 46, 55], ["cats", "SPECIES", 10, 14], ["cat", "SPECIES", 201, 204], ["viral RNA", "PROBLEM", 46, 55], ["the infected cat", "PROBLEM", 105, 121], ["tonsils", "ANATOMY", 78, 85], ["soft palate", "ANATOMY", 90, 101], ["infected cat", "OBSERVATION", 109, 121], ["nasal turbinate", "ANATOMY", 136, 151], ["soft palate", "ANATOMY", 153, 164], ["tonsils", "ANATOMY", 166, 173], ["trachea", "ANATOMY", 178, 185], ["exposed cat", "OBSERVATION", 193, 204]]], ["Thus, it was clear that the transmission through respiratory droplets had occurred.", [["respiratory droplets", "ANATOMY", 49, 69], ["respiratory droplets", "PROBLEM", 49, 69], ["respiratory droplets", "OBSERVATION", 49, 69]]], ["Furthermore, the results of the ELISA and neutralization assay revealed that antibodies of SARS-CoV-2 were found in all the three pre inoculated cats and one exposed cat (El-Duah et al. 2019).", [["SARS-CoV-2", "ORGANISM", 91, 101], ["cats", "ORGANISM", 145, 149], ["cat", "ORGANISM", 166, 169], ["antibodies", "PROTEIN", 77, 87], ["cats", "SPECIES", 145, 149], ["cat", "SPECIES", 166, 169], ["SARS-CoV", "SPECIES", 91, 99], ["the ELISA", "TEST", 28, 37], ["neutralization assay", "TEST", 42, 62], ["antibodies", "TEST", 77, 87], ["SARS", "PROBLEM", 91, 95], ["CoV", "TEST", 96, 99]]], ["Similar experiments were performed with juvenile cats and the histopathological examination revealed massive lesions in the nasal, mucosal and lungs of the cats.", [["lesions", "ANATOMY", 109, 116], ["nasal", "ANATOMY", 124, 129], ["mucosal", "ANATOMY", 131, 138], ["lungs", "ANATOMY", 143, 148], ["cats", "ORGANISM", 49, 53], ["lesions", "PATHOLOGICAL_FORMATION", 109, 116], ["nasal", "ORGANISM_SUBDIVISION", 124, 129], ["mucosal", "MULTI-TISSUE_STRUCTURE", 131, 138], ["lungs", "ORGAN", 143, 148], ["cats", "ORGANISM", 156, 160], ["cats", "SPECIES", 49, 53], ["cats", "SPECIES", 156, 160], ["juvenile cats", "TEST", 40, 53], ["the histopathological examination", "TEST", 58, 91], ["massive lesions in the nasal, mucosal and lungs of the cats", "PROBLEM", 101, 160], ["massive", "OBSERVATION_MODIFIER", 101, 108], ["lesions", "OBSERVATION", 109, 116], ["nasal", "ANATOMY", 124, 129], ["mucosal", "ANATOMY", 131, 138], ["lungs", "ANATOMY", 143, 148], ["cats", "OBSERVATION", 156, 160]]], ["Based on these studies, it has been found that SARS-CoV-2 can be replicated in both adult and young cats and the mode of transmission between cats was via respiratory droplets.Experiment on dogs ::: In-vivo experimental studies of SARS-CoV-2 transmission between animalsThe study examined the transmission and replication of SARS-CoV-2 in dogs.", [["respiratory droplets", "ANATOMY", 155, 175], ["SARS", "DISEASE", 231, 235], ["SARS", "DISEASE", 325, 329], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 47, 57], ["cats", "ORGANISM", 100, 104], ["cats", "ORGANISM", 142, 146], ["dogs", "ORGANISM", 190, 194], ["SARS-CoV-2", "ORGANISM", 231, 241], ["animals", "ORGANISM", 263, 270], ["SARS-CoV-2", "ORGANISM", 325, 335], ["dogs", "ORGANISM", 339, 343], ["cats", "SPECIES", 100, 104], ["cats", "SPECIES", 142, 146], ["dogs", "SPECIES", 190, 194], ["dogs", "SPECIES", 339, 343], ["SARS-CoV", "SPECIES", 231, 239], ["SARS-CoV", "SPECIES", 325, 333], ["these studies", "TEST", 9, 22], ["SARS", "PROBLEM", 47, 51], ["SARS", "PROBLEM", 231, 235], ["CoV", "TEST", 236, 239], ["The study", "TEST", 270, 279], ["the transmission", "TEST", 289, 305], ["SARS", "TEST", 325, 329], ["CoV", "TEST", 330, 333], ["respiratory droplets", "OBSERVATION", 155, 175]]], ["Five beagles of age 3 months were inoculated intranasal with 105pfu of CTan-H and were placed along with two naive dogs.", [["CTan-H", "CHEMICAL", 71, 77], ["CTan-H", "CELL", 71, 77], ["dogs", "ORGANISM", 115, 119], ["dogs", "SPECIES", 115, 119], ["naive dogs", "OBSERVATION", 109, 119]]], ["The rectal swabs and oropharyngeal swabs were collected until p.i day 14.", [["rectal swabs", "ANATOMY", 4, 16], ["oropharyngeal swabs", "ANATOMY", 21, 40], ["rectal swabs", "ORGANISM_SUBSTANCE", 4, 16], ["oropharyngeal swabs", "ORGANISM_SUBSTANCE", 21, 40], ["The rectal swabs", "TEST", 0, 16], ["oropharyngeal swabs", "TEST", 21, 40], ["rectal", "ANATOMY", 4, 10], ["oropharyngeal swabs", "ANATOMY", 21, 40]]], ["The viral RNA was detected only in two inoculated dogs on pi 2 and in rectal swabs of one dog on pi 6.", [["rectal swabs", "ANATOMY", 70, 82], ["dogs", "ORGANISM", 50, 54], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 70, 82], ["dog", "ORGANISM", 90, 93], ["viral RNA", "RNA", 4, 13], ["dogs", "SPECIES", 50, 54], ["dog", "SPECIES", 90, 93], ["The viral RNA", "PROBLEM", 0, 13], ["rectal swabs", "TEST", 70, 82], ["viral RNA", "OBSERVATION", 4, 13], ["rectal", "ANATOMY", 70, 76]]], ["The viral RNA positive dog did not show infection in any organs or tissues after it was euthanized from p.i 4.", [["organs", "ANATOMY", 57, 63], ["tissues", "ANATOMY", 67, 74], ["infection", "DISEASE", 40, 49], ["dog", "ORGANISM", 23, 26], ["organs", "ORGAN", 57, 63], ["tissues", "TISSUE", 67, 74], ["dog", "SPECIES", 23, 26], ["The viral RNA", "TEST", 0, 13], ["infection in any organs or tissues", "PROBLEM", 40, 74], ["viral RNA", "OBSERVATION", 4, 13], ["positive dog", "OBSERVATION", 14, 26], ["infection", "OBSERVATION", 40, 49], ["tissues", "ANATOMY", 67, 74]]], ["The results of the ELISA were seronegative for all except for two virus inoculated dogs which were found to be seroconverted on p.i day 14.", [["dogs", "ORGANISM", 83, 87], ["dogs", "SPECIES", 83, 87], ["the ELISA", "TEST", 15, 24], ["two virus inoculated dogs", "PROBLEM", 62, 87]]], ["Thus, it is clear from the experiment that dogs are less susceptible to SARS-CoV-2 infection (Shi et al. 2020).Experiments on pigs, chickens and ducks ::: In-vivo experimental studies of SARS-CoV-2 transmission between animalsA similar set of experiments were performed in pigs, chicken and ducks to investigate the virus susceptibility in these animals.", [["SARS-CoV-2 infection", "DISEASE", 72, 92], ["SARS", "DISEASE", 187, 191], ["dogs", "ORGANISM", 43, 47], ["SARS-CoV-2", "ORGANISM", 72, 82], ["pigs", "ORGANISM", 126, 130], ["chickens", "ORGANISM", 132, 140], ["ducks", "ORGANISM", 145, 150], ["SARS-CoV-2", "ORGANISM", 187, 197], ["pigs", "ORGANISM", 273, 277], ["chicken", "ORGANISM", 279, 286], ["ducks", "ORGANISM", 291, 296], ["dogs", "SPECIES", 43, 47], ["pigs", "SPECIES", 126, 130], ["chickens", "SPECIES", 132, 140], ["ducks", "SPECIES", 145, 150], ["pigs", "SPECIES", 273, 277], ["chicken", "SPECIES", 279, 286], ["ducks", "SPECIES", 291, 296], ["SARS-CoV-2", "SPECIES", 72, 82], ["pigs", "SPECIES", 126, 130], ["chickens", "SPECIES", 132, 140], ["SARS-CoV", "SPECIES", 187, 195], ["pigs", "SPECIES", 273, 277], ["chicken", "SPECIES", 279, 286], ["ducks", "SPECIES", 291, 296], ["SARS", "PROBLEM", 72, 76], ["CoV-2 infection", "PROBLEM", 77, 92], ["SARS", "PROBLEM", 187, 191], ["CoV", "TEST", 192, 195], ["the virus susceptibility", "PROBLEM", 312, 336], ["clear", "OBSERVATION", 12, 17], ["virus", "OBSERVATION", 316, 321]]], ["The results from the experiment clearly stated that neither the inoculated animals nor the naive contacted animals were detected with viral RNA in the swab test.", [["animals", "ORGANISM", 107, 114], ["viral RNA", "RNA", 134, 143], ["viral RNA", "PROBLEM", 134, 143], ["the swab test", "TEST", 147, 160]]], ["Similar results were observed in the ELISA experiment where all the animals were seronegative for SARS-CoV-2 on post inoculation day 14.", [["animals", "ORGANISM", 68, 75], ["SARS-CoV-2", "ORGANISM", 98, 108], ["SARS-CoV", "SPECIES", 98, 106], ["the ELISA experiment", "TEST", 33, 53], ["SARS", "PROBLEM", 98, 102]]], ["Based on the results of this experiment, we can infer that pigs, chickens, ducks are not susceptible to this virus (Shi et al. 2020).Can humans transmit COVID-19 virus to animals?As SARS-CoV-2 is widely disseminating in the human population, it is likely that animals in close contact with humans can get infected as well (Almendros 2020).", [["pigs", "ORGANISM", 59, 63], ["chickens", "ORGANISM", 65, 73], ["ducks", "ORGANISM", 75, 80], ["humans", "ORGANISM", 137, 143], ["COVID-19 virus", "ORGANISM", 153, 167], ["SARS-CoV-2", "ORGANISM", 182, 192], ["human", "ORGANISM", 224, 229], ["humans", "ORGANISM", 290, 296], ["pigs", "SPECIES", 59, 63], ["chickens", "SPECIES", 65, 73], ["ducks", "SPECIES", 75, 80], ["humans", "SPECIES", 137, 143], ["human", "SPECIES", 224, 229], ["humans", "SPECIES", 290, 296], ["pigs", "SPECIES", 59, 63], ["chickens", "SPECIES", 65, 73], ["humans", "SPECIES", 137, 143], ["COVID-19 virus", "SPECIES", 153, 167], ["SARS-CoV", "SPECIES", 182, 190], ["human", "SPECIES", 224, 229], ["humans", "SPECIES", 290, 296], ["this virus", "PROBLEM", 104, 114], ["COVID", "TEST", 153, 158], ["widely", "OBSERVATION_MODIFIER", 196, 202], ["disseminating", "OBSERVATION_MODIFIER", 203, 216], ["is likely", "UNCERTAINTY", 245, 254]]], ["Various studies are being carried out to understand the vulnerability of different animal species to the virus and in better assess the infection dynamics in these susceptible animals.", [["infection", "DISEASE", 136, 145], ["Various studies", "TEST", 0, 15], ["different animal species to the virus", "PROBLEM", 73, 110], ["the infection dynamics", "PROBLEM", 132, 154], ["infection", "OBSERVATION", 136, 145]]], ["Till date, some animals such as dog, cats, and tiger are found to be infected with the virus following close contact with infected humans (Goumenou et al. 2020).", [["dog", "ORGANISM", 32, 35], ["cats", "ORGANISM", 37, 41], ["tiger", "ORGANISM", 47, 52], ["humans", "ORGANISM", 131, 137], ["dog", "SPECIES", 32, 35], ["cats", "SPECIES", 37, 41], ["humans", "SPECIES", 131, 137], ["dog", "SPECIES", 32, 35], ["humans", "SPECIES", 131, 137], ["the virus", "PROBLEM", 83, 92], ["infected", "OBSERVATION", 69, 77]]], ["The latency period for SARS-CoV-2 is almost similar in both humans and animals.", [["SARS", "DISEASE", 23, 27], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 23, 33], ["humans", "ORGANISM", 60, 66], ["humans", "SPECIES", 60, 66], ["SARS-CoV", "SPECIES", 23, 31], ["humans", "SPECIES", 60, 66], ["SARS", "PROBLEM", 23, 27], ["latency", "OBSERVATION_MODIFIER", 4, 11]]], ["On average, it ranges from 3 to 7 days to upto 14 days.", [["average", "OBSERVATION_MODIFIER", 3, 10]]], ["Surprisingly, the symptoms in animals are not certain, some develop dry cough, etc. (Fig. 3).", [["dry cough", "DISEASE", 68, 77], ["the symptoms", "PROBLEM", 14, 26], ["dry cough", "PROBLEM", 68, 77], ["dry", "OBSERVATION_MODIFIER", 68, 71], ["cough", "OBSERVATION", 72, 77]]], ["This human animal interface may even remain asymptomatic and can sometimes be contagious and act as silent sources of transmission (Ng and Hiscox 2020).", [["human", "ORGANISM", 5, 10], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["asymptomatic", "PROBLEM", 44, 56]]], ["However, there is no current evidence suggesting the possibility of animals infected by humans in spreading the virus.Pomeranian dog ::: Human-to-canine transmission ::: Evidence in favor of human-animal interfaceHong Kong\u2019s Agriculture, Fisheries, and Conservation Department (AFCD) reported on February 27, 2020, that the nasal and oral cavity samples of a 17-year-old Pomeranian dog were diagnosed as \u201cweak positive\u201d according to the results of the RT-PCR (real-time reverse-transcriptase polymerase chain reaction).", [["nasal", "ANATOMY", 324, 329], ["oral cavity samples", "ANATOMY", 334, 353], ["animals", "ORGANISM", 68, 75], ["humans", "ORGANISM", 88, 94], ["Human", "ORGANISM", 137, 142], ["canine", "ORGANISM", 146, 152], ["human", "ORGANISM", 191, 196], ["nasal", "ORGANISM_SUBDIVISION", 324, 329], ["oral cavity samples", "CANCER", 334, 353], ["dog", "ORGANISM", 382, 385], ["humans", "SPECIES", 88, 94], ["Human", "SPECIES", 137, 142], ["human", "SPECIES", 191, 196], ["dog", "SPECIES", 382, 385], ["humans", "SPECIES", 88, 94], ["human", "SPECIES", 191, 196], ["Pomeranian dog", "SPECIES", 371, 385], ["animals infected", "PROBLEM", 68, 84], ["the RT", "TEST", 448, 454], ["PCR", "TEST", 455, 458], ["transcriptase polymerase chain reaction", "PROBLEM", 478, 517], ["no current evidence suggesting the possibility of", "UNCERTAINTY", 18, 67], ["animals", "OBSERVATION_MODIFIER", 68, 75], ["infected", "OBSERVATION", 76, 84], ["nasal", "ANATOMY", 324, 329]]], ["The dog was already quarantined as the owner of the dog had been earlier diagnosed with COVID-19 (Almendros 2020).", [["dog", "ORGANISM", 4, 7], ["dog", "ORGANISM", 52, 55], ["dog", "SPECIES", 4, 7], ["dog", "SPECIES", 52, 55], ["COVID", "TEST", 88, 93]]], ["The dog did not show any symptoms of illness.", [["illness", "DISEASE", 37, 44], ["dog", "ORGANISM", 4, 7], ["dog", "SPECIES", 4, 7], ["any symptoms of illness", "PROBLEM", 21, 44]]], ["However, the results of the fecal sample and the rectal swab were negative.", [["fecal sample", "ANATOMY", 28, 40], ["rectal swab", "ANATOMY", 49, 60], ["rectal swab", "ORGAN", 49, 60], ["the fecal sample", "TEST", 24, 40], ["the rectal swab", "TEST", 45, 60], ["fecal", "ANATOMY", 28, 33], ["rectal", "ANATOMY", 49, 55]]], ["The reports of RT-PCR testing on the nasal cavity repeated on February 28, March 2, 5, and 9 were again found to be weak positive, indicating the presence of a minute amount of SARS-CoV-2 RNA in these samples.", [["nasal cavity", "ANATOMY", 37, 49], ["samples", "ANATOMY", 201, 208], ["SARS", "DISEASE", 177, 181], ["nasal cavity", "MULTI-TISSUE_STRUCTURE", 37, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 177, 187], ["samples", "CANCER", 201, 208], ["SARS-CoV-2 RNA", "RNA", 177, 191], ["RT-PCR testing on the nasal cavity", "TEST", 15, 49], ["weak positive", "PROBLEM", 116, 129], ["SARS", "PROBLEM", 177, 181], ["CoV", "TEST", 182, 185], ["these samples", "TEST", 195, 208], ["nasal cavity", "ANATOMY", 37, 49], ["SARS", "OBSERVATION", 177, 181]]], ["Moreover, the results of the genome data sequencing of the dog and its close human contacts completed on March 12 suggested a high similarity between the viral sequences.", [["dog", "ORGANISM", 59, 62], ["human", "ORGANISM", 77, 82], ["viral sequences", "DNA", 154, 169], ["dog", "SPECIES", 59, 62], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["the genome data", "TEST", 25, 40], ["the viral sequences", "TEST", 150, 169]]], ["The virus neutralizing antibody test completed on March 12 was negative.", [["The virus neutralizing antibody test", "TEST", 0, 36]]], ["The RT-PCR conducted on March 12 and 13 consecutively were reported to be negative and thus the Pomeranian was released on the following day.", [["The RT-PCR", "TEST", 0, 10], ["negative", "OBSERVATION", 74, 82]]], ["However, the dog died three days later and unfortunately the owner of the dog did not allow a postmortem examination (Mallapaty 2020).", [["dog", "ORGANISM", 13, 16], ["dog", "ORGANISM", 74, 77], ["dog", "SPECIES", 13, 16], ["dog", "SPECIES", 74, 77], ["a postmortem examination", "TEST", 92, 116]]], ["The death was possibly due to various co-morbidities and the age of the dog and was unlikely to be associated to COVID-19.", [["death", "DISEASE", 4, 9], ["dog", "ORGANISM", 72, 75], ["The death", "PROBLEM", 0, 9], ["various co-morbidities", "PROBLEM", 30, 52], ["COVID", "TEST", 113, 118], ["possibly due to", "UNCERTAINTY", 14, 29]]], ["The scientist of Hong Kong University believed that there was a possibility of the transmission of the virus from the infected owner to the dog considering the persistence of the positive results from the Pomeranian\u2019s samples.German shepherd dog ::: Human-to-canine transmission ::: Evidence in favor of human-animal interfaceThe second possible human-to-dog transmission was reported on March 19 when a two year old German shepherd dog living in Pok Fu Lam was tested positive for COVID-19.", [["samples", "ANATOMY", 218, 225], ["dog", "ORGANISM", 140, 143], ["Human", "ORGANISM", 250, 255], ["canine", "ORGANISM", 259, 265], ["human", "ORGANISM", 304, 309], ["human", "ORGANISM", 346, 351], ["dog", "ORGANISM", 355, 358], ["dog", "ORGANISM", 433, 436], ["dog", "SPECIES", 242, 245], ["Human", "SPECIES", 250, 255], ["human", "SPECIES", 304, 309], ["human", "SPECIES", 346, 351], ["dog", "SPECIES", 433, 436], ["German shepherd dog", "SPECIES", 226, 245], ["human", "SPECIES", 304, 309], ["human", "SPECIES", 346, 351], ["German shepherd dog", "SPECIES", 417, 436], ["the virus", "PROBLEM", 99, 108], ["Fu Lam", "TEST", 451, 457], ["COVID", "TEST", 482, 487]]], ["As seen earlier, the 30 years old owner of the dog was also infected with the virus.", [["owner", "ORGANISM", 34, 39], ["dog", "ORGANISM", 47, 50], ["dog", "SPECIES", 47, 50], ["dog", "SPECIES", 47, 50], ["the virus", "PROBLEM", 74, 83], ["infected", "OBSERVATION", 60, 68], ["virus", "OBSERVATION", 78, 83]]], ["However, the dog did not show any symptoms of respiratory discomfort during its quarantine period (Sit et al. 2020).", [["respiratory", "ANATOMY", 46, 57], ["respiratory discomfort", "DISEASE", 46, 68], ["dog", "ORGANISM", 13, 16], ["dog", "SPECIES", 13, 16], ["any symptoms", "PROBLEM", 30, 42], ["respiratory discomfort", "PROBLEM", 46, 68], ["respiratory", "ANATOMY", 46, 57], ["discomfort", "OBSERVATION", 58, 68]]], ["The Agriculture, Fisheries and Conservation Department reported that the results of RT-PCR on the oral and nasal samples of the dog came out to be positive.", [["oral", "ANATOMY", 98, 102], ["nasal samples", "ANATOMY", 107, 120], ["oral", "ORGANISM_SUBDIVISION", 98, 102], ["nasal samples", "MULTI-TISSUE_STRUCTURE", 107, 120], ["dog", "ORGANISM", 128, 131], ["dog", "SPECIES", 128, 131], ["dog", "SPECIES", 128, 131], ["RT-PCR", "TEST", 84, 90], ["the oral and nasal samples", "TEST", 94, 120], ["the dog", "TEST", 124, 131], ["positive", "OBSERVATION", 147, 155]]], ["Until 25th March, 17 dogs and 8 cats of the owners with confirmed cases or people in contact with confirmed cases were tested and monitored.", [["dogs", "ORGANISM", 21, 25], ["cats", "ORGANISM", 32, 36], ["people", "ORGANISM", 75, 81], ["dogs", "SPECIES", 21, 25], ["cats", "SPECIES", 32, 36], ["people", "SPECIES", 75, 81]]], ["However, only 2 dogs mentioned earlier were positive for SARS-CoV-2.Cat in Belgium ::: Cases of human - cat (FELINE) transmission ::: Evidence in favor of human-animal interfaceThe Federal Agency for Safety of the Food Chain (FASFC) was informed on March 18,2020 by the Faculty of Veterinary Medicine at the University of Liege that a cat in Belgium was found to be positive for the coronavirus (Mallapaty 2020).", [["SARS", "DISEASE", 57, 61], ["coronavirus", "DISEASE", 383, 394], ["dogs", "ORGANISM", 16, 20], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 57, 67], ["human", "ORGANISM", 96, 101], ["human", "ORGANISM", 155, 160], ["cat", "ORGANISM", 335, 338], ["coronavirus", "ORGANISM", 383, 394], ["dogs", "SPECIES", 16, 20], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 155, 160], ["SARS-CoV", "SPECIES", 57, 65], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 155, 160], ["SARS", "PROBLEM", 57, 61], ["CoV", "TEST", 62, 65], ["the coronavirus", "PROBLEM", 379, 394]]], ["The reports of PCR (high throughput sequencing) detected the viral RNA of SARS-CoV-2 in the faeces and vomit of the cat.", [["faeces", "ANATOMY", 92, 98], ["SARS-CoV-2", "ORGANISM", 74, 84], ["faeces", "ORGANISM_SUBDIVISION", 92, 98], ["vomit", "ORGANISM_SUBDIVISION", 103, 108], ["cat", "ORGANISM", 116, 119], ["viral RNA", "RNA", 61, 70], ["cat", "SPECIES", 116, 119], ["SARS-CoV", "SPECIES", 74, 82], ["PCR", "TEST", 15, 18], ["CoV", "TEST", 79, 82], ["viral RNA", "OBSERVATION", 61, 70]]], ["The cat was likely to pick up the virus from its owner who after travelling to northern Italy fell sick with SARS-CoV-2.", [["SARS", "DISEASE", 109, 113], ["cat", "ORGANISM", 4, 7]]], ["The cat started to show symptoms of illness a week later and had signs of respiratory and digestive dysfunction.", [["respiratory", "ANATOMY", 74, 85], ["digestive", "ANATOMY", 90, 99], ["illness", "DISEASE", 36, 43], ["respiratory and digestive dysfunction", "DISEASE", 74, 111], ["cat", "ORGANISM", 4, 7], ["digestive", "ORGAN", 90, 99], ["symptoms", "PROBLEM", 24, 32], ["illness", "PROBLEM", 36, 43], ["respiratory and digestive dysfunction", "PROBLEM", 74, 111], ["respiratory", "ANATOMY", 74, 85], ["digestive dysfunction", "OBSERVATION", 90, 111]]], ["The cat was quarantined and recovered after nine days.", [["cat", "ORGANISM", 4, 7]]], ["Currently, we do not have any evidence regarding the potential other conditions which may lead to respiratory and gastrointestinal signs.", [["respiratory", "ANATOMY", 98, 109], ["gastrointestinal", "ANATOMY", 114, 130], ["respiratory and gastrointestinal signs", "DISEASE", 98, 136], ["gastrointestinal", "ORGAN", 114, 130], ["the potential other conditions", "PROBLEM", 49, 79], ["respiratory and gastrointestinal signs", "PROBLEM", 98, 136], ["gastrointestinal", "ANATOMY", 114, 130]]], ["Once the cat is released from quarantine, the research will be carried out for the SARS-CoV-2 antibodies in the blood test, which would provide the true proof of the infection.", [["blood", "ANATOMY", 112, 117], ["infection", "DISEASE", 166, 175], ["cat", "ORGANISM", 9, 12], ["blood", "ORGANISM_SUBSTANCE", 112, 117], ["SARS-CoV-2 antibodies", "PROTEIN", 83, 104], ["SARS-CoV", "SPECIES", 83, 91], ["the SARS", "TEST", 79, 87], ["CoV", "TEST", 88, 91], ["the blood test", "TEST", 108, 122], ["the infection", "PROBLEM", 162, 175], ["infection", "OBSERVATION", 166, 175]]], ["The virologist named Steven Van Gucht made it clear that this case was about human-to-animal transmission and not vice-versa.", [["human", "ORGANISM", 77, 82], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82]]], ["However, he also stated that this was a rare case and the possible risk of animal to human transmission is very small.Pet cat in Hong Kong ::: Cases of human - cat (FELINE) transmission ::: Evidence in favor of human-animal interfaceA pet cat in Hong Kong was tested positive with COVID- 19 on March 31, 2020 after it was quarantined on March 30 after its owner, a women of the Shek Pai Wan Estate, Aberdeen was infected with the corona virus.", [["human", "ORGANISM", 85, 90], ["human", "ORGANISM", 152, 157], ["human", "ORGANISM", 211, 216], ["cat", "ORGANISM", 239, 242], ["women", "ORGANISM", 365, 370], ["corona virus", "ORGANISM", 430, 442], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 211, 216], ["women", "SPECIES", 365, 370], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 211, 216], ["A pet cat", "SPECIES", 233, 242], ["COVID", "TEST", 281, 286], ["the corona virus", "PROBLEM", 426, 442], ["very", "OBSERVATION_MODIFIER", 107, 111], ["small", "OBSERVATION_MODIFIER", 112, 117], ["corona virus", "OBSERVATION", 430, 442]]], ["The samples collected from the nose, mouth, and rectum of the cat were tested positive for the virus.", [["samples", "ANATOMY", 4, 11], ["nose", "ANATOMY", 31, 35], ["mouth", "ANATOMY", 37, 42], ["rectum", "ANATOMY", 48, 54], ["nose", "ORGANISM_SUBDIVISION", 31, 35], ["mouth", "ORGANISM_SUBDIVISION", 37, 42], ["rectum", "ORGAN", 48, 54], ["cat", "ORGANISM", 62, 65], ["cat", "SPECIES", 62, 65], ["The samples collected from the nose, mouth, and rectum of the cat", "TEST", 0, 65], ["the virus", "PROBLEM", 91, 100], ["nose", "ANATOMY", 31, 35], ["mouth", "ANATOMY", 37, 42], ["rectum", "ANATOMY", 48, 54]]], ["However, the cat did not show any signs of the disease.", [["cat", "ORGANISM", 13, 16], ["the disease", "PROBLEM", 43, 54], ["disease", "OBSERVATION", 47, 54]]], ["It is believed to be the second cat in the world to be infected with this virus (Pet cat in Hong Kong 2020).Tiger in zoo- New York ::: Cases of human - cat (FELINE) transmission ::: Evidence in favor of human-animal interfaceA female Malayan tiger name Nadia from the Bronx Zoo in New York City was found to be having respiratory illness and thus tested positive for COVID-19 on April 72,020.", [["respiratory", "ANATOMY", 318, 329], ["respiratory illness", "DISEASE", 318, 337], ["cat", "ORGANISM", 32, 35], ["Pet cat", "ORGANISM", 81, 88], ["human", "ORGANISM", 144, 149], ["human", "ORGANISM", 203, 208], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 203, 208], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 203, 208], ["Malayan tiger", "SPECIES", 234, 247], ["this virus", "PROBLEM", 69, 79], ["respiratory illness", "PROBLEM", 318, 337], ["COVID", "TEST", 367, 372], ["believed to be", "UNCERTAINTY", 6, 20], ["infected", "OBSERVATION", 55, 63]]], ["The Samples of the four-year-old female tiger along with six other animals who had developed dry cough and started showing indications on the 27th of March were taken and are believed to be infected with COVID-19.", [["dry cough", "DISEASE", 93, 102], ["female", "ORGANISM", 33, 39], ["tiger", "ORGANISM", 40, 45], ["animals", "ORGANISM", 67, 74], ["The Samples", "TEST", 0, 11], ["dry cough", "PROBLEM", 93, 102], ["COVID", "TEST", 204, 209], ["cough", "OBSERVATION", 97, 102], ["believed to be", "UNCERTAINTY", 175, 189], ["infected", "OBSERVATION", 190, 198]]], ["However, till date only the results of Nadia are confirmed to be positive (Gollakner and Capua 2020).", [["Nadia", "TEST", 39, 44]]], ["This animal is believed to have acquired the infection from an asymptomatic zoo-keeper after which she started to display a loss of appetite and dry cough.", [["infection", "DISEASE", 45, 54], ["loss of appetite", "DISEASE", 124, 140], ["dry cough", "DISEASE", 145, 154], ["the infection", "PROBLEM", 41, 54], ["a loss of appetite", "PROBLEM", 122, 140], ["dry cough", "PROBLEM", 145, 154], ["infection", "OBSERVATION", 45, 54], ["cough", "OBSERVATION", 149, 154]]], ["This case was the first case to be documented of COVID-19 infection in US animals as well as tigers all over the world.", [["COVID-19", "CHEMICAL", 49, 57], ["infection", "DISEASE", 58, 67], ["COVID-19", "CELL", 49, 57], ["COVID-19 infection", "PROBLEM", 49, 67], ["infection", "OBSERVATION", 58, 67]]], ["These findings raise new questions about the transmission of the virus in animals.Minks in NetherlandsMinks are commonly farmed for their fur in Netherlands.", [["the virus", "PROBLEM", 61, 70]]], ["However, two of the mink farms (one in the province North Brabant, South Netherlands observed a increase in the mink mortality in mid April 2020.", [["mink", "SPECIES", 20, 24], ["mink", "SPECIES", 112, 116], ["increase", "OBSERVATION_MODIFIER", 96, 104]]], ["Some these minks displayed signs of respiratory signs (mostly nasal discharge).", [["respiratory", "ANATOMY", 36, 47], ["nasal", "ANATOMY", 62, 67], ["respiratory signs", "DISEASE", 36, 53], ["nasal", "ORGANISM_SUBDIVISION", 62, 67], ["respiratory signs", "PROBLEM", 36, 53], ["respiratory signs", "OBSERVATION", 36, 53]]], ["The necropsied samples from the dead minks tested positive for SARS-CoV-2.", [["samples", "ANATOMY", 15, 22], ["SARS", "DISEASE", 63, 67], ["SARS-CoV", "SPECIES", 63, 71], ["The necropsied samples", "TEST", 0, 22], ["the dead minks", "TEST", 28, 42], ["SARS", "PROBLEM", 63, 67], ["CoV", "TEST", 68, 71]]], ["Histological findings revealed severe diffuse pneumonia with hyperaemia, alveolar damage as well as air containing alveolar lumina in lungs of the dead minks.", [["alveolar", "ANATOMY", 73, 81], ["alveolar lumina", "ANATOMY", 115, 130], ["lungs", "ANATOMY", 134, 139], ["pneumonia", "DISEASE", 46, 55], ["hyperaemia", "DISEASE", 61, 71], ["alveolar damage", "DISEASE", 73, 88], ["alveolar", "TISSUE", 73, 81], ["alveolar lumina", "MULTI-TISSUE_STRUCTURE", 115, 130], ["lungs", "ORGAN", 134, 139], ["Histological findings", "TEST", 0, 21], ["severe diffuse pneumonia", "PROBLEM", 31, 55], ["hyperaemia", "PROBLEM", 61, 71], ["alveolar damage", "PROBLEM", 73, 88], ["air containing alveolar lumina in lungs of the dead minks", "PROBLEM", 100, 157], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["diffuse", "OBSERVATION_MODIFIER", 38, 45], ["pneumonia", "OBSERVATION", 46, 55], ["hyperaemia", "OBSERVATION", 61, 71], ["alveolar damage", "OBSERVATION", 73, 88], ["air", "OBSERVATION", 100, 103], ["alveolar", "ANATOMY_MODIFIER", 115, 123], ["lumina", "ANATOMY_MODIFIER", 124, 130], ["lungs", "ANATOMY", 134, 139], ["dead minks", "OBSERVATION", 147, 157]]], ["The qPCR analysis detected the presence of viral RNA in the liver and intestines of some animals.", [["liver", "ANATOMY", 60, 65], ["intestines", "ANATOMY", 70, 80], ["liver", "ORGAN", 60, 65], ["intestines", "ORGAN", 70, 80], ["viral RNA", "RNA", 43, 52], ["The qPCR analysis", "TEST", 0, 17], ["viral RNA in the liver", "PROBLEM", 43, 65], ["viral RNA", "OBSERVATION", 43, 52], ["liver", "ANATOMY", 60, 65], ["intestines", "ANATOMY", 70, 80]]], ["Also, the throat swabs of all the necropsied animals showed the presence of viral RNA.", [["throat swabs", "ANATOMY", 10, 22], ["throat swabs", "ORGANISM_SUBDIVISION", 10, 22], ["viral RNA", "RNA", 76, 85], ["the throat swabs", "TEST", 6, 22], ["viral RNA", "PROBLEM", 76, 85], ["throat", "ANATOMY", 10, 16], ["viral RNA", "OBSERVATION", 76, 85]]], ["On further investigation of the farm owners and workers, four members on one of the two farms have had respiratory disease symptoms in the start of april but did not get checked for SARS-CoV-2 infection.", [["respiratory", "ANATOMY", 103, 114], ["respiratory disease symptoms", "DISEASE", 103, 131], ["SARS-CoV-2 infection", "DISEASE", 182, 202], ["SARS-CoV-2", "ORGANISM", 182, 192], ["SARS-CoV-2", "SPECIES", 182, 192], ["respiratory disease symptoms", "PROBLEM", 103, 131], ["SARS", "PROBLEM", 182, 186], ["CoV-2 infection", "PROBLEM", 187, 202], ["respiratory", "ANATOMY", 103, 114], ["disease", "OBSERVATION", 115, 122], ["infection", "OBSERVATION", 193, 202]]], ["Additionally, one of the people who stayed in the farm was later detected with SARS-CoV-2 by the end of april.", [["SARS", "DISEASE", 79, 83], ["people", "ORGANISM", 25, 31], ["people", "SPECIES", 25, 31]]], ["Moreover, one of the workers of farm two was hospitalized on March 31 due to COVID-19.", [["COVID", "TEST", 77, 82]]], ["These results further confirm the possibility of transmission of the virus between humans and animals (here, minks).", [["humans", "ORGANISM", 83, 89], ["humans", "SPECIES", 83, 89], ["humans", "SPECIES", 83, 89], ["the virus", "PROBLEM", 65, 74], ["virus", "OBSERVATION", 69, 74]]], ["Inhalable dust samples were collected three times between April 28 and May 16 at different locations in the mink house.", [["dust samples", "ANATOMY", 10, 22], ["dust samples", "CANCER", 10, 22], ["mink", "ORGANISM", 108, 112], ["mink house", "SPECIES", 108, 118], ["Inhalable dust samples", "TEST", 0, 22]]], ["Viral Ran was detected in two of the three samples from farm one and one sample in farm two.", [["samples", "ANATOMY", 43, 50], ["Viral", "ORGANISM", 0, 5], ["Ran", "GENE_OR_GENE_PRODUCT", 6, 9], ["Viral Ran", "PROTEIN", 0, 9], ["Viral Ran", "PROBLEM", 0, 9]]], ["Also, 24 stray cats around the farms were sampled for the SARS-CoV-2 and results revealed the presence of antibodies against SARS-CoV-2 in seven cats and viral RNA in one cat.Minks in NetherlandsThe mink outbreaks are \u201cspillover\u201d from the human pandemic\u2014a zoonosis in reverse.", [["SARS", "DISEASE", 58, 62], ["zoonosis", "DISEASE", 256, 264], ["cats", "ORGANISM", 15, 19], ["SARS-CoV-2", "ORGANISM", 125, 135], ["cats", "ORGANISM", 145, 149], ["cat", "ORGANISM", 171, 174], ["human", "ORGANISM", 239, 244], ["antibodies", "PROTEIN", 106, 116], ["viral RNA", "RNA", 154, 163], ["cats", "SPECIES", 15, 19], ["cats", "SPECIES", 145, 149], ["cat", "SPECIES", 171, 174], ["human", "SPECIES", 239, 244], ["SARS-CoV", "SPECIES", 58, 66], ["SARS-CoV", "SPECIES", 125, 133], ["mink", "SPECIES", 199, 203], ["human", "SPECIES", 239, 244], ["the SARS", "TEST", 54, 62], ["CoV", "TEST", 63, 66], ["antibodies", "PROBLEM", 106, 116], ["SARS", "PROBLEM", 125, 129], ["CoV", "TEST", 130, 133], ["viral RNA", "PROBLEM", 154, 163], ["viral RNA", "OBSERVATION", 154, 163], ["mink", "OBSERVATION_MODIFIER", 199, 203], ["outbreaks", "OBSERVATION_MODIFIER", 204, 213]]], ["The most likely explanation for the widespread infection on the mink farms is the possibility of the introduction of the virus by the humans to the minks.", [["infection", "DISEASE", 47, 56], ["mink", "ORGANISM", 64, 68], ["humans", "ORGANISM", 134, 140], ["mink", "SPECIES", 64, 68], ["humans", "SPECIES", 134, 140], ["mink", "SPECIES", 64, 68], ["humans", "SPECIES", 134, 140], ["the widespread infection", "PROBLEM", 32, 56], ["the virus", "PROBLEM", 117, 126], ["most likely explanation for", "UNCERTAINTY", 4, 31], ["widespread", "OBSERVATION_MODIFIER", 36, 46], ["infection", "OBSERVATION", 47, 56]]], ["The minks were caged separately with non-permeable partition between the cages, precluding the direct contact as a mode of transmission amongst the minks.", [["non-permeable partition between the cages", "TREATMENT", 37, 78]]], ["Thus, the indirect transmission may have occurred through the food or the bedding material, infected droplets generated by the infected animals or by the contaminated fecal matter.", [["fecal matter", "ANATOMY", 167, 179], ["fecal", "ORGANISM_SUBDIVISION", 167, 172], ["infected droplets", "PROBLEM", 92, 109], ["the contaminated fecal matter", "PROBLEM", 150, 179], ["infected", "OBSERVATION_MODIFIER", 127, 135], ["contaminated", "OBSERVATION_MODIFIER", 154, 166], ["fecal matter", "OBSERVATION", 167, 179]]], ["Sequence analysis of mink-derived viruses pointed at humans as the probable source of the initial infection and demonstrated transmission between minks.", [["infection", "DISEASE", 98, 107], ["mink-derived viruses", "ORGANISM", 21, 41], ["humans", "ORGANISM", 53, 59], ["humans", "SPECIES", 53, 59], ["mink", "SPECIES", 21, 25], ["humans", "SPECIES", 53, 59], ["Sequence analysis", "TEST", 0, 17], ["derived viruses", "PROBLEM", 26, 41], ["the initial infection", "PROBLEM", 86, 107], ["transmission between minks", "PROBLEM", 125, 151], ["infection", "OBSERVATION", 98, 107]]], ["Furthermore, the presence of viral RNA in inhalable dust collected from the farms indicated a possible exposure of workers to virus excreted by minks.", [["viral RNA", "RNA", 29, 38], ["viral RNA in inhalable dust", "PROBLEM", 29, 56], ["viral RNA", "OBSERVATION", 29, 38]]], ["(Oreshkova et al. 2020).How to stay healthy around animalsIt is not yet comprehensive to comment whether animals, including livestock, pets, and wild life pose any risk of COVID-19 infection.", [["infection", "DISEASE", 181, 190], ["COVID-19", "ORGANISM", 172, 180], ["COVID-19", "SPECIES", 172, 180], ["COVID-19 infection", "PROBLEM", 172, 190], ["infection", "OBSERVATION", 181, 190]]], ["However, adequate precautions should be taken while dealing with pets or any other animals such as washing hands properly after any contact with the animals, their food, or animal waste (Marconato and Finotello 2020).", [["adequate precautions", "TREATMENT", 9, 29]]], ["Also, utmost care should be taken to clean up the pets properly and to follow a good pet hygiene as they may otherwise contain germs which may make humans sick.", [["germs", "ORGAN", 127, 132], ["humans", "ORGANISM", 148, 154], ["humans", "SPECIES", 148, 154], ["humans", "SPECIES", 148, 154], ["germs", "PROBLEM", 127, 132]]], ["There should be regular visits to the veterinarians or assistance from them if the need arises about pet health.How to protect pets if you are sick?Although there are very few reports on whether SARS-CoV-2 can be transmitted from humans to animals, it is recommended that confirmed as well as suspected individuals with COVID-19 to have restricted contact with pets or other animals until more information about the transmission is available.", [["SARS", "DISEASE", 195, 199], ["pet", "ORGANISM_SUBDIVISION", 101, 104], ["SARS-CoV-2", "ORGANISM", 195, 205], ["humans", "ORGANISM", 230, 236], ["humans", "SPECIES", 230, 236], ["SARS-CoV", "SPECIES", 195, 203], ["humans", "SPECIES", 230, 236], ["sick", "PROBLEM", 143, 147], ["SARS", "PROBLEM", 195, 199], ["COVID", "TEST", 320, 325], ["very", "OBSERVATION_MODIFIER", 167, 171], ["few", "OBSERVATION_MODIFIER", 172, 175]]], ["Continual exposure to humans hosting the corona virus would sooner or later possibly cause major threats to these animals to extinction.", [["humans", "ORGANISM", 22, 28], ["corona virus", "ORGANISM", 41, 53], ["humans", "SPECIES", 22, 28], ["humans", "SPECIES", 22, 28], ["the corona virus", "PROBLEM", 37, 53]]], ["It is also suggested that if there is no other member of the family to take care of the pet while the owner is infected, proper hygiene should be maintained around the pet.", [["pet", "ORGANISM", 88, 91], ["infected", "OBSERVATION", 111, 119]]], ["The owner or the infected person should avoid physical contact such as kissing, licking, snuggling, or sharing food with the pet and wash his hands before and after interaction with them.", [["person", "ORGANISM", 26, 32], ["person", "SPECIES", 26, 32]]], ["Safe hygiene practice needs to be ensured while handling and caring for the pets and special precautions should be taken when in close proximity with the animal, such as wearing a mask.", [["Safe hygiene practice", "TREATMENT", 0, 21], ["the pets", "TREATMENT", 72, 80], ["special precautions", "TREATMENT", 85, 104], ["a mask", "TREATMENT", 178, 184]]], ["When handling and caring for the animals, they should maintain good hygiene practices and wear a mask.", [["a mask", "TREATMENT", 95, 101]]], ["Moreover, the infected person should not have common drinking glasses, utensils, towels, bedding with pets at home (Huang et al. 2020).Keeping pets safeTo keep the pets safe during this pandemic, it is advisable to have an emergency kit prepared in advance containing sufficient food and medications for at least two weeks (Aitken 2020).", [["person", "ORGANISM", 23, 29], ["person", "SPECIES", 23, 29], ["an emergency kit", "TREATMENT", 220, 236], ["medications", "TREATMENT", 288, 299], ["infected", "OBSERVATION", 14, 22]]], ["Since there are not enough evidence that pets can spread the virus to other animals or humans, it is not recommended to remove pets from the homes of people where COVID-19 is confirmed or suspected in any member of the household.", [["humans", "ORGANISM", 87, 93], ["people", "ORGANISM", 150, 156], ["humans", "SPECIES", 87, 93], ["people", "SPECIES", 150, 156], ["humans", "SPECIES", 87, 93], ["not enough evidence", "UNCERTAINTY", 16, 35]]], ["In case if the pets are not able to be taken care properly, veterinarians are there to support the good health of the pets.Can pets spread COVID-19 to humans?We need to understand that there is a difference between the pets contracting the virus and a pet spreading the virus to humans.", [["COVID-19", "CHEMICAL", 139, 147], ["humans", "ORGANISM", 151, 157], ["pet", "ORGANISM_SUBDIVISION", 252, 255], ["humans", "ORGANISM", 279, 285], ["humans", "SPECIES", 151, 157], ["humans", "SPECIES", 279, 285], ["humans", "SPECIES", 151, 157], ["humans", "SPECIES", 279, 285], ["a difference between the pets contracting the virus", "PROBLEM", 194, 245]]], ["The research experts said that the likelihood of humans contracting COVID-19 from their pets is low.", [["humans", "ORGANISM", 49, 55], ["humans", "SPECIES", 49, 55], ["humans", "SPECIES", 49, 55], ["humans contracting COVID", "TEST", 49, 73], ["low", "OBSERVATION_MODIFIER", 96, 99]]], ["Also according to the CDC reports, there is no evidence for transmission of the novel corona virus from companion animals to humans.", [["corona virus", "ORGANISM", 86, 98], ["humans", "ORGANISM", 125, 131], ["humans", "SPECIES", 125, 131], ["humans", "SPECIES", 125, 131], ["the novel corona virus", "PROBLEM", 76, 98], ["no evidence for", "UNCERTAINTY", 44, 59], ["corona virus", "OBSERVATION", 86, 98]]], ["The major route of transmission appears to be from person-to- person by contact with saliva or other bodily secretions through cough or sneeze (COVID-19: Coronavirus and Pets FAQ 2020).", [["secretions", "ANATOMY", 108, 118], ["cough", "DISEASE", 127, 132], ["saliva", "ORGANISM_SUBSTANCE", 85, 91], ["secretions", "ORGANISM_SUBSTANCE", 108, 118], ["person", "SPECIES", 51, 57], ["person", "SPECIES", 62, 68], ["other bodily secretions", "PROBLEM", 95, 118], ["cough", "PROBLEM", 127, 132]]], ["However, non-porous materials such as door knobs have higher capacity to transmit the virus as compared to non-porous surfaces.", [["door knobs", "PROBLEM", 38, 48], ["higher capacity", "PROBLEM", 54, 69], ["the virus", "PROBLEM", 82, 91], ["non-porous materials", "OBSERVATION", 9, 29], ["higher capacity", "OBSERVATION_MODIFIER", 54, 69], ["virus", "OBSERVATION", 86, 91]]], ["Since pet furs belongs to the category of non-porous surfaces and are likely to trap and absorb the virus, it is harder to contract the virus onto them through simple touch.", [["the virus", "PROBLEM", 96, 105], ["virus", "OBSERVATION", 100, 105]]], ["On the contrary, there are chances of dissemination of the virus to humans from the body fluids of pet animals.", [["body fluids", "ANATOMY", 84, 95], ["humans", "ORGANISM", 68, 74], ["body", "ORGANISM_SUBDIVISION", 84, 88], ["humans", "SPECIES", 68, 74], ["humans", "SPECIES", 68, 74], ["the virus", "PROBLEM", 55, 64], ["dissemination", "OBSERVATION", 38, 51], ["virus", "OBSERVATION", 59, 64]]], ["Since pet dogs and cats are always in close proximity to their owners, there are chances of transmission through kissing, licking, and playing with the pets (Fig. 2).", [["pet dogs", "ORGANISM", 6, 14], ["cats", "ORGANISM", 19, 23], ["dogs", "SPECIES", 10, 14], ["cats", "SPECIES", 19, 23], ["pet dogs", "TEST", 6, 14]]], ["Moreover, researchers have found that most of the cats and ferrets that were infected with the virus are asymptomatic, showing no signs of coughing, sneezing, weight loss, or raised body temperature (Halfmann et al. 2020).", [["body", "ANATOMY", 182, 186], ["coughing", "DISEASE", 139, 147], ["sneezing", "DISEASE", 149, 157], ["weight loss", "DISEASE", 159, 170], ["cats", "ORGANISM", 50, 54], ["ferrets", "ORGANISM", 59, 66], ["body", "ORGANISM_SUBDIVISION", 182, 186], ["cats", "SPECIES", 50, 54], ["ferrets", "SPECIES", 59, 66], ["ferrets", "SPECIES", 59, 66], ["the cats and ferrets", "PROBLEM", 46, 66], ["the virus", "PROBLEM", 91, 100], ["coughing", "PROBLEM", 139, 147], ["sneezing", "PROBLEM", 149, 157], ["weight loss", "PROBLEM", 159, 170], ["raised body temperature", "PROBLEM", 175, 198], ["no signs of", "UNCERTAINTY", 127, 138], ["coughing", "OBSERVATION", 139, 147]]], ["Thus, it is likely that the owners of the infected pet animals would not have noticed any change in their pets.", [["pet", "ORGANISM", 51, 54], ["the infected pet animals", "PROBLEM", 38, 62], ["is likely", "UNCERTAINTY", 9, 18]]], ["In view of the fact that SARS-CoV-2 virus was also detected in the feces of animals experimentally inoculated with the human virus titre, there are chances that the virus contaminated faecal matter and urine of pet animals can transmit the virus to humans.", [["feces", "ANATOMY", 67, 72], ["faecal matter", "ANATOMY", 184, 197], ["urine", "ANATOMY", 202, 207], ["SARS", "DISEASE", 25, 29], ["SARS-CoV-2 virus", "ORGANISM", 25, 41], ["feces", "ORGANISM_SUBSTANCE", 67, 72], ["human", "ORGANISM", 119, 124], ["urine", "ORGANISM_SUBSTANCE", 202, 207], ["humans", "ORGANISM", 249, 255], ["CoV-2 virus", "SPECIES", 30, 41], ["human", "SPECIES", 119, 124], ["humans", "SPECIES", 249, 255], ["SARS-CoV-2 virus", "SPECIES", 25, 41], ["human virus", "SPECIES", 119, 130], ["humans", "SPECIES", 249, 255], ["SARS", "PROBLEM", 25, 29], ["CoV-2 virus", "PROBLEM", 30, 41], ["the human virus titre", "PROBLEM", 115, 136], ["the virus contaminated faecal matter", "PROBLEM", 161, 197]]], ["Social distancing (at least 6 ft) should be maintained even with pets or other companion animals outside the household.Can pets spread COVID-19 to humans?With the increasing reports of transmission of COVID-19 from infected humans to pets (like cats and dogs) and tigers and lions, there is an urgent need for public health officials to identify and investigate the possibility of virus transmission from pets to humans.", [["COVID-19", "CHEMICAL", 201, 209], ["COVID-19", "CHEMICAL", 135, 143], ["humans", "ORGANISM", 147, 153], ["COVID-19", "GENE_OR_GENE_PRODUCT", 201, 209], ["humans", "ORGANISM", 224, 230], ["cats", "ORGANISM", 245, 249], ["humans", "ORGANISM", 413, 419], ["humans", "SPECIES", 147, 153], ["humans", "SPECIES", 224, 230], ["cats", "SPECIES", 245, 249], ["dogs", "SPECIES", 254, 258], ["humans", "SPECIES", 413, 419], ["humans", "SPECIES", 147, 153], ["humans", "SPECIES", 224, 230], ["humans", "SPECIES", 413, 419], ["COVID", "TEST", 201, 206], ["virus transmission", "PROBLEM", 381, 399], ["increasing", "OBSERVATION_MODIFIER", 163, 173], ["virus", "OBSERVATION", 381, 386]]], ["At present, people should emphasize on preventing the possible transmission of SARS-CoV-2 on to their pets.", [["SARS", "DISEASE", 79, 83], ["people", "ORGANISM", 12, 18], ["people", "SPECIES", 12, 18], ["SARS-CoV", "SPECIES", 79, 87], ["SARS", "PROBLEM", 79, 83]]], ["In accordance with the data from various experimental reports, cats infected with the virus having no appreciable clinical signs can act as a silent transmitter of COVID-19 infection to humans (CDC 2020).", [["COVID-19", "CHEMICAL", 164, 172], ["infection", "DISEASE", 173, 182], ["cats", "ORGANISM", 63, 67], ["COVID-19", "ORGANISM", 164, 172], ["humans", "ORGANISM", 186, 192], ["cats", "SPECIES", 63, 67], ["humans", "SPECIES", 186, 192], ["humans", "SPECIES", 186, 192], ["the virus", "PROBLEM", 82, 91], ["appreciable clinical signs", "PROBLEM", 102, 128], ["COVID-19 infection", "PROBLEM", 164, 182]]], ["Recently, the CDC has issued the following guidelines for pet owners to keep themselves safe and healthy.Always wash your hands after contact with the pets or their belongings such as their cages, beds, food and food utensils, animal waste, etc.Do not allow children and elderly people to handle or be around the animals.The family members suffering from diseases like diabetes, hypertension, and other immunity compromised diseases should not come into contact with their pets.The pets and their food items should be kept away from the kitchen.Rough playing with the pets should be avoided to prevent any scratches and bites.", [["diabetes", "DISEASE", 369, 377], ["hypertension", "DISEASE", 379, 391], ["children", "ORGANISM", 258, 266], ["people", "ORGANISM", 279, 285], ["children", "SPECIES", 258, 266], ["people", "SPECIES", 279, 285], ["diseases", "PROBLEM", 355, 363], ["diabetes", "PROBLEM", 369, 377], ["hypertension", "PROBLEM", 379, 391], ["other immunity compromised diseases", "PROBLEM", 397, 432], ["the pets", "TREATMENT", 564, 572], ["any scratches and bites", "PROBLEM", 602, 625], ["diabetes", "OBSERVATION", 369, 377], ["hypertension", "OBSERVATION", 379, 391], ["scratches", "OBSERVATION", 606, 615]]], ["Moreover, avoid kissing, snuggling, or holding the animals close to the face.Can pets spread COVID-19 to humans?Immediate medical care should be given in case of any type of scratches or bites.", [["COVID-19", "CHEMICAL", 93, 101], ["humans", "ORGANISM", 105, 111], ["humans", "SPECIES", 105, 111], ["humans", "SPECIES", 105, 111], ["Immediate medical care", "TREATMENT", 112, 134], ["scratches", "PROBLEM", 174, 183], ["bites", "PROBLEM", 187, 192], ["face", "ANATOMY", 72, 76], ["scratches", "OBSERVATION", 174, 183]]], ["Furthermore, pets should also be monitored for clinical symptoms or any unusual change in their behavior.Are there any precautions to be taken with live animals or animal products?The World Health Organization (WHO) has advised people to take general precautions while visiting live animal markets, animal product markets, or wet markets because there is still uncertainty about the exact origin of this virus (Zhonghua 2020).", [["people", "ORGANISM", 228, 234], ["people", "SPECIES", 228, 234], ["clinical symptoms", "PROBLEM", 47, 64], ["any unusual change in their behavior", "PROBLEM", 68, 104], ["any precautions", "TREATMENT", 115, 130], ["general precautions", "TREATMENT", 243, 262], ["this virus", "PROBLEM", 399, 409]]], ["Also, it is recommended to wash hands regularly with soap and potable water after any contact with animals or their products as well as avoid touching eyes, nose or mouth after contact with sick animals or spoiled animal products.", [["eyes", "ANATOMY", 151, 155], ["nose", "ANATOMY", 157, 161], ["mouth", "ANATOMY", 165, 170], ["eyes", "ORGAN", 151, 155], ["nose", "ORGANISM_SUBDIVISION", 157, 161], ["mouth", "ORGANISM_SUBDIVISION", 165, 170], ["soap", "TREATMENT", 53, 57], ["nose", "ANATOMY", 157, 161], ["mouth", "ANATOMY", 165, 170]]], ["Adequate precautions should be taken to avoid any contact with animal waste or fluids on the soil or any other surfaces.", [["Adequate precautions", "TREATMENT", 0, 20], ["precautions", "OBSERVATION", 9, 20]]], ["Any contact with stray animals such as dogs, cats, birds, rodents living in the streets to be completely restricted.", [["dogs", "ORGANISM", 39, 43], ["cats", "ORGANISM", 45, 49], ["dogs", "SPECIES", 39, 43], ["cats", "SPECIES", 45, 49]]], ["Additionally, even though no research based evidence has proven the spread of this virus due to intake of seafood, chicken, or mutton, still the intake of any raw or uncooked milk, meat, or any kind of animal organs should be avoided as per the general good food safety practices (Wang et al. 2020).Precautionary measures for zoosSince the report of the New York zoo tiger tested positive for COVID-19, the Ministry of Environment, Forest and climate change has advised zoos to remain at high alert and regularly observe animals for any abnormal behaviors or symptoms.", [["milk", "ANATOMY", 175, 179], ["meat", "ANATOMY", 181, 185], ["organs", "ANATOMY", 209, 215], ["abnormal behaviors", "DISEASE", 537, 555], ["chicken", "ORGANISM", 115, 122], ["milk", "ORGANISM_SUBSTANCE", 175, 179], ["meat", "ORGANISM_SUBDIVISION", 181, 185], ["organs", "ORGAN", 209, 215], ["chicken", "SPECIES", 115, 122], ["milk", "SPECIES", 175, 179], ["chicken", "SPECIES", 115, 122], ["uncooked", "SPECIES", 166, 174], ["New York zoo tiger", "SPECIES", 354, 372], ["this virus", "PROBLEM", 78, 88], ["Precautionary measures", "TREATMENT", 299, 321], ["COVID", "TEST", 393, 398], ["any abnormal behaviors", "PROBLEM", 533, 555], ["symptoms", "PROBLEM", 559, 567]]], ["The advisory has ordered that the care takers of zoo animals should wear proper personal protective equipment and maintain limited contact with animals while feeding them.", [["zoo animals", "TREATMENT", 49, 60], ["proper personal protective equipment", "TREATMENT", 73, 109]]], ["In addition, the sick animals are advised to be quarantined and all zoo personnel should strictly follow the safety and disinfection protocol issued by the government (COVID-19: Alipore zoo 2020).", [["disinfection protocol", "TREATMENT", 120, 141]]], ["Proper screening, testing, and surveillance of the diagnostic samples should be done whenever required.", [["Proper screening", "TEST", 0, 16], ["testing", "TEST", 18, 25], ["the diagnostic samples", "TEST", 47, 69]]], ["Along with this, an advisory has been issued to all the chief Wildlife wardens of states and union territories by the Ministry of environment which includes the following instructions:Proper regulatory measures should be taken by all the National parks, Sanctuaries, and Tiger reserves to prevent the spread of SARS-CoV-2 from humans to animals.There should be reduction in the human and wildlife interface.Movement of people to the National parks and sanctuaries should be curtailed.Management of the current situation with the help of task force to be undertaken as soon as possible.A significant enhancement in the mapping, tracing, monitoring, and surveillance of the system in coordination with various departments.Emergency services for the treatment of animals, if required, should be undertaken.Proper reporting to the nodal officer should be done in any type of noticed cases.Other possible steps to be followed to prohibit the spread of the virus.ConclusionThe comparison of the human version of the coronavirus to previously isolated strains from animals was possible only due to the availability of the complete genetic sequencing of the SARS-CoV-2 (Kannan et al. 2020).", [["nodal officer", "ANATOMY", 827, 840], ["SARS", "DISEASE", 311, 315], ["SARS", "DISEASE", 1150, 1154], ["SARS-CoV-2", "ORGANISM", 311, 321], ["humans", "ORGANISM", 327, 333], ["human", "ORGANISM", 378, 383], ["people", "ORGANISM", 419, 425], ["human", "ORGANISM", 989, 994], ["coronavirus", "ORGANISM", 1010, 1021], ["SARS-CoV-2", "ORGANISM", 1150, 1160], ["humans", "SPECIES", 327, 333], ["human", "SPECIES", 378, 383], ["people", "SPECIES", 419, 425], ["human", "SPECIES", 989, 994], ["SARS-CoV", "SPECIES", 311, 319], ["humans", "SPECIES", 327, 333], ["human", "SPECIES", 378, 383], ["human", "SPECIES", 989, 994], ["SARS-CoV", "SPECIES", 1150, 1158], ["Proper regulatory measures", "TREATMENT", 184, 210], ["SARS", "PROBLEM", 311, 315], ["Management", "TREATMENT", 484, 494], ["task force", "TREATMENT", 537, 547], ["A significant enhancement", "PROBLEM", 585, 610], ["the mapping", "TEST", 614, 625], ["tracing", "TEST", 627, 634], ["monitoring", "TEST", 636, 646], ["the treatment of animals", "TREATMENT", 743, 767], ["the virus", "PROBLEM", 947, 956], ["the coronavirus", "PROBLEM", 1006, 1021], ["previously isolated strains", "PROBLEM", 1025, 1052], ["the SARS", "TEST", 1146, 1154], ["CoV", "TEST", 1155, 1158], ["reduction", "OBSERVATION_MODIFIER", 361, 370], ["significant", "OBSERVATION_MODIFIER", 587, 598], ["enhancement", "OBSERVATION", 599, 610]]], ["Various evidence suggested that bats are the primary reservoirs of the novel corona virus and thus the major source of infection to humans.", [["infection", "DISEASE", 119, 128], ["bats", "ORGANISM", 32, 36], ["corona virus", "ORGANISM", 77, 89], ["humans", "ORGANISM", 132, 138], ["humans", "SPECIES", 132, 138], ["corona virus", "SPECIES", 77, 89], ["humans", "SPECIES", 132, 138], ["the novel corona virus", "PROBLEM", 67, 89], ["infection", "PROBLEM", 119, 128], ["infection", "OBSERVATION", 119, 128]]], ["Since the SARS-CoV-2 genomic sequence in humans and pangolin has shown significant relatedness, these animals are suspected to be the intermediate host for this infection (Xu et al. 2020c).", [["pangolin", "CHEMICAL", 52, 60], ["infection", "DISEASE", 161, 170], ["CoV-2", "ORGANISM", 15, 20], ["humans", "ORGANISM", 41, 47], ["pangolin", "GENE_OR_GENE_PRODUCT", 52, 60], ["SARS-CoV-2 genomic sequence", "DNA", 10, 37], ["humans", "SPECIES", 41, 47], ["humans", "SPECIES", 41, 47], ["the SARS", "TEST", 6, 14], ["this infection", "PROBLEM", 156, 170], ["significant", "OBSERVATION_MODIFIER", 71, 82], ["relatedness", "OBSERVATION", 83, 94]]], ["Thus, comprehensive studies on how an animal virus crossed the species boundaries to infect human species are required to discover the precise routes of transmission.", [["human", "ORGANISM", 92, 97], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 92, 97], ["comprehensive studies", "TEST", 6, 27], ["an animal virus", "PROBLEM", 35, 50], ["infect human species", "PROBLEM", 85, 105]]], ["Besides, the veterinary community has also been trying to identify the risks to animals and possible zoonotic transmission.", [["zoonotic transmission", "DISEASE", 101, 122], ["zoonotic transmission", "PROBLEM", 101, 122], ["possible", "UNCERTAINTY", 92, 100], ["zoonotic", "OBSERVATION_MODIFIER", 101, 109]]], ["Various cases of human to animal transmission have also come up indicating the risk of the virus to domestic animals or pets (Oreshkova et al. 2020).", [["human", "ORGANISM", 17, 22], ["human", "SPECIES", 17, 22], ["human", "SPECIES", 17, 22], ["the virus", "PROBLEM", 87, 96]]], ["The literature reveals that cats and ferrets are susceptible to COVID-19 infection.", [["infection", "DISEASE", 73, 82], ["cats", "ORGANISM", 28, 32], ["ferrets", "ORGANISM", 37, 44], ["COVID-19", "ORGANISM", 64, 72], ["cats", "SPECIES", 28, 32], ["ferrets", "SPECIES", 37, 44], ["ferrets", "SPECIES", 37, 44], ["COVID-19 infection", "PROBLEM", 64, 82], ["infection", "OBSERVATION", 73, 82]]], ["These infected animals could efficiently spread the virus to naive animals directly in contact with them.", [["animals", "ORGANISM", 15, 22], ["These infected animals", "PROBLEM", 0, 22], ["infected", "OBSERVATION", 6, 14], ["virus", "OBSERVATION", 52, 57]]], ["Additionally, the ACE2 receptors in a few animal species are found to be similar to the human ACE2 receptors, thus further stipulating the possibility of the human-animal interface.", [["ACE2", "GENE_OR_GENE_PRODUCT", 18, 22], ["human", "ORGANISM", 88, 93], ["ACE2", "GENE_OR_GENE_PRODUCT", 94, 98], ["human", "ORGANISM", 158, 163], ["ACE2 receptors", "PROTEIN", 18, 32], ["human ACE2 receptors", "PROTEIN", 88, 108], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 88, 93], ["human", "SPECIES", 158, 163], ["the ACE2 receptors", "TEST", 14, 32], ["animal interface", "OBSERVATION", 164, 180]]], ["These findings also indicate that domestic cats and ferrets can be an effective animal model for screening candidate vaccines and drugs against SARS-CoV-2 (Hasan et al. 2020).", [["SARS", "DISEASE", 144, 148], ["cats", "ORGANISM", 43, 47], ["ferrets", "ORGANISM", 52, 59], ["SARS-CoV-2", "ORGANISM", 144, 154], ["cats", "SPECIES", 43, 47], ["ferrets", "SPECIES", 52, 59], ["ferrets", "SPECIES", 52, 59], ["SARS-CoV", "SPECIES", 144, 152], ["domestic cats and ferrets", "PROBLEM", 34, 59], ["screening candidate vaccines", "TREATMENT", 97, 125], ["drugs", "TREATMENT", 130, 135], ["SARS", "PROBLEM", 144, 148]]], ["Although it is still not certain that humans can transmit COVID-19 to their pets or other animals, it is recommended to follow some preventive measures and basic animal hygiene.", [["COVID-19", "CHEMICAL", 58, 66], ["humans", "ORGANISM", 38, 44], ["humans", "SPECIES", 38, 44], ["humans", "SPECIES", 38, 44]]], ["Moreover, we cannot believe that just if the pets can be infected with SARS-CoV-2, they can also spread it.", [["SARS", "DISEASE", 71, 75], ["SARS-CoV-2", "ORGANISM", 71, 81], ["SARS-CoV", "SPECIES", 71, 79], ["SARS", "PROBLEM", 71, 75]]], ["At this time, there is no literature proving the transmission of the virus from the infected pets to their owners.", [["the virus", "PROBLEM", 65, 74], ["no", "UNCERTAINTY", 23, 25], ["virus", "OBSERVATION", 69, 74], ["infected", "OBSERVATION", 84, 92]]], ["A lot of research is needed to determine the role of the animals in the spread of the virus.", [["the virus", "PROBLEM", 82, 91]]], ["However, social distancing needs to be maintained with animals as with humans.", [["humans", "ORGANISM", 71, 77], ["humans", "SPECIES", 71, 77], ["humans", "SPECIES", 71, 77]]], ["By doing so, we can reduce the human as well as zoonotic transmission of SARS-CoV-2.", [["SARS", "DISEASE", 73, 77], ["human", "ORGANISM", 31, 36], ["SARS-CoV-2", "ORGANISM", 73, 83], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["SARS-CoV", "SPECIES", 73, 81]]], ["Furthermore, some experimental studies and serosurveillance studies in different animal species should be continued to reach an effective conclusion and prevent further zoonotic events.", [["some experimental studies", "TEST", 13, 38], ["serosurveillance studies", "TEST", 43, 67], ["different animal species", "PROBLEM", 71, 95], ["further zoonotic events", "PROBLEM", 161, 184]]]], "bc5761e9d769b9fb1e723e1932ee3c5d4e21bd0a": [["IntroductionFeline viruses are of particularly opportunistic character.", [["Feline viruses", "DISEASE", 12, 26], ["Feline", "ORGANISM", 12, 18], ["IntroductionFeline viruses", "PROBLEM", 0, 26], ["viruses", "OBSERVATION", 19, 26]]], ["In order to adapt to the solitary way of life of ancestral felids, these pathogens have acquired elaborate means to persist within their host population over the course of time.", [["these pathogens", "PROBLEM", 67, 82]]], ["The infection of new hosts upon the rare contact between individuals was evolutionarily assured by very efficient transmission strategies and the induction of latent, chronic and/or asymptomatic infections.", [["infection", "DISEASE", 4, 13], ["infections", "DISEASE", 195, 205], ["The infection of new hosts", "PROBLEM", 0, 26], ["asymptomatic infections", "PROBLEM", 182, 205], ["infection", "OBSERVATION", 4, 13], ["new", "OBSERVATION_MODIFIER", 17, 20], ["chronic", "OBSERVATION_MODIFIER", 167, 174], ["asymptomatic", "OBSERVATION_MODIFIER", 182, 194], ["infections", "OBSERVATION", 195, 205]]], ["Often kept in multi-cat households and placed in catteries or shelters, today's domestic cat is consequently particularly susceptible to viral infections [1, 2] .", [["viral infections", "DISEASE", 137, 153], ["cat", "ORGANISM", 89, 92], ["viral infections", "PROBLEM", 137, 153]]], ["The close proximity and high social contact rate of animals with different vaccination states in these stressful environments further increases the risk of infection.", [["infection", "DISEASE", 156, 165], ["different vaccination", "TREATMENT", 65, 86], ["infection", "PROBLEM", 156, 165], ["high", "OBSERVATION_MODIFIER", 24, 28], ["infection", "OBSERVATION", 156, 165]]], ["Moreover, the strong antigenic variability of several common feline viruses including the feline calicivirus (FCV), the feline coronavirus (FCoV) and the feline leukemia virus (FeLV) support escape from immune responses and lower the efficacy of currently available vaccines [3] .", [["feline viruses", "DISEASE", 61, 75], ["feline calicivirus", "DISEASE", 90, 108], ["feline coronavirus", "DISEASE", 120, 138], ["feline leukemia virus", "DISEASE", 154, 175], ["feline viruses", "ORGANISM", 61, 75], ["feline calicivirus", "ORGANISM", 90, 108], ["FCV", "ORGANISM", 110, 113], ["feline coronavirus", "ORGANISM", 120, 138], ["FCoV", "CANCER", 140, 144], ["feline leukemia virus", "ORGANISM", 154, 175], ["FeLV", "ORGANISM", 177, 181], ["feline", "SPECIES", 61, 67], ["feline calicivirus", "SPECIES", 90, 108], ["feline coronavirus", "SPECIES", 120, 138], ["feline leukemia virus", "SPECIES", 154, 175], ["feline viruses", "SPECIES", 61, 75], ["feline calicivirus", "SPECIES", 90, 108], ["FCV", "SPECIES", 110, 113], ["feline coronavirus", "SPECIES", 120, 138], ["FCoV", "SPECIES", 140, 144], ["feline leukemia virus", "SPECIES", 154, 175], ["FeLV", "SPECIES", 177, 181], ["several common feline viruses", "PROBLEM", 46, 75], ["the feline calicivirus (FCV", "PROBLEM", 86, 113], ["the feline coronavirus (FCoV", "PROBLEM", 116, 144], ["the feline leukemia virus", "PROBLEM", 150, 175], ["immune responses", "PROBLEM", 203, 219], ["feline leukemia virus", "OBSERVATION", 154, 175]]], ["The availability of complementary prophylactic strategies could help protect pet cats in environments with high infectious pressure from long diseases and/or death caused by infections with fatal viruses.IntroductionA promising addition to vaccination is the manipulation of innate immunity.", [["death", "DISEASE", 158, 163], ["infections", "DISEASE", 174, 184], ["cats", "ORGANISM", 81, 85], ["cats", "SPECIES", 81, 85], ["complementary prophylactic strategies", "TREATMENT", 20, 57], ["high infectious pressure", "PROBLEM", 107, 131], ["long diseases", "PROBLEM", 137, 150], ["death", "PROBLEM", 158, 163], ["fatal viruses", "PROBLEM", 190, 203], ["vaccination", "TREATMENT", 240, 251], ["infections", "OBSERVATION", 174, 184]]], ["Innate pathogen recognition relies on a set of sensory molecules, the Toll-like receptors (TLRs), which enable the immediate reaction of specific immune cells to pathogen \"danger signals\", the so-called pathogen-associated molecular patterns (PAMPs) [4] .", [["immune cells", "ANATOMY", 146, 158], ["Toll-like receptors", "GENE_OR_GENE_PRODUCT", 70, 89], ["TLRs", "GENE_OR_GENE_PRODUCT", 91, 95], ["immune cells", "CELL", 146, 158], ["pathogen-associated molecular patterns", "GENE_OR_GENE_PRODUCT", 203, 241], ["sensory molecules", "PROTEIN", 47, 64], ["Toll-like receptors", "PROTEIN", 70, 89], ["TLRs", "PROTEIN", 91, 95], ["immune cells", "CELL_TYPE", 146, 158], ["PAMPs", "PROTEIN", 243, 248], ["Innate pathogen recognition", "PROBLEM", 0, 27], ["the so-called pathogen", "PROBLEM", 189, 211]]], ["Due to their abundance in all bacterial as well as some viral genomes, oligodeoxynucleotides (ODN) containing unmethylated cytosine-phosphate-guanosine (CpG) motifs are effectively recognized as PAMPs by the vertebrate innate immune system [5] .", [["ODN", "CHEMICAL", 94, 97], ["cytosine-phosphate", "CHEMICAL", 123, 141], ["guanosine", "CHEMICAL", 142, 151], ["CpG", "CHEMICAL", 153, 156], ["cytosine-phosphate", "CHEMICAL", 123, 141], ["guanosine", "CHEMICAL", 142, 151], ["CpG", "CHEMICAL", 153, 156], ["ODN", "SIMPLE_CHEMICAL", 94, 97], ["cytosine-phosphate-guanosine", "SIMPLE_CHEMICAL", 123, 151], ["CpG", "SIMPLE_CHEMICAL", 153, 156], ["PAMPs", "GENE_OR_GENE_PRODUCT", 195, 200], ["viral genomes", "DNA", 56, 69], ["unmethylated cytosine-phosphate-guanosine (CpG) motifs", "DNA", 110, 164], ["PAMPs", "PROTEIN", 195, 200], ["all bacterial", "PROBLEM", 26, 39], ["some viral genomes", "TREATMENT", 51, 69], ["oligodeoxynucleotides (ODN)", "TREATMENT", 71, 98], ["unmethylated cytosine-phosphate", "TREATMENT", 110, 141], ["guanosine (CpG) motifs", "TREATMENT", 142, 164], ["viral genomes", "OBSERVATION", 56, 69]]], ["Response to CpG ODN stimulation is conferred through TLR9, expressed mainly in the intracellular compartments of human B cells and plasmacytoid dendritic cells (pDCs) [6, 7] .", [["intracellular compartments", "ANATOMY", 83, 109], ["B cells", "ANATOMY", 119, 126], ["plasmacytoid dendritic cells", "ANATOMY", 131, 159], ["pDCs", "ANATOMY", 161, 165], ["ODN", "CHEMICAL", 16, 19], ["CpG", "CHEMICAL", 12, 15], ["TLR9", "GENE_OR_GENE_PRODUCT", 53, 57], ["intracellular compartments", "CELLULAR_COMPONENT", 83, 109], ["human", "ORGANISM", 113, 118], ["B cells", "CELL", 119, 126], ["plasmacytoid dendritic cells", "CELL", 131, 159], ["pDCs", "CELL", 161, 165], ["TLR9", "PROTEIN", 53, 57], ["human B cells", "CELL_TYPE", 113, 126], ["plasmacytoid dendritic cells", "CELL_TYPE", 131, 159], ["pDCs", "CELL_TYPE", 161, 165], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["CpG ODN stimulation", "TREATMENT", 12, 31], ["plasmacytoid dendritic cells", "PROBLEM", 131, 159], ["plasmacytoid dendritic cells", "OBSERVATION", 131, 159]]], ["Alarmed TLR9 is the initial instigator of gene expression profiles that strongly support antiviral mechanisms: upregulation of costimulatory molecules major histocompatibility complex (MHC) II, B7.1 and B7.2 on the surface of stimulated cells provides them with a stronger antigen presenting potential [8, 9] and production of cytokines such as type I interferon (IFN), interleukin (IL)-12, IFN\u03b3, IL-6 and tumor necrosis factor (TNF)\u03b1, contribute to providing an optimal immune environment for the development of innate and adaptive responses against intracellular pathogens [10, 11] .", [["surface", "ANATOMY", 215, 222], ["cells", "ANATOMY", 237, 242], ["intracellular", "ANATOMY", 551, 564], ["necrosis", "DISEASE", 412, 420], ["TLR9", "GENE_OR_GENE_PRODUCT", 8, 12], ["major histocompatibility complex (MHC) II", "GENE_OR_GENE_PRODUCT", 151, 192], ["B7.1", "GENE_OR_GENE_PRODUCT", 194, 198], ["B7.2", "GENE_OR_GENE_PRODUCT", 203, 207], ["surface", "CELLULAR_COMPONENT", 215, 222], ["cells", "CELL", 237, 242], ["type I interferon", "GENE_OR_GENE_PRODUCT", 345, 362], ["IFN", "GENE_OR_GENE_PRODUCT", 364, 367], ["interleukin (IL)-12", "GENE_OR_GENE_PRODUCT", 370, 389], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 391, 395], ["IL-6", "GENE_OR_GENE_PRODUCT", 397, 401], ["tumor necrosis factor (TNF)\u03b1", "GENE_OR_GENE_PRODUCT", 406, 434], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 551, 564], ["TLR9", "PROTEIN", 8, 12], ["costimulatory molecules", "PROTEIN", 127, 150], ["major histocompatibility complex (MHC) II", "PROTEIN", 151, 192], ["B7.1", "PROTEIN", 194, 198], ["B7.2", "PROTEIN", 203, 207], ["stimulated cells", "CELL_TYPE", 226, 242], ["cytokines", "PROTEIN", 327, 336], ["type I interferon", "PROTEIN", 345, 362], ["IFN", "PROTEIN", 364, 367], ["interleukin (IL)-12", "PROTEIN", 370, 389], ["IFN\u03b3", "PROTEIN", 391, 395], ["IL-6", "PROTEIN", 397, 401], ["tumor necrosis factor (TNF)\u03b1", "PROTEIN", 406, 434], ["gene expression profiles", "TREATMENT", 42, 66], ["stimulated cells", "TREATMENT", 226, 242], ["cytokines", "PROBLEM", 327, 336], ["type I interferon (IFN)", "TREATMENT", 345, 368], ["interleukin (IL)", "TREATMENT", 370, 386], ["IL", "TEST", 397, 399], ["tumor necrosis factor", "PROBLEM", 406, 427], ["intracellular pathogens", "PROBLEM", 551, 574], ["tumor", "OBSERVATION_MODIFIER", 406, 411], ["necrosis", "OBSERVATION", 412, 420]]], ["Probably the most important antiviral property of CpG ODN resides in their potential to stimulate the production of high amounts of type I IFN by pDCs [12] .", [["pDCs", "ANATOMY", 146, 150], ["ODN", "CHEMICAL", 54, 57], ["CpG", "CHEMICAL", 50, 53], ["CpG ODN", "SIMPLE_CHEMICAL", 50, 57], ["type I IFN", "GENE_OR_GENE_PRODUCT", 132, 142], ["pDCs", "CELL", 146, 150], ["type I IFN", "PROTEIN", 132, 142], ["pDCs", "CELL_TYPE", 146, 150], ["antiviral property of CpG ODN", "TREATMENT", 28, 57]]], ["This family of cytokines, which includes IFN\u03b1, IFN\u03c9 and IFN\u03b2, has been shown to considerably enhance natural killer (NK) cell cytotoxicity [13] , promote differentiation, maturation and immunostimulatory functions of monocytes and DCs [14] , induce B cell production of immunoglobulin [15] and T-helper (Th) 1 differentiation of T cells [16, 17] .", [["natural killer (NK) cell", "ANATOMY", 101, 125], ["monocytes", "ANATOMY", 217, 226], ["DCs", "ANATOMY", 231, 234], ["B cell", "ANATOMY", 249, 255], ["T cells", "ANATOMY", 329, 336], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 41, 45], ["IFN\u03c9", "GENE_OR_GENE_PRODUCT", 47, 51], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 56, 60], ["natural killer (NK) cell", "CELL", 101, 125], ["monocytes", "CELL", 217, 226], ["DCs", "CELL", 231, 234], ["B cell", "CELL", 249, 255], ["immunoglobulin [15", "GENE_OR_GENE_PRODUCT", 270, 288], ["Th) 1", "GENE_OR_GENE_PRODUCT", 304, 309], ["T cells", "CELL", 329, 336], ["cytokines", "PROTEIN", 15, 24], ["IFN\u03b1", "PROTEIN", 41, 45], ["IFN\u03c9", "PROTEIN", 47, 51], ["IFN\u03b2", "PROTEIN", 56, 60], ["natural killer (NK) cell", "CELL_TYPE", 101, 125], ["monocytes", "CELL_TYPE", 217, 226], ["DCs", "CELL_TYPE", 231, 234], ["T cells", "CELL_TYPE", 329, 336], ["cell cytotoxicity", "TEST", 121, 138], ["monocytes", "TEST", 217, 226], ["DCs", "TEST", 231, 234], ["immunoglobulin", "TEST", 270, 284]]], ["Moreover, upon binding to their ubiquitously distributed receptor, type I IFNs effectively induce the synthesis of various intracellular proteins which interfere with the replication of a broad range of viruses [18] .", [["intracellular", "ANATOMY", 123, 136], ["type I IFNs", "GENE_OR_GENE_PRODUCT", 67, 78], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 123, 136], ["type I IFNs", "PROTEIN", 67, 78], ["intracellular proteins", "PROTEIN", 123, 145], ["type I IFNs", "PROBLEM", 67, 78], ["the synthesis of various intracellular proteins", "PROBLEM", 98, 145], ["a broad range of viruses", "TREATMENT", 186, 210]]], ["The myxovirusresistance protein (Mx) GTPase is a well-studied example of these intracellular antiviral effectors.", [["intracellular", "ANATOMY", 79, 92], ["myxovirusresistance protein", "GENE_OR_GENE_PRODUCT", 4, 31], ["Mx", "GENE_OR_GENE_PRODUCT", 33, 35], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 79, 92], ["myxovirusresistance protein (Mx) GTPase", "PROTEIN", 4, 43], ["intracellular antiviral effectors", "PROTEIN", 79, 112], ["The myxovirusresistance protein", "TEST", 0, 31], ["these intracellular antiviral effectors", "PROBLEM", 73, 112], ["intracellular", "OBSERVATION", 79, 92], ["antiviral effectors", "OBSERVATION", 93, 112]]], ["This enzyme is known to be directly regulated by the type I IFN, and its detection is readily used as marker for upregulation and biological activity of this cytokine family [19] .IntroductionDistinct classes of ODN have been shown to induce differential immune responses [20] .", [["ODN", "CHEMICAL", 212, 215], ["type I IFN", "GENE_OR_GENE_PRODUCT", 53, 63], ["ODN", "SIMPLE_CHEMICAL", 212, 215], ["type I IFN", "PROTEIN", 53, 63], ["cytokine family", "PROTEIN", 158, 173], ["This enzyme", "TEST", 0, 11], ["its detection", "TEST", 69, 82], ["IntroductionDistinct classes of ODN", "TREATMENT", 180, 215], ["known to be", "UNCERTAINTY", 15, 26]]], ["Class A CpG ODN (CpG-A) consist of CpG motifs in a phosphodiester core, flanked on both ends by phosphorothioate poly (G) sequences.", [["ODN", "CHEMICAL", 12, 15], ["CpG-A", "CHEMICAL", 17, 22], ["phosphodiester", "CHEMICAL", 51, 65], ["phosphorothioate poly", "CHEMICAL", 96, 117], ["CpG", "CHEMICAL", 35, 38], ["phosphodiester", "CHEMICAL", 51, 65], ["phosphorothioate", "CHEMICAL", 96, 112], ["CpG-A", "GENE_OR_GENE_PRODUCT", 17, 22], ["Class A CpG ODN", "DNA", 0, 15], ["CpG-A", "DNA", 17, 22], ["CpG motifs", "DNA", 35, 45], ["phosphodiester core", "DNA", 51, 70], ["phosphorothioate poly (G) sequences", "DNA", 96, 131], ["Class A CpG ODN (CpG-A)", "TREATMENT", 0, 23], ["CpG motifs in a phosphodiester core", "TREATMENT", 35, 70], ["phosphorothioate poly (G) sequences", "TREATMENT", 96, 131]]], ["CpG ODN of this class are characterized by their potential to both induce massive type I IFN secretion by pDCs [12] and increase NK cytotoxicity [21] , rendering them ideal candidates as prophylactic enhancers of innate immunity to viral infections.", [["pDCs", "ANATOMY", 106, 110], ["NK", "ANATOMY", 129, 131], ["ODN", "CHEMICAL", 4, 7], ["viral infections", "DISEASE", 232, 248], ["CpG", "CHEMICAL", 0, 3], ["type I IFN", "GENE_OR_GENE_PRODUCT", 82, 92], ["NK", "CELL", 129, 131], ["IFN", "PROTEIN", 89, 92], ["pDCs", "CELL_TYPE", 106, 110], ["massive type I IFN secretion", "PROBLEM", 74, 102], ["increase NK cytotoxicity", "PROBLEM", 120, 144], ["prophylactic enhancers", "TREATMENT", 187, 209], ["viral infections", "PROBLEM", 232, 248]]], ["Conversely, class B CpG ODN (CpG-B), which encode multiple CpG motifs on a phosphorothioate backbone, promote monocyte maturation and B cell activation, thus substantially supporting the development of humoral immune responses [22] [23] [24] .", [["monocyte", "ANATOMY", 110, 118], ["B cell", "ANATOMY", 134, 140], ["ODN", "CHEMICAL", 24, 27], ["phosphorothioate", "CHEMICAL", 75, 91], ["CpG", "CHEMICAL", 59, 62], ["phosphorothioate", "CHEMICAL", 75, 91], ["class B CpG ODN", "GENE_OR_GENE_PRODUCT", 12, 27], ["CpG-B", "GENE_OR_GENE_PRODUCT", 29, 34], ["monocyte", "CELL", 110, 118], ["B cell", "CELL", 134, 140], ["class B CpG ODN", "DNA", 12, 27], ["CpG-B", "DNA", 29, 34], ["CpG motifs", "DNA", 59, 69], ["class B CpG ODN (CpG-B)", "TREATMENT", 12, 35], ["multiple CpG motifs", "TREATMENT", 50, 69], ["a phosphorothioate backbone", "TREATMENT", 73, 100], ["promote monocyte maturation", "TREATMENT", 102, 129], ["B cell activation", "PROBLEM", 134, 151], ["humoral immune responses", "TEST", 202, 226], ["monocyte maturation", "OBSERVATION", 110, 129], ["B cell activation", "OBSERVATION", 134, 151]]], ["Both CpG-A and CpG-B have indicated immunostimulatory properties in immune cells of mice, primates and many domestic species in vitro [25] [26] [27] [28] [29] [30] [31] , while in vivo studies in outbred animals have mainly been carried out with CpG-B [24, 32, 33] .", [["immune cells", "ANATOMY", 68, 80], ["CpG-B", "CHEMICAL", 246, 251], ["CpG-B", "CHEMICAL", 246, 251], ["CpG-A", "GENE_OR_GENE_PRODUCT", 5, 10], ["CpG-B", "GENE_OR_GENE_PRODUCT", 15, 20], ["immune cells", "CELL", 68, 80], ["mice", "ORGANISM", 84, 88], ["primates", "ORGANISM", 90, 98], ["[25] [26] [27] [28] [29] [30] [31]", "SIMPLE_CHEMICAL", 134, 168], ["CpG-B", "GENE_OR_GENE_PRODUCT", 246, 251], ["CpG-A and CpG-B", "DNA", 5, 20], ["immune cells", "CELL_TYPE", 68, 80], ["mice", "SPECIES", 84, 88], ["mice", "SPECIES", 84, 88], ["A and CpG-B", "TREATMENT", 9, 20], ["immunostimulatory properties", "TREATMENT", 36, 64], ["vivo studies", "TEST", 180, 192], ["CpG", "TEST", 246, 249]]], ["Concerning the cat, specifically synthesized CpG-A molecules were recently shown to induce IFN\u03b3 [34] ; CpG-B molecules indicated the capability to induce proliferation of feline cells [35] , and CpG-B-adjuvanted allergen indicated potential for immunotherapy in a feline asthma model [36] .", [["cells", "ANATOMY", 178, 183], ["CpG-A", "CHEMICAL", 45, 50], ["CpG-B", "CHEMICAL", 195, 200], ["feline asthma", "DISEASE", 264, 277], ["CpG", "CHEMICAL", 45, 48], ["cat", "ORGANISM", 15, 18], ["CpG-A", "SIMPLE_CHEMICAL", 45, 50], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 91, 95], ["CpG-B", "GENE_OR_GENE_PRODUCT", 103, 108], ["feline", "ORGANISM", 171, 177], ["cells", "CELL", 178, 183], ["CpG-B", "GENE_OR_GENE_PRODUCT", 195, 200], ["feline", "ORGANISM", 264, 270], ["IFN", "PROTEIN", 91, 94], ["CpG-B molecules", "PROTEIN", 103, 118], ["feline cells", "CELL_TYPE", 171, 183], ["IFN", "TEST", 91, 94], ["CpG", "TEST", 103, 106], ["the capability", "PROBLEM", 129, 143], ["proliferation of feline cells", "PROBLEM", 154, 183], ["CpG-B-adjuvanted allergen", "TREATMENT", 195, 220], ["immunotherapy", "TREATMENT", 245, 258], ["a feline asthma model", "PROBLEM", 262, 283]]], ["Although class C [37, 38] and class P ODN [39] were developed in more recent years in an effort to combine the advantageous effects of both CpG-A and CpG-B and increase immunogenicity, CpG-A remain the strongest inducers of type I IFN described to date.IntroductionThe potential of CpG ODN as prophylactic standalone inducers of innate defense mechanisms has been the subject of only few studies.", [["ODN", "CHEMICAL", 38, 41], ["CpG-B", "CHEMICAL", 150, 155], ["CpG-A", "CHEMICAL", 185, 190], ["ODN", "CHEMICAL", 286, 289], ["CpG-B", "CHEMICAL", 150, 155], ["CpG", "CHEMICAL", 282, 285], ["CpG-A", "GENE_OR_GENE_PRODUCT", 140, 145], ["CpG-B", "GENE_OR_GENE_PRODUCT", 150, 155], ["CpG-A", "GENE_OR_GENE_PRODUCT", 185, 190], ["type I IFN", "GENE_OR_GENE_PRODUCT", 224, 234], ["CpG ODN", "SIMPLE_CHEMICAL", 282, 289], ["CpG-A and CpG-B", "DNA", 140, 155], ["type I IFN", "PROTEIN", 224, 234], ["both CpG", "TREATMENT", 135, 143], ["A and CpG-B and increase immunogenicity", "TREATMENT", 144, 183], ["type I IFN", "PROBLEM", 224, 234], ["CpG ODN", "TREATMENT", 282, 289], ["prophylactic standalone inducers", "TREATMENT", 293, 325], ["innate defense mechanisms", "TREATMENT", 329, 354]]], ["Most works in this field initially described protection of mice against bacterial [40] [41] [42] [43] [44] and parasitic [45] [46] [47] infections.", [["[40] [41] [42] [43] [44] and parasitic [45] [46] [47] infections", "DISEASE", 82, 146], ["mice", "ORGANISM", 59, 63], ["bacterial [40] [41] [42] [43] [44]", "SIMPLE_CHEMICAL", 72, 106], ["parasitic [45] [46] [47]", "SIMPLE_CHEMICAL", 111, 135], ["mice", "SPECIES", 59, 63], ["mice", "SPECIES", 59, 63], ["infections", "PROBLEM", 136, 146]]], ["More recently, induction of resistance to viral infections was shown also in mouse models for Herpes Simplex Virus [48] , neurotropic arenavirus [49] , foot and mouth disease virus [50] and Vaccinia virus [51] .", [["viral infections", "DISEASE", 42, 58], ["Herpes Simplex Virus", "DISEASE", 94, 114], ["neurotropic arenavirus", "DISEASE", 122, 144], ["foot and mouth disease", "DISEASE", 152, 174], ["mouse", "ORGANISM", 77, 82], ["Herpes Simplex Virus", "ORGANISM", 94, 114], ["neurotropic arenavirus", "ORGANISM", 122, 144], ["foot and mouth disease virus", "ORGANISM", 152, 180], ["Vaccinia virus", "ORGANISM", 190, 204], ["mouse", "SPECIES", 77, 82], ["Herpes Simplex Virus", "SPECIES", 94, 114], ["foot and mouth disease virus", "SPECIES", 152, 180], ["Vaccinia virus", "SPECIES", 190, 204], ["mouse", "SPECIES", 77, 82], ["Herpes Simplex Virus", "SPECIES", 94, 114], ["foot and mouth disease virus", "SPECIES", 152, 180], ["Vaccinia virus", "SPECIES", 190, 204], ["viral infections", "PROBLEM", 42, 58], ["Herpes Simplex Virus", "PROBLEM", 94, 114], ["neurotropic arenavirus", "PROBLEM", 122, 144], ["foot and mouth disease virus", "PROBLEM", 152, 180], ["Vaccinia virus", "PROBLEM", 190, 204], ["foot", "ANATOMY", 152, 156], ["mouth", "ANATOMY", 161, 166]]], ["With exception of the latter, all these studies were carried out with CpG-B.", [["CpG", "CHEMICAL", 70, 73], ["all these studies", "TEST", 30, 47]]], ["In an outbred species, partial antiviral protection has only been described in two studies so far, in which reduced shedding of herpes and parainfluenza viruses was observed in lambs after administration also of a CpG-B [52, 53] .", [["herpes and parainfluenza viruses", "DISEASE", 128, 160], ["CpG-B", "CHEMICAL", 214, 219], ["herpes", "ORGANISM", 128, 134], ["parainfluenza viruses", "ORGANISM", 139, 160], ["lambs", "ORGANISM", 177, 182], ["parainfluenza", "SPECIES", 139, 152], ["lambs", "SPECIES", 177, 182], ["an outbred species", "PROBLEM", 3, 21], ["partial antiviral protection", "TREATMENT", 23, 51], ["herpes", "PROBLEM", 128, 134], ["parainfluenza viruses", "PROBLEM", 139, 160], ["outbred species", "OBSERVATION", 6, 21], ["partial", "OBSERVATION_MODIFIER", 23, 30], ["antiviral protection", "OBSERVATION", 31, 51], ["herpes", "OBSERVATION", 128, 134], ["parainfluenza viruses", "OBSERVATION", 139, 160]]], ["To our knowledge, prophylactic antiviral potential of CpG-A has not yet been described in outbred animals.IntroductionWe carried out a series of experiments with the objective to characterize both the immunomodulatory and antiviral properties of CpG-A in the domestic cat.", [["CpG-A", "CHEMICAL", 54, 59], ["CpG-A", "CHEMICAL", 246, 251], ["CpG-A", "SIMPLE_CHEMICAL", 54, 59], ["outbred animals", "ORGANISM", 90, 105], ["CpG-A", "SIMPLE_CHEMICAL", 246, 251], ["cat", "ORGANISM", 268, 271], ["cat", "SPECIES", 268, 271], ["prophylactic antiviral potential of CpG", "TREATMENT", 18, 57], ["antiviral properties of CpG", "TREATMENT", 222, 249]]], ["In vitro, the prototype of CpG-A, ODN 2216 [12] , strengthened the antiviral qualities of feline immune cells and stimulated their production of soluble molecules that inhibited the replication of five different families of viruses: Coronaviridae, Herpesviridae, Caliciviridae, Parvoviridae, and Retroviridae.", [["immune cells", "ANATOMY", 97, 109], ["CpG-A", "CHEMICAL", 27, 32], ["ODN 2216", "CHEMICAL", 34, 42], ["CpG-A", "SIMPLE_CHEMICAL", 27, 32], ["feline", "ORGANISM", 90, 96], ["immune cells", "CELL", 97, 109], ["Herpesviridae", "GENE_OR_GENE_PRODUCT", 248, 261], ["feline immune cells", "CELL_TYPE", 90, 109], ["soluble molecules", "PROTEIN", 145, 162], ["feline", "SPECIES", 90, 96], ["feline immune cells", "TREATMENT", 90, 109], ["soluble molecules", "PROBLEM", 145, 162], ["Coronaviridae", "TREATMENT", 233, 246], ["Herpesviridae", "TREATMENT", 248, 261], ["Caliciviridae", "TREATMENT", 263, 276], ["Parvoviridae", "TREATMENT", 278, 290], ["Retroviridae", "TREATMENT", 296, 308]]], ["In vivo, ODN 2216 induced a systemic antiviral state.Animals and ethics statementFourteen male castrated SPF cats divided in four different age groups were used in this study: group 1 (c01-c04, 10 weeks), group 2 (c05-c08, 1.5 years), group 3 (c09-c12, 7 years) and group 4 (c13 and c14, 14 years).", [["ODN 2216", "CHEMICAL", 9, 17], ["ODN 2216", "SIMPLE_CHEMICAL", 9, 17], ["SPF", "ORGANISM", 105, 108], ["cats", "ORGANISM", 109, 113], ["cats", "SPECIES", 109, 113], ["a systemic antiviral state", "PROBLEM", 26, 52], ["castrated SPF cats", "TREATMENT", 95, 113], ["this study", "TEST", 164, 174], ["systemic antiviral", "OBSERVATION", 28, 46]]], ["The in vivo experiments were conducted when cats c05-c08 were 3 years of age.", [["cats", "ORGANISM", 44, 48], ["cats", "SPECIES", 44, 48], ["cats c05", "TEST", 44, 52]]], ["This study was carried out in strict accordance with regulations of the Swiss law for animal protection (SR 445.1).", [["This study", "TEST", 0, 10]]], ["The Veterinary Office of the Swiss Canton of Zurich officially revised the protocol and approved the study (Permit no. TVB 99/2007 and TVB 100/2007).", [["the protocol", "TREATMENT", 71, 83], ["the study", "TEST", 97, 106], ["TVB", "TEST", 119, 122], ["TVB", "TEST", 135, 138]]], ["The animals were housed in groups in an animalfriendly barrier facility under optimal ethological conditions [55] .", [["animals", "ORGANISM", 4, 11]]], ["For blood collections and injections, the cats were sedated with a combination of ketamin and midazolam, and all possible efforts were made to minimize stress and suffering.Animals and ethics statementFeline PBMC isolation, cell lines, ODNs, cell culture and cell viability assay Feline PBMCs were isolated from EDTA-anticoagulated whole blood by Ficoll-Hypaque density gradient centrifugation using a standard protocol [56] .", [["blood", "ANATOMY", 4, 9], ["PBMC", "ANATOMY", 208, 212], ["cell lines", "ANATOMY", 224, 234], ["ODNs", "ANATOMY", 236, 240], ["cell", "ANATOMY", 242, 246], ["cell", "ANATOMY", 259, 263], ["PBMCs", "ANATOMY", 287, 292], ["blood", "ANATOMY", 338, 343], ["ketamin", "CHEMICAL", 82, 89], ["midazolam", "CHEMICAL", 94, 103], ["ketamin", "CHEMICAL", 82, 89], ["midazolam", "CHEMICAL", 94, 103], ["EDTA", "CHEMICAL", 312, 316], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["cats", "ORGANISM", 42, 46], ["ketamin", "SIMPLE_CHEMICAL", 82, 89], ["midazolam", "SIMPLE_CHEMICAL", 94, 103], ["Feline", "ORGANISM", 201, 207], ["PBMC", "CELL", 208, 212], ["cell lines", "CELL", 224, 234], ["ODNs", "CELL", 236, 240], ["cell", "CELL", 242, 246], ["cell", "CELL", 259, 263], ["Feline", "ORGANISM", 280, 286], ["PBMCs", "CELL", 287, 292], ["EDTA", "SIMPLE_CHEMICAL", 312, 316], ["blood", "ORGANISM_SUBSTANCE", 338, 343], ["PBMC", "CELL_TYPE", 208, 212], ["cell lines", "CELL_LINE", 224, 234], ["Feline PBMCs", "CELL_TYPE", 280, 292], ["cats", "SPECIES", 42, 46], ["blood collections", "TEST", 4, 21], ["injections", "TREATMENT", 26, 36], ["ketamin", "TREATMENT", 82, 89], ["midazolam", "TREATMENT", 94, 103], ["stress", "PROBLEM", 152, 158], ["Feline PBMC isolation", "TREATMENT", 201, 222], ["cell lines", "TREATMENT", 224, 234], ["ODNs", "PROBLEM", 236, 240], ["cell culture", "TEST", 242, 254], ["cell viability assay", "TEST", 259, 279], ["PBMCs", "TEST", 287, 292], ["EDTA", "TEST", 312, 316], ["Ficoll-Hypaque density gradient centrifugation", "TREATMENT", 347, 393], ["a standard protocol", "TREATMENT", 400, 419], ["collections", "OBSERVATION", 10, 21], ["cell lines", "OBSERVATION", 224, 234]]], ["Purified cells were counted prior to their utilization in the different experiments using the Sysmex XT 2000iV (Sysmex, Norderstedt, Germany) as described previously [57] , and cultured in RPMI 1640 with Glutamax I (Gibco \u00ae , Invitrogen, Basel, Switzerland).", [["cells", "ANATOMY", 9, 14], ["Glutamax I", "CHEMICAL", 204, 214], ["Glutamax I", "CHEMICAL", 204, 214], ["cells", "CELL", 9, 14], ["Purified cells", "PROBLEM", 0, 14], ["the Sysmex XT", "TREATMENT", 90, 103], ["Glutamax I", "TREATMENT", 204, 214], ["cells", "OBSERVATION", 9, 14]]], ["Adherent CRFK (ATCC no. CCL-94) and FEA cells were maintained in RPMI 1640 with Glutamax I, while adherent fcwf-4 cells (ATCC no. CRL-2787) were cultured in EMEM (ATCCProliferation assayPBMCs were seeded immediately after isolation at a concentration of 3 \u00d7 10 6 cells/mL in 96-well U-bottom plates.", [["CCL-94", "ANATOMY", 24, 30], ["FEA cells", "ANATOMY", 36, 45], ["fcwf-4 cells", "ANATOMY", 107, 119], ["ATCC", "ANATOMY", 121, 125], ["CRL-2787", "ANATOMY", 130, 138], ["cells", "ANATOMY", 263, 268], ["Glutamax I", "CHEMICAL", 80, 90], ["CRL-2787", "CHEMICAL", 130, 138], ["Glutamax I", "CHEMICAL", 80, 90], ["CCL-94", "CELL", 24, 30], ["FEA cells", "CELL", 36, 45], ["Glutamax I", "GENE_OR_GENE_PRODUCT", 80, 90], ["fcwf-4 cells", "CELL", 107, 119], ["ATCC", "CELL", 121, 125], ["CRL-2787", "CELL", 130, 138], ["EMEM", "CELL", 157, 161], ["ATCCProliferation assayPBMCs", "CELL", 163, 191], ["CRFK", "CELL_LINE", 9, 13], ["CCL-94", "CELL_LINE", 24, 30], ["FEA cells", "CELL_LINE", 36, 45], ["Glutamax I", "PROTEIN", 80, 90], ["adherent fcwf-4 cells", "CELL_LINE", 98, 119], ["EMEM", "CELL_LINE", 157, 161], ["ATCCProliferation assayPBMCs", "CELL_LINE", 163, 191], ["Adherent CRFK", "PROBLEM", 0, 13], ["CCL", "TEST", 24, 27], ["FEA cells", "TEST", 36, 45], ["RPMI", "TEST", 65, 69], ["Glutamax I", "TEST", 80, 90], ["ATCC", "TEST", 121, 125], ["CRL", "TEST", 130, 133], ["ATCCProliferation assayPBMCs", "PROBLEM", 163, 191], ["U-bottom plates", "TREATMENT", 283, 298], ["CRFK", "OBSERVATION", 9, 13], ["bottom plates", "ANATOMY_MODIFIER", 285, 298]]], ["Triplicate cultures for each cat were treated with either 4 \u03bcg/mL ODN 2216 or 2243 or an equal volume of endotoxin-free PBS.", [["ODN 2216 or 2243", "CHEMICAL", 66, 82], ["endotoxin", "CHEMICAL", 105, 114], ["cat", "ORGANISM", 29, 32], ["endotoxin", "SIMPLE_CHEMICAL", 105, 114], ["Triplicate cultures", "TEST", 0, 19], ["each cat", "TEST", 24, 32], ["endotoxin-free PBS", "TREATMENT", 105, 123]]], ["After an initial incubation of 18 h, the cells were pulsed for 24 h with 3 H-thymidine (Perkin Elmer, Schwerzenbach, Switzerland).", [["cells", "ANATOMY", 41, 46], ["H-thymidine", "CHEMICAL", 75, 86], ["Perkin Elmer", "CHEMICAL", 88, 100], ["3 H-thymidine", "CHEMICAL", 73, 86], ["cells", "CELL", 41, 46], ["H-thymidine", "SIMPLE_CHEMICAL", 75, 86], ["the cells", "TREATMENT", 37, 46]]], ["Standard liquid scintillation protocols were used for harvesting of the cells and uptake of 3 H was assessed with the Packard Tri-Carb 1600TR liquid scintillation analyzer (Perkin Elmer).", [["cells", "ANATOMY", 72, 77], ["3 H", "CHEMICAL", 92, 95], ["cells", "CELL", 72, 77], ["Standard liquid scintillation protocols", "TREATMENT", 0, 39], ["harvesting of the cells", "TREATMENT", 54, 77], ["the Packard Tri-Carb", "TREATMENT", 114, 134]]], ["Proliferation rates were calculated as the mean counts per minute (c.p.m) of triplicate cultures.", [["Proliferation rates", "TEST", 0, 19], ["triplicate cultures", "TEST", 77, 96]]], ["The stimulation index (SI) depicted in Figure 1 was calculated as follows:Proliferation assayMean c:p:m:of ODN \u00c0 treated cultures Mean c:p:m of PBS \u00c0 treated culturesFlow cytometryPBMCs were treated at a density of 3 \u00d7 10 6 cells/mL with 4 \u03bcg/mL ODN 2216 or ODN 2243 or an equivalent volume of endotoxin-free PBS and cultured for 24 h in a 12-well format.", [["cells", "ANATOMY", 224, 229], ["ODN 2216", "CHEMICAL", 246, 254], ["ODN 2243", "CHEMICAL", 258, 266], ["endotoxin", "CHEMICAL", 294, 303], ["ODN 2243", "SIMPLE_CHEMICAL", 258, 266], ["endotoxin", "SIMPLE_CHEMICAL", 294, 303], ["endotoxin", "PROTEIN", 294, 303], ["The stimulation index", "TEST", 0, 21], ["Proliferation assay", "TEST", 74, 93], ["p:m:of ODN", "TREATMENT", 100, 110], ["cultures", "TEST", 121, 129], ["PBS", "TEST", 144, 147], ["cultures", "TEST", 158, 166], ["Flow cytometryPBMCs", "TEST", 166, 185], ["endotoxin-free PBS", "TREATMENT", 294, 312]]], ["During collection of the cells, the adherent cell fraction was removed with 0.05% trypsin-EDTA (Gibco \u00ae , Invitrogen).", [["cells", "ANATOMY", 25, 30], ["cell", "ANATOMY", 45, 49], ["trypsin-EDTA", "CHEMICAL", 82, 94], ["cells", "CELL", 25, 30], ["cell", "CELL", 45, 49], ["trypsin-EDTA", "SIMPLE_CHEMICAL", 82, 94], ["Gibco \u00ae", "SIMPLE_CHEMICAL", 96, 103], ["adherent cell fraction", "CELL_TYPE", 36, 58], ["the adherent cell fraction", "TREATMENT", 32, 58], ["0.05% trypsin-EDTA (Gibco \u00ae", "TREATMENT", 76, 103], ["Invitrogen", "TREATMENT", 106, 116], ["cells", "ANATOMY", 25, 30], ["adherent", "OBSERVATION_MODIFIER", 36, 44], ["cell fraction", "OBSERVATION", 45, 58]]], ["Harvested cells were divided into 3 fractions labeled separately with either anti-feline B7.1 mouse monoclonal IgG (kindly provided by Prof Mary Tompkins, Flow Cytometry and Cell Sorting Laboratory, NC State College of Veterinary Medicine, USA), anti-feline MHCII mouse monoclonal IgG1 (Department of Pathology, Microbiology and Immunology, University of California, Davis, USA) or fluoresceinisothiocyanate (FITC)-conjugated mouse IgG1 as isotype control (BD Bioscience, Allschwil, Swizerland).", [["cells", "ANATOMY", 10, 15], ["Cell", "ANATOMY", 174, 178], ["fluoresceinisothiocyanate", "CHEMICAL", 382, 407], ["fluoresceinisothiocyanate", "CHEMICAL", 382, 407], ["FITC", "CHEMICAL", 409, 413], ["cells", "CELL", 10, 15], ["B7.1", "GENE_OR_GENE_PRODUCT", 89, 93], ["mouse", "ORGANISM", 94, 99], ["IgG", "GENE_OR_GENE_PRODUCT", 111, 114], ["Cell", "CELL", 174, 178], ["MHCII", "GENE_OR_GENE_PRODUCT", 258, 263], ["mouse", "ORGANISM", 264, 269], ["fluoresceinisothiocyanate", "SIMPLE_CHEMICAL", 382, 407], ["FITC", "SIMPLE_CHEMICAL", 409, 413], ["mouse", "ORGANISM", 426, 431], ["IgG1", "GENE_OR_GENE_PRODUCT", 432, 436], ["anti-feline B7.1 mouse monoclonal IgG", "PROTEIN", 77, 114], ["anti-feline MHCII mouse monoclonal IgG1", "PROTEIN", 246, 285], ["fluoresceinisothiocyanate (FITC)-conjugated mouse IgG1", "PROTEIN", 382, 436], ["mouse", "SPECIES", 94, 99], ["mouse", "SPECIES", 264, 269], ["mouse", "SPECIES", 426, 431], ["mouse", "SPECIES", 94, 99], ["mouse", "SPECIES", 264, 269], ["mouse", "SPECIES", 426, 431], ["Harvested cells", "TREATMENT", 0, 15], ["fluoresceinisothiocyanate (FITC)", "TREATMENT", 382, 414], ["conjugated mouse IgG1", "TREATMENT", 415, 436], ["isotype control", "TREATMENT", 440, 455]]], ["The fractions were subsequently stained with R-Phycoerythrin (RPE)-conjugated goat anti-mouse IgG1 (BioConcept, Allschwil, Swizerland).", [["fractions", "ANATOMY", 4, 13], ["R-Phycoerythrin", "CHEMICAL", 45, 60], ["R-Phycoerythrin", "SIMPLE_CHEMICAL", 45, 60], ["RPE", "TISSUE", 62, 65], ["goat", "ORGANISM", 78, 82], ["R-Phycoerythrin (RPE)-conjugated goat anti-mouse IgG1", "PROTEIN", 45, 98], ["goat", "SPECIES", 78, 82], ["anti-mouse", "SPECIES", 83, 93], ["goat", "SPECIES", 78, 82], ["R-Phycoerythrin", "TREATMENT", 45, 60], ["conjugated goat anti-mouse IgG1", "TREATMENT", 67, 98]]], ["Fluorescence data was obtained using the FACSCalibur \u00ae instrument (Becton Dickinson, Allschwil, Switzerland) and the CellQuestPro\u2122 software.", [["Fluorescence data", "TEST", 0, 17]]], ["Gates representing lymphocyte and non-lymphocyte populations were set on the basis of forward versus side scatter, and a total of 50 000 events were acquired in the nonlymphocyte gate.", [["lymphocyte", "ANATOMY", 19, 29], ["nonlymphocyte", "ANATOMY", 165, 178], ["lymphocyte", "CELL", 19, 29], ["non-lymphocyte populations", "CELL", 34, 60], ["lymphocyte and non-lymphocyte populations", "CELL_TYPE", 19, 60], ["lymphocyte and non-lymphocyte populations", "PROBLEM", 19, 60], ["lymphocyte", "OBSERVATION", 19, 29]]], ["Data was analyzed with the FlowJo software (Tree Star, Olten, Switzerland), whereby an additional gate was set comprising both lymphocyte and non-lymphocyte populations (PBMC gate).", [["lymphocyte", "ANATOMY", 127, 137], ["non-lymphocyte populations", "ANATOMY", 142, 168], ["PBMC", "ANATOMY", 170, 174], ["lymphocyte", "CELL", 127, 137], ["non-lymphocyte populations", "CELL", 142, 168], ["PBMC", "CELL", 170, 174], ["lymphocyte and non-lymphocyte populations", "CELL_TYPE", 127, 168], ["PBMC", "CELL_TYPE", 170, 174]]], ["MHCII and B7.1 expression levels were determined as mean of fluorescence intensity for each gated cell population.", [["cell", "ANATOMY", 98, 102], ["MHCII", "GENE_OR_GENE_PRODUCT", 0, 5], ["B7.1", "GENE_OR_GENE_PRODUCT", 10, 14], ["cell", "CELL", 98, 102], ["MHCII", "PROTEIN", 0, 5], ["B7.1", "PROTEIN", 10, 14], ["gated cell population", "CELL_LINE", 92, 113], ["B7.1 expression levels", "TEST", 10, 32], ["fluorescence intensity", "PROBLEM", 60, 82], ["each gated cell population", "TREATMENT", 87, 113], ["cell population", "OBSERVATION", 98, 113]]], ["Identical gates were set for all cats in such a way that they comprise the desired cell populations of each animal.Relative gene expression analysisPBMCs were stimulated with ODN 2216, ODN 2243 or endotoxin-free PBS at a density of 3 \u00d7 10 6 cells/mL directly after isolation, while CrFK, FEA or fcwf-4 cells were cultured to confluency prior to stimulation.", [["cell", "ANATOMY", 83, 87], ["cells", "ANATOMY", 241, 246], ["fcwf-4 cells", "ANATOMY", 295, 307], ["ODN 2216", "CHEMICAL", 175, 183], ["ODN 2243", "CHEMICAL", 185, 193], ["endotoxin", "CHEMICAL", 197, 206], ["cats", "ORGANISM", 33, 37], ["cell populations", "CELL", 83, 99], ["ODN 2216", "SIMPLE_CHEMICAL", 175, 183], ["ODN 2243", "SIMPLE_CHEMICAL", 185, 193], ["endotoxin", "SIMPLE_CHEMICAL", 197, 206], ["CrFK", "SIMPLE_CHEMICAL", 282, 286], ["fcwf-4 cells", "CELL", 295, 307], ["CrFK, FEA or fcwf-4 cells", "CELL_LINE", 282, 307], ["Relative gene expression analysisPBMCs", "PROBLEM", 115, 153], ["ODN", "TEST", 175, 178], ["ODN", "TEST", 185, 188], ["endotoxin", "TEST", 197, 206], ["isolation", "TEST", 265, 274], ["CrFK", "TEST", 282, 286], ["FEA", "TEST", 288, 291], ["fcwf", "TEST", 295, 299], ["4 cells", "PROBLEM", 300, 307], ["stimulation", "TEST", 345, 356], ["desired cell populations", "OBSERVATION", 75, 99]]], ["For stimulation of adherent cells with supernatants (production see below), total cell culture medium was discarded from the wells and the monolayers were further cultured in 100 \u03bcL undiluted supernatants for the rest of the experiment.", [["cells", "ANATOMY", 28, 33], ["supernatants", "ANATOMY", 39, 51], ["cell", "ANATOMY", 82, 86], ["monolayers", "ANATOMY", 139, 149], ["supernatants", "ANATOMY", 192, 204], ["cells", "CELL", 28, 33], ["cell", "CELL", 82, 86], ["monolayers", "CELL", 139, 149], ["adherent cells", "CELL_TYPE", 19, 33], ["adherent cells", "PROBLEM", 19, 33], ["supernatants", "PROBLEM", 39, 51], ["total cell culture medium", "TEST", 76, 101], ["the monolayers", "TEST", 135, 149], ["adherent cells", "OBSERVATION", 19, 33]]], ["At time points relevant to each experiment, the supernatants were removed and cells were lysed with mRNA lysis buffer (mRNA isolation kit I, Roche Diagnostics, Rotkreuz, Switzerland). mRNA extractions were performed with the mRNA Isolation Kit I and MagNA Pure LC Instrument (Roche Diagnostics) and first strand cDNA was synthesized with the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Rotkreuz, Switzerland).", [["supernatants", "ANATOMY", 48, 60], ["cells", "ANATOMY", 78, 83], ["cells", "CELL", 78, 83], ["mRNA", "RNA", 184, 188], ["first strand cDNA", "DNA", 299, 316], ["the supernatants", "TREATMENT", 44, 60], ["cells", "TREATMENT", 78, 83], ["mRNA lysis buffer", "TREATMENT", 100, 117], ["mRNA extractions", "TREATMENT", 184, 200], ["the mRNA Isolation", "TREATMENT", 221, 239], ["first strand cDNA", "TREATMENT", 299, 316], ["the High Capacity cDNA", "TREATMENT", 338, 360]]], ["Real-time quantitative PCR (qPCR) reactions consisted of 5 \u03bcL cDNA in a total volume of 25 \u03bcL per reaction using the TaqMan \u00ae Fast Universal PCR Master Mix (Applied Biosystems).", [["\u03bcL cDNA", "DNA", 59, 66], ["quantitative PCR", "TEST", 10, 26], ["5 \u03bcL cDNA", "TREATMENT", 57, 66], ["a total volume", "TREATMENT", 70, 84], ["the TaqMan", "TEST", 113, 123], ["Fast Universal PCR Master Mix", "TREATMENT", 126, 155]]], ["Thermocycling conditions included an initial denaturation of 20 s at 95\u00b0C followed by 45 cycles of amplification by melting at 95\u00b0C for 3 s and annealing at 60\u00b0C for 45 s.", [["Thermocycling conditions", "PROBLEM", 0, 24], ["an initial denaturation", "PROBLEM", 34, 57], ["amplification", "TREATMENT", 99, 112]]], ["Primers and probes for feline genes have been previously described [58] . mRNA expression factors of selected genes, which correspond to ratios of mRNA levels measured in ODN 2216 or ODN 2243 stimulated versus PBS stimulated cells, were calculated and normalized with GeNorm version 3.5 [59] , using either both feline \u03b2-glucuronidase (GUSB) and tryptophan 5-monooxygenase activation protein zeta polypeptide (YWHAZ) (usually) or Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) alone (when specified) as reference genes, under conditions validated for the feline species [60] .", [["cells", "ANATOMY", 225, 230], ["ODN 2216", "CHEMICAL", 171, 179], ["ODN 2243", "CHEMICAL", 183, 191], ["tryptophan", "CHEMICAL", 346, 356], ["Glyceraldehyde 3-phosphate", "CHEMICAL", 430, 456], ["tryptophan", "CHEMICAL", 346, 356], ["Glyceraldehyde 3-phosphate", "CHEMICAL", 430, 456], ["feline", "ORGANISM", 23, 29], ["ODN 2216", "SIMPLE_CHEMICAL", 171, 179], ["cells", "CELL", 225, 230], ["feline", "ORGANISM", 312, 318], ["\u03b2-glucuronidase", "GENE_OR_GENE_PRODUCT", 319, 334], ["GUSB", "GENE_OR_GENE_PRODUCT", 336, 340], ["tryptophan 5-monooxygenase activation protein zeta polypeptide", "GENE_OR_GENE_PRODUCT", 346, 408], ["YWHAZ", "GENE_OR_GENE_PRODUCT", 410, 415], ["Glyceraldehyde 3-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 430, 470], ["GAPDH", "GENE_OR_GENE_PRODUCT", 472, 477], ["feline", "ORGANISM", 557, 563], ["feline genes", "DNA", 23, 35], ["mRNA", "RNA", 74, 78], ["PBS stimulated cells", "CELL_LINE", 210, 230], ["feline \u03b2-glucuronidase", "PROTEIN", 312, 334], ["GUSB", "PROTEIN", 336, 340], ["tryptophan 5-monooxygenase activation protein zeta polypeptide", "PROTEIN", 346, 408], ["YWHAZ", "PROTEIN", 410, 415], ["Glyceraldehyde 3-phosphate dehydrogenase", "PROTEIN", 430, 470], ["GAPDH", "PROTEIN", 472, 477], ["feline", "SPECIES", 312, 318], ["Primers and probes for feline genes", "PROBLEM", 0, 35], ["mRNA expression factors", "PROBLEM", 74, 97], ["mRNA levels", "TEST", 147, 158], ["PBS stimulated cells", "TEST", 210, 230], ["GeNorm version", "TEST", 268, 282], ["tryptophan", "TREATMENT", 346, 356], ["monooxygenase activation protein zeta polypeptide (YWHAZ)", "TREATMENT", 359, 416], ["Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)", "TREATMENT", 430, 478]]], ["Generally depicted in the graphs are mean expression factors calculated from duplicate experiments carried out simultaneously.", [["mean expression factors", "PROBLEM", 37, 60], ["duplicate experiments", "TEST", 77, 98]]], ["Where results of one cat are illustrated, experiments were conducted with cells of at least 3 individual animals and representative data is shown.Production of supernatantsFor each cat, PBMCs were resuspended in supplemented RPMI 1640 with Glutamax I (Gibco \u00ae , Invitrogen) at a concentration of 10 6 cells/mL in 6-well plates and stimulated immediately after isolation with 4 \u03bcg/mL ODN 2216, 4 \u03bcg/mL ODN 2243 or an equivalent volume of endotoxin-free PBS.", [["cells", "ANATOMY", 74, 79], ["supernatants", "ANATOMY", 160, 172], ["PBMCs", "ANATOMY", 186, 191], ["cells", "ANATOMY", 301, 306], ["Glutamax I", "CHEMICAL", 240, 250], ["ODN 2216", "CHEMICAL", 383, 391], ["ODN 2243", "CHEMICAL", 401, 409], ["endotoxin", "CHEMICAL", 437, 446], ["Glutamax I", "CHEMICAL", 240, 250], ["cat", "ORGANISM", 21, 24], ["cells", "CELL", 74, 79], ["cat", "ORGANISM", 181, 184], ["PBMCs", "CELL", 186, 191], ["Glutamax I", "SIMPLE_CHEMICAL", 240, 250], ["Gibco \u00ae", "SIMPLE_CHEMICAL", 252, 259], ["Invitrogen", "SIMPLE_CHEMICAL", 262, 272], ["endotoxin", "SIMPLE_CHEMICAL", 437, 446], ["PBMCs", "CELL_TYPE", 186, 191], ["endotoxin", "PROTEIN", 437, 446], ["cat", "SPECIES", 181, 184], ["Production of supernatants", "PROBLEM", 146, 172], ["PBMCs", "TREATMENT", 186, 191], ["Glutamax I (Gibco \u00ae", "TREATMENT", 240, 259], ["Invitrogen", "TREATMENT", 262, 272], ["isolation", "TREATMENT", 360, 369], ["endotoxin-free PBS", "TREATMENT", 437, 455], ["supernatants", "OBSERVATION", 160, 172]]], ["After 24 h incubation , supernatants were harvested by centrifugation of the cultures twice at 2000 \u00d7 g for 10 min, aliquoted and stored at \u221220\u00b0C. Large supernatant quantities were produced with PBMCs purified after one blood collection, enabling the utilization of the same supernatants for virus inhibition experiments concerning VSV, FCV, FCoV, FHV and FPV.", [["supernatants", "ANATOMY", 24, 36], ["supernatant", "ANATOMY", 153, 164], ["PBMCs", "ANATOMY", 195, 200], ["blood", "ANATOMY", 220, 225], ["supernatants", "ANATOMY", 275, 287], ["PBMCs", "CELL", 195, 200], ["blood", "ORGANISM_SUBSTANCE", 220, 225], ["VSV", "ORGANISM", 332, 335], ["FCV", "ORGANISM", 337, 340], ["FCoV", "GENE_OR_GENE_PRODUCT", 342, 346], ["FHV", "GENE_OR_GENE_PRODUCT", 348, 351], ["FPV", "ORGANISM", 356, 359], ["PBMCs", "CELL_TYPE", 195, 200], ["VSV", "SPECIES", 332, 335], ["FCV", "SPECIES", 337, 340], ["FCoV", "SPECIES", 342, 346], ["FHV", "SPECIES", 348, 351], ["FPV", "SPECIES", 356, 359], ["supernatants", "TREATMENT", 24, 36], ["the cultures", "TEST", 73, 85], ["Large supernatant quantities", "PROBLEM", 147, 175], ["PBMCs", "TREATMENT", 195, 200], ["one blood collection", "PROBLEM", 216, 236], ["the same supernatants", "TREATMENT", 266, 287], ["virus inhibition experiments", "TREATMENT", 292, 320], ["VSV", "PROBLEM", 332, 335], ["supernatant quantities", "OBSERVATION", 153, 175]]], ["New supernatant batches were produced for use in FeLV inhibition assays.", [["supernatant", "ANATOMY", 4, 15], ["FeLV", "ORGANISM", 49, 53], ["FeLV", "SPECIES", 49, 53], ["New supernatant batches", "TREATMENT", 0, 23], ["FeLV inhibition assays", "TEST", 49, 71], ["supernatant batches", "OBSERVATION", 4, 23]]], ["Supernatants derived from PBMCs stimulated with ODN 2216, ODN 2243 and endotoxin-free PBS are referred to as Sup2216, Sup 2243 and Sup Neg in the text and in the figures.Western blotCrFK and fcwf-4 grown to confluency in 12-well plates were stimulated with 600 \u03bcL of PBMC supernatants produced as explained above.", [["Supernatants", "ANATOMY", 0, 12], ["PBMCs", "ANATOMY", 26, 31], ["PBMC supernatants", "ANATOMY", 267, 284], ["ODN 2216", "CHEMICAL", 48, 56], ["ODN 2243", "CHEMICAL", 58, 66], ["endotoxin", "CHEMICAL", 71, 80], ["Supernatants", "CELL", 0, 12], ["PBMCs", "CELL", 26, 31], ["ODN 2216", "SIMPLE_CHEMICAL", 48, 56], ["ODN 2243", "SIMPLE_CHEMICAL", 58, 66], ["endotoxin", "SIMPLE_CHEMICAL", 71, 80], ["blotCrFK", "CELL", 178, 186], ["fcwf-4", "GENE_OR_GENE_PRODUCT", 191, 197], ["PBMC", "CELL", 267, 271], ["PBMCs", "CELL_TYPE", 26, 31], ["Western blotCrFK and fcwf-4", "DNA", 170, 197], ["PBMC", "CELL_TYPE", 267, 271], ["ODN", "TREATMENT", 48, 51], ["endotoxin-free PBS", "TEST", 71, 89], ["fcwf", "TEST", 191, 195], ["PBMC supernatants", "TREATMENT", 267, 284]]], ["At the time points indicated, cells were harvested and counted.", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35]]], ["10 6 cells of either cell line were resuspended in 30 \u03bcL sample buffer (0.5 M Tris(hydroxymethyl)aminomethane, 5% SDS, 10% \u03b2mercaptoethanol, 40% glycerol, and 0.05% bromphenol blue) and boiled at 95\u00b0C for 5 min.", [["cells", "ANATOMY", 5, 10], ["cell line", "ANATOMY", 21, 30], ["aminomethane", "CHEMICAL", 97, 109], ["\u03b2mercaptoethanol", "CHEMICAL", 123, 139], ["glycerol", "CHEMICAL", 145, 153], ["bromphenol blue", "CHEMICAL", 165, 180], ["Tris(hydroxymethyl)aminomethane", "CHEMICAL", 78, 109], ["\u03b2mercaptoethanol", "CHEMICAL", 123, 139], ["glycerol", "CHEMICAL", 145, 153], ["bromphenol blue", "CHEMICAL", 165, 180], ["cells", "CELL", 5, 10], ["cell line", "CELL", 21, 30], ["Tris(hydroxymethyl)aminomethane", "SIMPLE_CHEMICAL", 78, 109], ["\u03b2mercaptoethanol", "SIMPLE_CHEMICAL", 123, 139], ["glycerol", "SIMPLE_CHEMICAL", 145, 153], ["bromphenol blue", "SIMPLE_CHEMICAL", 165, 180], ["cell line", "CELL_LINE", 21, 30], ["cell line", "TREATMENT", 21, 30], ["0.5 M Tris(hydroxymethyl)aminomethane", "TREATMENT", 72, 109], ["\u03b2mercaptoethanol", "TREATMENT", 123, 139], ["40% glycerol", "TREATMENT", 141, 153], ["0.05% bromphenol blue", "TREATMENT", 159, 180], ["cell line", "OBSERVATION", 21, 30]]], ["SDS-PAGE separation and submersed immunoblotting procedures were carried out as previously described [61] .", [["submersed immunoblotting procedures", "TREATMENT", 24, 59]]], ["The Spectra Multicolor Broad Range Protein Ladder (Fermentas GmbH, St. Leon-Rot, Germany) served as molecular weight standard marker for each blot.", [["The Spectra Multicolor", "TEST", 0, 22], ["Protein Ladder", "TEST", 35, 49], ["Fermentas", "TEST", 51, 60]]], ["For protein visualization, membranes were first cut immediately below the 80kB marker band.", [["membranes", "ANATOMY", 27, 36], ["membranes", "CELLULAR_COMPONENT", 27, 36], ["protein visualization", "TEST", 4, 25]]], ["The top and bottom membrane fractions were incubated with murine anti-human Mx MAb M143 (generously provided by Dr J. Pavlovic, Institute for Virology, University of Z\u00fcrich, Switzerland) and murine anti-\u03b2-actin monoclonal antibody as a loading control (Sigma Aldrich GMbH, Buchs, Switzerland) respectively.", [["membrane fractions", "ANATOMY", 19, 37], ["murine", "ORGANISM", 58, 64], ["murine", "ORGANISM", 191, 197], ["murine anti-human Mx MAb M143", "PROTEIN", 58, 87], ["murine anti-\u03b2-actin monoclonal antibody", "PROTEIN", 191, 230], ["murine", "SPECIES", 58, 64], ["murine", "SPECIES", 191, 197], ["The top and bottom membrane fractions", "TEST", 0, 37], ["murine anti-human Mx MAb", "TREATMENT", 58, 82], ["Z\u00fcrich", "TREATMENT", 166, 172], ["murine anti-\u03b2-actin monoclonal antibody", "TREATMENT", 191, 230], ["a loading control", "TREATMENT", 234, 251], ["top", "OBSERVATION_MODIFIER", 4, 7], ["bottom", "ANATOMY_MODIFIER", 12, 18], ["membrane fractions", "OBSERVATION", 19, 37]]], ["Both fractions were subsequently incubated with a peroxidase-labelled goat anti-mouse IgG (Jackson Immunoresearch, Newmarket, Suffolk, UK).", [["peroxidase", "GENE_OR_GENE_PRODUCT", 50, 60], ["goat", "ORGANISM", 70, 74], ["peroxidase", "PROTEIN", 50, 60], ["goat anti-mouse IgG", "PROTEIN", 70, 89], ["goat", "SPECIES", 70, 74], ["anti-mouse", "SPECIES", 75, 85], ["goat", "SPECIES", 70, 74], ["a peroxidase", "TEST", 48, 60]]], ["Bands were digitalized using the Chemigenius 2 BioImaging System (Syngene, Cambridge, UK).", [["Bands", "TEST", 0, 5]]], ["With the exception of assays carried out with FPV, viral inhibition experiments were conducted simultaneously and with supernatants thawed an equal number of times.", [["supernatants", "ANATOMY", 119, 131], ["FPV", "ORGANISM", 46, 49], ["FPV", "SPECIES", 46, 49], ["assays", "TEST", 22, 28], ["FPV", "TREATMENT", 46, 49], ["viral inhibition experiments", "PROBLEM", 51, 79]]], ["The treated cells were then inoculated with virus (VSV, FCV, FHV, FCoV) or trypsinized with 0.05% trypsin-EDTA (Gibco \u00ae , Invitrogen) and allowed to settle in viral suspension (FPV), and inhibition assays were carried out after 24 h (72 h for FCoV and FPV) according to the procedure described previously [62] .", [["cells", "ANATOMY", 12, 17], ["trypsin-EDTA", "CHEMICAL", 98, 110], ["EDTA", "CHEMICAL", 106, 110], ["cells", "CELL", 12, 17], ["VSV", "ORGANISM", 51, 54], ["FCV", "ORGANISM", 56, 59], ["trypsin-EDTA", "SIMPLE_CHEMICAL", 98, 110], ["Gibco \u00ae", "SIMPLE_CHEMICAL", 112, 119], ["treated cells", "CELL_LINE", 4, 17], ["VSV", "SPECIES", 51, 54], ["FCV", "SPECIES", 56, 59], ["FHV", "SPECIES", 61, 64], ["FCoV", "SPECIES", 66, 70], ["FPV", "SPECIES", 177, 180], ["FPV", "SPECIES", 252, 255], ["The treated cells", "PROBLEM", 0, 17], ["virus", "PROBLEM", 44, 49], ["FCV", "PROBLEM", 56, 59], ["0.05% trypsin-EDTA", "TREATMENT", 92, 110], ["Invitrogen", "TREATMENT", 122, 132], ["viral suspension", "TREATMENT", 159, 175], ["inhibition assays", "TEST", 187, 204], ["FCoV", "PROBLEM", 243, 247], ["the procedure", "TREATMENT", 270, 283]]], ["Briefly, supernatants were discarded and cell debris was removed from the wells by 3 cycles of washing with Hank's balanced salt solution (HBSS) (Gibco, Invitrogen) and shaking on an orbital shaker for 15 s.", [["supernatants", "ANATOMY", 9, 21], ["cell debris", "ANATOMY", 41, 52], ["cell", "CELL", 41, 45], ["cell debris", "PROBLEM", 41, 52], ["washing", "TREATMENT", 95, 102], ["Hank's balanced salt solution", "TREATMENT", 108, 137], ["shaking", "PROBLEM", 169, 176], ["cell debris", "OBSERVATION", 41, 52], ["orbital", "ANATOMY", 183, 190]]], ["Remaining cells were fixed with 5% formalin and stained with a crystal violet solution.", [["cells", "ANATOMY", 10, 15], ["formalin", "CHEMICAL", 35, 43], ["formalin", "CHEMICAL", 35, 43], ["cells", "CELL", 10, 15], ["formalin", "SIMPLE_CHEMICAL", 35, 43], ["5% formalin", "TREATMENT", 32, 43], ["a crystal violet solution", "TREATMENT", 61, 86]]], ["For spectrophotometric measurements, 100% methanol was added to the dried out wells and absorbance was read at 595 nm on a SpectraMax Plus 384 microtiter plate reader (Molecular Devices, Bucher Biotec AG, Basel, Switzerland).", [["methanol", "CHEMICAL", 42, 50], ["methanol", "CHEMICAL", 42, 50], ["methanol", "SIMPLE_CHEMICAL", 42, 50], ["spectrophotometric measurements", "TEST", 4, 35], ["100% methanol", "TREATMENT", 37, 50], ["a SpectraMax Plus 384 microtiter plate", "TREATMENT", 121, 159], ["Molecular Devices", "TREATMENT", 168, 185]]], ["Viral inhibition rates were calculated with the following formula:Viruses and viral inhibition assaysMean optical density OD \u00f0 \u00devalues of duplicate wells treated with Supernatant Mean OD values of quadruplicate wells treated with medium alone FeLV-A Glasgow-1 strain (a generous gift from Prof. M. Hosie and O. Jarret, University of Glasgow, Great Britain) was titrated on FEA cells, and the lowest stock dilution leading to productive infection of the cells after 48 h was used for inhibition assays.", [["FEA cells", "ANATOMY", 373, 382], ["cells", "ANATOMY", 453, 458], ["infection", "DISEASE", 436, 445], ["Viral", "ORGANISM", 0, 5], ["FEA cells", "CELL", 373, 382], ["cells", "CELL", 453, 458], ["FEA cells", "CELL_LINE", 373, 382], ["Viral inhibition rates", "TEST", 0, 22], ["Viruses", "PROBLEM", 66, 73], ["viral inhibition assays", "PROBLEM", 78, 101], ["Mean optical density OD \u00f0 \u00devalues of duplicate wells", "PROBLEM", 101, 153], ["Supernatant Mean OD values of quadruplicate wells", "TREATMENT", 167, 216], ["FEA cells", "TREATMENT", 373, 382], ["the lowest stock dilution", "TREATMENT", 388, 413], ["productive infection of the cells", "PROBLEM", 425, 458], ["inhibition assays", "TEST", 483, 500], ["viral inhibition", "OBSERVATION", 78, 94], ["density", "OBSERVATION", 114, 121], ["productive", "OBSERVATION_MODIFIER", 425, 435], ["infection", "OBSERVATION", 436, 445]]], ["Experiments were carried out in 96-well plates and cells were treated with 100 \u03bcL of supernatants or relevant controls immediately prior to inoculation.", [["cells", "ANATOMY", 51, 56], ["supernatants", "ANATOMY", 85, 97], ["cells", "CELL", 51, 56], ["supernatants", "TREATMENT", 85, 97]]], ["Every second day thereafter, 50 \u03bcL culture medium was replaced by the same volume of fresh supernatant.", [["supernatant", "ANATOMY", 91, 102], ["50 \u03bcL culture medium", "TEST", 29, 49], ["fresh supernatant", "OBSERVATION", 85, 102]]], ["At appropriate time points, cells and supernatants were harvested and total nucleic acid was extracted from both the cells and supernatants using the MagNA Pure LC DNA Isolation Kit I and MagNA Pure LC Instrument (Roche Diagnostics).", [["cells", "ANATOMY", 28, 33], ["supernatants", "ANATOMY", 38, 50], ["cells", "ANATOMY", 117, 122], ["supernatants", "ANATOMY", 127, 139], ["nucleic acid", "CHEMICAL", 76, 88], ["cells", "CELL", 28, 33], ["cells", "CELL", 117, 122], ["cells and supernatants", "TREATMENT", 28, 50], ["total nucleic acid", "TEST", 70, 88], ["the MagNA Pure LC", "TREATMENT", 146, 163]]], ["Viral replication in supernatants and proviral loads in cells were measured by real-time RT-PCR and real-time PCR respectively, with assays previously described [63] .", [["Viral", "ANATOMY", 0, 5], ["supernatants", "ANATOMY", 21, 33], ["cells", "ANATOMY", 56, 61], ["Viral", "ORGANISM", 0, 5], ["cells", "CELL", 56, 61], ["Viral replication in supernatants", "TREATMENT", 0, 33], ["proviral loads in cells", "TEST", 38, 61], ["RT-PCR", "TEST", 89, 95], ["assays", "TEST", 133, 139]]], ["The time course experiments were conducted with supernatants derived from PBMCs of three cats and the measurements on day 8 post inoculation were carried out with material derived from two additional cats.", [["supernatants", "ANATOMY", 48, 60], ["PBMCs", "ANATOMY", 74, 79], ["PBMCs", "CELL", 74, 79], ["cats", "ORGANISM", 89, 93], ["cats", "ORGANISM", 200, 204], ["PBMCs", "CELL_TYPE", 74, 79], ["cats", "SPECIES", 89, 93], ["cats", "SPECIES", 200, 204]]], ["In order to facilitate interpretation of the figures illustrating measurements of viral RNA loads, 45 cycles-cycle threshold (Ct) values were calculated and means of duplicate wells are depicted.In vivo experimentCats c05 and c06 were administered ODN 2216 once subcutaneously at a dose of 0.2 mg/kg body weight while cats c07 and c08 received endotoxin-free PBS as control.", [["subcutaneously", "ANATOMY", 262, 276], ["body", "ANATOMY", 300, 304], ["ODN 2216", "CHEMICAL", 248, 256], ["endotoxin", "CHEMICAL", 344, 353], ["ODN 2216", "SIMPLE_CHEMICAL", 248, 256], ["body", "ORGANISM_SUBDIVISION", 300, 304], ["cats", "ORGANISM", 318, 322], ["endotoxin", "SIMPLE_CHEMICAL", 344, 353], ["cats", "SPECIES", 318, 322], ["viral RNA loads", "TEST", 82, 97], ["Ct) values", "TEST", 126, 136], ["c06", "TREATMENT", 226, 229], ["ODN", "TREATMENT", 248, 251], ["body weight", "TEST", 300, 311], ["cats", "TEST", 318, 322], ["endotoxin", "TREATMENT", 344, 353], ["free PBS", "TREATMENT", 354, 362]]], ["The treatments were distributed in equal portions bilaterally in axillary and inguinal regions.", [["axillary", "ANATOMY", 65, 73], ["inguinal regions", "ANATOMY", 78, 94], ["axillary", "MULTI-TISSUE_STRUCTURE", 65, 73], ["inguinal regions", "MULTI-TISSUE_STRUCTURE", 78, 94], ["The treatments", "TREATMENT", 0, 14], ["equal", "ANATOMY_MODIFIER", 35, 40], ["portions", "ANATOMY_MODIFIER", 41, 49], ["bilaterally", "ANATOMY_MODIFIER", 50, 61], ["axillary", "ANATOMY", 65, 73], ["inguinal", "ANATOMY", 78, 86], ["regions", "ANATOMY_MODIFIER", 87, 94]]], ["Heparinized blood was collected at time points 0 h (just before injection of the treatment), 8 h, 24 h, 48 h, 96 h and 192 h.", [["blood", "ANATOMY", 12, 17], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["Heparinized blood", "TREATMENT", 0, 17], ["the treatment)", "TREATMENT", 77, 91]]], ["The cats were clinically examined and body temperature was measured at each time point.", [["body", "ANATOMY", 38, 42], ["cats", "ORGANISM", 4, 8], ["body", "ORGANISM_SUBDIVISION", 38, 42], ["cats", "SPECIES", 4, 8], ["body temperature", "TEST", 38, 54]]], ["Whole blood samples were used in part for the assessment of hematological paramaters with the Sysmex XT 2000iV (Sysmex, Norderstedt, Germany) as previously described [57] .", [["Whole blood samples", "ANATOMY", 0, 19], ["blood samples", "ORGANISM_SUBSTANCE", 6, 19], ["Whole blood samples", "TEST", 0, 19], ["the assessment", "TEST", 42, 56]]], ["The rest of the blood was mixed with mRNA lysis buffer (Roche Diagnostics) immediately upon blood collection and processed as recommended by the manufacturer.", [["blood", "ANATOMY", 16, 21], ["blood", "ANATOMY", 92, 97], ["blood", "ORGANISM_SUBSTANCE", 16, 21], ["blood", "ORGANISM_SUBSTANCE", 92, 97], ["mRNA lysis buffer", "TREATMENT", 37, 54], ["blood collection", "TEST", 92, 108]]], ["Plasma was obtained by centrifugation of whole blood samples for 10 min at 1500 \u00d7 g and conserved at \u221280\u00b0C until use for in vitro experiments.", [["blood samples", "ANATOMY", 47, 60], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["blood samples", "ORGANISM_SUBSTANCE", 47, 60], ["Plasma", "TEST", 0, 6], ["whole blood samples", "TEST", 41, 60]]], ["Mx mRNA expression was measured by qPCR and normalized to the expression of two feline housekeeping genes as described above.", [["Mx", "GENE_OR_GENE_PRODUCT", 0, 2], ["feline", "ORGANISM", 80, 86], ["Mx mRNA", "RNA", 0, 7], ["feline housekeeping genes", "DNA", 80, 105], ["Mx mRNA expression", "PROBLEM", 0, 18], ["qPCR", "TEST", 35, 39]]], ["The expression factors depicted in the figures represent the ratio of mRNA levels from a specific time point to mRNA levels from time point 0 h.", [["expression factors", "PROTEIN", 4, 22], ["The expression factors", "PROBLEM", 0, 22], ["mRNA levels", "TEST", 70, 81], ["mRNA levels", "TEST", 112, 123]]], ["For viral inhibition assays, the plasma collected from each cat at each time point was incubated for 24 h with fcwf-4 cells prior to their inoculation with FCV.", [["plasma", "ANATOMY", 33, 39], ["fcwf-4 cells", "ANATOMY", 111, 123], ["plasma", "ORGANISM_SUBSTANCE", 33, 39], ["cat", "ORGANISM", 60, 63], ["fcwf-4 cells", "CELL", 111, 123], ["FCV", "ORGANISM", 156, 159], ["FCV", "SPECIES", 156, 159], ["viral inhibition assays", "TEST", 4, 27], ["the plasma", "TEST", 29, 39], ["their inoculation", "TREATMENT", 133, 150], ["FCV", "TREATMENT", 156, 159]]], ["The assays were carried out as described above and viral inhibition factors were calculated as follows:In vivo experimentMean optical density OD \u00f0 \u00devalues of duplicate wells treated with plasma from timepoint 0h Mean OD values of duplicate wells treated with plasma from timepoint XhStatistical analysisAll statistical analyzes were performed using GraphPad Prism for Windows, version 3.0 (GraphPad Software, San Diego California USA).", [["plasma", "ANATOMY", 187, 193], ["plasma", "ANATOMY", 259, 265], ["plasma", "ORGANISM_SUBSTANCE", 187, 193], ["plasma", "ORGANISM_SUBSTANCE", 259, 265], ["viral inhibition factors", "PROTEIN", 51, 75], ["The assays", "TEST", 0, 10], ["viral inhibition factors", "PROBLEM", 51, 75], ["Mean optical density OD \u00f0 \u00devalues of duplicate wells", "PROBLEM", 121, 173], ["plasma from timepoint", "TEST", 187, 208], ["Mean OD values", "TEST", 212, 226], ["plasma from timepoint XhStatistical analysis", "TEST", 259, 303], ["All statistical analyzes", "TEST", 303, 327], ["density", "OBSERVATION", 134, 141]]], ["Due to the limited number of cats integrated in the study, we refrained from using a parametric approach in the statistical tests.", [["cats", "ORGANISM", 29, 33], ["the study", "TEST", 48, 57], ["a parametric approach", "TREATMENT", 83, 104], ["the statistical tests", "TEST", 108, 129]]], ["As such tests require a larger sample size than n = 4, it was not possible to calculate p-values for the induction in expression of each gene shown in Figure 2 .", [["such tests", "TEST", 3, 13], ["p-values", "TEST", 88, 96]]], ["Differences between treatment groups in proliferation of PBMCs were analyzed with a Mann-Whitney test and expression of costimulatory molecules on the surface of these cells were analyzed with a Wilcoxon signed rank test, where values for each cat were paired.", [["PBMCs", "ANATOMY", 57, 62], ["surface", "ANATOMY", 151, 158], ["cells", "ANATOMY", 168, 173], ["PBMCs", "CELL", 57, 62], ["surface", "CELLULAR_COMPONENT", 151, 158], ["cells", "CELL", 168, 173], ["cat", "ORGANISM", 244, 247], ["PBMCs", "CELL_TYPE", 57, 62], ["costimulatory molecules", "PROTEIN", 120, 143], ["treatment groups", "TREATMENT", 20, 36], ["PBMCs", "TEST", 57, 62], ["Whitney test", "TEST", 89, 101], ["a Wilcoxon signed rank test", "TEST", 193, 220]]], ["Relative Mx mRNA expression, OD values from viral inhibition assays, ratios for FeLV provirus and Ct values for FeLV viral RNA loads were analyzed with a Wilcoxon signed rank test with pairing of values for each cat when treatment with different supernatants were compared, or a Mann-Whitney test when incubation with supernatant was opposed to treatment with medium alone or rfeIFN\u03b1.", [["supernatants", "ANATOMY", 246, 258], ["supernatant", "ANATOMY", 318, 329], ["Mx", "GENE_OR_GENE_PRODUCT", 9, 11], ["FeLV", "ORGANISM", 80, 84], ["FeLV", "ORGANISM", 112, 116], ["cat", "ORGANISM", 212, 215], ["rfeIFN\u03b1", "SIMPLE_CHEMICAL", 376, 383], ["Mx mRNA", "RNA", 9, 16], ["FeLV", "SPECIES", 80, 84], ["FeLV", "SPECIES", 112, 116], ["OD values", "TEST", 29, 38], ["viral inhibition assays", "TEST", 44, 67], ["ratios", "TEST", 69, 75], ["FeLV provirus", "PROBLEM", 80, 93], ["Ct values", "TEST", 98, 107], ["FeLV viral RNA loads", "PROBLEM", 112, 132], ["a Wilcoxon signed rank test", "TEST", 152, 179], ["treatment", "TREATMENT", 221, 230], ["supernatant", "TREATMENT", 318, 329]]], ["Normalized and relative TLR9 mRNA expression ratios between different animal age groups were also compared with a Mann-Whitney test.", [["TLR9", "GENE_OR_GENE_PRODUCT", 24, 28], ["TLR9 mRNA", "RNA", 24, 33], ["relative TLR9 mRNA expression ratios", "PROBLEM", 15, 51], ["TLR9 mRNA", "OBSERVATION", 24, 33]]], ["Longitudinal effects on FeLV viral and proviral loads were compared with each other using a Mann-Whitney test carried out with Area Under the Curve (AUC) values.", [["FeLV", "ORGANISM", 24, 28], ["FeLV", "SPECIES", 24, 28], ["Longitudinal effects", "PROBLEM", 0, 20], ["FeLV viral and proviral loads", "TREATMENT", 24, 53], ["Whitney test", "TEST", 97, 109], ["FeLV viral", "OBSERVATION", 24, 34]]], ["Correlations were assessed using the Spearman test. p-values < 0.05 were considered statistically significant.ResultsPrototype CpG-A, ODN 2216, induce proliferation of primary feline immune cells and enhance their expression of costimulatory surface molecules Proliferation of PBMCs in response to treatment with CpG ODN gives strong indications about the biological activity of the stimulatory molecule and has been used to screen ODN in many species [25] .", [["immune cells", "ANATOMY", 183, 195], ["PBMCs", "ANATOMY", 277, 282], ["ODN 2216", "CHEMICAL", 134, 142], ["ODN", "CHEMICAL", 317, 320], ["ODN", "CHEMICAL", 432, 435], ["CpG", "CHEMICAL", 313, 316], ["CpG-A", "SIMPLE_CHEMICAL", 127, 132], ["ODN 2216", "SIMPLE_CHEMICAL", 134, 142], ["feline", "ORGANISM", 176, 182], ["immune cells", "CELL", 183, 195], ["PBMCs", "CELL", 277, 282], ["CpG ODN", "SIMPLE_CHEMICAL", 313, 320], ["primary feline immune cells", "CELL_TYPE", 168, 195], ["costimulatory surface molecules", "PROTEIN", 228, 259], ["PBMCs", "CELL_TYPE", 277, 282], ["stimulatory molecule", "PROTEIN", 383, 403], ["the Spearman test", "TEST", 33, 50], ["p-values", "TEST", 52, 60], ["primary feline immune cells", "PROBLEM", 168, 195], ["costimulatory surface molecules", "TREATMENT", 228, 259], ["PBMCs", "PROBLEM", 277, 282], ["treatment", "TREATMENT", 298, 307], ["CpG ODN", "TREATMENT", 313, 320], ["primary feline immune cells", "OBSERVATION", 168, 195]]], ["In relation to this, the potential of CpG-A to induce proliferation of feline PBMCs were assessed by measurement of 3 H-thymidine incorporation after stimulation.", [["PBMCs", "ANATOMY", 78, 83], ["CpG-A", "CHEMICAL", 38, 43], ["H-thymidine", "CHEMICAL", 118, 129], ["CpG-A", "CHEMICAL", 38, 43], ["3 H-thymidine", "CHEMICAL", 116, 129], ["CpG-A", "GENE_OR_GENE_PRODUCT", 38, 43], ["feline", "ORGANISM", 71, 77], ["PBMCs", "CELL", 78, 83], ["thymidine", "SIMPLE_CHEMICAL", 120, 129], ["feline PBMCs", "CELL_TYPE", 71, 83], ["feline", "SPECIES", 71, 77], ["feline", "SPECIES", 71, 77], ["proliferation of feline PBMCs", "PROBLEM", 54, 83], ["3 H-thymidine incorporation", "TREATMENT", 116, 143], ["feline PBMCs", "OBSERVATION", 71, 83]]], ["Although considerable variability was observed between individuals, a 2-fold increase in proliferation was observed after stimulation with ODN 2216 when compared to stimulation with inactive control ODN 2243 (p = 0.0281, Figure 1A ).", [["ODN 2216", "CHEMICAL", 139, 147], ["ODN 2243", "CHEMICAL", 199, 207], ["ODN 2216", "SIMPLE_CHEMICAL", 139, 147], ["considerable variability", "PROBLEM", 9, 33], ["a 2-fold increase in proliferation", "PROBLEM", 68, 102], ["stimulation with ODN", "TREATMENT", 122, 142], ["inactive control ODN", "TREATMENT", 182, 202], ["considerable", "OBSERVATION_MODIFIER", 9, 21], ["variability", "OBSERVATION", 22, 33], ["increase", "OBSERVATION_MODIFIER", 77, 85], ["proliferation", "OBSERVATION", 89, 102]]], ["The cells of three cats (c08, c09, c12) could be stimulated to particularly high proliferative rates by ODN 2216 (values above the mean of eight cats illustrated in Figure 1A ) in the following order: c08 > c12 > c09.ResultsAnother characteristic feature of stimulatory ODN is their ability to enhance interactions between various immune cell populations by upregulation of cell surface costimulatory molecules.", [["cells", "ANATOMY", 4, 9], ["immune cell", "ANATOMY", 331, 342], ["cell surface", "ANATOMY", 374, 386], ["ODN 2216", "CHEMICAL", 104, 112], ["ODN", "CHEMICAL", 270, 273], ["cells", "CELL", 4, 9], ["cats", "ORGANISM", 19, 23], ["c08", "ORGANISM", 25, 28], ["c12", "ORGANISM", 35, 38], ["ODN", "SIMPLE_CHEMICAL", 270, 273], ["immune cell populations", "CELL", 331, 354], ["cell", "CELL", 374, 378], ["immune cell populations", "CELL_TYPE", 331, 354], ["cell surface costimulatory molecules", "PROTEIN", 374, 410], ["cats", "SPECIES", 19, 23], ["three cats", "TEST", 13, 23], ["stimulatory ODN", "TREATMENT", 258, 273], ["various immune cell populations", "TREATMENT", 323, 354], ["upregulation of cell surface costimulatory molecules", "TREATMENT", 358, 410], ["immune cell", "OBSERVATION", 331, 342], ["cell", "OBSERVATION", 374, 378], ["surface", "OBSERVATION_MODIFIER", 379, 386], ["costimulatory molecules", "OBSERVATION", 387, 410]]], ["With the objective to test whether ODN 2216 could exert such properties in feline immune cells, the expression of B7.1 and MHCII was measured by flow cytometry in stimulated PBMCs of the same eight cats as above.", [["immune cells", "ANATOMY", 82, 94], ["PBMCs", "ANATOMY", 174, 179], ["ODN 2216", "CHEMICAL", 35, 43], ["ODN 2216", "SIMPLE_CHEMICAL", 35, 43], ["feline", "ORGANISM", 75, 81], ["immune cells", "CELL", 82, 94], ["B7.1", "GENE_OR_GENE_PRODUCT", 114, 118], ["MHCII", "GENE_OR_GENE_PRODUCT", 123, 128], ["PBMCs", "CELL", 174, 179], ["cats", "ORGANISM", 198, 202], ["feline immune cells", "CELL_TYPE", 75, 94], ["B7.1", "PROTEIN", 114, 118], ["MHCII", "PROTEIN", 123, 128], ["PBMCs", "CELL_TYPE", 174, 179], ["such properties in feline immune cells", "PROBLEM", 56, 94], ["flow cytometry", "TEST", 145, 159]]], ["The expression of both co-stimulatory molecules was evaluated in gates defined to contain a PBMC population, a lymphocyte population and a non-lymphocyte population of cells.", [["PBMC", "ANATOMY", 92, 96], ["lymphocyte", "ANATOMY", 111, 121], ["non-lymphocyte", "ANATOMY", 139, 153], ["cells", "ANATOMY", 168, 173], ["PBMC", "CELL", 92, 96], ["lymphocyte", "CELL", 111, 121], ["cells", "CELL", 168, 173], ["co-stimulatory molecules", "PROTEIN", 23, 47], ["PBMC population", "CELL_TYPE", 92, 107], ["lymphocyte population", "CELL_TYPE", 111, 132], ["both co-stimulatory molecules", "PROBLEM", 18, 47], ["a PBMC population", "PROBLEM", 90, 107], ["a lymphocyte population", "PROBLEM", 109, 132], ["a non-lymphocyte population of cells", "PROBLEM", 137, 173], ["both", "OBSERVATION_MODIFIER", 18, 22], ["co-stimulatory molecules", "OBSERVATION", 23, 47], ["PBMC", "ANATOMY", 92, 96]]], ["The observed effects varied considerably between the cells of individual cats, ranging from no alterations to an increase of 400% stained cells in some cellular subpopulations after ODN 2216 stimulation.", [["cells", "ANATOMY", 53, 58], ["cells", "ANATOMY", 138, 143], ["cellular", "ANATOMY", 152, 160], ["ODN 2216", "CHEMICAL", 182, 190], ["cells", "CELL", 53, 58], ["cats", "ORGANISM", 73, 77], ["cells", "CELL", 138, 143], ["cellular", "CELL", 152, 160], ["individual cats", "TEST", 62, 77], ["increase", "OBSERVATION_MODIFIER", 113, 121], ["cellular subpopulations", "OBSERVATION", 152, 175]]], ["Also, in some animals, stimulation with the control ODN 2243 indicated similar staining patterns as PBS, whereas in other cats the induction of effects comparable to those of ODN 2216 could be observed.", [["ODN 2243", "CHEMICAL", 52, 60], ["ODN 2216", "CHEMICAL", 175, 183], ["cats", "ORGANISM", 122, 126], ["ODN 2216", "SIMPLE_CHEMICAL", 175, 183], ["the control ODN", "TREATMENT", 40, 55], ["similar staining patterns as PBS", "PROBLEM", 71, 103]]], ["The response of cells originating from a particular cat to stimulation with ODN 2243 did not however correlate with the influence of ODN 2216 on the expression of either surface molecule on these same cells.", [["cells", "ANATOMY", 16, 21], ["surface", "ANATOMY", 170, 177], ["cells", "ANATOMY", 201, 206], ["ODN 2243", "CHEMICAL", 76, 84], ["ODN 2216", "CHEMICAL", 133, 141], ["ODN 2243", "CHEMICAL", 76, 84], ["cells", "CELL", 16, 21], ["cat", "ORGANISM", 52, 55], ["ODN 2243", "SIMPLE_CHEMICAL", 76, 84], ["ODN 2216", "SIMPLE_CHEMICAL", 133, 141], ["cells", "CELL", 201, 206], ["surface molecule", "PROTEIN", 170, 186], ["cells", "PROBLEM", 16, 21], ["ODN", "TREATMENT", 133, 136], ["cells", "OBSERVATION", 16, 21]]], ["Overall, an increased expression of both B7.1 and MHCII was measured in gated PBMCs upon a 24 h stimulation with ODN 2216 when overlaid with the expression of these molecules after ODN 2243 or PBS stimulation ( Figure 1B and C) .", [["PBMCs", "ANATOMY", 78, 83], ["ODN 2216", "CHEMICAL", 113, 121], ["ODN 2243", "CHEMICAL", 181, 189], ["B7.1", "GENE_OR_GENE_PRODUCT", 41, 45], ["MHCII", "GENE_OR_GENE_PRODUCT", 50, 55], ["PBMCs", "CELL", 78, 83], ["ODN 2216", "SIMPLE_CHEMICAL", 113, 121], ["ODN 2243", "SIMPLE_CHEMICAL", 181, 189], ["B7.1", "PROTEIN", 41, 45], ["MHCII", "PROTEIN", 50, 55], ["gated PBMCs", "CELL_TYPE", 72, 83], ["a 24 h stimulation with ODN", "TREATMENT", 89, 116], ["ODN", "TREATMENT", 181, 184], ["PBS stimulation", "TEST", 193, 208], ["increased", "OBSERVATION_MODIFIER", 12, 21]]], ["Considering all eight cats, lymphocytic cells expressed significantly higher levels of B7.1 and MHCII when exposed to ODN 2216 than after treatment with PBS (p = 0.0195 and p = 0.039 respectively, Figure 1D and F).", [["lymphocytic cells", "ANATOMY", 28, 45], ["ODN 2216", "CHEMICAL", 118, 126], ["cats", "ORGANISM", 22, 26], ["lymphocytic cells", "CELL", 28, 45], ["B7.1", "GENE_OR_GENE_PRODUCT", 87, 91], ["MHCII", "GENE_OR_GENE_PRODUCT", 96, 101], ["lymphocytic cells", "CELL_TYPE", 28, 45], ["B7.1", "PROTEIN", 87, 91], ["MHCII", "PROTEIN", 96, 101], ["lymphocytic cells", "PROBLEM", 28, 45], ["PBS", "TEST", 153, 156], ["p", "TEST", 158, 159], ["lymphocytic cells", "OBSERVATION", 28, 45]]], ["Feline MHCII expression on lymphocytes also seemed to be affected by ODN 2216 and ODN 2243 in a similar manner ( Figure 1F ).", [["lymphocytes", "ANATOMY", 27, 38], ["ODN 2216", "CHEMICAL", 69, 77], ["ODN 2243", "CHEMICAL", 82, 90], ["ODN 2243", "CHEMICAL", 82, 90], ["Feline", "ORGANISM", 0, 6], ["MHCII", "GENE_OR_GENE_PRODUCT", 7, 12], ["lymphocytes", "CELL", 27, 38], ["ODN 2216", "SIMPLE_CHEMICAL", 69, 77], ["ODN 2243", "SIMPLE_CHEMICAL", 82, 90], ["MHCII", "PROTEIN", 7, 12], ["lymphocytes", "CELL_TYPE", 27, 38], ["lymphocytes", "TEST", 27, 38], ["ODN", "TEST", 82, 85], ["MHCII", "OBSERVATION", 7, 12]]], ["For nonlymphocytic cells, ODN 2216 more specifically affected the expression of B7.1 molecules, inducing significant upregulation of surface levels of this molecule when compared to stimulation with ODN 2243 (p = 0.0391) and PBS (p = 0.0039) for 24 h ( Figure 1E ).", [["nonlymphocytic cells", "ANATOMY", 4, 24], ["surface", "ANATOMY", 133, 140], ["nonlymphocytic", "DISEASE", 4, 18], ["ODN 2216", "CHEMICAL", 26, 34], ["ODN 2243", "CHEMICAL", 199, 207], ["nonlymphocytic cells", "CELL", 4, 24], ["ODN 2216", "SIMPLE_CHEMICAL", 26, 34], ["B7.1", "GENE_OR_GENE_PRODUCT", 80, 84], ["ODN 2243", "SIMPLE_CHEMICAL", 199, 207], ["nonlymphocytic cells", "CELL_TYPE", 4, 24], ["B7.1 molecules", "PROTEIN", 80, 94], ["nonlymphocytic cells", "PROBLEM", 4, 24], ["B7.1 molecules", "PROBLEM", 80, 94], ["significant upregulation of surface levels of this molecule", "PROBLEM", 105, 164], ["ODN", "TEST", 199, 202], ["PBS", "TEST", 225, 228], ["nonlymphocytic cells", "OBSERVATION", 4, 24], ["significant", "OBSERVATION_MODIFIER", 105, 116], ["upregulation", "OBSERVATION_MODIFIER", 117, 129], ["surface", "OBSERVATION_MODIFIER", 133, 140]]], ["In contrast, the expression of MHCII was not significantly altered in cells gated as non-lymphocytes at this time point after stimulation ( Figure 1G ).", [["cells", "ANATOMY", 70, 75], ["non-lymphocytes", "ANATOMY", 85, 100], ["MHCII", "GENE_OR_GENE_PRODUCT", 31, 36], ["cells", "CELL", 70, 75], ["non-lymphocytes", "CELL", 85, 100], ["MHCII", "PROTEIN", 31, 36], ["non-lymphocytes", "CELL_TYPE", 85, 100], ["significantly altered in cells gated as non-lymphocytes", "PROBLEM", 45, 100], ["MHCII", "OBSERVATION", 31, 36]]], ["Finally, the cells of the three cats (c08, c09 and c12) that exhibited the highest proliferation rates in response to ODN 2216 ( Figure 1A ) also indicated the strongest increase in expression of both cell surface molecules in all cellular subpopulations tested.ODN 2216 influence type I IFN and proinflammatory gene expression in primary feline immune cellsThrough interaction with the TLR9, CpG-A typically induce expression of both type I IFN and proinflammatory cytokines in stimulated cells [12] .", [["cells", "ANATOMY", 13, 18], ["cell surface", "ANATOMY", 201, 213], ["cellular", "ANATOMY", 231, 239], ["immune cells", "ANATOMY", 346, 358], ["cells", "ANATOMY", 490, 495], ["ODN 2216", "CHEMICAL", 118, 126], ["ODN 2216", "CHEMICAL", 262, 270], ["cells", "CELL", 13, 18], ["cats", "ORGANISM", 32, 36], ["c09", "GENE_OR_GENE_PRODUCT", 43, 46], ["c12", "CELL", 51, 54], ["cell", "CELL", 201, 205], ["cellular", "CELL", 231, 239], ["type I IFN", "GENE_OR_GENE_PRODUCT", 281, 291], ["feline", "ORGANISM", 339, 345], ["immune cells", "CELL", 346, 358], ["TLR9", "GENE_OR_GENE_PRODUCT", 387, 391], ["CpG-A", "GENE_OR_GENE_PRODUCT", 393, 398], ["type I IFN", "GENE_OR_GENE_PRODUCT", 435, 445], ["cells", "CELL", 490, 495], ["cell surface molecules", "PROTEIN", 201, 223], ["type I IFN", "PROTEIN", 281, 291], ["primary feline immune cells", "CELL_TYPE", 331, 358], ["TLR9", "PROTEIN", 387, 391], ["type I IFN", "PROTEIN", 435, 445], ["proinflammatory cytokines", "PROTEIN", 450, 475], ["cats", "SPECIES", 32, 36], ["feline", "SPECIES", 339, 345], ["the highest proliferation rates", "PROBLEM", 71, 102], ["both cell surface molecules", "PROBLEM", 196, 223], ["ODN", "TREATMENT", 262, 265], ["type I IFN", "PROBLEM", 281, 291], ["proinflammatory gene expression in primary feline immune cells", "PROBLEM", 296, 358], ["proinflammatory cytokines in stimulated cells", "TREATMENT", 450, 495], ["highest proliferation", "OBSERVATION", 75, 96], ["strongest", "OBSERVATION_MODIFIER", 160, 169], ["increase", "OBSERVATION_MODIFIER", 170, 178], ["both cell", "OBSERVATION", 196, 205], ["surface molecules", "OBSERVATION", 206, 223], ["all", "OBSERVATION_MODIFIER", 227, 230], ["cellular subpopulations", "OBSERVATION", 231, 254], ["immune cells", "OBSERVATION", 346, 358]]], ["In order to understand whether ODN 2216 exert similar effects in the cat, treated cultures of feline PBMCs, FEA, CrFK and fcwf-4 cells were systematically screened for increased mRNA expression of IFN\u03b1 and IL-6 following stimulation.", [["cultures", "ANATOMY", 82, 90], ["PBMCs", "ANATOMY", 101, 106], ["CrFK", "ANATOMY", 113, 117], ["fcwf-4 cells", "ANATOMY", 122, 134], ["ODN 2216", "CHEMICAL", 31, 39], ["ODN 2216", "SIMPLE_CHEMICAL", 31, 39], ["cat", "ORGANISM", 69, 72], ["feline", "ORGANISM", 94, 100], ["PBMCs", "CELL", 101, 106], ["CrFK", "CELL", 113, 117], ["fcwf-4 cells", "CELL", 122, 134], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 197, 201], ["IL-6", "GENE_OR_GENE_PRODUCT", 206, 210], ["treated cultures", "CELL_LINE", 74, 90], ["feline PBMCs", "CELL_TYPE", 94, 106], ["FEA, CrFK and fcwf-4 cells", "CELL_LINE", 108, 134], ["IFN\u03b1", "PROTEIN", 197, 201], ["IL-6", "PROTEIN", 206, 210], ["cat", "SPECIES", 69, 72], ["feline", "SPECIES", 94, 100], ["cultures of feline PBMCs", "TEST", 82, 106], ["FEA", "TEST", 108, 111], ["CrFK", "TEST", 113, 117], ["fcwf", "TEST", 122, 126], ["IFN", "TEST", 197, 200], ["IL", "TEST", 206, 208]]], ["Although all tested immortalized feline cell lines expressed TLR9 mRNA (data not shown), they failed to respond to stimulation with ODN 2216 ( Figure 3A and B and data not shown).", [["cell lines", "ANATOMY", 40, 50], ["ODN 2216", "CHEMICAL", 132, 140], ["feline", "ORGANISM", 33, 39], ["cell lines", "CELL", 40, 50], ["TLR9", "GENE_OR_GENE_PRODUCT", 61, 65], ["immortalized feline cell lines", "CELL_LINE", 20, 50], ["TLR9 mRNA", "RNA", 61, 70], ["feline", "SPECIES", 33, 39], ["TLR9 mRNA", "TEST", 61, 70], ["stimulation with ODN", "TREATMENT", 115, 135], ["feline cell lines", "OBSERVATION", 33, 50], ["TLR9 mRNA", "OBSERVATION", 61, 70]]], ["However, this molecule exhibited potent immunomodulatory properties in feline PBMCs: when measured 24 h post stimulation, a concentration of only 1 \u03bcg/mL ODN 2216 was sufficient to enhance transcription of IFN\u03b1 by 40-fold, and a maximum induction of this gene was observed when 4 \u03bcg/mL ODN were used ( Figure 3C ).", [["PBMCs", "ANATOMY", 78, 83], ["ODN 2216", "CHEMICAL", 154, 162], ["ODN", "CHEMICAL", 286, 289], ["feline", "ORGANISM", 71, 77], ["PBMCs", "CELL", 78, 83], ["ODN 2216", "SIMPLE_CHEMICAL", 154, 162], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 206, 210], ["ODN", "SIMPLE_CHEMICAL", 286, 289], ["feline PBMCs", "CELL_TYPE", 71, 83], ["IFN\u03b1", "PROTEIN", 206, 210], ["feline", "SPECIES", 71, 77], ["a concentration", "TEST", 122, 137], ["IFN\u03b1", "TREATMENT", 206, 210], ["4 \u03bcg/mL ODN", "TREATMENT", 278, 289], ["potent", "OBSERVATION_MODIFIER", 33, 39], ["immunomodulatory properties", "OBSERVATION", 40, 67], ["feline PBMCs", "OBSERVATION", 71, 83]]], ["Although affected in a similar pattern, the mRNA expression of the proinflammatory cytokine IL-6 remained comparatively low at all concentrations tested ( Figure 3D ).", [["IL-6", "GENE_OR_GENE_PRODUCT", 92, 96], ["proinflammatory cytokine IL-6", "PROTEIN", 67, 96], ["the proinflammatory cytokine IL", "TEST", 63, 94], ["proinflammatory", "OBSERVATION_MODIFIER", 67, 82]]], ["In experiments foreseen to determine gene expression kinetics in feline cells after stimulation with the ODN 2216 molecule, an influence on IFN\u03b1 transcription could be measured as early as 3 h after treatment of PBMCs, whereas increased levels of IL-6 mRNA were observed only as of 6 h post stimulation ( Figure 3E and F).", [["cells", "ANATOMY", 72, 77], ["PBMCs", "ANATOMY", 212, 217], ["ODN 2216", "CHEMICAL", 105, 113], ["feline", "ORGANISM", 65, 71], ["cells", "CELL", 72, 77], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 140, 144], ["PBMCs", "CELL", 212, 217], ["IL-6", "GENE_OR_GENE_PRODUCT", 247, 251], ["feline cells", "CELL_TYPE", 65, 77], ["IFN\u03b1", "PROTEIN", 140, 144], ["PBMCs", "CELL_TYPE", 212, 217], ["IL-6 mRNA", "RNA", 247, 256], ["gene expression kinetics in feline cells", "PROBLEM", 37, 77], ["stimulation with the ODN", "TREATMENT", 84, 108], ["IFN\u03b1 transcription", "TREATMENT", 140, 158], ["PBMCs", "PROBLEM", 212, 217], ["IL", "TEST", 247, 249]]], ["Notably, the highest induction of both genes was measured 24 h after addition of ODN 2216 to the cultures, with transcription increasing by 9000-fold and 39fold at this time point for IFN\u03b1 and IL-6 respectively ( Figure 3E and F).", [["cultures", "ANATOMY", 97, 105], ["ODN 2216", "CHEMICAL", 81, 89], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 184, 188], ["IL-6", "GENE_OR_GENE_PRODUCT", 193, 197], ["IFN\u03b1", "PROTEIN", 184, 188], ["IL", "PROTEIN", 193, 195], ["ODN", "TREATMENT", 81, 84], ["the cultures", "TEST", 93, 105], ["IFN", "TEST", 184, 187], ["IL", "TEST", 193, 195], ["highest", "OBSERVATION_MODIFIER", 13, 20]]], ["The observed effects were specifically conferred by the CpG motifs comprised in the 2216 ODN, since specific control ODN 2243 only induced slight elevations in the expression of the genes tested ( Figure 3C-F) .", [["ODN", "CHEMICAL", 89, 92], ["ODN 2243", "CHEMICAL", 117, 125], ["CpG", "CHEMICAL", 56, 59], ["CpG motifs", "DNA", 56, 66], ["the CpG motifs", "TEST", 52, 66], ["specific control ODN", "TREATMENT", 100, 120], ["slight elevations", "PROBLEM", 139, 156], ["slight", "OBSERVATION_MODIFIER", 139, 145], ["elevations", "OBSERVATION_MODIFIER", 146, 156]]], ["Importantly, trypan blue exclusion experiments indicated no evidence of cellular toxicity after treatment neither with ODN 2216 nor with ODN 2243 at all concentrations tested (data not shown).ODN 2216 broadly influence the gene expression profile in primary feline immune cells of adult catsIn an effort to assess both the breadth of the effects conferred by treatment with a CpG-A and possible variability in the responses obtained in individual cats, the mRNA expression of ten genes relevant to early immune responses was measured in ODN 2216 stimulated PBMCs of fourteen cats divided in four different age groups (group 1: 10 weeks (n = 4), group 2: 1.5 years (n = 4), group 3: 7 years (n = 4), group 4: 14 years (n = 2)).", [["cellular", "ANATOMY", 72, 80], ["immune cells", "ANATOMY", 265, 277], ["PBMCs", "ANATOMY", 557, 562], ["trypan blue", "CHEMICAL", 13, 24], ["toxicity", "DISEASE", 81, 89], ["ODN 2216", "CHEMICAL", 119, 127], ["ODN 2243", "CHEMICAL", 137, 145], ["ODN 2216", "CHEMICAL", 192, 200], ["ODN 2216", "CHEMICAL", 537, 545], ["trypan blue", "CHEMICAL", 13, 24], ["trypan blue", "SIMPLE_CHEMICAL", 13, 24], ["cellular", "CELL", 72, 80], ["ODN 2216", "SIMPLE_CHEMICAL", 119, 127], ["ODN 2243", "SIMPLE_CHEMICAL", 137, 145], ["feline", "ORGANISM", 258, 264], ["immune cells", "CELL", 265, 277], ["cats", "ORGANISM", 287, 291], ["cats", "ORGANISM", 447, 451], ["ODN 2216", "CELL", 537, 545], ["PBMCs", "CELL", 557, 562], ["cats", "ORGANISM", 575, 579], ["primary feline immune cells", "CELL_TYPE", 250, 277], ["ODN 2216", "CELL_LINE", 537, 545], ["PBMCs", "CELL_TYPE", 557, 562], ["cats", "SPECIES", 287, 291], ["cats", "SPECIES", 575, 579], ["cats", "SPECIES", 287, 291], ["trypan blue exclusion experiments", "TEST", 13, 46], ["cellular toxicity", "PROBLEM", 72, 89], ["treatment", "TREATMENT", 96, 105], ["the gene expression profile", "PROBLEM", 219, 246], ["adult cats", "TEST", 281, 291], ["a CpG", "TREATMENT", 374, 379], ["fourteen cats", "TREATMENT", 566, 579], ["no evidence of", "UNCERTAINTY", 57, 71], ["cellular toxicity", "OBSERVATION", 72, 89]]], ["Only slight individual variability in gene induction was observed after 24 h stimulation of immune cells from adult cats ranging between 1.5 and 14 years of age ( Figure 2B-D) .", [["immune cells", "ANATOMY", 92, 104], ["immune cells", "CELL", 92, 104], ["cats", "ORGANISM", 116, 120], ["immune cells", "CELL_TYPE", 92, 104], ["cats", "SPECIES", 116, 120], ["slight individual variability", "PROBLEM", 5, 34], ["gene induction", "TREATMENT", 38, 52], ["immune cells", "PROBLEM", 92, 104], ["adult cats", "TEST", 110, 120], ["slight", "OBSERVATION_MODIFIER", 5, 11], ["individual", "OBSERVATION_MODIFIER", 12, 22], ["variability", "OBSERVATION_MODIFIER", 23, 34], ["gene induction", "OBSERVATION", 38, 52]]], ["Moreover, all individual IFN\u03b1 subtypes tested were induced at similar levels in the cells of four adult cats from group 2 ( Figure 2E ).", [["cells", "ANATOMY", 84, 89], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 25, 29], ["cells", "CELL", 84, 89], ["cats", "ORGANISM", 104, 108], ["IFN\u03b1", "PROTEIN", 25, 29], ["cats", "SPECIES", 104, 108], ["all individual IFN\u03b1 subtypes", "TEST", 10, 38]]], ["Increased levels of proinflammatory cytokine mRNA were also measured in most individuals of groups 2-4, with IL-6 more systematically increased than TNF\u03b1.", [["IL-6", "GENE_OR_GENE_PRODUCT", 109, 113], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 149, 153], ["proinflammatory cytokine mRNA", "RNA", 20, 49], ["IL", "PROTEIN", 109, 111], ["TNF", "PROTEIN", 149, 152], ["Increased levels of proinflammatory cytokine mRNA", "PROBLEM", 0, 49], ["IL", "TEST", 109, 111], ["proinflammatory cytokine mRNA", "OBSERVATION", 20, 49], ["increased", "OBSERVATION_MODIFIER", 134, 143]]], ["The cells from these cats indicated a typical Th1 orientation after stimulation, with enhanced transcription of IL-12 in 9/ 10 and IFN\u03b3 in 6/10 animals, together with absent or only low induction of IL-4.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["cats", "ORGANISM", 21, 25], ["IL-12", "GENE_OR_GENE_PRODUCT", 112, 117], ["10", "GENE_OR_GENE_PRODUCT", 124, 126], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 131, 135], ["IL-4", "GENE_OR_GENE_PRODUCT", 199, 203], ["IL", "PROTEIN", 112, 114], ["IFN\u03b3", "PROTEIN", 131, 135], ["IL-4", "PROTEIN", 199, 203], ["cats", "SPECIES", 21, 25], ["these cats", "TEST", 15, 25], ["IL", "TEST", 112, 114], ["typical", "OBSERVATION_MODIFIER", 38, 45], ["Th1", "OBSERVATION", 46, 49]]], ["Stimulation of PBMCs with ODN 2216 also created an optimal environment for NK cell activity, as indicated by the increases in mRNA expression of the NK cell stimulator IL-15 by up to 20-fold and of the NK cell effector Granzyme B by up to 7-fold.", [["PBMCs", "ANATOMY", 15, 20], ["NK cell", "ANATOMY", 75, 82], ["NK cell", "ANATOMY", 149, 156], ["NK cell", "ANATOMY", 202, 209], ["ODN 2216", "CHEMICAL", 26, 34], ["PBMCs", "CELL", 15, 20], ["ODN 2216", "SIMPLE_CHEMICAL", 26, 34], ["NK cell", "CELL", 75, 82], ["NK cell", "CELL", 149, 156], ["IL-15", "GENE_OR_GENE_PRODUCT", 168, 173], ["NK cell", "CELL", 202, 209], ["Granzyme B", "GENE_OR_GENE_PRODUCT", 219, 229], ["PBMCs", "CELL_TYPE", 15, 20], ["NK cell stimulator IL-15", "PROTEIN", 149, 173], ["NK cell effector Granzyme B", "PROTEIN", 202, 229], ["Stimulation of PBMCs with ODN", "TREATMENT", 0, 29], ["NK cell activity", "TEST", 75, 91], ["the NK cell stimulator IL", "TEST", 145, 170], ["Granzyme B", "TEST", 219, 229], ["NK cell activity", "OBSERVATION", 75, 91]]], ["The cells of those cats (c08, c09, c12) that had most effectively proliferated ( Figure 1A ) and/or exhibited the strongest expression of co-stimulatory molecules ( Figure 1B-E) following ODN 2216 stimulation also consistently expressed the highest mRNA levels of IFN\u03b1, IFN\u03c9, IL-6, Il-12, IL-15 and Granzyme B. PBMCs of cat c08 (group 2, Figure 1B) were also by far most responsive to stimulation with ODN 2216.", [["cells", "ANATOMY", 4, 9], ["PBMCs", "ANATOMY", 311, 316], ["ODN 2216", "CHEMICAL", 188, 196], ["ODN 2216", "CHEMICAL", 402, 410], ["cells", "CELL", 4, 9], ["cats", "ORGANISM", 19, 23], ["c12", "CELL", 35, 38], ["Figure 1B-E", "GENE_OR_GENE_PRODUCT", 165, 176], ["ODN 2216", "SIMPLE_CHEMICAL", 188, 196], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 264, 268], ["IFN\u03c9", "GENE_OR_GENE_PRODUCT", 270, 274], ["IL-6", "GENE_OR_GENE_PRODUCT", 276, 280], ["Il-12", "GENE_OR_GENE_PRODUCT", 282, 287], ["IL-15", "GENE_OR_GENE_PRODUCT", 289, 294], ["Granzyme", "GENE_OR_GENE_PRODUCT", 299, 307], ["PBMCs", "CELL", 311, 316], ["cat", "ORGANISM", 320, 323], ["c08", "ORGANISM", 324, 327], ["ODN 2216", "SIMPLE_CHEMICAL", 402, 410], ["co-stimulatory molecules", "PROTEIN", 138, 162], ["Figure 1B-E", "PROTEIN", 165, 176], ["IFN\u03b1", "PROTEIN", 264, 268], ["IFN\u03c9", "PROTEIN", 270, 274], ["IL-6", "PROTEIN", 276, 280], ["Il-12", "PROTEIN", 282, 287], ["IL-15", "PROTEIN", 289, 294], ["PBMCs", "CELL_TYPE", 311, 316], ["cat c08", "PROTEIN", 320, 327], ["cats", "SPECIES", 19, 23], ["those cats", "TEST", 13, 23], ["IFN\u03b1", "TEST", 264, 268], ["IFN\u03c9", "TEST", 270, 274], ["IL", "TEST", 276, 278], ["Il", "TEST", 282, 284], ["IL", "TEST", 289, 291], ["Granzyme B. PBMCs", "TEST", 299, 316], ["stimulation with ODN", "TREATMENT", 385, 405]]], ["When cells from kittens of group 1 were stimulated, higher individual variability was observed than in adult animals ( Figure 2A ).", [["cells", "ANATOMY", 5, 10], ["cells", "CELL", 5, 10], ["higher individual variability", "PROBLEM", 52, 81]]], ["The PBMCs of only 2 out of 4 cats from this group could be stimulated with ODN 2216 to increase mRNA expression of the tested genes.", [["PBMCs", "ANATOMY", 4, 9], ["ODN 2216", "CHEMICAL", 75, 83], ["PBMCs", "CELL", 4, 9], ["cats", "ORGANISM", 29, 33], ["ODN 2216", "SIMPLE_CHEMICAL", 75, 83], ["PBMCs", "CELL_TYPE", 4, 9], ["The PBMCs", "TEST", 0, 9], ["ODN", "TREATMENT", 75, 78]]], ["In both individuals, not only the mRNA expression of type I IFN genes was enhanced at much lower levels than observed in adult cats but the overall immune response favored a Th2 direction, characterized by upregulated IL-4 and downregulated IL-12 mRNA levels ( Figure 2A) .ODN 2216 broadly influence the gene expression profile in primary feline immune cells of adult catsIn order to determine whether a discrepancy in expression of TLR9 between the PBMCs of adult animals and kittens could play a role in these observations, mRNA levels of this gene were measured in immune cells of each cat.", [["immune cells", "ANATOMY", 346, 358], ["PBMCs", "ANATOMY", 450, 455], ["immune cells", "ANATOMY", 568, 580], ["ODN 2216", "CHEMICAL", 273, 281], ["type I IFN", "GENE_OR_GENE_PRODUCT", 53, 63], ["cats", "ORGANISM", 127, 131], ["IL-4", "GENE_OR_GENE_PRODUCT", 218, 222], ["IL-12", "GENE_OR_GENE_PRODUCT", 241, 246], ["feline", "ORGANISM", 339, 345], ["immune cells", "CELL", 346, 358], ["cats", "ORGANISM", 368, 372], ["TLR9", "GENE_OR_GENE_PRODUCT", 433, 437], ["PBMCs", "CELL", 450, 455], ["adult animals", "ORGANISM", 459, 472], ["kittens", "ORGANISM", 477, 484], ["immune cells", "CELL", 568, 580], ["cat", "ORGANISM", 589, 592], ["type I IFN genes", "DNA", 53, 69], ["IL-4", "PROTEIN", 218, 222], ["primary feline immune cells", "CELL_TYPE", 331, 358], ["TLR9", "PROTEIN", 433, 437], ["PBMCs", "CELL_TYPE", 450, 455], ["immune cells", "CELL_TYPE", 568, 580], ["cats", "SPECIES", 127, 131], ["cats", "SPECIES", 368, 372], ["cat", "SPECIES", 589, 592], ["cats", "SPECIES", 368, 372], ["type I IFN genes", "PROBLEM", 53, 69], ["upregulated IL", "TEST", 206, 220], ["downregulated IL", "TEST", 227, 243], ["mRNA levels", "TEST", 247, 258], ["the gene expression profile", "PROBLEM", 300, 327], ["adult cats", "TEST", 362, 372], ["mRNA levels", "TEST", 526, 537]]], ["Although basal TLR9 expression was similar in the PBMCs of the cats of all age groups ( Figure 2F ), ODN 2216 stimulation increased TLR9 transcription in the cells of kittens, but decreased transcription of this gene in the cells of adult cats so that differences in the mRNA levels of this receptor were significantly higher in young cats (group 1) than in adult cats of groups 2 and 3 (p = 0.0286) ( Figure 2G ).ODN 2216 induce the production of soluble molecules that activate intracellular antiviral mechanisms in feline target cellsProtective properties of type I IFN against viruses originate from their ability to trigger the production of potent antiviral proteins in nearby cells.", [["PBMCs", "ANATOMY", 50, 55], ["cells", "ANATOMY", 158, 163], ["cells", "ANATOMY", 224, 229], ["intracellular", "ANATOMY", 480, 493], ["cells", "ANATOMY", 532, 537], ["cells", "ANATOMY", 683, 688], ["ODN 2216", "CHEMICAL", 101, 109], ["ODN 2216", "CHEMICAL", 414, 422], ["TLR9", "GENE_OR_GENE_PRODUCT", 15, 19], ["PBMCs", "CELL", 50, 55], ["cats", "ORGANISM", 63, 67], ["ODN 2216", "SIMPLE_CHEMICAL", 101, 109], ["TLR9", "GENE_OR_GENE_PRODUCT", 132, 136], ["cells", "CELL", 158, 163], ["kittens", "ORGANISM", 167, 174], ["cells", "CELL", 224, 229], ["cats", "ORGANISM", 239, 243], ["cats", "ORGANISM", 335, 339], ["cats", "ORGANISM", 364, 368], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 480, 493], ["feline", "ORGANISM", 518, 524], ["cells", "CELL", 532, 537], ["type I IFN", "GENE_OR_GENE_PRODUCT", 562, 572], ["cells", "CELL", 683, 688], ["TLR9", "PROTEIN", 15, 19], ["PBMCs", "CELL_TYPE", 50, 55], ["TLR9", "PROTEIN", 132, 136], ["soluble molecules", "PROTEIN", 448, 465], ["feline target cells", "CELL_TYPE", 518, 537], ["type I IFN", "PROTEIN", 562, 572], ["antiviral proteins", "PROTEIN", 654, 672], ["nearby cells", "CELL_TYPE", 676, 688], ["cats", "SPECIES", 63, 67], ["cats", "SPECIES", 239, 243], ["cats", "SPECIES", 335, 339], ["cats", "SPECIES", 364, 368], ["basal TLR9 expression", "PROBLEM", 9, 30], ["ODN", "TREATMENT", 101, 104], ["stimulation increased TLR9 transcription", "TREATMENT", 110, 150], ["the mRNA levels", "TEST", 267, 282], ["soluble molecules", "PROBLEM", 448, 465], ["intracellular antiviral mechanisms in feline target cells", "PROBLEM", 480, 537], ["type I IFN", "PROBLEM", 562, 572], ["viruses", "PROBLEM", 581, 588], ["potent antiviral proteins", "TREATMENT", 647, 672], ["basal", "ANATOMY_MODIFIER", 9, 14], ["TLR9 expression", "OBSERVATION", 15, 30], ["intracellular antiviral", "OBSERVATION", 480, 503], ["feline target cells", "OBSERVATION", 518, 537]]], ["The expression of one of these antiviral proteins, the Mx GTPase, is known to be directly stimulated by type I IFN and can be used as marker for the induction of intracellular antiviral mechanisms by these cytokines in cats as well as in other species [19, 64] .", [["intracellular", "ANATOMY", 162, 175], ["Mx", "GENE_OR_GENE_PRODUCT", 55, 57], ["type I IFN", "GENE_OR_GENE_PRODUCT", 104, 114], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 162, 175], ["cats", "ORGANISM", 219, 223], ["antiviral proteins", "PROTEIN", 31, 49], ["Mx GTPase", "PROTEIN", 55, 64], ["type I IFN", "PROTEIN", 104, 114], ["cytokines", "PROTEIN", 206, 215], ["cats", "SPECIES", 219, 223], ["these antiviral proteins", "TREATMENT", 25, 49], ["type I IFN", "PROBLEM", 104, 114], ["intracellular antiviral mechanisms", "TREATMENT", 162, 196], ["these cytokines in cats", "PROBLEM", 200, 223]]], ["Thus, as detection of feline type I IFN on a protein level is rendered difficult by the unavailability of antibodies specifically recognizing these proteins, mRNA levels of Mx were measured in feline PBMCs after stimulation with ODN 2216, as indication for production of type I IFN.", [["PBMCs", "ANATOMY", 200, 205], ["ODN 2216", "CHEMICAL", 229, 237], ["feline", "ORGANISM", 22, 28], ["type I IFN", "GENE_OR_GENE_PRODUCT", 29, 39], ["Mx", "GENE_OR_GENE_PRODUCT", 173, 175], ["feline", "ORGANISM", 193, 199], ["PBMCs", "CELL", 200, 205], ["ODN 2216", "SIMPLE_CHEMICAL", 229, 237], ["type I IFN", "GENE_OR_GENE_PRODUCT", 271, 281], ["feline type I IFN", "PROTEIN", 22, 39], ["antibodies", "PROTEIN", 106, 116], ["Mx", "PROTEIN", 173, 175], ["feline PBMCs", "CELL_TYPE", 193, 205], ["type I IFN", "PROTEIN", 271, 281], ["feline type I IFN", "PROBLEM", 22, 39], ["a protein level", "TEST", 43, 58], ["antibodies", "PROBLEM", 106, 116], ["these proteins", "TEST", 142, 156], ["mRNA levels", "TEST", 158, 169], ["Mx", "TEST", 173, 175], ["stimulation with ODN", "TREATMENT", 212, 232], ["type I IFN", "PROBLEM", 271, 281]]], ["Transcription of Mx was significantly enhanced and remained proportional to mRNA expression of type I IFN in stimulated PBMCs of individual cats ( Figure 4AODN 2216 inhibit replication of common feline viruses in vitroFelids are frequently affected by four viruses of different families: the feline herpesvirus (FHV), calicivirus (FCV), parvovirus (FPV) and coronavirus (FCoV).", [["PBMCs", "ANATOMY", 120, 125], ["4AODN 2216", "CHEMICAL", 154, 164], ["feline viruses", "DISEASE", 195, 209], ["feline herpesvirus (FHV), calicivirus (FCV), parvovirus (FPV) and coronavirus", "DISEASE", 292, 369], ["Mx", "GENE_OR_GENE_PRODUCT", 17, 19], ["type I IFN", "GENE_OR_GENE_PRODUCT", 95, 105], ["PBMCs", "CELL", 120, 125], ["cats", "ORGANISM", 140, 144], ["Figure 4AODN 2216", "ORGANISM", 147, 164], ["feline viruses", "ORGANISM", 195, 209], ["vitroFelids", "CANCER", 213, 224], ["feline herpesvirus", "ORGANISM", 292, 310], ["FHV", "ORGANISM", 312, 315], ["calicivirus (FCV), parvovirus", "ORGANISM", 318, 347], ["FPV", "ORGANISM", 349, 352], ["coronavirus", "ORGANISM", 358, 369], ["FCoV", "CANCER", 371, 375], ["Mx", "PROTEIN", 17, 19], ["type I IFN", "PROTEIN", 95, 105], ["PBMCs", "CELL_TYPE", 120, 125], ["cats", "SPECIES", 140, 144], ["feline herpesvirus", "SPECIES", 292, 310], ["coronavirus", "SPECIES", 358, 369], ["feline herpesvirus", "SPECIES", 292, 310], ["FHV", "SPECIES", 312, 315], ["FCV", "SPECIES", 331, 334], ["FPV", "SPECIES", 349, 352], ["FCoV", "SPECIES", 371, 375], ["common feline viruses in vitroFelids", "PROBLEM", 188, 224], ["the feline herpesvirus", "PROBLEM", 288, 310], ["calicivirus (FCV", "PROBLEM", 318, 334], ["parvovirus", "PROBLEM", 337, 347], ["coronavirus", "PROBLEM", 358, 369], ["common feline", "OBSERVATION_MODIFIER", 188, 201], ["viruses", "OBSERVATION", 202, 209]]], ["Although these viruses cannot productively infect purified PBMCs in vitro, they share the ability to induce cytopathic effects (CPE) in CrFK and fcwf-4 cells.", [["PBMCs", "ANATOMY", 59, 64], ["CrFK", "ANATOMY", 136, 140], ["fcwf-4 cells", "ANATOMY", 145, 157], ["PBMCs", "CELL", 59, 64], ["CrFK", "CELL", 136, 140], ["fcwf-4 cells", "CELL", 145, 157], ["PBMCs", "CELL_TYPE", 59, 64], ["CrFK and fcwf-4 cells", "CELL_LINE", 136, 157], ["these viruses", "PROBLEM", 9, 22], ["cytopathic effects (CPE) in CrFK and fcwf-4 cells", "PROBLEM", 108, 157], ["viruses", "OBSERVATION", 15, 22]]], ["These feline cell lines, however, do not alter their mRNA levels of genes selected as markers for innate immunity upon direct treatment with ODN 2216 ( Figure 3A and B and data not shown), preventing from assessing the potential of this molecule to inhibit viral replication directly in these cells.", [["cell lines", "ANATOMY", 13, 23], ["cells", "ANATOMY", 293, 298], ["ODN 2216", "CHEMICAL", 141, 149], ["feline", "ORGANISM", 6, 12], ["cell lines", "CELL", 13, 23], ["cells", "CELL", 293, 298], ["feline cell lines", "CELL_LINE", 6, 23], ["These feline cell lines", "TREATMENT", 0, 23], ["direct treatment with ODN", "TREATMENT", 119, 144], ["this molecule", "PROBLEM", 232, 245], ["viral replication", "TREATMENT", 257, 274], ["feline cell lines", "OBSERVATION", 6, 23]]], ["Thus, CrFK and fcwf-4 cells were incubated, prior to their inoculation, with the cell-free supernatants of PBMCs mentioned above: Sup 2216, Sup 2243 and Sup Neg.", [["fcwf-4 cells", "ANATOMY", 15, 27], ["cell", "ANATOMY", 81, 85], ["supernatants", "ANATOMY", 91, 103], ["PBMCs", "ANATOMY", 107, 112], ["CrFK", "GENE_OR_GENE_PRODUCT", 6, 10], ["fcwf-4 cells", "CELL", 15, 27], ["cell", "CELL", 81, 85], ["PBMCs", "CELL", 107, 112], ["CrFK", "PROTEIN", 6, 10], ["fcwf-4 cells", "CELL_LINE", 15, 27], ["PBMCs", "CELL_TYPE", 107, 112], ["CrFK", "TEST", 6, 10], ["fcwf-4 cells", "PROBLEM", 15, 27], ["their inoculation", "TEST", 53, 70], ["the cell", "TEST", 77, 85], ["PBMCs", "TEST", 107, 112]]], ["To this aim, supernatants derived from PBMCs treated for 24 h were selected, as Sup 2216 produced by the cells of several adult cats were estimated to contain optimal type I IFN amounts at this time point, according to the induction of Mx transcription measured directly in these immune cells ( Figure 4A and 4B ).", [["supernatants", "ANATOMY", 13, 25], ["PBMCs", "ANATOMY", 39, 44], ["cells", "ANATOMY", 105, 110], ["immune cells", "ANATOMY", 280, 292], ["Sup 2216", "CHEMICAL", 80, 88], ["PBMCs", "CELL", 39, 44], ["Sup 2216", "SIMPLE_CHEMICAL", 80, 88], ["cells", "CELL", 105, 110], ["cats", "ORGANISM", 128, 132], ["type I IFN", "GENE_OR_GENE_PRODUCT", 167, 177], ["Mx", "GENE_OR_GENE_PRODUCT", 236, 238], ["immune cells", "CELL", 280, 292], ["PBMCs", "CELL_TYPE", 39, 44], ["IFN", "PROTEIN", 174, 177], ["Mx", "PROTEIN", 236, 238], ["immune cells", "CELL_TYPE", 280, 292], ["cats", "SPECIES", 128, 132], ["Mx transcription", "TREATMENT", 236, 252]]], ["CrFK and fcwf-4 target cells were then incubated with the supernatants for 24 h before inoculation, as this time span had indicated highest induction of antiviral mechanisms ( Figure 4F ).", [["fcwf-4", "ANATOMY", 9, 15], ["cells", "ANATOMY", 23, 28], ["supernatants", "ANATOMY", 58, 70], ["CrFK", "GENE_OR_GENE_PRODUCT", 0, 4], ["fcwf-4", "GENE_OR_GENE_PRODUCT", 9, 15], ["cells", "CELL", 23, 28], ["CrFK", "PROTEIN", 0, 4], ["fcwf", "PROTEIN", 9, 13], ["CrFK", "TEST", 0, 4], ["fcwf", "TEST", 9, 13], ["4 target cells", "PROBLEM", 14, 28], ["the supernatants", "TREATMENT", 54, 70], ["inoculation", "TREATMENT", 87, 98], ["antiviral mechanisms", "TREATMENT", 153, 173]]], ["The antiviral effects of the supernatants were initially tested on vesicular stomatitis virus (VSV) as control, as this virus is widely recognized for both its potential to induce CPE in cell lines of multiple species and for its particularly high sensitivity to the effects of type I IFN [65, 66] .", [["supernatants", "ANATOMY", 29, 41], ["cell lines", "ANATOMY", 187, 197], ["vesicular stomatitis", "DISEASE", 67, 87], ["CPE", "CHEMICAL", 180, 183], ["vesicular stomatitis virus", "ORGANISM", 67, 93], ["VSV", "ORGANISM", 95, 98], ["cell lines", "CELL", 187, 197], ["type I IFN", "GENE_OR_GENE_PRODUCT", 278, 288], ["cell lines", "CELL_LINE", 187, 197], ["type I IFN", "PROTEIN", 278, 288], ["vesicular stomatitis virus", "SPECIES", 67, 93], ["vesicular stomatitis virus", "SPECIES", 67, 93], ["VSV", "SPECIES", 95, 98], ["The antiviral effects", "TREATMENT", 0, 21], ["the supernatants", "TREATMENT", 25, 41], ["vesicular stomatitis virus", "PROBLEM", 67, 93], ["this virus", "PROBLEM", 115, 125], ["CPE in cell lines", "PROBLEM", 180, 197], ["multiple species", "PROBLEM", 201, 217], ["antiviral", "OBSERVATION", 4, 13], ["cell lines", "OBSERVATION", 187, 197], ["multiple", "OBSERVATION_MODIFIER", 201, 209], ["species", "OBSERVATION", 210, 217]]], ["When the Sup 2216 derived from the PBMCs of eight adult cats that had broadly responded to in vitro ODN 2216 stimulation ( Figure 2B and C, groups 2 and 3) were incubated with fcwf-4 cells prior to their inoculation, significant inhibition of VSV replication was observed (p = 0.0039) ( Figure 5A ).", [["PBMCs", "ANATOMY", 35, 40], ["fcwf-4 cells", "ANATOMY", 176, 188], ["ODN 2216", "CHEMICAL", 100, 108], ["PBMCs", "CELL", 35, 40], ["cats", "ORGANISM", 56, 60], ["fcwf-4 cells", "CELL", 176, 188], ["VSV", "ORGANISM", 243, 246], ["Sup 2216", "CELL_LINE", 9, 17], ["PBMCs", "CELL_TYPE", 35, 40], ["cats", "SPECIES", 56, 60], ["VSV", "SPECIES", 243, 246], ["vitro ODN", "TREATMENT", 94, 103], ["their inoculation", "TEST", 198, 215], ["VSV replication", "TREATMENT", 243, 258], ["VSV replication", "OBSERVATION", 243, 258]]], ["The replication of this virus was also to some degree repressed by Sup 2243 (p = 0.0078), an observation Table 1 ).", [["this virus", "PROBLEM", 19, 29]]], ["Both Sup 2243 and Sup Neg failed to inhibit replication of this heterogeneous group of feline viruses, underlining the essential role of the 2216 molecule in conferring the observed effects.", [["Sup 2243", "CHEMICAL", 5, 13], ["feline viruses", "DISEASE", 87, 101], ["Sup 2243", "GENE_OR_GENE_PRODUCT", 5, 13], ["feline", "ORGANISM", 87, 93], ["2216 molecule", "PROTEIN", 141, 154], ["feline viruses", "PROBLEM", 87, 101], ["feline viruses", "OBSERVATION", 87, 101]]], ["Importantly, cells stimulated with ODN 2216 directly did not indicate any resistance to viral replication, in concordance to their impaired response to this molecule already measured on a genetic level ( Figure 3A and B and data not shown).", [["cells", "ANATOMY", 13, 18], ["ODN 2216", "CHEMICAL", 35, 43], ["cells", "CELL", 13, 18], ["ODN 2216", "SIMPLE_CHEMICAL", 35, 43], ["ODN", "TREATMENT", 35, 38], ["viral replication", "TREATMENT", 88, 105], ["a genetic level", "TEST", 186, 201], ["viral replication", "OBSERVATION", 88, 105]]], ["With respect to the younger cats, the Sup 2216 of those 2 kittens whose cells responded to ODN 2216 stimulation (Figure 2A , group 1) could also inhibit both VSV and FCV on fcwf-4 cells, while the supernatants derived from the PBMCs of the other 2 kittens indicated no inhibition potential on these viruses ( Figure 5K and L).", [["cells", "ANATOMY", 72, 77], ["fcwf-4 cells", "ANATOMY", 173, 185], ["supernatants", "ANATOMY", 197, 209], ["PBMCs", "ANATOMY", 227, 232], ["ODN 2216", "CHEMICAL", 91, 99], ["cats", "ORGANISM", 28, 32], ["kittens", "ORGANISM", 58, 65], ["cells", "CELL", 72, 77], ["ODN 2216", "SIMPLE_CHEMICAL", 91, 99], ["VSV", "ORGANISM", 158, 161], ["FCV", "ORGANISM", 166, 169], ["fcwf-4 cells", "CELL", 173, 185], ["PBMCs", "CELL", 227, 232], ["kittens", "ORGANISM", 248, 255], ["PBMCs", "CELL_TYPE", 227, 232], ["cats", "SPECIES", 28, 32], ["VSV", "SPECIES", 158, 161], ["FCV", "SPECIES", 166, 169], ["ODN", "TREATMENT", 91, 94], ["no", "UNCERTAINTY", 266, 268]]], ["Altogether, the viral suppression potential of Sup 2216 from all the cats could be compared to that conferred by treatment of the cells with 10 to 100U rfeIFN\u03b1, a quantity determined in titration experiments of rfeIFN\u03b1 conducted together with the viral inhibition assays (data not shown).ODN 2216 inhibit replication of common feline viruses in vitroThe differential inhibition of the viruses tested by the same supernatants is reflected by the distinct viral inhibition ratios observed ( Figure 5B -E and Table 1 ).", [["cells", "ANATOMY", 130, 135], ["supernatants", "ANATOMY", 412, 424], ["Sup 2216", "CHEMICAL", 47, 55], ["ODN 2216", "CHEMICAL", 288, 296], ["feline viruses", "DISEASE", 327, 341], ["Sup 2216", "CHEMICAL", 47, 55], ["Sup 2216", "CELL", 47, 55], ["cats", "ORGANISM", 69, 73], ["cells", "CELL", 130, 135], ["rfeIFN\u03b1", "GENE_OR_GENE_PRODUCT", 152, 159], ["rfeIFN\u03b1", "GENE_OR_GENE_PRODUCT", 211, 218], ["ODN 2216", "SIMPLE_CHEMICAL", 288, 296], ["feline", "ORGANISM", 327, 333], ["rfeIFN\u03b1", "PROTEIN", 211, 218], ["cats", "SPECIES", 69, 73], ["feline", "SPECIES", 327, 333], ["the cells", "PROBLEM", 126, 135], ["the viral inhibition assays", "TEST", 243, 270], ["common feline viruses", "PROBLEM", 320, 341], ["the viruses", "PROBLEM", 381, 392], ["the distinct viral inhibition ratios", "PROBLEM", 441, 477], ["Figure 5B", "TEST", 489, 498], ["common feline", "OBSERVATION_MODIFIER", 320, 333], ["viruses", "OBSERVATION", 334, 341], ["differential", "OBSERVATION_MODIFIER", 354, 366], ["inhibition", "OBSERVATION_MODIFIER", 367, 377], ["viruses", "OBSERVATION", 385, 392], ["distinct", "OBSERVATION_MODIFIER", 445, 453], ["viral inhibition", "OBSERVATION", 454, 470]]], ["Sensitivity of each virus to rfeIFN\u03b1 correlated with sensitivity to the Sup 2216 and induction of Mx in target cells by the supernatants highly correlated with the inhibition of all viruses ( Figure 5F-I) .", [["cells", "ANATOMY", 111, 116], ["supernatants", "ANATOMY", 124, 136], ["Sup 2216", "CHEMICAL", 72, 80], ["rfeIFN\u03b1", "GENE_OR_GENE_PRODUCT", 29, 36], ["Mx", "GENE_OR_GENE_PRODUCT", 98, 100], ["cells", "CELL", 111, 116], ["rfeIFN\u03b1", "PROTEIN", 29, 36], ["Mx", "DNA", 98, 100], ["target cells", "CELL_TYPE", 104, 116], ["each virus", "PROBLEM", 15, 25], ["induction of Mx in target cells", "TREATMENT", 85, 116], ["the supernatants", "TEST", 120, 136]]], ["Finally, Sup 2216 derived from PBMCs of cats c08, whose cells had indicated strong responsiveness to stimulation with ODN 2216 in previous experiments, most efficiently inhibited the replication of all viruses.ODN 2216 inhibit replication of common feline viruses in vitroSimilar results were notably obtained when the supernatants of PBMCs derived from all cats were incubated with CrFK cells prior to their inoculation with all the above-mentioned viruses (data not shown).", [["PBMCs", "ANATOMY", 31, 36], ["cells", "ANATOMY", 56, 61], ["supernatants", "ANATOMY", 319, 331], ["PBMCs", "ANATOMY", 335, 340], ["CrFK cells", "ANATOMY", 383, 393], ["Sup 2216", "CHEMICAL", 9, 17], ["ODN 2216", "CHEMICAL", 118, 126], ["ODN 2216", "CHEMICAL", 210, 218], ["Sup 2216", "CELL", 9, 17], ["PBMCs", "CELL", 31, 36], ["cats", "ORGANISM", 40, 44], ["c08", "GENE_OR_GENE_PRODUCT", 45, 48], ["cells", "CELL", 56, 61], ["ODN 2216", "SIMPLE_CHEMICAL", 118, 126], ["ODN 2216", "SIMPLE_CHEMICAL", 210, 218], ["feline", "ORGANISM", 249, 255], ["PBMCs", "CELL", 335, 340], ["cats", "ORGANISM", 358, 362], ["CrFK cells", "CELL", 383, 393], ["Sup 2216", "PROTEIN", 9, 17], ["PBMCs", "CELL_TYPE", 31, 36], ["PBMCs", "CELL_TYPE", 335, 340], ["CrFK cells", "CELL_LINE", 383, 393], ["cats", "SPECIES", 40, 44], ["cats", "SPECIES", 358, 362], ["stimulation with ODN", "TREATMENT", 101, 121], ["ODN", "TREATMENT", 210, 213], ["common feline viruses", "PROBLEM", 242, 263], ["PBMCs", "TEST", 335, 340], ["CrFK cells", "PROBLEM", 383, 393], ["their inoculation", "TEST", 403, 420], ["all viruses", "OBSERVATION", 198, 209], ["common feline", "OBSERVATION_MODIFIER", 242, 255]]], ["This cell line has previously indicated less sensitivity to the antiviral effects of type I IFN [66] and generally 10-fold higher amounts of rfeIFN\u03b1 were found in titration experiments to be required for the inhibition of all five viruses.", [["cell line", "ANATOMY", 5, 14], ["cell line", "CELL", 5, 14], ["type I IFN", "GENE_OR_GENE_PRODUCT", 85, 95], ["rfeIFN\u03b1", "GENE_OR_GENE_PRODUCT", 141, 148], ["rfeIFN\u03b1", "PROTEIN", 141, 148], ["This cell line", "TREATMENT", 0, 14], ["type I IFN", "PROBLEM", 85, 95], ["titration experiments", "TREATMENT", 163, 184], ["cell line", "OBSERVATION", 5, 14], ["less sensitivity", "OBSERVATION_MODIFIER", 40, 56], ["antiviral", "OBSERVATION", 64, 73]]], ["Concordantly, average fold viral inhibition in CrFK cells by the Sup 2216 was approximately half that observed in fcwf-4 cells.ODN 2216 inhibits replication of a retrovirus in vitroThe life cycle of retroviruses is characterized by the reverse transcription of their genomic RNA into DNA and subsequent integration of this viral DNA as provirus into the genome of the host, causing permanent infection most often accompanied by persistent virus production by infected cells.", [["CrFK cells", "ANATOMY", 47, 57], ["fcwf-4 cells", "ANATOMY", 114, 126], ["cells", "ANATOMY", 468, 473], ["Sup 2216", "CHEMICAL", 65, 73], ["ODN 2216", "CHEMICAL", 127, 135], ["infection", "DISEASE", 392, 401], ["Sup 2216", "CHEMICAL", 65, 73], ["CrFK cells", "CELL", 47, 57], ["fcwf-4 cells", "CELL", 114, 126], ["ODN 2216", "SIMPLE_CHEMICAL", 127, 135], ["retrovirus", "ORGANISM", 162, 172], ["retroviruses", "ORGANISM", 199, 211], ["DNA", "CELLULAR_COMPONENT", 284, 287], ["DNA", "CELLULAR_COMPONENT", 329, 332], ["cells", "CELL", 468, 473], ["CrFK cells", "CELL_LINE", 47, 57], ["fcwf-4 cells", "CELL_LINE", 114, 126], ["genomic RNA", "RNA", 267, 278], ["viral DNA", "DNA", 323, 332], ["infected cells", "CELL_TYPE", 459, 473], ["average fold viral inhibition in CrFK cells", "PROBLEM", 14, 57], ["a retrovirus in vitro", "TREATMENT", 160, 181], ["retroviruses", "TREATMENT", 199, 211], ["this viral DNA", "PROBLEM", 318, 332], ["permanent infection", "PROBLEM", 382, 401], ["persistent virus production", "PROBLEM", 428, 455], ["infected cells", "PROBLEM", 459, 473], ["viral inhibition", "OBSERVATION", 27, 43], ["retroviruses", "OBSERVATION", 199, 211], ["permanent", "OBSERVATION_MODIFIER", 382, 391], ["infection", "OBSERVATION", 392, 401], ["persistent", "OBSERVATION_MODIFIER", 428, 438], ["virus", "OBSERVATION", 439, 444], ["infected cells", "OBSERVATION", 459, 473]]], ["The feline leukemia virus (FeLV), a gammaretrovirus that can be propagated on FEA cells in vitro, affects domestic cats worldwide.", [["FEA cells", "ANATOMY", 78, 87], ["feline leukemia virus", "DISEASE", 4, 25], ["feline leukemia virus", "ORGANISM", 4, 25], ["FeLV", "ORGANISM", 27, 31], ["FEA cells", "CELL", 78, 87], ["cats", "ORGANISM", 115, 119], ["FEA cells", "CELL_LINE", 78, 87], ["feline leukemia virus", "SPECIES", 4, 25], ["cats", "SPECIES", 115, 119], ["feline leukemia virus", "SPECIES", 4, 25], ["FeLV", "SPECIES", 27, 31], ["The feline leukemia virus (FeLV)", "PROBLEM", 0, 32], ["a gammaretrovirus", "PROBLEM", 34, 51], ["feline leukemia virus", "OBSERVATION", 4, 25]]], ["As viral replication in chronically infected cats can be lowered by treatment with IFN\u03b1 [67] , the potential of Sup 2216 produced by the PBMCs of five adult cats (c06 and c08 from group 2; c09, c10, c12 from group 3) to inhibit productive infection of FEA cells was analyzed.", [["PBMCs", "ANATOMY", 137, 142], ["FEA cells", "ANATOMY", 252, 261], ["Sup 2216", "CHEMICAL", 112, 120], ["infection", "DISEASE", 239, 248], ["Sup 2216", "CHEMICAL", 112, 120], ["cats", "ORGANISM", 45, 49], ["Sup 2216", "SIMPLE_CHEMICAL", 112, 120], ["PBMCs", "CELL", 137, 142], ["cats", "ORGANISM", 157, 161], ["c09", "ORGANISM", 189, 192], ["c10", "ORGANISM", 194, 197], ["FEA cells", "CELL", 252, 261], ["IFN", "PROTEIN", 83, 86], ["PBMCs", "CELL_TYPE", 137, 142], ["FEA cells", "CELL_LINE", 252, 261], ["cats", "SPECIES", 45, 49], ["cats", "SPECIES", 157, 161], ["viral replication in chronically infected cats", "TREATMENT", 3, 49], ["the PBMCs", "TEST", 133, 142], ["c09", "TEST", 189, 192], ["c10", "TEST", 194, 197], ["productive infection of FEA cells", "PROBLEM", 228, 261], ["chronically", "OBSERVATION_MODIFIER", 24, 35], ["infected", "OBSERVATION", 36, 44], ["productive", "OBSERVATION_MODIFIER", 228, 238], ["infection", "OBSERVATION", 239, 248], ["FEA cells", "OBSERVATION", 252, 261]]], ["In initial experiments, this cell line exhibited similar responses as fcwf-4 and CrFK cells to both direct treatment with ODN 2216 and incubation with the different supernatants ( Figure 3A , 4C and D and data not shown).", [["cell line", "ANATOMY", 29, 38], ["fcwf-4", "ANATOMY", 70, 76], ["CrFK cells", "ANATOMY", 81, 91], ["supernatants", "ANATOMY", 165, 177], ["ODN 2216", "CHEMICAL", 122, 130], ["cell line", "CELL", 29, 38], ["fcwf-4", "CELL", 70, 76], ["CrFK cells", "CELL", 81, 91], ["ODN 2216", "SIMPLE_CHEMICAL", 122, 130], ["cell line", "CELL_LINE", 29, 38], ["fcwf-4", "CELL_LINE", 70, 76], ["CrFK cells", "CELL_LINE", 81, 91], ["this cell line", "TREATMENT", 24, 38], ["fcwf", "TEST", 70, 74], ["CrFK cells", "PROBLEM", 81, 91], ["ODN", "TREATMENT", 122, 125], ["incubation", "TREATMENT", 135, 145], ["4C and D and data", "TEST", 192, 209]]], ["Compared to incubation with medium alone, treatment of FEA cells with Sup 2216 for 24 h prior to inoculation with FeLV followed by repetitive treatments of the cells with this supernatant every 2 days thereafter significantly reduced viral RNA (p < 0.05) and DNA (p < 0.05) Figure 6A and B).", [["FEA cells", "ANATOMY", 55, 64], ["cells", "ANATOMY", 160, 165], ["supernatant", "ANATOMY", 176, 187], ["Sup 2216", "CHEMICAL", 70, 78], ["Sup 2216", "CHEMICAL", 70, 78], ["FEA cells", "CELL", 55, 64], ["Sup 2216", "CELL", 70, 78], ["FeLV", "ORGANISM", 114, 118], ["cells", "CELL", 160, 165], ["DNA", "CELLULAR_COMPONENT", 259, 262], ["B", "GENE_OR_GENE_PRODUCT", 288, 289], ["FEA cells", "CELL_LINE", 55, 64], ["viral RNA", "RNA", 234, 243], ["FeLV", "SPECIES", 114, 118], ["FEA cells", "PROBLEM", 55, 64], ["FeLV", "TREATMENT", 114, 118], ["repetitive treatments of the cells", "TREATMENT", 131, 165], ["this supernatant", "TREATMENT", 171, 187], ["significantly reduced viral RNA", "PROBLEM", 212, 243], ["DNA", "TEST", 259, 262]]], ["The antiviral potential of the supernatants from the individual cats was very similar; however the best results were conferred by the Sup 2216 derived from cells of c08 (depicted in Figure 6A and B).The kinetic curve of viral RNA loads in cultures of cells treated with Sup 2216 of this cat was similar to those obtained in cells treated with 50U rfeIFN\u03b1 (data not shown).", [["supernatants", "ANATOMY", 31, 43], ["cells", "ANATOMY", 156, 161], ["cultures", "ANATOMY", 239, 247], ["cells", "ANATOMY", 251, 256], ["cells", "ANATOMY", 324, 329], ["Sup 2216", "CHEMICAL", 134, 142], ["Sup 2216", "CHEMICAL", 270, 278], ["Sup 2216", "CHEMICAL", 270, 278], ["cats", "ORGANISM", 64, 68], ["cells", "CELL", 156, 161], ["cells", "CELL", 251, 256], ["cat", "ORGANISM", 287, 290], ["cells", "CELL", 324, 329], ["Sup 2216", "PROTEIN", 134, 142], ["50U rfeIFN\u03b1", "PROTEIN", 343, 354], ["cats", "SPECIES", 64, 68], ["the individual cats", "TEST", 49, 68], ["The kinetic curve", "TEST", 199, 216], ["viral RNA loads in cultures of cells", "PROBLEM", 220, 256], ["antiviral", "OBSERVATION_MODIFIER", 4, 13], ["viral RNA loads", "OBSERVATION", 220, 235]]], ["Also, treatment of the cells with ODN 2216 directly affected neither viral RNA nor viral DNA loads measured in the supernatants and the cells respectively (data not shown).", [["cells", "ANATOMY", 23, 28], ["supernatants", "ANATOMY", 115, 127], ["cells", "ANATOMY", 136, 141], ["ODN 2216", "CHEMICAL", 34, 42], ["cells", "CELL", 23, 28], ["ODN 2216", "SIMPLE_CHEMICAL", 34, 42], ["DNA", "CELLULAR_COMPONENT", 89, 92], ["cells", "CELL", 136, 141], ["viral RNA", "RNA", 69, 78], ["the cells", "PROBLEM", 19, 28], ["ODN", "TREATMENT", 34, 37], ["viral RNA", "TEST", 69, 78], ["viral DNA loads", "TEST", 83, 98], ["viral RNA", "OBSERVATION", 69, 78], ["viral DNA loads", "OBSERVATION", 83, 98]]], ["Mx mRNA expression was 80-fold higher in the Sup 2216 treated cells than in all controls 8 days post inoculation, indicating the ability of these supernatants to sustain antiviral mechanisms when applied to the cells repeatedly ( Figure 6C ).", [["Sup 2216", "ANATOMY", 45, 53], ["cells", "ANATOMY", 62, 67], ["supernatants", "ANATOMY", 146, 158], ["cells", "ANATOMY", 211, 216], ["Sup 2216", "CHEMICAL", 45, 53], ["Sup 2216", "CHEMICAL", 45, 53], ["Mx", "GENE_OR_GENE_PRODUCT", 0, 2], ["Sup 2216", "CELL", 45, 53], ["cells", "CELL", 62, 67], ["cells", "CELL", 211, 216], ["Mx mRNA", "RNA", 0, 7], ["Sup 2216 treated cells", "CELL_LINE", 45, 67], ["Mx mRNA expression", "TEST", 0, 18], ["inoculation", "PROBLEM", 101, 112], ["these supernatants", "TREATMENT", 140, 158], ["antiviral mechanisms", "TREATMENT", 170, 190]]], ["Furthermore at this time point, the Sup 2216 treated cells exhibited significantly lower viral DNA loads (p = 0.0313) and produced significantly less virus (p = 0.0313) than cells treated with Sup 2243, Sup Neg or medium alone ( Figure 6D and E).", [["cells", "ANATOMY", 53, 58], ["cells", "ANATOMY", 174, 179], ["Sup 2216", "CHEMICAL", 36, 44], ["Sup 2243", "CHEMICAL", 193, 201], ["Sup 2216", "CHEMICAL", 36, 44], ["Sup 2243", "CHEMICAL", 193, 201], ["cells", "CELL", 53, 58], ["DNA", "CELLULAR_COMPONENT", 95, 98], ["cells", "CELL", 174, 179], ["Sup 2243", "SIMPLE_CHEMICAL", 193, 201], ["Sup 2216 treated cells", "CELL_LINE", 36, 58], ["significantly lower viral DNA loads", "PROBLEM", 69, 104], ["significantly less virus", "PROBLEM", 131, 155]]], ["The extent of Mx transcription conferred by the Sup 2216 of the cats strongly correlated with lower provirus (p = 0.0053) and virus (p = 0.0012) loads measured in the FEA cells and supernatants respectively on day 8 post inoculation (p = 0.0053).", [["FEA cells", "ANATOMY", 167, 176], ["supernatants", "ANATOMY", 181, 193], ["Mx", "GENE_OR_GENE_PRODUCT", 14, 16], ["Sup 2216", "GENE_OR_GENE_PRODUCT", 48, 56], ["cats", "ORGANISM", 64, 68], ["FEA cells", "CELL", 167, 176], ["Mx", "PROTEIN", 14, 16], ["Sup 2216", "DNA", 48, 56], ["FEA cells", "CELL_TYPE", 167, 176], ["cats", "SPECIES", 64, 68], ["Mx transcription", "TREATMENT", 14, 30], ["lower provirus", "PROBLEM", 94, 108], ["virus", "PROBLEM", 126, 131], ["FEA cells", "OBSERVATION", 167, 176]]], ["Also, the highest Mx mRNA levels in target cells were conferred by Sup 2216 of cat c08 and reflected by the lowest viral and proviral loads measured at this time point in our experiments.ODN 2216 induces an antiviral state in the domestic cat in vivoIn a final step, the induction of antiviral responses by ODN 2216 was measured in vivo and characterized using ex vivo assays.", [["cells", "ANATOMY", 43, 48], ["ODN 2216", "CHEMICAL", 187, 195], ["ODN 2216", "CHEMICAL", 307, 315], ["Mx", "GENE_OR_GENE_PRODUCT", 18, 20], ["cells", "CELL", 43, 48], ["cat", "ORGANISM", 79, 82], ["c08", "GENE_OR_GENE_PRODUCT", 83, 86], ["cat", "ORGANISM", 239, 242], ["ODN 2216", "SIMPLE_CHEMICAL", 307, 315], ["Mx mRNA", "RNA", 18, 25], ["target cells", "CELL_TYPE", 36, 48], ["cat c08", "PROTEIN", 79, 86], ["the highest Mx mRNA levels", "TEST", 6, 32], ["cat c08", "TEST", 79, 86], ["the lowest viral and proviral loads", "PROBLEM", 104, 139], ["ex vivo assays", "TEST", 361, 375], ["proviral loads", "OBSERVATION", 125, 139], ["antiviral state", "OBSERVATION", 207, 222]]], ["The molecule was administered once subcutaneously to two cats (c07 and c08), while two other cats (c05 and c06) received endotoxin-free PBS as a negative control.", [["subcutaneously", "ANATOMY", 35, 49], ["endotoxin", "CHEMICAL", 121, 130], ["cats", "ORGANISM", 57, 61], ["cats", "ORGANISM", 93, 97], ["endotoxin", "SIMPLE_CHEMICAL", 121, 130], ["endotoxin", "PROTEIN", 121, 130], ["cats", "SPECIES", 57, 61], ["cats", "SPECIES", 93, 97], ["The molecule", "TREATMENT", 0, 12], ["two other cats", "TEST", 83, 97], ["endotoxin-free PBS", "TREATMENT", 121, 139], ["molecule", "OBSERVATION", 4, 12]]], ["The injections were well tolerated by all cats: no rise in body temperature, no local reactions at the injection site and no other undesired side effects were noted.", [["body", "ANATOMY", 59, 63], ["cats", "ORGANISM", 42, 46], ["body", "ORGANISM_SUBDIVISION", 59, 63], ["The injections", "TREATMENT", 0, 14], ["rise in body temperature", "PROBLEM", 51, 75], ["local reactions at the injection site", "PROBLEM", 80, 117], ["other undesired side effects", "PROBLEM", 125, 153], ["no", "UNCERTAINTY", 48, 50], ["rise", "OBSERVATION_MODIFIER", 51, 55], ["no", "UNCERTAINTY", 77, 79], ["local", "OBSERVATION_MODIFIER", 80, 85], ["reactions", "OBSERVATION", 86, 95]]], ["Absolute monocyte counts increased 1.5 to 2-fold in the first 12 h in cats that had received ODN 2216 (data not shown).", [["monocyte", "ANATOMY", 9, 17], ["ODN 2216", "CHEMICAL", 93, 101], ["monocyte", "CELL", 9, 17], ["cats", "ORGANISM", 70, 74], ["Absolute monocyte counts", "TEST", 0, 24], ["ODN", "TREATMENT", 93, 96], ["monocyte counts", "OBSERVATION", 9, 24]]], ["No other treatment-specific alterations were noted in hematological values throughout the experiment.", [["hematological", "ANATOMY", 54, 67], ["other treatment", "TREATMENT", 3, 18], ["specific alterations", "PROBLEM", 19, 39], ["treatment", "OBSERVATION", 9, 18]]], ["Mx expression was measured in blood at early time points after injection as marker for the induction of antiviral immune processes. mRNA levels of Mx increased by 8.8 and 3.8-fold within 24 h in both treated cats and decreased gradually thereafter until 192 h post treatment ( Figure 7A ).", [["blood", "ANATOMY", 30, 35], ["Mx", "GENE_OR_GENE_PRODUCT", 0, 2], ["blood", "ORGANISM_SUBSTANCE", 30, 35], ["Mx", "GENE_OR_GENE_PRODUCT", 147, 149], ["cats", "ORGANISM", 208, 212], ["Mx", "PROTEIN", 0, 2], ["mRNA", "RNA", 132, 136], ["Mx", "PROTEIN", 147, 149], ["injection", "TREATMENT", 63, 72], ["antiviral immune processes", "TREATMENT", 104, 130], ["mRNA levels", "TEST", 132, 143], ["Mx", "TEST", 147, 149], ["treatment", "TREATMENT", 265, 274], ["antiviral immune", "OBSERVATION", 104, 120], ["increased", "OBSERVATION_MODIFIER", 150, 159], ["decreased", "OBSERVATION_MODIFIER", 217, 226]]], ["In accordance with observations from in vitro experiments, cat c08 exhibited a stronger response to ODN 2216 than cat c07.", [["ODN 2216", "CHEMICAL", 100, 108], ["cat", "ORGANISM", 59, 62], ["c08", "GENE_OR_GENE_PRODUCT", 63, 66], ["ODN 2216", "SIMPLE_CHEMICAL", 100, 108], ["cat", "ORGANISM", 114, 117], ["cat c08", "PROTEIN", 59, 66], ["cat c08", "TEST", 59, 66]]], ["No increase in Mx expression was observed in the blood of the control cats (c05 and c06).", [["blood", "ANATOMY", 49, 54], ["Mx", "GENE_OR_GENE_PRODUCT", 15, 17], ["blood", "ORGANISM_SUBSTANCE", 49, 54], ["cats", "ORGANISM", 70, 74], ["Mx", "PROTEIN", 15, 17], ["cats", "SPECIES", 70, 74], ["increase in Mx expression", "PROBLEM", 3, 28], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["Mx expression", "OBSERVATION", 15, 28]]], ["In a further experiment, plasma was collected from all four cats at regular intervals post injection and was utilized in an in vitro inhibition assay.", [["plasma", "ANATOMY", 25, 31], ["plasma", "ORGANISM_SUBSTANCE", 25, 31], ["cats", "ORGANISM", 60, 64]]], ["The plasma obtained from both treated cats 24 and 48 h after administration of the molecule was able to inhibit replication of FCV in vitro ( Figure 7B ).", [["plasma", "ANATOMY", 4, 10], ["plasma", "ORGANISM_SUBSTANCE", 4, 10], ["cats", "ORGANISM", 38, 42], ["FCV", "ORGANISM", 127, 130], ["cats", "SPECIES", 38, 42], ["FCV", "SPECIES", 127, 130], ["The plasma", "TEST", 0, 10], ["the molecule", "TREATMENT", 79, 91]]], ["In contrast, plasma from untreated cats seemed to slightly enhance the susceptibility of target cells to FCV inoculation.DiscussionIn the present study, we conducted both in vitro and in vivo experiments that characterize immunomodulatory and antiviral effects of a CpG-A molecule in the domestic cat.", [["plasma", "ANATOMY", 13, 19], ["cells", "ANATOMY", 96, 101], ["CpG-A", "CHEMICAL", 266, 271], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["cats", "ORGANISM", 35, 39], ["cells", "CELL", 96, 101], ["FCV", "ORGANISM", 105, 108], ["CpG-A molecule", "GENE_OR_GENE_PRODUCT", 266, 280], ["cat", "ORGANISM", 297, 300], ["target cells", "CELL_TYPE", 89, 101], ["cats", "SPECIES", 35, 39], ["cat", "SPECIES", 297, 300], ["FCV", "SPECIES", 105, 108], ["plasma from untreated cats", "PROBLEM", 13, 39], ["the present study", "TEST", 134, 151], ["a CpG", "TREATMENT", 264, 269]]], ["We show that ODN 2216, the first described CpG-A [12] , can upregulate the expression of a series of genes in feline immune cells that play important roles in early responses to viruses.", [["immune cells", "ANATOMY", 117, 129], ["ODN 2216", "CHEMICAL", 13, 21], ["ODN 2216", "SIMPLE_CHEMICAL", 13, 21], ["CpG-A [12]", "GENE_OR_GENE_PRODUCT", 43, 53], ["feline", "ORGANISM", 110, 116], ["immune cells", "CELL", 117, 129], ["feline immune cells", "CELL_TYPE", 110, 129], ["genes in feline immune cells", "TREATMENT", 101, 129], ["feline immune cells", "OBSERVATION", 110, 129]]], ["Soluble molecules produced by feline PBMCs upon ODN 2216 stimulation significantly increased resistance of various feline target cell lines to propagation of viruses from five different families, namely FCV, FPV, FHV, FCoV and FeLV.", [["PBMCs", "ANATOMY", 37, 42], ["cell lines", "ANATOMY", 129, 139], ["ODN 2216", "CHEMICAL", 48, 56], ["feline", "ORGANISM", 30, 36], ["PBMCs", "CELL", 37, 42], ["ODN 2216", "SIMPLE_CHEMICAL", 48, 56], ["feline", "ORGANISM", 115, 121], ["cell lines", "CELL", 129, 139], ["FCV", "ORGANISM", 203, 206], ["FPV", "ORGANISM", 208, 211], ["FHV", "GENE_OR_GENE_PRODUCT", 213, 216], ["FCoV", "GENE_OR_GENE_PRODUCT", 218, 222], ["FeLV", "ORGANISM", 227, 231], ["Soluble molecules", "PROTEIN", 0, 17], ["feline PBMCs", "CELL_TYPE", 30, 42], ["feline target cell lines", "CELL_LINE", 115, 139], ["feline", "SPECIES", 30, 36], ["feline", "SPECIES", 30, 36], ["FCV", "SPECIES", 203, 206], ["FPV", "SPECIES", 208, 211], ["FHV", "SPECIES", 213, 216], ["FCoV", "SPECIES", 218, 222], ["ODN", "TREATMENT", 48, 51], ["various feline target cell lines", "TREATMENT", 107, 139], ["viruses", "PROBLEM", 158, 165], ["various feline", "OBSERVATION_MODIFIER", 107, 121], ["target cell lines", "OBSERVATION", 122, 139], ["viruses", "OBSERVATION", 158, 165], ["FCoV", "OBSERVATION", 218, 222]]], ["The observed repression of viral replication highly correlated with the mRNA expression of type I IFN genes in stimulated PBMCs as well as the induction, prior to inoculation, of antiviral mechanisms in the target cells.", [["PBMCs", "ANATOMY", 122, 127], ["cells", "ANATOMY", 214, 219], ["type I IFN", "GENE_OR_GENE_PRODUCT", 91, 101], ["PBMCs", "CELL", 122, 127], ["cells", "CELL", 214, 219], ["type I IFN genes", "DNA", 91, 107], ["PBMCs", "CELL_TYPE", 122, 127], ["target cells", "CELL_TYPE", 207, 219], ["viral replication", "PROBLEM", 27, 44], ["type I IFN genes in stimulated PBMCs", "PROBLEM", 91, 127], ["inoculation", "TREATMENT", 163, 174], ["antiviral mechanisms", "PROBLEM", 179, 199], ["viral replication", "OBSERVATION", 27, 44], ["target cells", "OBSERVATION", 207, 219]]], ["Furthermore, a single administration of ODN 2216 significantly increased the expression of Mx in the blood of treated cats.", [["blood", "ANATOMY", 101, 106], ["ODN 2216", "CHEMICAL", 40, 48], ["ODN 2216", "CHEMICAL", 40, 48], ["ODN 2216", "SIMPLE_CHEMICAL", 40, 48], ["Mx", "GENE_OR_GENE_PRODUCT", 91, 93], ["blood", "ORGANISM_SUBSTANCE", 101, 106], ["cats", "ORGANISM", 118, 122], ["Mx", "PROTEIN", 91, 93], ["cats", "SPECIES", 118, 122], ["a single administration of ODN", "TREATMENT", 13, 43]]], ["Plasma from these animals could also inhibit replication of FCV in vitro.", [["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["FCV", "ORGANISM", 60, 63], ["FCV", "SPECIES", 60, 63], ["FCV", "OBSERVATION", 60, 63]]], ["Our data underline the prophylactic potential of ODN 2216 in an outbred species as a stand-alone agent and against a large range of viral pathogens simultaneously.", [["ODN 2216", "CHEMICAL", 49, 57], ["ODN 2216", "SIMPLE_CHEMICAL", 49, 57], ["Our data", "TEST", 0, 8], ["ODN", "TREATMENT", 49, 52], ["a stand-alone agent", "TREATMENT", 83, 102], ["viral pathogens", "PROBLEM", 132, 147], ["large", "OBSERVATION_MODIFIER", 117, 122], ["viral pathogens", "OBSERVATION", 132, 147]]], ["Cats may highly benefit from such a molecule when placed in environments with strong infectious pressure such as catteries, shelters or pet shows.DiscussionCells of the feline immune system were strongly influenced when cultured in the presence of ODN 2216.", [["ODN 2216", "CHEMICAL", 248, 256], ["feline", "ORGANISM", 169, 175], ["immune system", "ANATOMICAL_SYSTEM", 176, 189], ["feline", "SPECIES", 169, 175], ["infectious", "OBSERVATION", 85, 95]]], ["First, feline PBMCs significantly proliferated in presence of ODN 2216, indicating a direct and /or indirect stimulation of one or more immune cell subpopulations by this molecule.", [["PBMCs", "ANATOMY", 14, 19], ["immune cell", "ANATOMY", 136, 147], ["ODN 2216", "CHEMICAL", 62, 70], ["feline", "ORGANISM", 7, 13], ["PBMCs", "CELL", 14, 19], ["ODN 2216", "SIMPLE_CHEMICAL", 62, 70], ["immune cell", "CELL", 136, 147], ["feline PBMCs", "CELL_TYPE", 7, 19], ["immune cell subpopulations", "CELL_TYPE", 136, 162], ["feline PBMCs", "TEST", 7, 19], ["immune cell subpopulations", "OBSERVATION", 136, 162]]], ["Although in contrast to other classes of ODN CpG-A does not generally induce lymphocyte proliferation in mice [12] , similar effects have previously been observed in ovine cells, where higher concentrations of CpG-A could induce minimal levels of proliferation [68] .", [["lymphocyte", "ANATOMY", 77, 87], ["cells", "ANATOMY", 172, 177], ["ODN", "CHEMICAL", 41, 44], ["CpG-A", "CHEMICAL", 45, 50], ["CpG-A", "CHEMICAL", 210, 215], ["CpG-A", "CHEMICAL", 45, 50], ["ODN CpG-A", "SIMPLE_CHEMICAL", 41, 50], ["lymphocyte", "CELL", 77, 87], ["mice", "ORGANISM", 105, 109], ["ovine", "ORGANISM", 166, 171], ["cells", "CELL", 172, 177], ["CpG-A", "GENE_OR_GENE_PRODUCT", 210, 215], ["ovine cells", "CELL_TYPE", 166, 177], ["mice", "SPECIES", 105, 109], ["mice", "SPECIES", 105, 109], ["ODN CpG", "TREATMENT", 41, 48], ["lymphocyte proliferation", "PROBLEM", 77, 101], ["higher concentrations of CpG", "PROBLEM", 185, 213], ["lymphocyte proliferation", "OBSERVATION", 77, 101], ["minimal", "OBSERVATION_MODIFIER", 229, 236]]], ["Additionally, ODN 2216 increased the expression of cell surface co-stimulatory molecules in PBMCs, reinforcing possible interactions between various immune cell populations in subsequent specific responses.", [["cell surface", "ANATOMY", 51, 63], ["PBMCs", "ANATOMY", 92, 97], ["immune cell", "ANATOMY", 149, 160], ["ODN 2216", "CHEMICAL", 14, 22], ["ODN 2216", "SIMPLE_CHEMICAL", 14, 22], ["cell", "CELL", 51, 55], ["PBMCs", "CELL", 92, 97], ["immune cell populations", "CELL", 149, 172], ["cell surface co-stimulatory molecules", "PROTEIN", 51, 88], ["PBMCs", "CELL_TYPE", 92, 97], ["immune cell populations", "CELL_TYPE", 149, 172], ["cell surface co-stimulatory molecules", "TREATMENT", 51, 88], ["various immune cell populations", "TREATMENT", 141, 172], ["immune cell", "OBSERVATION", 149, 160]]], ["While B7.1 molecules were upregulated on both lymphocytic and non-lymphocytic cells after ODN 2216 stimulation, MHCII expression could only be increased on lymphocytic cells.", [["lymphocytic", "ANATOMY", 46, 57], ["non-lymphocytic cells", "ANATOMY", 62, 83], ["lymphocytic cells", "ANATOMY", 156, 173], ["ODN 2216", "CHEMICAL", 90, 98], ["B7.1", "GENE_OR_GENE_PRODUCT", 6, 10], ["lymphocytic", "CELL", 46, 57], ["non-lymphocytic cells", "CELL", 62, 83], ["ODN 2216", "SIMPLE_CHEMICAL", 90, 98], ["MHCII", "GENE_OR_GENE_PRODUCT", 112, 117], ["lymphocytic cells", "CELL", 156, 173], ["B7.1 molecules", "PROTEIN", 6, 20], ["lymphocytic and non-lymphocytic cells", "CELL_TYPE", 46, 83], ["MHCII", "PROTEIN", 112, 117], ["lymphocytic cells", "CELL_TYPE", 156, 173], ["lymphocytic and non-lymphocytic cells", "TREATMENT", 46, 83], ["ODN", "TREATMENT", 90, 93], ["lymphocytic cells", "PROBLEM", 156, 173], ["non-lymphocytic cells", "OBSERVATION", 62, 83], ["increased", "OBSERVATION_MODIFIER", 143, 152], ["lymphocytic cells", "OBSERVATION", 156, 173]]], ["This observation may be linked to the time point of our measurements, or to the necessity of transport to the cell surface of MHCII molecules coupled with antigen for presentation to other immune cells.", [["cell surface", "ANATOMY", 110, 122], ["immune cells", "ANATOMY", 189, 201], ["cell surface", "CELLULAR_COMPONENT", 110, 122], ["MHCII", "GENE_OR_GENE_PRODUCT", 126, 131], ["immune cells", "CELL", 189, 201], ["MHCII molecules", "PROTEIN", 126, 141], ["immune cells", "CELL_TYPE", 189, 201], ["immune cells", "OBSERVATION", 189, 201]]], ["Finally, the transcription of a series of markers of innate immune responses was considerably influenced in feline PBMCs by stimulation with ODN 2216.", [["PBMCs", "ANATOMY", 115, 120], ["ODN 2216", "CHEMICAL", 141, 149], ["feline", "ORGANISM", 108, 114], ["PBMCs", "CELL", 115, 120], ["ODN 2216", "SIMPLE_CHEMICAL", 141, 149], ["feline PBMCs", "CELL_TYPE", 108, 120], ["feline", "SPECIES", 108, 114], ["stimulation with ODN", "TREATMENT", 124, 144]]], ["The most astonishing effects of this molecule thereby remain the potent induction of IFN\u03b1 and IFN\u03c9, with mRNA expression of these genes increased by up to 12 000 and 35 000-fold respectively in PBMCs of certain animals.", [["PBMCs", "ANATOMY", 194, 199], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 85, 89], ["IFN\u03c9", "GENE_OR_GENE_PRODUCT", 94, 98], ["PBMCs", "CELL", 194, 199], ["IFN\u03b1", "PROTEIN", 85, 89], ["IFN\u03c9", "PROTEIN", 94, 98], ["PBMCs", "CELL_TYPE", 194, 199], ["IFN\u03b1", "TREATMENT", 85, 89], ["mRNA expression of these genes", "PROBLEM", 105, 135], ["most astonishing", "OBSERVATION_MODIFIER", 4, 20], ["increased", "OBSERVATION_MODIFIER", 136, 145]]], ["In line with observations published recently, the induction of IFN\u03b3 by this CpG ODN remained moderate [34] ; nevertheless, the measurements carried out 24 h after stimulation of purified feline cells support induction of Th1-oriented immune responses and enhanced NK cell activity, both highly desired in the contexts of viral infection.DiscussionVariability in the immunomodulatory and antiviral effects of ODN 2216 on feline cells was mainly related to the age of the cats.", [["cells", "ANATOMY", 194, 199], ["NK cell", "ANATOMY", 264, 271], ["cells", "ANATOMY", 427, 432], ["ODN", "CHEMICAL", 80, 83], ["viral infection", "DISEASE", 321, 336], ["ODN 2216", "CHEMICAL", 408, 416], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 63, 67], ["feline", "ORGANISM", 187, 193], ["cells", "CELL", 194, 199], ["Th1", "GENE_OR_GENE_PRODUCT", 221, 224], ["NK cell", "CELL", 264, 271], ["ODN 2216", "SIMPLE_CHEMICAL", 408, 416], ["feline", "ORGANISM", 420, 426], ["cells", "CELL", 427, 432], ["cats", "ORGANISM", 470, 474], ["IFN\u03b3", "PROTEIN", 63, 67], ["feline cells", "CELL_TYPE", 187, 199], ["feline cells", "CELL_TYPE", 420, 432], ["feline", "SPECIES", 420, 426], ["cats", "SPECIES", 470, 474], ["IFN\u03b3", "TREATMENT", 63, 67], ["this CpG ODN", "TREATMENT", 71, 83], ["the measurements", "TEST", 123, 139], ["stimulation of purified feline cells", "TREATMENT", 163, 199], ["enhanced NK cell activity", "PROBLEM", 255, 280], ["viral infection", "PROBLEM", 321, 336], ["antiviral effects of ODN", "TREATMENT", 387, 411], ["feline cells", "TREATMENT", 420, 432], ["NK cell activity", "OBSERVATION", 264, 280], ["viral", "OBSERVATION_MODIFIER", 321, 326], ["infection", "OBSERVATION", 327, 336]]], ["Among middle-aged adult cats, consistency in the stimulatory potential of this molecule was reflected through the highly similar patterns in gene expression profiles induced in immune cells after stimulation, as well as through the moderate deviations in those experiments aiming to characterize the immunomodulatory properties of ODN 2216 (Figure 1 ).", [["immune cells", "ANATOMY", 177, 189], ["ODN 2216", "CHEMICAL", 331, 339], ["cats", "ORGANISM", 24, 28], ["immune cells", "CELL", 177, 189], ["ODN 2216", "SIMPLE_CHEMICAL", 331, 339], ["immune cells", "CELL_TYPE", 177, 189], ["cats", "SPECIES", 24, 28], ["immune cells", "TREATMENT", 177, 189], ["the moderate deviations in those experiments", "PROBLEM", 228, 272], ["middle", "ANATOMY_MODIFIER", 6, 12], ["immune cells", "OBSERVATION", 177, 189], ["moderate", "OBSERVATION_MODIFIER", 232, 240], ["deviations", "OBSERVATION", 241, 251]]], ["The cells of several animals however, in particular cat c08, but also c09 and c12, indicated particularly strong responsiveness to stimulation throughout the study.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["cat", "ORGANISM", 52, 55], ["c08", "GENE_OR_GENE_PRODUCT", 56, 59], ["c09", "GENE_OR_GENE_PRODUCT", 70, 73], ["c12", "GENE_OR_GENE_PRODUCT", 78, 81], ["cat c08", "PROTEIN", 52, 59], ["c09", "PROTEIN", 70, 73], ["c12", "PROTEIN", 78, 81], ["the study", "TEST", 154, 163], ["several", "OBSERVATION_MODIFIER", 13, 20], ["animals", "OBSERVATION_MODIFIER", 21, 28], ["c12", "ANATOMY", 78, 81]]], ["Such observations are most likely linked to the genetic variability of individuals of an outbred species, as inherited factors are known to play an important role in the magnitude of innate immune responses [69] .", [["an outbred species", "PROBLEM", 86, 104], ["most likely", "UNCERTAINTY", 22, 33]]], ["With respect to this observation, it should be noted that the SPF origin and maintenance in a barrier facility of the animals included in this study may slightly lower the variability in strength and breadth of innate immune responses, and studies with cells obtained from field cats would give further information on divergence in response to stimulation of the innate immune cells of individual animals.", [["cells", "ANATOMY", 253, 258], ["immune cells", "ANATOMY", 370, 382], ["cells", "CELL", 253, 258], ["cats", "ORGANISM", 279, 283], ["innate immune cells", "CELL", 363, 382], ["innate immune cells", "CELL_TYPE", 363, 382], ["this observation", "TEST", 16, 32], ["this study", "TEST", 138, 148], ["stimulation", "TREATMENT", 344, 355]]], ["The immune cells of cats of 14 years of age seemed to respond slightly less well to ODN 2216 than those of younger adult animals, while PBMCs of kittens indicated much more reticence to stimulation, with either limited or absent upregulation of both type I IFN and other genes measured after incubation with ODN 2216.", [["immune cells", "ANATOMY", 4, 16], ["PBMCs", "ANATOMY", 136, 141], ["ODN 2216", "CHEMICAL", 84, 92], ["ODN 2216", "CHEMICAL", 308, 316], ["immune cells", "CELL", 4, 16], ["cats", "ORGANISM", 20, 24], ["PBMCs", "CELL", 136, 141], ["kittens", "ORGANISM", 145, 152], ["type I IFN", "GENE_OR_GENE_PRODUCT", 250, 260], ["ODN 2216", "SIMPLE_CHEMICAL", 308, 316], ["immune cells", "CELL_TYPE", 4, 16], ["PBMCs", "CELL_TYPE", 136, 141], ["type I IFN", "PROTEIN", 250, 260], ["cats", "SPECIES", 20, 24], ["ODN", "TREATMENT", 308, 311], ["immune cells", "OBSERVATION", 4, 16]]], ["Stimulated PBMCs from this group of young animals moreover indicated a tendency to develop an immunologic environment with a Th2 orientation, including higher production of IL-4 and impaired induction of IL-12 compared to cells from adult cats.", [["PBMCs", "ANATOMY", 11, 16], ["cells", "ANATOMY", 222, 227], ["PBMCs", "CELL", 11, 16], ["animals", "ORGANISM", 42, 49], ["IL-4", "GENE_OR_GENE_PRODUCT", 173, 177], ["IL-12", "GENE_OR_GENE_PRODUCT", 204, 209], ["cells", "CELL", 222, 227], ["cats", "ORGANISM", 239, 243], ["PBMCs", "CELL_TYPE", 11, 16], ["IL-4", "PROTEIN", 173, 177], ["IL-12", "PROTEIN", 204, 209], ["cats", "SPECIES", 239, 243], ["an immunologic environment", "PROBLEM", 91, 117], ["higher production of IL", "PROBLEM", 152, 175], ["impaired induction of IL", "TREATMENT", 182, 206]]], ["Although the kittens included in this study were already of 10 weeks of age, these observations strongly corroborate the immature IFN system of neonatal mice [70] , the impaired immune cell activation via TLR9 in human neonatal mononuclear cells [71, 72] and the bias towards Th2 rather than Th1 responses in human fetuses and neonates [73, 74] .", [["immune cell", "ANATOMY", 178, 189], ["neonatal mononuclear cells", "ANATOMY", 219, 245], ["fetuses", "ANATOMY", 315, 322], ["kittens", "ORGANISM", 13, 20], ["IFN", "GENE_OR_GENE_PRODUCT", 130, 133], ["mice", "ORGANISM", 153, 157], ["immune cell", "CELL", 178, 189], ["TLR9", "GENE_OR_GENE_PRODUCT", 205, 209], ["human", "ORGANISM", 213, 218], ["neonatal mononuclear cells", "CELL", 219, 245], ["Th2", "GENE_OR_GENE_PRODUCT", 276, 279], ["Th1", "GENE_OR_GENE_PRODUCT", 292, 295], ["human", "ORGANISM", 309, 314], ["fetuses", "DEVELOPING_ANATOMICAL_STRUCTURE", 315, 322], ["IFN", "PROTEIN", 130, 133], ["TLR9", "PROTEIN", 205, 209], ["human neonatal mononuclear cells", "CELL_TYPE", 213, 245], ["mice", "SPECIES", 153, 157], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 309, 314], ["mice", "SPECIES", 153, 157], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 309, 314], ["this study", "TEST", 33, 43], ["these observations", "TEST", 77, 95], ["the impaired immune cell activation", "PROBLEM", 165, 200], ["TLR9 in human neonatal mononuclear cells", "TEST", 205, 245], ["neonates", "TEST", 327, 335], ["immune cell activation", "OBSERVATION", 178, 200], ["human fetuses", "ANATOMY", 309, 322]]], ["Furthermore, concordantly to findings in human neonatal blood [75, 76] , basal TLR9 transcription in kittens indicated levels similar to those of adults.", [["neonatal blood", "ANATOMY", 47, 61], ["human", "ORGANISM", 41, 46], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["TLR9", "GENE_OR_GENE_PRODUCT", 79, 83], ["kittens", "ORGANISM", 101, 108], ["TLR9", "PROTEIN", 79, 83], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["human neonatal blood", "TEST", 41, 61], ["basal TLR9 transcription", "TREATMENT", 73, 97]]], ["However, ODN 2216 stimulation increased mRNA expression of this gene only in the young animals ( Figure 2C) .", [["ODN 2216", "CHEMICAL", 9, 17], ["ODN 2216", "SIMPLE_CHEMICAL", 9, 17], ["ODN", "TREATMENT", 9, 12]]], ["These results open new perspectives on possible explanations for the qualitative discrepancy between innate immune responses in newborns and adults.", [["newborns", "ORGANISM", 128, 136], ["the qualitative discrepancy", "PROBLEM", 65, 92]]], ["The availability of specific antibodies to feline TLR9 would greatly support further investigations in this direction.DiscussionThe experiments conducted both in vitro and in vivo in this study underline the feasibility of utilizing Mx as a marker for induction of resistance to viral infections in the domestic cat.", [["viral infections", "DISEASE", 279, 295], ["feline", "ORGANISM", 43, 49], ["TLR9", "GENE_OR_GENE_PRODUCT", 50, 54], ["Mx", "GENE_OR_GENE_PRODUCT", 233, 235], ["cat", "ORGANISM", 312, 315], ["specific antibodies", "PROTEIN", 20, 39], ["feline TLR9", "PROTEIN", 43, 54], ["Mx", "PROTEIN", 233, 235], ["cat", "SPECIES", 312, 315], ["further investigations", "TEST", 77, 99], ["this study", "TEST", 183, 193], ["viral infections", "PROBLEM", 279, 295], ["viral", "OBSERVATION_MODIFIER", 279, 284], ["infections", "OBSERVATION", 285, 295]]], ["Admittedly, both the supernatants of PBMCs stimulated with CpG-A and serum of treated cats contain a mixture of molecules that could play a role in the observed antiviral effects.", [["supernatants", "ANATOMY", 21, 33], ["PBMCs", "ANATOMY", 37, 42], ["serum", "ANATOMY", 69, 74], ["CpG-A", "CHEMICAL", 59, 64], ["PBMCs", "CELL", 37, 42], ["CpG-A", "GENE_OR_GENE_PRODUCT", 59, 64], ["serum", "ORGANISM_SUBSTANCE", 69, 74], ["cats", "ORGANISM", 86, 90], ["PBMCs", "CELL_TYPE", 37, 42], ["cats", "SPECIES", 86, 90], ["CpG", "TREATMENT", 59, 62], ["antiviral effects", "OBSERVATION", 161, 178]]], ["However, the viral inhibition in our in vitro assays was similar to that obtained after treatment of the cells with rfeIFN\u03b1 and highly correlated with the induction of Mx transcription in the cell lines incubated with the supernatants.", [["cells", "ANATOMY", 105, 110], ["cell lines", "ANATOMY", 192, 202], ["supernatants", "ANATOMY", 222, 234], ["cells", "CELL", 105, 110], ["rfeIFN\u03b1", "GENE_OR_GENE_PRODUCT", 116, 123], ["Mx", "GENE_OR_GENE_PRODUCT", 168, 170], ["cell lines", "CELL", 192, 202], ["rfeIFN\u03b1", "PROTEIN", 116, 123], ["Mx", "PROTEIN", 168, 170], ["cell lines", "CELL_LINE", 192, 202], ["the viral inhibition", "PROBLEM", 9, 29], ["vitro assays", "TEST", 40, 52], ["the cells", "PROBLEM", 101, 110], ["Mx transcription", "TREATMENT", 168, 184], ["the cell lines", "TREATMENT", 188, 202], ["viral inhibition", "OBSERVATION", 13, 29], ["cell lines", "OBSERVATION", 192, 202]]], ["After ODN 2216 injection in vivo, Mx expression in plasma also strongly correlated with its antiviral potential.", [["plasma", "ANATOMY", 51, 57], ["ODN 2216", "CHEMICAL", 6, 14], ["ODN 2216", "SIMPLE_CHEMICAL", 6, 14], ["Mx", "GENE_OR_GENE_PRODUCT", 34, 36], ["plasma", "ORGANISM_SUBSTANCE", 51, 57], ["Mx", "PROTEIN", 34, 36], ["ODN", "TREATMENT", 6, 9]]], ["It is however important to note that Mx mRNA and protein cannot be mechanistically linked to inhibition of the viruses tested.", [["Mx", "GENE_OR_GENE_PRODUCT", 37, 39], ["Mx mRNA", "RNA", 37, 44], ["Mx mRNA", "TEST", 37, 44], ["viruses", "OBSERVATION", 111, 118]]], ["Although the expression of other antiviral molecules such as 2'5'oligoadenylate synthetase (OAS) and the RNA-dependent protein kinase (PKR) was not measured, their induction has been reported following CpG ODN stimulation of PBMCs in other species [77, 78] and differential interplay between several effector mechanisms most likely leads to the inhibition of individual viruses.DiscussionIn comparison to ODN of other groups, CpG-A have been used in much fewer studies concerning innate antiviral responses.", [["PBMCs", "ANATOMY", 225, 230], ["ODN", "CHEMICAL", 206, 209], ["CpG-A", "CHEMICAL", 426, 431], ["2'5'oligoadenylate", "CHEMICAL", 61, 79], ["CpG", "CHEMICAL", 202, 205], ["2'5'oligoadenylate synthetase", "GENE_OR_GENE_PRODUCT", 61, 90], ["OAS", "GENE_OR_GENE_PRODUCT", 92, 95], ["RNA-dependent protein kinase", "GENE_OR_GENE_PRODUCT", 105, 133], ["PKR", "GENE_OR_GENE_PRODUCT", 135, 138], ["CpG ODN", "SIMPLE_CHEMICAL", 202, 209], ["PBMCs", "CELL", 225, 230], ["CpG-A", "SIMPLE_CHEMICAL", 426, 431], ["antiviral molecules", "PROTEIN", 33, 52], ["2'5'oligoadenylate synthetase", "PROTEIN", 61, 90], ["OAS", "PROTEIN", 92, 95], ["RNA-dependent protein kinase", "PROTEIN", 105, 133], ["PKR", "PROTEIN", 135, 138], ["PBMCs", "CELL_TYPE", 225, 230], ["other antiviral molecules", "PROBLEM", 27, 52], ["2'5'oligoadenylate synthetase", "TREATMENT", 61, 90], ["the RNA-dependent protein kinase", "TEST", 101, 133], ["PKR", "TEST", 135, 138], ["CpG ODN stimulation", "TREATMENT", 202, 221], ["PBMCs in other species", "PROBLEM", 225, 247], ["several effector mechanisms", "PROBLEM", 292, 319], ["individual viruses", "PROBLEM", 359, 377]]], ["This is most likely the result of the more time consuming and costly manufacturing process of these molecules linked to the synthesis of the flanking poly (G) strings necessary for optimal immune effects [31] .", [["the flanking poly (G) strings", "TREATMENT", 137, 166], ["most likely", "UNCERTAINTY", 8, 19]]], ["Also, CpG-A exhibit only weak stimulation of B cells, which produce antibodies that are valuable in later antiviral responses.", [["B cells", "ANATOMY", 45, 52], ["CpG-A", "CHEMICAL", 6, 11], ["CpG-A", "GENE_OR_GENE_PRODUCT", 6, 11], ["B cells", "CELL", 45, 52], ["B cells", "CELL_TYPE", 45, 52], ["antibodies", "PROTEIN", 68, 78], ["weak stimulation of B cells", "PROBLEM", 25, 52]]], ["Stability of CpG-A in vivo has also been questioned due to the only partial phosphorothioate backbone of these molecules.", [["CpG-A", "CHEMICAL", 13, 18], ["phosphorothioate", "CHEMICAL", 76, 92], ["CpG", "CHEMICAL", 13, 16], ["phosphorothioate", "CHEMICAL", 76, 92], ["CpG-A", "SIMPLE_CHEMICAL", 13, 18], ["CpG", "OBSERVATION", 13, 16]]], ["This can be partially compensated however, by the formation, through association of their poly (G) stretches, of highly ordered Gtetrad structures with enhanced stability [12] .", [["poly (G)", "CHEMICAL", 90, 98], ["poly (G) stretches", "PROTEIN", 90, 108], ["their poly (G) stretches", "TREATMENT", 84, 108], ["compensated", "OBSERVATION", 22, 33], ["stability", "OBSERVATION_MODIFIER", 161, 170]]], ["Their smaller content in synthetic backbones could moreover help reduce possible long-term side effects [79, 80] .", [["Their smaller content in synthetic backbones", "PROBLEM", 0, 44], ["long-term side effects", "PROBLEM", 81, 103], ["smaller", "OBSERVATION_MODIFIER", 6, 13], ["content", "OBSERVATION", 14, 21]]], ["Most importantly, CpG-A remain the most potent inducers of type I IFN, themselves the most biologically active antiviral molecules known to date [19] .", [["CpG-A", "CHEMICAL", 18, 23], ["CpG-A", "GENE_OR_GENE_PRODUCT", 18, 23], ["type I IFN", "GENE_OR_GENE_PRODUCT", 59, 69], ["type I IFN", "PROTEIN", 59, 69], ["antiviral molecules", "PROTEIN", 111, 130], ["type I IFN", "PROBLEM", 59, 69]]], ["With regard to this, a recombinant feline type I IFN marketed in both Japan (Intercat \u00ae ) and Europe (Virbagen Omega \u00ae ) has made its way into therapeutic protocols for FCV, FHV, FeLV and canine parvovirus infections [67, [81] [82] [83] [84] [85] [86] and has demonstrated preventive capacities in a cattery developing an outbreak of FPV [87] .", [["type I IFN", "CHEMICAL", 42, 52], ["parvovirus infections", "DISEASE", 195, 216], ["feline", "ORGANISM", 35, 41], ["type I IFN", "GENE_OR_GENE_PRODUCT", 42, 52], ["FCV", "ORGANISM", 169, 172], ["FHV", "ORGANISM", 174, 177], ["FeLV", "ORGANISM", 179, 183], ["canine parvovirus", "ORGANISM", 188, 205], ["[81] [82] [83] [84] [85", "SIMPLE_CHEMICAL", 222, 245], ["recombinant feline type I IFN", "PROTEIN", 23, 52], ["feline", "SPECIES", 35, 41], ["canine", "SPECIES", 188, 194], ["FCV", "SPECIES", 169, 172], ["FHV", "SPECIES", 174, 177], ["FeLV", "SPECIES", 179, 183], ["canine parvovirus", "SPECIES", 188, 205], ["FPV", "SPECIES", 334, 337], ["a recombinant feline type I IFN", "TREATMENT", 21, 52], ["Europe (Virbagen Omega \u00ae", "TREATMENT", 94, 118], ["therapeutic protocols", "TREATMENT", 143, 164], ["FCV", "PROBLEM", 169, 172], ["FHV", "PROBLEM", 174, 177], ["FeLV and canine parvovirus infections", "PROBLEM", 179, 216], ["preventive capacities", "PROBLEM", 273, 294]]], ["However, when compared to direct initiation of antiviral mechanisms by a recombinant IFN\u03b1 protein, administration of CpG ODN holds the advantage of inducing the production of all type I IFN and their subtypes, which have been shown to possess differential antiviral properties and kinetics [88] .", [["CpG ODN", "CHEMICAL", 117, 124], ["CpG", "CHEMICAL", 117, 120], ["IFN\u03b1", "GENE_OR_GENE_PRODUCT", 85, 89], ["CpG ODN", "SIMPLE_CHEMICAL", 117, 124], ["type I IFN", "GENE_OR_GENE_PRODUCT", 179, 189], ["recombinant IFN\u03b1 protein", "PROTEIN", 73, 97], ["type I IFN", "PROTEIN", 179, 189], ["antiviral mechanisms", "TREATMENT", 47, 67], ["a recombinant IFN\u03b1 protein", "TREATMENT", 71, 97], ["administration of CpG ODN", "TREATMENT", 99, 124]]], ["Our data demonstrate that five viral species belonging to the Calicivirus, Herpesvirus, Parvovirus, Coronavirus and Retrovirus families were highly sensitive to the immunologic effects of ODN 2216 in feline cells.", [["cells", "ANATOMY", 207, 212], ["ODN 2216", "CHEMICAL", 188, 196], ["Herpesvirus", "ORGANISM", 75, 86], ["Parvovirus", "ORGANISM", 88, 98], ["Coronavirus", "GENE_OR_GENE_PRODUCT", 100, 111], ["ODN 2216", "SIMPLE_CHEMICAL", 188, 196], ["feline", "ORGANISM", 200, 206], ["cells", "CELL", 207, 212], ["feline cells", "CELL_TYPE", 200, 212], ["feline", "SPECIES", 200, 206], ["Our data", "TEST", 0, 8], ["five viral species", "PROBLEM", 26, 44], ["the Calicivirus", "PROBLEM", 58, 73], ["Herpesvirus", "PROBLEM", 75, 86], ["Parvovirus", "PROBLEM", 88, 98], ["Coronavirus", "PROBLEM", 100, 111], ["Retrovirus families", "PROBLEM", 116, 135], ["the immunologic effects of ODN", "TREATMENT", 161, 191], ["feline cells", "OBSERVATION", 200, 212]]], ["Strength and breadth of antiviral defense mechanisms induced in vivo by this molecule have the potential to outweigh those observed with recombinant IFN.DiscussionIn frame with the results of our in vitro experiments, the administration of ODN 2216 in vivo could promote an antiviral state in the domestic cat in the absence of adverse reactions.", [["ODN 2216", "CHEMICAL", 240, 248], ["IFN", "GENE_OR_GENE_PRODUCT", 149, 152], ["ODN 2216", "SIMPLE_CHEMICAL", 240, 248], ["cat", "ORGANISM", 306, 309], ["recombinant IFN", "PROTEIN", 137, 152], ["antiviral defense mechanisms", "TREATMENT", 24, 52], ["ODN", "TREATMENT", 240, 243], ["adverse reactions", "PROBLEM", 328, 345], ["antiviral defense", "OBSERVATION", 24, 41], ["antiviral", "OBSERVATION", 274, 283]]], ["Just as stimulated PBMCs exhibited high mRNA expression of type I IFN and only a marginal increase in mRNA levels of the proinflammatory cytokines IL-6 and TNF\u03b1, treated cats showed significantly increased Mx expression in their blood and lacked flu-like symptoms generally linked with administration of immunostimulatory molecules in vivo.", [["PBMCs", "ANATOMY", 19, 24], ["blood", "ANATOMY", 229, 234], ["PBMCs", "CELL", 19, 24], ["type I IFN", "GENE_OR_GENE_PRODUCT", 59, 69], ["IL-6", "GENE_OR_GENE_PRODUCT", 147, 151], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 156, 160], ["cats", "ORGANISM", 170, 174], ["Mx", "GENE_OR_GENE_PRODUCT", 206, 208], ["blood", "ORGANISM_SUBSTANCE", 229, 234], ["PBMCs", "CELL_TYPE", 19, 24], ["type I IFN", "PROTEIN", 59, 69], ["proinflammatory cytokines", "PROTEIN", 121, 146], ["IL-6", "PROTEIN", 147, 151], ["TNF\u03b1", "PROTEIN", 156, 160], ["Mx", "PROTEIN", 206, 208], ["immunostimulatory molecules", "PROTEIN", 304, 331], ["type I IFN", "PROBLEM", 59, 69], ["a marginal increase in mRNA levels", "PROBLEM", 79, 113], ["the proinflammatory cytokines IL", "TEST", 117, 149], ["TNF", "TEST", 156, 159], ["significantly increased Mx expression in their blood", "PROBLEM", 182, 234], ["lacked flu-like symptoms", "PROBLEM", 239, 263], ["immunostimulatory molecules", "TREATMENT", 304, 331], ["marginal", "OBSERVATION_MODIFIER", 81, 89], ["increase", "OBSERVATION_MODIFIER", 90, 98], ["significantly", "OBSERVATION_MODIFIER", 182, 195], ["increased", "OBSERVATION_MODIFIER", 196, 205], ["Mx expression", "OBSERVATION", 206, 219], ["flu", "OBSERVATION", 246, 249]]], ["Additionally, although our in vivo studies included a limited number of cats, the strength of responses to ODN 2216 stimulation in vitro and in vivo for individual animals strongly correlated, indicating that individual sensitivity to stimulation most likely can be predicted with in vitro experiments.", [["ODN 2216", "CHEMICAL", 107, 115], ["cats", "ORGANISM", 72, 76], ["vivo studies", "TEST", 30, 42], ["ODN", "TREATMENT", 107, 110], ["individual sensitivity", "PROBLEM", 209, 231]]], ["Our data further show that a single subcutaneous injection of ODN 2216 sufficed to induce the systemic presence of antiviral molecules for 24 to 36 h in the plasma of treated cats; during this time, an increase of Mx expression of at least 4-fold in the blood of treated cats was indicative of significant inhibition of viral replication in vitro.", [["subcutaneous", "ANATOMY", 36, 48], ["plasma", "ANATOMY", 157, 163], ["blood", "ANATOMY", 254, 259], ["ODN 2216", "CHEMICAL", 62, 70], ["ODN 2216", "SIMPLE_CHEMICAL", 62, 70], ["plasma", "ORGANISM_SUBSTANCE", 157, 163], ["cats", "ORGANISM", 175, 179], ["Mx", "GENE_OR_GENE_PRODUCT", 214, 216], ["blood", "ORGANISM_SUBSTANCE", 254, 259], ["cats", "ORGANISM", 271, 275], ["antiviral molecules", "PROTEIN", 115, 134], ["Mx", "PROTEIN", 214, 216], ["cats", "SPECIES", 175, 179], ["a single subcutaneous injection of ODN", "TREATMENT", 27, 65], ["antiviral molecules", "TREATMENT", 115, 134], ["Mx expression", "TREATMENT", 214, 227], ["viral replication", "TREATMENT", 320, 337], ["increase", "OBSERVATION_MODIFIER", 202, 210], ["indicative of", "UNCERTAINTY", 280, 293], ["significant", "OBSERVATION_MODIFIER", 294, 305], ["inhibition", "OBSERVATION", 306, 316], ["viral replication", "OBSERVATION", 320, 337]]], ["These observations support possible resistance to viral infection by ODN 2216 for several days, a phenomenon described already in mouse models [89] .DiscussionAltogether, this study underlines the strong potential for ODN 2216 in the prevention of a large variety of viral diseases.", [["viral infection", "DISEASE", 50, 65], ["ODN 2216", "CHEMICAL", 69, 77], ["ODN 2216", "CHEMICAL", 218, 226], ["viral diseases", "DISEASE", 267, 281], ["ODN 2216", "SIMPLE_CHEMICAL", 69, 77], ["mouse", "ORGANISM", 130, 135], ["mouse", "SPECIES", 130, 135], ["mouse", "SPECIES", 130, 135], ["resistance to viral infection", "PROBLEM", 36, 65], ["a phenomenon", "PROBLEM", 96, 108], ["this study", "TEST", 171, 181], ["ODN", "TREATMENT", 218, 221], ["viral diseases", "PROBLEM", 267, 281], ["viral", "OBSERVATION_MODIFIER", 50, 55], ["infection", "OBSERVATION", 56, 65], ["large", "OBSERVATION_MODIFIER", 250, 255], ["variety", "OBSERVATION_MODIFIER", 256, 263], ["viral diseases", "OBSERVATION", 267, 281]]], ["CpG-A molecules should thus not be left aside when stimulating innate immunity for prophylactic purposes.", [["CpG-A molecules", "GENE_OR_GENE_PRODUCT", 0, 15], ["prophylactic purposes", "TREATMENT", 83, 104]]], ["Future studies should aim at optimizing the kinetics of these molecules in vivo, while addressing safety, stability and manufacturing issues.", [["Future studies", "TEST", 0, 14]]], ["Combinations with adjuvants or other TLR agonists as well as optimized administration protocols should support research in this direction.", [["adjuvants", "TREATMENT", 18, 27], ["other TLR agonists", "TREATMENT", 31, 49], ["optimized administration protocols", "TREATMENT", 61, 95]]], ["Field studies with larger cohorts of animals will provide further insights on the utilization of CpG-A molecules for the prevention of viral infections in a clinical setting.", [["CpG-A", "CHEMICAL", 97, 102], ["viral infections", "DISEASE", 135, 151], ["CpG", "CHEMICAL", 97, 100], ["CpG-A", "GENE_OR_GENE_PRODUCT", 97, 102], ["Field studies", "TEST", 0, 13], ["CpG", "TREATMENT", 97, 100], ["A molecules", "TREATMENT", 101, 112], ["viral infections", "PROBLEM", 135, 151], ["viral", "OBSERVATION_MODIFIER", 135, 140], ["infections", "OBSERVATION", 141, 151]]]], "8b13983de0f31ea257c5dcdafd71aab6da76408f": [["As we proof this (March 30, 2020), COVID-19, caused by the SARS-CoV-2 virus and labeled a global pandemic by the World Health Organization, is sweeping across the globe-over 730 000 cases and 35 000 deaths, with cases reported in over 190 countries.", [["deaths", "DISEASE", 199, 205], ["SARS-CoV-2 virus", "ORGANISM", 59, 75], ["CoV-2 virus", "SPECIES", 64, 75], ["SARS-CoV-2 virus", "SPECIES", 59, 75], ["COVID", "TEST", 35, 40], ["the SARS", "PROBLEM", 55, 63], ["global", "OBSERVATION_MODIFIER", 90, 96], ["pandemic", "OBSERVATION", 97, 105], ["globe", "ANATOMY", 163, 168]]]], "25615501bc9f54fd01b72047cec1f8ec619b1e69": [["Introduction AIDS (acquired immune deficiency syndrome) remains the great unconquered threat to global public health.", [["AIDS", "DISEASE", 13, 17], ["acquired immune deficiency syndrome", "DISEASE", 19, 54], ["Introduction AIDS (acquired immune deficiency syndrome", "PROBLEM", 0, 54]]], ["An effective HIV vaccine is urgently needed.", [["HIV", "ORGANISM", 13, 16], ["HIV", "SPECIES", 13, 16], ["An effective HIV vaccine", "TREATMENT", 0, 24], ["effective", "OBSERVATION_MODIFIER", 3, 12], ["HIV", "OBSERVATION", 13, 16]]], ["Ninety percent of AIDS cases are transmitted through mucosal routes, such as sexual contact [1] .", [["mucosal", "ANATOMY", 53, 60], ["AIDS", "DISEASE", 18, 22], ["mucosal routes", "MULTI-TISSUE_STRUCTURE", 53, 67], ["AIDS cases", "PROBLEM", 18, 28]]], ["Targeting immune responses to the site of viral entry can protect the body and help clear the viral reservoir before HIV dissemination [2, 3] .", [["body", "ANATOMY", 70, 74], ["body", "ORGANISM_SUBDIVISION", 70, 74], ["HIV", "SPECIES", 117, 120], ["viral entry", "PROBLEM", 42, 53], ["the viral reservoir", "TREATMENT", 90, 109], ["HIV dissemination", "PROBLEM", 117, 134], ["viral reservoir", "OBSERVATION", 94, 109]]], ["There is evidence that HIV-specific S-IgA could neutralize HIV in the cervicovaginal lavage fluids of uninfected partners of highly exposed persons [4, 5, 6, 7, 8] .", [["cervicovaginal lavage fluids", "ANATOMY", 70, 98], ["HIV", "ORGANISM", 23, 26], ["S-IgA", "GENE_OR_GENE_PRODUCT", 36, 41], ["HIV", "ORGANISM", 59, 62], ["cervicovaginal lavage fluids", "ORGANISM_SUBSTANCE", 70, 98], ["persons", "ORGANISM", 140, 147], ["IgA", "PROTEIN", 38, 41], ["HIV", "SPECIES", 59, 62], ["persons", "SPECIES", 140, 147], ["HIV", "SPECIES", 23, 26], ["HIV", "SPECIES", 59, 62], ["HIV", "PROBLEM", 23, 26], ["HIV", "PROBLEM", 59, 62], ["the cervicovaginal lavage fluids", "TREATMENT", 66, 98], ["cervicovaginal", "ANATOMY", 70, 84], ["lavage", "OBSERVATION", 85, 91]]], ["The SIV-specific CTLs, which are induced by immunization with an attenuated SHIV, were found to be associated with protection against vaginal challenge in rhesus macaques [9] .", [["CTLs", "ANATOMY", 17, 21], ["vaginal", "ANATOMY", 134, 141], ["SIV", "ORGANISM", 4, 7], ["CTLs", "CELL", 17, 21], ["SHIV", "ORGANISM", 76, 80], ["vaginal", "ORGANISM_SUBDIVISION", 134, 141], ["rhesus", "ORGANISM", 155, 161], ["macaques", "ORGANISM", 162, 170], ["CTLs", "CELL_TYPE", 17, 21], ["rhesus macaques", "SPECIES", 155, 170], ["SIV", "SPECIES", 4, 7], ["SHIV", "SPECIES", 76, 80], ["rhesus macaques", "SPECIES", 155, 170], ["immunization", "TREATMENT", 44, 56], ["an attenuated SHIV", "PROBLEM", 62, 80], ["vaginal challenge in rhesus macaques", "TREATMENT", 134, 170]]], ["Most researchers believe that a vaccine against HIV-1 would need to induce a neutralizing antibody, CD4 + Th, and competent CD8 + CTL responses at the initial site of viral entry.", [["CD4 + Th", "ANATOMY", 100, 108], ["CD8 + CTL", "ANATOMY", 124, 133], ["HIV-1", "ORGANISM", 48, 53], ["CD4", "GENE_OR_GENE_PRODUCT", 100, 103], ["CD8", "GENE_OR_GENE_PRODUCT", 124, 127], ["CD4", "PROTEIN", 100, 103], ["CD8", "PROTEIN", 124, 127], ["HIV-1", "SPECIES", 48, 53], ["HIV-1", "SPECIES", 48, 53], ["a vaccine", "TREATMENT", 30, 39], ["HIV", "PROBLEM", 48, 51], ["a neutralizing antibody", "TEST", 75, 98], ["CD4", "TEST", 100, 103], ["viral entry", "OBSERVATION", 167, 178]]], ["Systemic vaccination is not sufficient to generate effective compartmentalized mucosal immunity [2, 10] .", [["mucosal", "ANATOMY", 79, 86], ["mucosal", "MULTI-TISSUE_STRUCTURE", 79, 86], ["Systemic vaccination", "TREATMENT", 0, 20]]]], "c4c5a6fd756afc5414847e5f83feb0478117db04": [["INTRODUCTIONOxygen has been recognized as a powerful radiosensitizing agent.", [["INTRODUCTIONOxygen", "CHEMICAL", 0, 18], ["INTRODUCTIONOxygen", "TREATMENT", 0, 18], ["a powerful radiosensitizing agent", "TREATMENT", 42, 75]]], ["In solid tumors, areas of vascular insufficiency and necrosis may cause some cells to be chronically hypoxic and, consequently, resistant to radiation.", [["solid tumors", "ANATOMY", 3, 15], ["vascular", "ANATOMY", 26, 34], ["cells", "ANATOMY", 77, 82], ["tumors", "DISEASE", 9, 15], ["vascular insufficiency", "DISEASE", 26, 48], ["necrosis", "DISEASE", 53, 61], ["solid tumors", "CANCER", 3, 15], ["vascular", "MULTI-TISSUE_STRUCTURE", 26, 34], ["cells", "CELL", 77, 82], ["solid tumors", "PROBLEM", 3, 15], ["vascular insufficiency", "PROBLEM", 26, 48], ["necrosis", "PROBLEM", 53, 61], ["some cells", "PROBLEM", 72, 82], ["chronically hypoxic", "PROBLEM", 89, 108], ["radiation", "TREATMENT", 141, 150], ["solid", "OBSERVATION_MODIFIER", 3, 8], ["tumors", "OBSERVATION", 9, 15], ["areas", "OBSERVATION_MODIFIER", 17, 22], ["vascular", "ANATOMY", 26, 34], ["insufficiency", "OBSERVATION", 35, 48], ["necrosis", "OBSERVATION", 53, 61], ["chronically", "OBSERVATION_MODIFIER", 89, 100], ["hypoxic", "OBSERVATION", 101, 108]]], ["Chemical radiosensitizers have been used in attempts to enhance radiation effects on the hypoxic cell fraction with limited clinical success.'* Teicher and Rose' ' and Rockwell\" have shown that administration of Fluosol-DA 20%) to tumor-bearing mice prior to and during radiation significantly delayed tumor regrowth.", [["cell", "ANATOMY", 97, 101], ["tumor", "ANATOMY", 231, 236], ["tumor", "ANATOMY", 302, 307], ["Fluosol-DA", "CHEMICAL", 212, 222], ["tumor", "DISEASE", 231, 236], ["tumor", "DISEASE", 302, 307], ["hypoxic cell", "CELL", 89, 101], ["Fluosol-DA", "SIMPLE_CHEMICAL", 212, 222], ["tumor", "CANCER", 231, 236], ["mice", "ORGANISM", 245, 249], ["tumor", "CANCER", 302, 307], ["mice", "SPECIES", 245, 249], ["mice", "SPECIES", 245, 249], ["Chemical radiosensitizers", "TREATMENT", 0, 25], ["radiation effects", "TREATMENT", 64, 81], ["the hypoxic cell fraction", "TREATMENT", 85, 110], ["Fluosol", "TREATMENT", 212, 219], ["DA", "TREATMENT", 220, 222], ["delayed tumor regrowth", "PROBLEM", 294, 316], ["hypoxic cell fraction", "OBSERVATION", 89, 110], ["tumor", "OBSERVATION", 302, 307]]], ["However, a clinical treatment course may require multiple Fluosol infusions.", [["Fluosol", "CHEMICAL", 58, 65], ["Fluosol", "CHEMICAL", 58, 65], ["Fluosol", "SIMPLE_CHEMICAL", 58, 65], ["a clinical treatment course", "TREATMENT", 9, 36], ["multiple Fluosol infusions", "TREATMENT", 49, 75]]], ["This study was designed to assess the possible effects of multiple Fluosol doses on the reticuloendothelial system (RES) and compare the effects of multiple infusions with previous work using single bolus doses.AND MATERIALSMale Sprague-Dawley rats? (< 150 gm) were divided into four groups (n=20 per group): control, room air (CRA); control, oxygen 100% O2 (COX); Fluosol, room air (FRA); and Fluosol, oxygen 100% O2 (FOX).", [["reticuloendothelial system", "ANATOMY", 88, 114], ["Fluosol", "CHEMICAL", 67, 74], ["oxygen", "CHEMICAL", 343, 349], ["O2", "CHEMICAL", 355, 357], ["Fluosol", "CHEMICAL", 365, 372], ["Fluosol", "CHEMICAL", 394, 401], ["oxygen", "CHEMICAL", 403, 409], ["O2", "CHEMICAL", 415, 417], ["Fluosol", "CHEMICAL", 67, 74], ["oxygen", "CHEMICAL", 343, 349], ["O2", "CHEMICAL", 355, 357], ["Fluosol", "CHEMICAL", 365, 372], ["Fluosol", "CHEMICAL", 394, 401], ["oxygen", "CHEMICAL", 403, 409], ["O2", "CHEMICAL", 415, 417], ["FOX", "CHEMICAL", 419, 422], ["Fluosol", "SIMPLE_CHEMICAL", 67, 74], ["reticuloendothelial system", "MULTI-TISSUE_STRUCTURE", 88, 114], ["RES", "ANATOMICAL_SYSTEM", 116, 119], ["Sprague-Dawley rats", "ORGANISM", 229, 248], ["oxygen", "SIMPLE_CHEMICAL", 343, 349], ["O2", "SIMPLE_CHEMICAL", 355, 357], ["COX", "SIMPLE_CHEMICAL", 359, 362], ["Fluosol", "SIMPLE_CHEMICAL", 365, 372], ["Fluosol", "SIMPLE_CHEMICAL", 394, 401], ["oxygen", "SIMPLE_CHEMICAL", 403, 409], ["O2", "SIMPLE_CHEMICAL", 415, 417], ["FOX", "SIMPLE_CHEMICAL", 419, 422], ["Sprague-Dawley rats", "SPECIES", 229, 248], ["This study", "TEST", 0, 10], ["multiple Fluosol doses", "TREATMENT", 58, 80], ["multiple infusions", "TREATMENT", 148, 166], ["single bolus doses", "TREATMENT", 192, 210], ["oxygen", "TREATMENT", 343, 349], ["Fluosol", "TREATMENT", 365, 372], ["Fluosol", "TREATMENT", 394, 401], ["oxygen", "TREATMENT", 403, 409], ["reticuloendothelial system", "ANATOMY", 88, 114]]], ["Treatment animals received a total of 50 ml/kg (1Ogm PFC/ kg body weight) of Fluosol in 10 ml/kg bolus doses via the tail vein on treatment days 1,3,8, 10, and 15.", [["body", "ANATOMY", 61, 65], ["tail vein", "ANATOMY", 117, 126], ["Fluosol", "CHEMICAL", 77, 84], ["Fluosol", "CHEMICAL", 77, 84], ["body", "ORGANISM_SUBDIVISION", 61, 65], ["Fluosol", "SIMPLE_CHEMICAL", 77, 84], ["tail vein", "MULTI-TISSUE_STRUCTURE", 117, 126], ["1Ogm PFC/ kg body weight", "TREATMENT", 48, 72], ["Fluosol", "TREATMENT", 77, 84], ["the tail vein", "TREATMENT", 113, 126], ["tail vein", "ANATOMY", 117, 126]]], ["Control animals were not injected.", [["animals", "ORGANISM", 8, 15]]], ["COX and FOX animals received 100% oxygen for three hours daily on the first 13 weekday treatment days.", [["oxygen", "CHEMICAL", 34, 40], ["oxygen", "CHEMICAL", 34, 40], ["COX", "GENE_OR_GENE_PRODUCT", 0, 3], ["FOX", "GENE_OR_GENE_PRODUCT", 8, 11], ["oxygen", "SIMPLE_CHEMICAL", 34, 40], ["COX", "PROTEIN", 0, 3], ["100% oxygen", "TREATMENT", 29, 40]]], ["Animals (n=4) from each group were killed by exsanguination at 24,43, 92 and 183 days post-treatment.", [["Animals", "ORGANISM", 0, 7]]], ["Blood samples obtained at death were analyzed for SGOT, SGPT, alkaline phosphatase, hemoglobin, and red and white cell levels.", [["Blood samples", "ANATOMY", 0, 13], ["white cell", "ANATOMY", 108, 118], ["death", "DISEASE", 26, 31], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["SGOT", "SIMPLE_CHEMICAL", 50, 54], ["SGPT", "SIMPLE_CHEMICAL", 56, 60], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 62, 82], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 84, 94], ["white cell", "CELL", 108, 118], ["SGOT", "PROTEIN", 50, 54], ["SGPT", "PROTEIN", 56, 60], ["alkaline phosphatase", "PROTEIN", 62, 82], ["hemoglobin", "PROTEIN", 84, 94], ["Blood samples", "TEST", 0, 13], ["SGOT", "TEST", 50, 54], ["SGPT", "TEST", 56, 60], ["alkaline phosphatase", "TEST", 62, 82], ["hemoglobin", "TEST", 84, 94], ["red and white cell levels", "TEST", 100, 125], ["white cell levels", "OBSERVATION", 108, 125]]], ["Tissue samples were obtained from the lung, liver, and spleen, and histological analyses were performed using weighed samples fixed in formalin.", [["Tissue samples", "ANATOMY", 0, 14], ["lung", "ANATOMY", 38, 42], ["liver", "ANATOMY", 44, 49], ["spleen", "ANATOMY", 55, 61], ["samples", "ANATOMY", 118, 125], ["formalin", "CHEMICAL", 135, 143], ["formalin", "CHEMICAL", 135, 143], ["Tissue samples", "CANCER", 0, 14], ["lung", "ORGAN", 38, 42], ["liver", "ORGAN", 44, 49], ["spleen", "ORGAN", 55, 61], ["formalin", "SIMPLE_CHEMICAL", 135, 143], ["Tissue samples", "TEST", 0, 14], ["histological analyses", "TEST", 67, 88], ["weighed samples", "TEST", 110, 125], ["lung", "ANATOMY", 38, 42], ["liver", "ANATOMY", 44, 49], ["spleen", "ANATOMY", 55, 61]]], ["PFC's were extracted from tissues (Yamanouchi, et ) and quantitated on a gas chromatograph# using known perlluorotripropylamine (FI'PA) and pertluorodecalin (FDC) standards.", [["tissues", "ANATOMY", 26, 33], ["perlluorotripropylamine", "CHEMICAL", 104, 127], ["pertluorodecalin", "CHEMICAL", 140, 156], ["perlluorotripropylamine", "CHEMICAL", 104, 127], ["pertluorodecalin", "CHEMICAL", 140, 156], ["PFC", "SIMPLE_CHEMICAL", 0, 3], ["tissues", "TISSUE", 26, 33], ["perlluorotripropylamine", "SIMPLE_CHEMICAL", 104, 127], ["pertluorodecalin", "SIMPLE_CHEMICAL", 140, 156], ["PFC's", "TREATMENT", 0, 5], ["a gas chromatograph", "TEST", 71, 90], ["known perlluorotripropylamine (FI'PA)", "TREATMENT", 98, 135], ["pertluorodecalin (FDC)", "TREATMENT", 140, 162]]], ["Serum from randomly selected animals was screened for antibodies to murine pneumonia virus, corona virus, sendai virus, and mycoplasma.RESULTSOnly slight differences were noted between treatment and control liver enzyme and hemogram values.", [["Serum", "ANATOMY", 0, 5], ["liver", "ANATOMY", 207, 212], ["murine pneumonia", "DISEASE", 68, 84], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["murine pneumonia virus", "ORGANISM", 68, 90], ["corona virus", "ORGANISM", 92, 104], ["sendai virus", "ORGANISM", 106, 118], ["liver", "ORGAN", 207, 212], ["antibodies", "PROTEIN", 54, 64], ["liver enzyme", "PROTEIN", 207, 219], ["murine", "SPECIES", 68, 74], ["pneumonia virus", "SPECIES", 75, 90], ["sendai virus", "SPECIES", 106, 118], ["murine pneumonia virus", "SPECIES", 68, 90], ["corona virus", "SPECIES", 92, 104], ["sendai virus", "SPECIES", 106, 118], ["Serum", "TEST", 0, 5], ["antibodies", "PROBLEM", 54, 64], ["murine pneumonia virus", "PROBLEM", 68, 90], ["corona virus", "PROBLEM", 92, 104], ["sendai virus", "PROBLEM", 106, 118], ["mycoplasma", "PROBLEM", 124, 134], ["slight differences", "PROBLEM", 147, 165], ["treatment", "TREATMENT", 185, 194], ["control liver enzyme", "TEST", 199, 219], ["hemogram values", "TEST", 224, 239], ["slight", "OBSERVATION_MODIFIER", 147, 153], ["liver", "ANATOMY", 207, 212]]], ["Alkaline phosphatase levels were somewhat lower (p < 0.05) in the FOX group (154.5 f 18.8 IU/L) (mean -t Standard deviation), than in the COX group (200.6 + 35.7 IU/L) at 43 days post-treatment and were similarly lower (102.4 + 13.3 IU/L) than CRA (140.6 f 28.5 IU/L), or COX (144.6 * 16.0 IU/L) groups at 92 days post-treatment.", [["Alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 0, 20], ["FOX", "GENE_OR_GENE_PRODUCT", 66, 69], ["COX", "GENE_OR_GENE_PRODUCT", 138, 141], ["COX", "GENE_OR_GENE_PRODUCT", 272, 275], ["Alkaline phosphatase", "PROTEIN", 0, 20], ["COX", "PROTEIN", 272, 275], ["Alkaline phosphatase levels", "TEST", 0, 27], ["somewhat lower", "PROBLEM", 33, 47], ["the COX group", "TEST", 134, 147], ["treatment", "TREATMENT", 184, 193], ["CRA", "TEST", 244, 247], ["COX", "TEST", 272, 275], ["IU", "TEST", 290, 292], ["lower", "OBSERVATION_MODIFIER", 213, 218]]], ["A difference (p < 0.05) in SGOT levels between CR4 (96.1 + 22.3 IU/L) and FOX (62.0 + 13.5 IU/L) groups was seen at 43 days post-treatment.", [["SGOT", "SIMPLE_CHEMICAL", 27, 31], ["FOX", "GENE_OR_GENE_PRODUCT", 74, 77], ["SGOT", "PROTEIN", 27, 31], ["SGOT levels", "TEST", 27, 38], ["CR4", "TEST", 47, 50], ["IU", "TEST", 64, 66], ["FOX", "TEST", 74, 77]]], ["There were no differences between treatment and control SGPT values.RESULTSWhite blood cell counts for FRA and FOX (16.1-17.0 X 103/mm3 at 43 days and 14.6-16.7 X 103/mm3 at 92 days post-treatment) were slightly elevated (p < 0.05) over CRA and COX values (11.1 X 103/mm3 for controls at 43 days and 10.2-12.0 X 103/mm3 at 92 days post-treatment).", [["blood cell", "ANATOMY", 81, 91], ["SGPT", "SIMPLE_CHEMICAL", 56, 60], ["blood cell", "CELL", 81, 91], ["FRA", "GENE_OR_GENE_PRODUCT", 103, 106], ["FOX", "GENE_OR_GENE_PRODUCT", 111, 114], ["COX", "GENE_OR_GENE_PRODUCT", 245, 248], ["SGPT", "PROTEIN", 56, 60], ["FRA", "PROTEIN", 103, 106], ["FOX", "PROTEIN", 111, 114], ["COX", "PROTEIN", 245, 248], ["treatment", "TREATMENT", 34, 43], ["SGPT values", "TEST", 56, 67], ["blood cell counts", "TEST", 81, 98], ["FRA", "TEST", 103, 106], ["FOX", "TEST", 111, 114], ["mm3", "TEST", 132, 135], ["treatment", "TREATMENT", 187, 196], ["slightly elevated", "PROBLEM", 203, 220], ["CRA", "TEST", 237, 240], ["COX values", "TEST", 245, 255], ["controls", "TEST", 276, 284], ["treatment", "TREATMENT", 336, 345], ["no", "UNCERTAINTY", 11, 13]]], ["The reason for this elevation is unknown, but counts resolved with no observable effects on the animals.", [["this elevation", "PROBLEM", 15, 29], ["counts", "TEST", 46, 52], ["elevation", "OBSERVATION", 20, 29]]], ["Serology results showed only low level mycoplasma titers in some animals from both treatment and control groups.RESULTSPFC analysis revealed marked FTPA and FDC accumulation in the spleen and liver of FRA and FOX animals at 24 days post-treatment (Table 1 ).", [["FDC", "ANATOMY", 157, 160], ["spleen", "ANATOMY", 181, 187], ["liver", "ANATOMY", 192, 197], ["FTPA", "SIMPLE_CHEMICAL", 148, 152], ["FDC", "SIMPLE_CHEMICAL", 157, 160], ["spleen", "ORGAN", 181, 187], ["liver", "ORGAN", 192, 197], ["FOX", "GENE_OR_GENE_PRODUCT", 209, 212], ["FDC", "CELL_TYPE", 157, 160], ["Serology", "TEST", 0, 8], ["low level mycoplasma titers", "PROBLEM", 29, 56], ["both treatment", "TREATMENT", 78, 92], ["RESULTSPFC analysis", "TEST", 112, 131], ["marked FTPA", "PROBLEM", 141, 152], ["FDC accumulation in the spleen", "PROBLEM", 157, 187], ["low level", "OBSERVATION_MODIFIER", 29, 38], ["mycoplasma titers", "OBSERVATION", 39, 56], ["marked", "OBSERVATION_MODIFIER", 141, 147], ["FTPA", "OBSERVATION", 148, 152], ["FDC accumulation", "OBSERVATION", 157, 173], ["spleen", "ANATOMY", 181, 187], ["liver", "ANATOMY", 192, 197]]], ["PFC accumulation was most pronounced in the spleen, with 146.41 f 30.79 mg/gm of FTPA and 152.40 If: 33.01 mg/gm of FDC recovered from FOX animals and similar PFC amounts recovered from FRA animals at 24 days post-treatment.", [["PFC", "ANATOMY", 0, 3], ["spleen", "ANATOMY", 44, 50], ["FDC", "ANATOMY", 116, 119], ["PFC", "ANATOMY", 159, 162], ["FTPA", "CHEMICAL", 81, 85], ["FTPA", "CHEMICAL", 81, 85], ["PFC", "SIMPLE_CHEMICAL", 0, 3], ["spleen", "ORGAN", 44, 50], ["FDC", "CELL", 116, 119], ["FOX", "GENE_OR_GENE_PRODUCT", 135, 138], ["PFC", "SIMPLE_CHEMICAL", 159, 162], ["FDC", "CELL_TYPE", 116, 119], ["PFC accumulation", "PROBLEM", 0, 16], ["FTPA", "TEST", 81, 85], ["FDC", "TREATMENT", 116, 119], ["most pronounced", "OBSERVATION_MODIFIER", 21, 36], ["spleen", "ANATOMY", 44, 50]]], ["Less than 1.5 mg/gm of total PFC's was recovered from lung tissues.", [["lung tissues", "ANATOMY", 54, 66], ["PFC", "SIMPLE_CHEMICAL", 29, 32], ["lung tissues", "TISSUE", 54, 66], ["total PFC's", "TREATMENT", 23, 34], ["lung tissues", "ANATOMY", 54, 66]]], ["The PFC content of tissues decreased over time, with FDC clearing more rapidly than FTPA in all organs.", [["PFC", "ANATOMY", 4, 7], ["tissues", "ANATOMY", 19, 26], ["organs", "ANATOMY", 96, 102], ["FTPA", "CHEMICAL", 84, 88], ["PFC", "MULTI-TISSUE_STRUCTURE", 4, 7], ["tissues", "TISSUE", 19, 26], ["FDC", "SIMPLE_CHEMICAL", 53, 56], ["FTPA", "SIMPLE_CHEMICAL", 84, 88], ["organs", "ORGAN", 96, 102], ["FDC", "CELL_TYPE", 53, 56], ["PFC content", "OBSERVATION", 4, 15], ["tissues", "OBSERVATION_MODIFIER", 19, 26], ["decreased", "OBSERVATION_MODIFIER", 27, 36], ["FDC", "OBSERVATION_MODIFIER", 53, 56], ["clearing", "OBSERVATION_MODIFIER", 57, 65], ["more", "OBSERVATION_MODIFIER", 66, 70], ["rapidly", "OBSERVATION_MODIFIER", 71, 78], ["organs", "ANATOMY", 96, 102]]], ["At the end of the study, measurable FDC (0.15 mg/gm) remained only in spleen.", [["spleen", "ANATOMY", 70, 76], ["FDC", "SIMPLE_CHEMICAL", 36, 39], ["spleen", "ORGAN", 70, 76], ["FDC", "CELL_TYPE", 36, 39], ["the study", "TEST", 14, 23], ["spleen", "ANATOMY", 70, 76]]], ["FIPA was recovered from both spleen (61.63-94.76 mg/gm) and liver (4.55-4.75 mg/gm) at 183 days post-treatment.", [["spleen", "ANATOMY", 29, 35], ["liver", "ANATOMY", 60, 65], ["FIPA", "SIMPLE_CHEMICAL", 0, 4], ["spleen", "ORGAN", 29, 35], ["liver", "ORGAN", 60, 65], ["FIPA", "PROTEIN", 0, 4], ["FIPA", "TEST", 0, 4], ["liver", "TEST", 60, 65], ["treatment", "TREATMENT", 101, 110], ["spleen", "ANATOMY", 29, 35], ["liver", "ANATOMY", 60, 65]]], ["However, both FDC and FTPA clearance was essentially complete from lung tissues by six months post-treatment.RESULTSFluosol accumulation in the cell, were observed in the RES of the spleen and liver in Fluosol treated animals.", [["lung tissues", "ANATOMY", 67, 79], ["cell", "ANATOMY", 144, 148], ["spleen", "ANATOMY", 182, 188], ["liver", "ANATOMY", 193, 198], ["RESULTSFluosol", "CHEMICAL", 109, 123], ["Fluosol", "CHEMICAL", 202, 209], ["FTPA", "CHEMICAL", 22, 26], ["RESULTSFluosol", "CHEMICAL", 109, 123], ["RES", "CHEMICAL", 171, 174], ["Fluosol", "CHEMICAL", 202, 209], ["FDC", "SIMPLE_CHEMICAL", 14, 17], ["FTPA", "SIMPLE_CHEMICAL", 22, 26], ["lung tissues", "TISSUE", 67, 79], ["RESULTSFluosol", "SIMPLE_CHEMICAL", 109, 123], ["cell", "CELL", 144, 148], ["spleen", "ORGAN", 182, 188], ["liver", "ORGAN", 193, 198], ["Fluosol", "SIMPLE_CHEMICAL", 202, 209], ["FDC", "CELL_TYPE", 14, 17], ["FTPA clearance", "TEST", 22, 36], ["RESULTSFluosol accumulation in the cell", "PROBLEM", 109, 148], ["Fluosol", "TREATMENT", 202, 209], ["both", "OBSERVATION_MODIFIER", 9, 13], ["FDC", "OBSERVATION", 14, 17], ["lung", "ANATOMY", 67, 71], ["cell", "OBSERVATION", 144, 148], ["spleen", "ANATOMY", 182, 188], ["liver", "ANATOMY", 193, 198], ["Fluosol treated", "OBSERVATION", 202, 217]]], ["In the spleen, there was marked accumulation of foamy macrophages throughout the red pulp at 24 days posttreatment (Fig. 1) ; accumulation was also observed in the lymphoid germinal follicles of some samples.", [["spleen", "ANATOMY", 7, 13], ["foamy macrophages", "ANATOMY", 48, 65], ["red pulp", "ANATOMY", 81, 89], ["lymphoid germinal follicles", "ANATOMY", 164, 191], ["samples", "ANATOMY", 200, 207], ["spleen", "ORGAN", 7, 13], ["foamy macrophages", "CELL", 48, 65], ["red pulp", "TISSUE", 81, 89], ["lymphoid germinal follicles", "MULTI-TISSUE_STRUCTURE", 164, 191], ["foamy macrophages", "CELL_TYPE", 48, 65], ["marked accumulation of foamy macrophages", "PROBLEM", 25, 65], ["accumulation", "PROBLEM", 126, 138], ["spleen", "ANATOMY", 7, 13], ["marked", "OBSERVATION_MODIFIER", 25, 31], ["accumulation of", "OBSERVATION", 32, 47], ["foamy macrophages", "OBSERVATION", 48, 65], ["red pulp", "OBSERVATION", 81, 89], ["lymphoid germinal follicles", "OBSERVATION", 164, 191]]], ["These changes remained prominent at 43 days post-treatment, but by 183 days, there remained only mild to moderate focal accumulation of foamy macrophage in the red pulp and no accumulation in the germinal centers (Fig. 2) .", [["foamy macrophage", "ANATOMY", 136, 152], ["red pulp", "ANATOMY", 160, 168], ["germinal centers", "ANATOMY", 196, 212], ["foamy macrophage", "CELL", 136, 152], ["red pulp", "TISSUE", 160, 168], ["germinal centers", "MULTI-TISSUE_STRUCTURE", 196, 212], ["foamy macrophage", "CELL_TYPE", 136, 152], ["treatment", "TREATMENT", 49, 58], ["mild to moderate focal accumulation of foamy macrophage", "PROBLEM", 97, 152], ["the red pulp", "PROBLEM", 156, 168], ["accumulation in the germinal centers", "PROBLEM", 176, 212], ["prominent", "OBSERVATION_MODIFIER", 23, 32], ["mild", "OBSERVATION_MODIFIER", 97, 101], ["moderate", "OBSERVATION_MODIFIER", 105, 113], ["focal", "OBSERVATION_MODIFIER", 114, 119], ["accumulation of", "OBSERVATION", 120, 135], ["foamy macrophage", "OBSERVATION", 136, 152], ["red pulp", "OBSERVATION", 160, 168], ["no", "UNCERTAINTY", 173, 175], ["accumulation", "OBSERVATION_MODIFIER", 176, 188], ["germinal", "ANATOMY_MODIFIER", 196, 204], ["centers", "OBSERVATION_MODIFIER", 205, 212]]], ["At 24 days post-treatment, the livers of animals in both treatment groups contained moderate numbers of large foamy Kupffer cells and enlarged foamy hepatocytes (Fig. 3 ) reflecting the accumulation of Fluosoi in these cells.", [["livers", "ANATOMY", 31, 37], ["Kupffer cells", "ANATOMY", 116, 129], ["foamy hepatocytes", "ANATOMY", 143, 160], ["cells", "ANATOMY", 219, 224], ["Fluosoi", "CHEMICAL", 202, 209], ["livers", "ORGAN", 31, 37], ["foamy Kupffer cells", "CELL", 110, 129], ["foamy hepatocytes", "CELL", 143, 160], ["Fluosoi", "SIMPLE_CHEMICAL", 202, 209], ["cells", "CELL", 219, 224], ["foamy Kupffer cells", "CELL_TYPE", 110, 129], ["foamy hepatocytes", "CELL_TYPE", 143, 160], ["moderate numbers of large foamy Kupffer cells", "PROBLEM", 84, 129], ["enlarged foamy hepatocytes", "PROBLEM", 134, 160], ["the accumulation of Fluosoi in these cells", "PROBLEM", 182, 224], ["livers", "ANATOMY", 31, 37], ["moderate", "OBSERVATION_MODIFIER", 84, 92], ["numbers", "OBSERVATION_MODIFIER", 93, 100], ["large", "OBSERVATION_MODIFIER", 104, 109], ["foamy Kupffer cells", "OBSERVATION", 110, 129], ["enlarged", "OBSERVATION_MODIFIER", 134, 142], ["foamy hepatocytes", "OBSERVATION", 143, 160], ["accumulation of Fluosoi", "OBSERVATION", 186, 209], ["these cells", "OBSERVATION", 213, 224]]], ["These cells decreased in number gradually until only scattered foamy cells were observed by 183 days post-treatment (Fig. 4) .", [["cells", "ANATOMY", 6, 11], ["foamy cells", "ANATOMY", 63, 74], ["cells", "CELL", 6, 11], ["foamy cells", "CELL", 63, 74], ["scattered foamy cells", "CELL_TYPE", 53, 74], ["These cells", "PROBLEM", 0, 11], ["scattered foamy cells", "PROBLEM", 53, 74], ["cells", "OBSERVATION", 6, 11], ["decreased", "OBSERVATION_MODIFIER", 12, 21], ["scattered", "OBSERVATION_MODIFIER", 53, 62], ["foamy cells", "OBSERVATION", 63, 74]]], ["Scattered foamy macrophages were observed in the alveoli and interstitium of lung tissues from treatment animals at 24 days, but by 183 days post-treatment, only occasional foamy cells were observed.", [["foamy macrophages", "ANATOMY", 10, 27], ["alveoli", "ANATOMY", 49, 56], ["interstitium", "ANATOMY", 61, 73], ["lung tissues", "ANATOMY", 77, 89], ["foamy cells", "ANATOMY", 173, 184], ["foamy macrophages", "CELL", 10, 27], ["alveoli", "TISSUE", 49, 56], ["interstitium", "TISSUE", 61, 73], ["lung tissues", "TISSUE", 77, 89], ["foamy cells", "CELL", 173, 184], ["foamy macrophages", "CELL_TYPE", 10, 27], ["foamy cells", "CELL_TYPE", 173, 184], ["Scattered foamy macrophages", "PROBLEM", 0, 27], ["treatment animals", "TREATMENT", 95, 112], ["treatment", "TREATMENT", 146, 155], ["occasional foamy cells", "PROBLEM", 162, 184], ["foamy macrophages", "OBSERVATION", 10, 27], ["alveoli", "ANATOMY_MODIFIER", 49, 56], ["interstitium", "ANATOMY_MODIFIER", 61, 73], ["lung tissues", "ANATOMY", 77, 89], ["foamy cells", "OBSERVATION", 173, 184]]], ["Control tissue samples were histologically normal, except for evidence of mycoplasmosis observed in the lungs of some control and treatment animals.RESULTSLight microscopic examination revealed no tissue damage although, foamy macrophages, indicative of Whole body weights increased and relative organ weights decreased over time for all groups, reflecting the growth of the animals.", [["tissue samples", "ANATOMY", 8, 22], ["lungs", "ANATOMY", 104, 109], ["tissue", "ANATOMY", 197, 203], ["foamy macrophages", "ANATOMY", 221, 238], ["body", "ANATOMY", 260, 264], ["organ", "ANATOMY", 296, 301], ["mycoplasmosis", "DISEASE", 74, 87], ["tissue samples", "CANCER", 8, 22], ["lungs", "ORGAN", 104, 109], ["tissue", "TISSUE", 197, 203], ["foamy macrophages", "CELL", 221, 238], ["body", "ORGANISM_SUBDIVISION", 260, 264], ["organ", "ORGAN", 296, 301], ["foamy macrophages", "CELL_TYPE", 221, 238], ["Control tissue samples", "TEST", 0, 22], ["mycoplasmosis", "PROBLEM", 74, 87], ["treatment animals", "TREATMENT", 130, 147], ["RESULTSLight microscopic examination", "TEST", 148, 184], ["tissue damage", "PROBLEM", 197, 210], ["foamy macrophages", "PROBLEM", 221, 238], ["Whole body weights", "PROBLEM", 254, 272], ["relative organ weights", "PROBLEM", 287, 309], ["mycoplasmosis", "OBSERVATION", 74, 87], ["lungs", "ANATOMY", 104, 109], ["no", "UNCERTAINTY", 194, 196], ["tissue", "ANATOMY", 197, 203], ["damage", "OBSERVATION", 204, 210], ["foamy macrophages", "OBSERVATION", 221, 238]]], ["There were no differences in whole body weights between FRA animals and control animals during the study.", [["whole body", "ANATOMY", 29, 39], ["body", "ORGANISM_SUBDIVISION", 35, 39], ["whole body weights", "TEST", 29, 47], ["the study", "TEST", 95, 104], ["no", "UNCERTAINTY", 11, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25]]], ["However, in the FOX group, weight gain was depressed (p < 0.05) both at 24 days (0.9 times control) and 92 days (0.8 times control) post-treatment, but had returned to control levels by the termination of the study.", [["weight gain", "DISEASE", 27, 38], ["depressed", "DISEASE", 43, 52], ["FOX", "GENE_OR_GENE_PRODUCT", 16, 19], ["weight gain", "PROBLEM", 27, 38], ["depressed", "PROBLEM", 43, 52], ["treatment", "TREATMENT", 137, 146], ["the study", "TEST", 205, 214]]], ["The etiology of this weight change was not examined.", [["this weight change", "PROBLEM", 16, 34]]], ["As expected, both liver and spleen weights were initially elevated after Fluosol treatment (Table 2) .", [["liver", "ANATOMY", 18, 23], ["spleen", "ANATOMY", 28, 34], ["Fluosol", "CHEMICAL", 73, 80], ["Fluosol", "CHEMICAL", 73, 80], ["liver", "ORGAN", 18, 23], ["spleen", "ORGAN", 28, 34], ["Fluosol", "SIMPLE_CHEMICAL", 73, 80], ["both liver and spleen weights", "TEST", 13, 42], ["Fluosol treatment", "TREATMENT", 73, 90], ["both", "ANATOMY_MODIFIER", 13, 17], ["liver", "ANATOMY", 18, 23], ["spleen", "ANATOMY", 28, 34], ["elevated", "OBSERVATION_MODIFIER", 58, 66]]], ["Animals receiving Fluosol had relative liver weights about 1.6 and 1.7 times the relative weights of their corresponding controls at 24 days post-treatment (p < 0.05).", [["liver", "ANATOMY", 39, 44], ["Fluosol", "CHEMICAL", 18, 25], ["Fluosol", "CHEMICAL", 18, 25], ["Animals", "ORGANISM", 0, 7], ["Fluosol", "SIMPLE_CHEMICAL", 18, 25], ["liver", "ORGAN", 39, 44], ["Fluosol", "TREATMENT", 18, 25], ["relative liver weights", "TEST", 30, 52], ["liver", "ANATOMY", 39, 44]]], ["In the spleen, increases of 2.0 and 2.1 times over control weights were observed for the FRA and FOX groups, respectively (p < 0.05).", [["spleen", "ANATOMY", 7, 13], ["spleen", "ORGAN", 7, 13], ["FOX", "GENE_OR_GENE_PRODUCT", 97, 100], ["spleen", "ANATOMY", 7, 13], ["increases", "OBSERVATION_MODIFIER", 15, 24]]], ["These differences resolved gradually over time and were almost completely normalized at 183 days posttreatment.", [["differences", "OBSERVATION_MODIFIER", 6, 17], ["resolved", "OBSERVATION_MODIFIER", 18, 26], ["gradually", "OBSERVATION_MODIFIER", 27, 36]]], ["There were no differences in organ weights, attributable to the inspiration of high oxygen, in either control or treatment groups.", [["organ", "ANATOMY", 29, 34], ["oxygen", "CHEMICAL", 84, 90], ["oxygen", "CHEMICAL", 84, 90], ["organ", "ORGAN", 29, 34], ["oxygen", "SIMPLE_CHEMICAL", 84, 90], ["differences in organ weights", "PROBLEM", 14, 42], ["high oxygen", "TREATMENT", 79, 90], ["treatment groups", "TREATMENT", 113, 129], ["no", "UNCERTAINTY", 11, 13], ["differences", "OBSERVATION_MODIFIER", 14, 25], ["high oxygen", "OBSERVATION", 79, 90]]], ["No differences in lung weights were observed between treatment and control groups.DISCUSSIONAdministration of Fluosol in multiple doses to a total of 50 ml/kg resulted in no markedly adverse effects in the animals tested.", [["lung", "ANATOMY", 18, 22], ["Fluosol", "CHEMICAL", 110, 117], ["Fluosol", "CHEMICAL", 110, 117], ["lung", "ORGAN", 18, 22], ["Fluosol", "SIMPLE_CHEMICAL", 110, 117], ["differences in lung weights", "PROBLEM", 3, 30], ["treatment and control groups", "TREATMENT", 53, 81], ["Fluosol", "TREATMENT", 110, 117], ["markedly adverse effects", "PROBLEM", 174, 198], ["differences", "OBSERVATION_MODIFIER", 3, 14], ["lung", "ANATOMY", 18, 22], ["weights", "OBSERVATION", 23, 30], ["no", "UNCERTAINTY", 171, 173], ["markedly", "OBSERVATION_MODIFIER", 174, 182]]], ["Both perfluorochemical and histological analyses confirmed that PFC's were taken up by the RES, as previously reported.", [["RES", "CHEMICAL", 91, 94], ["PFC", "SIMPLE_CHEMICAL", 64, 67], ["RES", "SIMPLE_CHEMICAL", 91, 94], ["histological analyses", "TEST", 27, 48], ["PFC's", "TREATMENT", 64, 69]]], ["5,6 Histological examination confirmed the accumulation of the PFC-containing foamy macrophages without other structural or inflammatory changes.", [["PFC", "ANATOMY", 63, 66], ["macrophages", "ANATOMY", 84, 95], ["PFC", "SIMPLE_CHEMICAL", 63, 66], ["foamy macrophages", "CELL", 78, 95], ["foamy macrophages", "CELL_TYPE", 78, 95], ["Histological examination", "TEST", 4, 28], ["the PFC", "TEST", 59, 66], ["other structural or inflammatory changes", "PROBLEM", 104, 144], ["PFC", "ANATOMY", 63, 66], ["foamy macrophages", "OBSERVATION", 78, 95], ["without other", "UNCERTAINTY", 96, 109], ["structural", "OBSERVATION_MODIFIER", 110, 120], ["inflammatory", "OBSERVATION", 124, 136]]], ["Previous light and electron microscopic studies in rats,5,9 rabbits,6 dogs5 and monkeys' injected with perfluorochemical emulsions have also documented PFCcontaining macrophages in the RES without damage to tissue architecture.", [["macrophages", "ANATOMY", 166, 177], ["tissue", "ANATOMY", 207, 213], ["RES", "CHEMICAL", 185, 188], ["rats", "ORGANISM", 51, 55], ["rabbits", "ORGANISM", 60, 67], ["dogs5", "ORGANISM", 70, 75], ["monkeys", "ORGANISM", 80, 87], ["PFCcontaining macrophages", "CELL", 152, 177], ["RES", "SIMPLE_CHEMICAL", 185, 188], ["tissue", "TISSUE", 207, 213], ["PFCcontaining macrophages", "CELL_TYPE", 152, 177], ["rats", "SPECIES", 51, 55], ["rabbits", "SPECIES", 60, 67], ["monkeys", "SPECIES", 80, 87], ["electron microscopic studies", "TEST", 19, 47], ["rats", "TEST", 51, 55], ["perfluorochemical emulsions", "TREATMENT", 103, 130], ["PFCcontaining macrophages", "PROBLEM", 152, 177], ["damage to tissue architecture", "PROBLEM", 197, 226], ["perfluorochemical emulsions", "OBSERVATION", 103, 130], ["PFCcontaining macrophages", "OBSERVATION", 152, 177]]], ["The PFC content of liver and spleen decreased over time and organ weights normalized; correspondingly fewer macrophages were observed as this clearance took place.", [["PFC", "ANATOMY", 4, 7], ["liver", "ANATOMY", 19, 24], ["spleen", "ANATOMY", 29, 35], ["organ", "ANATOMY", 60, 65], ["macrophages", "ANATOMY", 108, 119], ["PFC", "MULTI-TISSUE_STRUCTURE", 4, 7], ["liver", "ORGAN", 19, 24], ["spleen", "ORGAN", 29, 35], ["organ", "ORGAN", 60, 65], ["macrophages", "CELL", 108, 119], ["macrophages", "CELL_TYPE", 108, 119], ["The PFC content", "TEST", 0, 15], ["organ weights", "TEST", 60, 73], ["correspondingly fewer macrophages", "PROBLEM", 86, 119], ["PFC content", "OBSERVATION", 4, 15], ["liver", "ANATOMY", 19, 24], ["spleen", "ANATOMY", 29, 35], ["decreased", "OBSERVATION", 36, 45], ["fewer", "OBSERVATION_MODIFIER", 102, 107], ["macrophages", "OBSERVATION", 108, 119]]], ["In this study, the clearance of PFC's from organs is similar to that reported by Lutz,2 using a single 10 gm/kg PFC dose.", [["PFC", "ANATOMY", 32, 35], ["organs", "ANATOMY", 43, 49], ["PFC", "SIMPLE_CHEMICAL", 32, 35], ["organs", "ORGAN", 43, 49], ["PFC", "SIMPLE_CHEMICAL", 112, 115], ["this study", "TEST", 3, 13], ["PFC's", "PROBLEM", 32, 37], ["a single 10 gm/kg PFC dose", "TREATMENT", 94, 120]]], ["However, the rate of clearance appears more prolonged here than in studies using an exchange transfusion model.5 The more rapid clearance of FDC from all organs, observed here and in previous studies,5 reflects the difference in elimination rate constants for the two PFCS.~ Only slight PFC accumulation was noted in the lung and the small numbers of foamy macrophages observed there also decreased over time.", [["FDC", "ANATOMY", 141, 144], ["organs", "ANATOMY", 154, 160], ["PFC", "ANATOMY", 287, 290], ["lung", "ANATOMY", 321, 325], ["foamy macrophages", "ANATOMY", 351, 368], ["FDC", "CELL", 141, 144], ["organs", "ORGAN", 154, 160], ["PFC", "SIMPLE_CHEMICAL", 287, 290], ["lung", "ORGAN", 321, 325], ["foamy macrophages", "CELL", 351, 368], ["FDC", "CELL_TYPE", 141, 144], ["foamy macrophages", "CELL_TYPE", 351, 368], ["an exchange transfusion", "TREATMENT", 81, 104], ["previous studies", "TEST", 183, 199], ["the difference in elimination rate constants", "PROBLEM", 211, 255], ["slight PFC accumulation", "PROBLEM", 280, 303], ["foamy macrophages", "PROBLEM", 351, 368], ["rapid", "OBSERVATION_MODIFIER", 122, 127], ["clearance", "OBSERVATION_MODIFIER", 128, 137], ["FDC", "OBSERVATION", 141, 144], ["organs", "ANATOMY", 154, 160], ["slight", "OBSERVATION_MODIFIER", 280, 286], ["PFC accumulation", "OBSERVATION", 287, 303], ["lung", "ANATOMY", 321, 325], ["small", "OBSERVATION_MODIFIER", 334, 339], ["numbers", "OBSERVATION_MODIFIER", 340, 347], ["foamy macrophages", "OBSERVATION", 351, 368], ["decreased", "OBSERVATION_MODIFIER", 389, 398]]], ["PFC's are eliminated from the body primarily by expiration through the lungs.'", [["PFC", "ANATOMY", 0, 3], ["body", "ANATOMY", 30, 34], ["lungs", "ANATOMY", 71, 76], ["PFC", "SIMPLE_CHEMICAL", 0, 3], ["body", "ORGANISM_SUBDIVISION", 30, 34], ["lungs", "ORGAN", 71, 76], ["PFC's", "TREATMENT", 0, 5], ["body", "ANATOMY_MODIFIER", 30, 34], ["lungs", "ANATOMY", 71, 76]]], ["In this study, although, some PFC was detected in the lungs, no structural damage due to PFC transport was observed.DISCUSSIONHemograms, serology, and hepatic enzyme values were not affected by Fluosol administration.", [["PFC", "ANATOMY", 30, 33], ["lungs", "ANATOMY", 54, 59], ["hepatic", "ANATOMY", 151, 158], ["Fluosol", "CHEMICAL", 194, 201], ["Fluosol", "CHEMICAL", 194, 201], ["PFC", "CANCER", 30, 33], ["lungs", "ORGAN", 54, 59], ["PFC", "SIMPLE_CHEMICAL", 89, 92], ["hepatic", "ORGAN", 151, 158], ["Fluosol", "SIMPLE_CHEMICAL", 194, 201], ["hepatic enzyme", "PROTEIN", 151, 165], ["this study", "TEST", 3, 13], ["some PFC", "PROBLEM", 25, 33], ["structural damage", "PROBLEM", 64, 81], ["PFC transport", "TREATMENT", 89, 102], ["DISCUSSIONHemograms", "TEST", 116, 135], ["serology", "TEST", 137, 145], ["hepatic enzyme values", "TEST", 151, 172], ["Fluosol administration", "TREATMENT", 194, 216], ["some", "OBSERVATION_MODIFIER", 25, 29], ["PFC", "OBSERVATION", 30, 33], ["lungs", "ANATOMY", 54, 59], ["no", "UNCERTAINTY", 61, 63], ["structural damage", "OBSERVATION", 64, 81], ["hepatic", "ANATOMY", 151, 158]]], ["The few differences observed in hepatic enzymes were attributable to random variation in individual animals, indicating that no liver dysfunction resulted from Pluosol infusion.", [["hepatic", "ANATOMY", 32, 39], ["liver", "ANATOMY", 128, 133], ["liver dysfunction", "DISEASE", 128, 145], ["Pluosol", "CHEMICAL", 160, 167], ["Pluosol", "CHEMICAL", 160, 167], ["hepatic", "ORGAN", 32, 39], ["liver", "ORGAN", 128, 133], ["Pluosol", "SIMPLE_CHEMICAL", 160, 167], ["hepatic enzymes", "PROTEIN", 32, 47], ["hepatic enzymes", "TEST", 32, 47], ["random variation in individual animals", "PROBLEM", 69, 107], ["liver dysfunction", "PROBLEM", 128, 145], ["Pluosol infusion", "TREATMENT", 160, 176], ["few", "OBSERVATION_MODIFIER", 4, 7], ["hepatic", "ANATOMY", 32, 39], ["no", "UNCERTAINTY", 125, 127], ["liver", "ANATOMY", 128, 133], ["dysfunction", "OBSERVATION", 134, 145]]], ["Transient alterations in SGGT, SGPT, alkaline phosphatase, and WBC counts have been observed3Y4 in both pre-clinical and clinical studies, but were not attributed to a pathological response Metzenauer and Lutz3 reported transient elevations in hepatic enzymes after administration of Fluosol at 14 gm PFC/kg.", [["WBC", "ANATOMY", 63, 66], ["hepatic", "ANATOMY", 244, 251], ["Lutz3", "CHEMICAL", 205, 210], ["Fluosol", "CHEMICAL", 284, 291], ["Fluosol", "CHEMICAL", 284, 291], ["SGGT", "GENE_OR_GENE_PRODUCT", 25, 29], ["SGPT", "GENE_OR_GENE_PRODUCT", 31, 35], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 37, 57], ["Metzenauer", "SIMPLE_CHEMICAL", 190, 200], ["Lutz3", "SIMPLE_CHEMICAL", 205, 210], ["hepatic", "ORGAN", 244, 251], ["Fluosol", "SIMPLE_CHEMICAL", 284, 291], ["SGGT", "PROTEIN", 25, 29], ["SGPT", "PROTEIN", 31, 35], ["alkaline phosphatase", "PROTEIN", 37, 57], ["WBC", "PROTEIN", 63, 66], ["hepatic enzymes", "PROTEIN", 244, 259], ["Transient alterations", "PROBLEM", 0, 21], ["SGGT", "TEST", 25, 29], ["SGPT", "TEST", 31, 35], ["alkaline phosphatase", "TEST", 37, 57], ["WBC counts", "TEST", 63, 73], ["clinical studies", "TEST", 121, 137], ["a pathological response Metzenauer", "PROBLEM", 166, 200], ["transient elevations in hepatic enzymes", "PROBLEM", 220, 259], ["Fluosol", "TREATMENT", 284, 291], ["transient", "OBSERVATION_MODIFIER", 220, 229], ["elevations", "OBSERVATION_MODIFIER", 230, 240], ["hepatic", "ANATOMY", 244, 251]]], ["However, the rapid return of these enzymes to control levels suggested that there was no organ damage or marked dysfunction.DISCUSSIONA depression in whole body weight gain was observed in the FOX group as compared to the CRA and COX groups at 24 and 92 days post-treatment.", [["organ", "ANATOMY", 89, 94], ["body", "ANATOMY", 156, 160], ["organ damage", "DISEASE", 89, 101], ["depression", "DISEASE", 136, 146], ["weight gain", "DISEASE", 161, 172], ["organ", "ORGAN", 89, 94], ["body", "ORGANISM_SUBDIVISION", 156, 160], ["FOX", "GENE_OR_GENE_PRODUCT", 193, 196], ["COX", "GENE_OR_GENE_PRODUCT", 230, 233], ["enzymes", "PROTEIN", 35, 42], ["FOX", "PROTEIN", 193, 196], ["COX", "PROTEIN", 230, 233], ["these enzymes", "TEST", 29, 42], ["organ damage", "PROBLEM", 89, 101], ["marked dysfunction", "PROBLEM", 105, 123], ["depression", "PROBLEM", 136, 146], ["whole body weight gain", "PROBLEM", 150, 172], ["no", "UNCERTAINTY", 86, 88], ["organ", "ANATOMY", 89, 94], ["damage", "OBSERVATION", 95, 101], ["marked", "OBSERVATION_MODIFIER", 105, 111], ["dysfunction", "OBSERVATION", 112, 123]]], ["The data obtained in this study do not suggest an explanation for this difference; however, we surmise that extra handling of the animals in the FOX group during the study contributed to this depression in weight gain.", [["depression", "DISEASE", 192, 202], ["weight gain", "DISEASE", 206, 217], ["FOX", "CHEMICAL", 145, 148], ["FOX", "GENE_OR_GENE_PRODUCT", 145, 148], ["The data", "TEST", 0, 8], ["this study", "TEST", 21, 31], ["the study", "TEST", 162, 171], ["this depression in weight gain", "PROBLEM", 187, 217]]], ["Goodman et al.' reported a five-fold increase in spleen weight and a two-fold increase in liver weight, following multiple infusions of Pluosol to 10 gm PFC/kg total dose.", [["spleen", "ANATOMY", 49, 55], ["liver", "ANATOMY", 90, 95], ["Pluosol", "CHEMICAL", 136, 143], ["spleen", "ORGAN", 49, 55], ["liver", "ORGAN", 90, 95], ["Pluosol", "SIMPLE_CHEMICAL", 136, 143], ["a five-fold increase in spleen weight", "PROBLEM", 25, 62], ["a two-fold increase in liver weight", "PROBLEM", 67, 102], ["multiple infusions of Pluosol", "TREATMENT", 114, 143], ["increase", "OBSERVATION_MODIFIER", 37, 45], ["spleen", "ANATOMY", 49, 55], ["two-fold", "OBSERVATION_MODIFIER", 69, 77], ["increase", "OBSERVATION", 78, 86], ["liver", "ANATOMY", 90, 95]]], ["Our data show 1.6-1.7 and 2.0-2.1 fold increases in liver and spleen weights, respectively.", [["liver", "ANATOMY", 52, 57], ["spleen", "ANATOMY", 62, 68], ["liver", "ORGAN", 52, 57], ["spleen", "ORGAN", 62, 68], ["Our data", "TEST", 0, 8], ["2.0-2.1 fold increases in liver and spleen weights", "PROBLEM", 26, 76], ["increases", "OBSERVATION_MODIFIER", 39, 48], ["liver", "ANATOMY", 52, 57], ["spleen", "ANATOMY", 62, 68]]], ["The reason for this difference in observed spleen weights is not known; however, other studies have also failed to show comparable splenic enlargement at similar Fluosol doses.2,13DISCUSSIONIncreases in spleen and liver weights observed in treated animals reflect PFC storage in these organs.", [["spleen", "ANATOMY", 43, 49], ["splenic", "ANATOMY", 131, 138], ["spleen", "ANATOMY", 203, 209], ["liver", "ANATOMY", 214, 219], ["organs", "ANATOMY", 285, 291], ["splenic enlargement", "DISEASE", 131, 150], ["Fluosol", "CHEMICAL", 162, 169], ["Fluosol", "CHEMICAL", 162, 169], ["spleen", "ORGAN", 43, 49], ["splenic", "ORGAN", 131, 138], ["Fluosol", "SIMPLE_CHEMICAL", 162, 169], ["spleen", "ORGAN", 203, 209], ["liver", "ORGAN", 214, 219], ["PFC", "SIMPLE_CHEMICAL", 264, 267], ["organs", "ORGAN", 285, 291], ["this difference in observed spleen weights", "PROBLEM", 15, 57], ["other studies", "TEST", 81, 94], ["comparable splenic enlargement", "PROBLEM", 120, 150], ["similar Fluosol doses", "TREATMENT", 154, 175], ["liver weights", "TEST", 214, 227], ["PFC storage in these organs", "PROBLEM", 264, 291], ["spleen", "ANATOMY", 43, 49], ["splenic", "ANATOMY", 131, 138], ["enlargement", "OBSERVATION", 139, 150], ["Fluosol doses", "OBSERVATION", 162, 175], ["spleen", "ANATOMY", 203, 209], ["liver", "ANATOMY", 214, 219], ["PFC storage", "OBSERVATION", 264, 275], ["organs", "ANATOMY", 285, 291]]], ["In agreement with previous work,**13 the total weight gain in liver and spleen observed in this study exceeds the amount of PFC's retained in these organs.", [["liver", "ANATOMY", 62, 67], ["spleen", "ANATOMY", 72, 78], ["organs", "ANATOMY", 148, 154], ["weight gain", "DISEASE", 47, 58], ["liver", "ORGAN", 62, 67], ["spleen", "ORGAN", 72, 78], ["PFC", "SIMPLE_CHEMICAL", 124, 127], ["organs", "ORGAN", 148, 154], ["**13", "DNA", 32, 36], ["PFC", "PROTEIN", 124, 127], ["the total weight gain", "TEST", 37, 58], ["this study", "TEST", 91, 101], ["PFC's", "TREATMENT", 124, 129], ["liver", "ANATOMY", 62, 67], ["spleen", "ANATOMY", 72, 78], ["organs", "ANATOMY", 148, 154]]], ["This gain has been attributed to either hyperplasia* or hypertrophy; the data reported here do not permit elucidation of the mechanism of weight gain in these organs.", [["organs", "ANATOMY", 159, 165], ["hypertrophy", "DISEASE", 56, 67], ["weight gain", "DISEASE", 138, 149], ["organs", "ORGAN", 159, 165], ["hyperplasia*", "PROBLEM", 40, 52], ["hypertrophy", "PROBLEM", 56, 67], ["the data", "TEST", 69, 77], ["weight gain in these organs", "PROBLEM", 138, 165], ["hyperplasia*", "OBSERVATION", 40, 52], ["hypertrophy", "OBSERVATION", 56, 67], ["organs", "ANATOMY", 159, 165]]], ["In another study, no changes in fibroid tissue were observed in the liver or lung within one year following multiple doses of Fluosol to a total of 22 gm PFC/kg of body weight8DISCUSSIONThe results reported in this study indicate that Fluosol has no marked detrimental effects at this dosage level and suggest that effects following multiple injections to 10 gm PFC/kg (50 ml/kg) are similar to results obtained for bolus injections of Fluosol to 50 ml/kg.", [["fibroid tissue", "ANATOMY", 32, 46], ["liver", "ANATOMY", 68, 73], ["lung", "ANATOMY", 77, 81], ["body", "ANATOMY", 164, 168], ["Fluosol", "CHEMICAL", 126, 133], ["Fluosol", "CHEMICAL", 235, 242], ["Fluosol", "CHEMICAL", 436, 443], ["Fluosol", "CHEMICAL", 126, 133], ["Fluosol", "CHEMICAL", 235, 242], ["fibroid tissue", "TISSUE", 32, 46], ["liver", "ORGAN", 68, 73], ["lung", "ORGAN", 77, 81], ["Fluosol", "SIMPLE_CHEMICAL", 126, 133], ["body", "ORGANISM_SUBDIVISION", 164, 168], ["Fluosol", "SIMPLE_CHEMICAL", 235, 242], ["Fluosol", "SIMPLE_CHEMICAL", 436, 443], ["another study", "TEST", 3, 16], ["changes in fibroid tissue", "PROBLEM", 21, 46], ["Fluosol", "TREATMENT", 126, 133], ["this study", "TEST", 210, 220], ["Fluosol", "TREATMENT", 235, 242], ["marked detrimental effects", "PROBLEM", 250, 276], ["multiple injections", "TREATMENT", 333, 352], ["Fluosol", "TREATMENT", 436, 443], ["no", "UNCERTAINTY", 18, 20], ["fibroid", "OBSERVATION", 32, 39], ["liver", "ANATOMY", 68, 73], ["lung", "ANATOMY", 77, 81], ["no", "UNCERTAINTY", 247, 249], ["marked", "OBSERVATION_MODIFIER", 250, 256]]]]}